memoria2015

SCIENTIFIC REPORT 

2015

Published by: 

Fundación Investigación Hospital Clínico Universitario de Valencia 

INCLIVA Health Research Institute 

Avd. Menéndez Pelayo, 4 Accesorio – 46010 Valencia 

Direction: 

Dr. Josep Redón i Mas. Scientific Director. 

Coordination and writing: 

Scientific Management Department 

Fundación Investigación Hospital Clínico Universitario de Valencia 


Design and layout: 

www.valledor.net 

Pictograms: Freepik.com 

Printing: 

Gráficas Papallona (Valencia)

Index 

i 

1 

2 

3 

4 

5 

6 

7 

8 

1. Introduction 5 

2. INCLIVA Health Research Institute 11 

2.1 History 13 

2.2 Organizational structure 14 

3. INCLIVA global analysis 23 

3.1 Scientific production global analysis 25 

3.2 Financial resources 27 

3.3 Cooperative research networks 29 

3.4 Knowledge transfer 30 

4. Scientific activity 37 

4.1. Research areas 39 

4.1.1 Cardiovascular area 41 

4.1.2 Oncology area 82 

4.1.3 Metabolism and organic damage area 127 

4.1.4 Reproductive medicine area 182 

4.2 Other scientific contributions from the Hospital Divisions 199 

and the Valencia Clínico-Malvarrosa Health Department 

4.3 Other scientific contributions from scientific platforms 218 

4.3.1 Biobank resources 218 

4.3.2 Oncology phase I clinical trials unit 221 

5. Clinical trials and other studies 223 

5.1 Ethical Committee in Clinical Research (ECCR) Activity 224 

5.2 Assessment activity during last 5 years 227 

5.3 Ongoing studies in the Valencia Clínico-Malvarrosa Health Department 228 

6. Initiatives for research promotion 231 

6.1 VLC-Bioclinic grants 232 

6.2 Grants for intramural projects by emerging researchers 233 

6.3 Grants for secondments in centers of excellence 235 

6.4 Training and teaching activities 236 

7. Highlights 245 

8. INCLIVA solidary 249 

8.1 Solidary projects 250 

8.2 Solidary news 251 

8.3 Solidary private donations and acknowledgment 252

Introduction 

1

Introduction 

1 

7 

It is a big pleasure to present the INCLIVA Annual Scientific 

Report 2015, which provides an assessment of the scientific 

activities carried out during the year 2015 by INCLIVA’s research 

groups. As the main novelty, the document presents this year 

two new chapters (highlights of the year and INCLIVA’s solidarity) 

and a new graphic design that we hope will contribute to show 

the information more attractively. INCLIVA Annual Scientific 

Report represents a unique opportunity to take stock of the 

activities and goals achieved and, therefore, to be able to face 

new challenges in the coming years. This year has represented a 

truly milestone for several reasons. 

First of all, in 2015 INCLIVA launched its new strategic plan which 

includes institutional goals and actions to be implemented during 

the next five years (2015-2019). Following External Scientific 

Committee specific recommendations, the plan organizes 

INCLIVA’s research activities around seven research programs – 

early cardiovascular risk in obese subjects; myocardial ischemic 

injury; biomarkers, rare diseases; translational oncology; 

endometrial receptivity and embryo viability; aging and 

associated diseases; and neurological impairment– and three 

scientific platforms – genetics and epigenetics, metabolomics 

and free radicals and inflammation–. These multidisciplinary 

disease-oriented initiatives will provide the basis for the 

institute’s scientific strategy of upcoming years. 

Second, being aware that the processes of innovation and 

technology transfer require multidisciplinary collaboration 

among professionals from various fields, INCLIVA launched 

together with the University of Valencia the VLC-Bioclinic 

Program, an initiative whose main goal is to promote 

multidisciplinary translational research between researchers 

and practitioners from both institutions. The program funded 

both innovative collaborative projects and preparatory actions 

for cooperative research projects. 

Moreover, following the efforts in the area of quality, INCLIVA 

was able to maintain its R&D management services and its 

Ethical Committee in Clinical Research (ECCR) ISO 9001:2008 

certifications and expanded its quality management systems to 

INCLIVA’s Biobank, which was eventually certify on September. 

In addition, during the year the institute focused its attention to 

renew its accreditation as Health Research Institute by the Carlos 

III Health Institute since the external audit is expected to be held 

during the first quarter of 2016. 

Scientific output during the year reached 635 papers, surpassed 

the barrier of 2500 impact factor at once for the very first time, 

and confirmed the steady tendency in recent years. It is worth 

noting that papers published in journals within the first and 

second quartiles of their respective categories have represented 

53% and 20% of the total production, respectively. 

Regarding scientific activities, INCLIVA’s research groups 

competitively secured and developed 179 research initiatives 

during the year, both internationally (9 projects within the 7 th 

Framework Program and 3 non EU projects), as well as nationally 

(66 projects under the National R&D&I Plan) and regionally (17 

projects funded by the Valencian Government). Additionally, 25 

competitive grants from private funding entities were secured. 

Furthermore, research groups were active in national research 

networks (3 Platforms, 8 CIBER and 7 RETICS). Finally, INCLIVA 

was able to secure a Carlos III Health Institute Excellent Integrated 

Project, which provided funding to develop an ambitious 

personalized medicine project in diagnosis, prediction, and 

prevention of cardiac damage in reperfused acute myocardial 

infarction. 

Regarding clinical research activities, the Ethical Committee 

in Clinical Research (ECCR) has processed 120 additional trials. 

With the kick off of these studies, a total of 396 clinical trials and 

other studies were carried out during the year. In fact, 75% of 

these studies were clinical trials, while the remaining 25% were 

observational studies. It is worth noting the high relative weight 

of early stage clinical research, since the number of Phase I and

1 Introduction 

8 

Phase II trials currently represent almost 31% of the studies 

developed at the Institute. 

The present report also shows data reflecting the commitment 

of INCLIVA to training and transfer of biomedical research. The 

involvement of university research groups has resulted in high 

participation in graduate programmes, generating 45 doctoral 

theses this year. Regarding innovation and transfer activities it is 

noteworthy that INCLIVA joint the Patents Bank, a joint program 

of the Valencian Regional Government and public research 

organizations to promote meetings between entrepreneurs, 

businessmen and innovation knowledge centers, in order 

to facilitate technological transfer to business. Moreover, 

the institute was awarded by a grant for the first FIPSE call 

for feasibility studies of health innovation. Finally, INCLIVA’s 

innovation pipeline comprised, in 2015, 2 granted patents, 3 

patent international extensions and 2 software records. 

Among the activities to promote research culture, during 

2015 INCLIVA continued with its Training Plan by collaborating 

with the different hospital departments in the organization and 

management of 62 training initiatives, including 15 courses, 8 

workshops and 9 seminars and 30 conferences. In addition, as 

every year the Institute provided grants for research secondments 

in centers of excellence, that allowed 17 INCLIVA’s researchers to 

acquire new knowledge in clinical and research. 

We cannot conclude without expressing our gratitude to all 

the professionals who enable INCLIVA to continue advancing. 

Thanks to the efforts of our over 500 researchers, 180 of which 

are directly hired by the Foundation, INCLIVA is able to maintain 

its present privileged position. However, all at INCLIVA face 

the challenge of continuing to generate scientific knowledge, 

guiding research excellence for the benefit of society and being 

an important part of solidarity initiatives. 

Rafael Carmena Rodríguez 

General Director 

Josep Redón i Mas 

Scientific Director

INCLIVA 

Health 

Research 

Institute 

2


2 

2.1. History 

13 

In the year 2000 the Foundation for the Research of the Hospital 

Clínico Universitario of Valencia was constituted, being the first 

Valencian research foundation attached to a public hospital. 

Ten years later, some excellence groups in biomedical research 

from the University of Valencia and IUIVI (Valencian Infertility 

Institute) joined the Foundation through the establishment of 

specific agreements, so the INCLIVA Health Research Institute 

was created. 

The main aims of INCLIVA are to manage the biomedical 

research carried out by the Hospital Clínico Universitario of 

Valencia and its Health Department and to encourage teaching 

and scientific activities, thus improving patient treatment and 

knowledge sharing. 

In 2011 INCLIVA was accredited as a Health Research Institute 

by the Ministry of Science and Innovation (Ministerio de Ciencia 

e Innovación) so it obtained preferential treatment by the Carlos 

III Health Institute (Instituto de Salud Carlos III), being recognized 

its excellent research.

2 


2.2. Organizational structure 

2.2.1. Government structure 

The highest government body in the Foundation, the Board 

of Trustees, is headed by the Regional Minister of Health of the 

Valencian Government. This body appoints a Board of Governors 

–headed by the Chief Executive Officer of the Health De- 

partment– the General Director, the Scientific Director and the 

Financial Director. All of them count on the guidance of two Research 

Committees: the External Scientific Committee and the 

Internal Scientific Committee. 

14 

Board of Trustees 

Board of Governors 

External Associated Body 

External Scientific Committee 

ECCR 


Internal Scientific Committee 

Financial Director 

Scientific Director 

2.2.1.1 Board of Trustees 

With a high representation from the Valencian society, it is the 

highest collegiate body in the Institute and its function is to establish 

INCLIVA strategy and policies. 

Dated December 31 st 2015, its members are the following: 

President 

• Ms. Carmen Montón, Honorable Consellera de la Consellería 

de Sanidad Universal y Salud Pública of the Valencian Government 

Vice-president 

• Mr. Álvaro Bonet, Chief Executive Officer of the Hospital Clínico 

Universitario of Valencia and of the Valencia Clínico – Malvarrosa 

Health Department 

Board members according to their positions 

• Mr. Esteban Morcillo Sánchez, Most Illustrious Dean of the 

University of Valencia 

• Mr. Federico Pallardó Calatayud, Most Illustrious Dean of the 

Faculty of Medicine 

• Mr. José Noblejas Pérez, Valencia Chamber of Commerce 

• Mr. Martín Quirós Palau, Valencian Council of Culture 

• Mr. Manuel Broseta Duprè, Social Council of the University of 

Valencia 

• Mr. Ángel Daniel Villanueva Pareja, Bancaja Foundation 

• Mr. Rafael Alcón, Cañada Blanch Foundation 

• Mr. Óscar Zurriaga, General Director of Research, Innovation, 

Technology and Quality of the Consellería de Sanidad Universal 

y Salud Pública of the Valencian Government 

• Ms. Dolores Salas, Secretary of the Consellería de Sanidad Universal 

y Salud Pública of the Valencian Government 

• Mr. Carlos Simón Vallés, Scientific Director of the Valencian Infertility 

Institute 

• Mr. Carlos Segovia, Instituto de Salud Carlos III 

• Mr. Rafael Carmena, INCLIVA General Director 

Board members in their names 

• Mr. Carlos Pascual de Miguel 

• Mr. Joaquín Ortega Serrano 

• Mr. Tomás Trenor Puig 

• Mr. Manuel Montánchez Morera 

The Scientific Director and Financial Director attend the meetings 

with right to speak but without a vote.


2 

2.2.1.2 Board of Governors 

The Board of Governors executes and enforces the Board of 

Trustees’ agreements. They have other duties such as prepare 

and pass the proposals and research projects and decide and allocate 

the budgetary means. 

Dated December 31 st 2015, its members are the following: 

President 

• Dr. Álvaro Bonet, Chief Executive Officer, Hospital Clínico Universitario 

of Valencia 

Vice-president 

• Prof. Federico Pallardó Calatayud, Most Illustrious Dean of the 

Faculty of Medicine 

Board members 

• Prof. Rafael Carmena, INCLIVA General Director 

• Prof. Josep Redón, INCLIVA Scientific Director 

• Dr. Manuel Alós, Head of the Pharmacy Service, Hospital Clínico 

Universitario of Valencia 

• Prof. Andrés Cervantes, Oncology Department, Hospital Clínico 


• Dr. Jorge Navarro, Medical Director, Hospital Clínico Universitario 

of Valencia 

• Prof. Salvador Lluch, Department of Physiology, University of 

Valencia 

• Dr. Ana Sanmartin, Director of Primary Health Care, Health 

Service Department in Valencia Clínico-Malvarrosa 

• Prof. Carlos Simón, Scientific Director, Instituto Universitario IVI 

• Prof. Pascual Medina, Coordinator of Research Support Platform 

(UCIM), University of Valencia 

• Dr. Antonio Peláez, President of the Ethical Committee in Clinical 

Research (ECCR), Hospital Clínico Universitario of Valencia 

2.2.1.3 General Director 

The highest person responsible for the execution of scientific, 

economic and administrative policies appointed by the Board of 

Trustees is the Foundation’s General Director. The position has 

been held by Prof. Rafael Carmena Rodríguez since May 2012. 

He graduated with Honors in Medicine from the Valencia’s 

Faculty of Medicine in 1964, and he is Doctor “cum laude” from 

the Universitat de València in 1966. He is specialist in internal 

medicine and endocrinology. Professor of Pathology and Medical 

Clinics (Internal Medicine) at the universities of Valencia and 

Murcia, he has been Chief of the Internal Medicine Department 

of the Ciudad Sanitaria Virgen de la Arrixaca of Murcia (1974- 

1982), and Chief of both the Welfare Department, and the 

Endocrinology and Nutrition Department of the Hospital Clínico 


for the last 28 years. 

His research interest 

is focused on the lipid 

metabolism, the effects 

of dietary fats on cholesterolemia; 

conditions of 

resistance to insulin and 

its treatment; metabolic 

syndrome; genetics of hypercholesterolemia 

and 

treatment of diabetes 

dyslipidaemia. 

2.2.1.4 Scientific Director 

The Scientific Director is appointed by government bodies. The 

scientific direction has been headed by Prof. Josep Redón since 

2010. Prof. Redón is specialist in Internal Medicine, Research 

Fellow in Hypertension in Northwestern University (Chicago), 

and Fellow of the Council for High Blood Pressure of the American 

Heart Association. He 

is currently Professor of 

Medicine, Head of the Internal 

Medicine Department 

and Coordinator 

of the Hypertension Unit 

of the Hospital Clínico 

Universitario of Valencia. 

Nowadays, he is member 

of the European Society 

of Hypertension, and he 

has authored many research 

works on hypertension 

and diabetes. 

He is also a member of 

the editorial committees 

of several international 

journals on the field of 

hypertension and cardiovascular 

risk. 

15

2 


16 

2.2.1.5 External Scientific Committee 

The External Scientific Committee assesses the collegiate 

government bodies regarding the research carried out and 

safeguards the quality of that research. 

Their national and international members are appointed by 

the Board of Trustees that choose at least one expert in every 

INCLIVA priority area of research. The Committee is constituted 

by well-known standing professionals among the scientific community. 

The composition of the External Scientific Committee, dated 

December 31 st 2015, is the following: 

President: 

• Dr. Javier Díez. Professor of Medicine, University of Navarra. 

Director of the Cardiovascular Sciences Area, Applied Medical 

Research Center (CIMA). 

Members: 

• Dr. José Baselga. Physician in Chief of the Memorial Sloan- 

Kettering of New York (U.S.A.). Professor of Medicine, Autonomous 

University of Barcelona. Director of the Vall d’Hebron 

Institute of Oncology, Barcelona. 

• Dr. Juan Carlos Lacal. Research Professor in CSIC. Biomedical 

Research Institute, Madrid. 

• Dr. Nick S. Macklon. Professor in Obstetrics and Gynecology. 

Division of Developmental Origins of Adult Diseases (DOHaD). 

University of Southampton. Princess Anne Hospital. Coxford 

Road, Southampton (United Kingdom). 

• Dr. José María Medina. Professor in Biochemistry and Molecular 

Biology. University of Salamanca. Castilla y León Neuroscience 

Institute (INCYL). 

• Dr. Josep Tabernero. Chief of Medical Oncology Department. 

Vall d’Hebrón Hospital, Barcelona. 

• Dr. Manuel Tena-Sempere. Professor in Cell Biology, Physiology, 

and Immunology Department. University of Córdoba. 

• Dr. Antonio Vidal-Puig. Professor in Molecular Nutrition and 

Metabolism. University of Cambridge. 

• Dr. Alberto Zanchetti. Professor Emeritus of Internal Medicine. 

Università di Milano. Director of the Istituto Auxologico Italiano 

(Italy). Consultant in WHO. 

During 2015, the External Scientific Committee INCLIVA held two 

meetings: a teleconference held in May and a physical meeting of 

two days of duration held on November 5 th and 6 th . 

Due to the new period of strategic planning, the committee activity 

focused on the analysis and evaluation of the new cross-research 

programs. Each program coordinator presented to the 

Committee members information about the SWOT analysis, the 

overall objectives of the programs, the different research lines and 

the related action plan. Committee members, in turn, provided 

specific feedback that greatly enriched the research programs. 

Finally, as in previous years, INCLIVA’s advisors evaluated the 

scientific and financial reports, and examined how the strategic, 

integration and training plans were put into practice. 

2.2.1.6 Internal Scientific Committee 

INCLIVA’s Internal Scientific Committee acts as a counsellor to 

the General Director and the Scientific Director evaluating and 

supervising the scientific content of the research areas. 

Dated December 31 st 2015, the Committee composition is as 

follows: 

President: 

• Dr. Josep Redón i Mas 

General Director: 

• Dr. Rafael Carmena Rodríguez 

Medical Director of the Hospital Clínico Universitario of Valencia: 

• Dr. Jorge Navarro Pérez 

Coordinators of the priority areas of research: 

• Dr. Andrés Cervantes Ruipérez 

• Dr. José Viña Ribes 

• Dr. Carlos Simón Vallés 

• Dr. Javier Chorro Gascó 

Board members: 

• Dr. Esteban Morcillo Sánchez 

• Dr. Pilar Eroles Asensio 

• Dr. Carlos Hermenegildo Caudevilla 

• Dr. Ana Lluch Hernández 

• Dr. Javier Chaves Martínez 

• Dr. Eduardo Otero Coto 

• Dr. Federico Pallardó Calatayud 

• Dr. Gloria Ribas Despuig 

• Dr. Irene Cervelló Alcaraz 

• Dr. Felipe Vilella Mitjana 

• Dr. Daniel Monleón Salvadó 

• Dr. Fernando Martínez García 

• Dr. Carlos Solano Vercet 

• Dr. Rosa Zaragozá Colom 

• Dr. Luis Sabater Ortí (invited member) 

• Dr. Marina Soro Domingo (invited member)


2 

2.2.1.7 Ethical Committee in Clinical Research 

The Ethical Committee in Clinical Research (ECCR) of the Hospital 

Clínico Universitario of Valencia is the independent body 

whose task is to safeguard the protection of the rights, security 

and welfare of the subjects taking part in a clinical trial or research 

project. 

Among others tasks, this Committee assesses the protocol, the 

aptitude of the participating researchers, the adequacy of the 

center’s facilities, and ensures the use and quality of the Fact 

Sheet for Patients in order to secure the informed consent. 

The members of the ECCR in the Hospital Clínico Universitario 

of Valencia, dated December 31 st 2015, are the following: 

President: 

• Dr. Antonio Peláez Hernández. Head of the Allergy Unit 

Vice-president: 

• Dr. Marina Soro Domingo. Head of Section of the Anesthesiology 

and Reanimation Unit 

Secretary: 

• Dr. Cristina Gomis Gozalbo. Specialist of the Ginecology Department 

Substitute Secretary: 

• Ms. Begoña Hernández Genovés. Head of Supplies Service. 

Graduated in Law 

Members: 

• Dr. Manuel Alós Head of the Pharmacy Department 

• Ms. Mª Ángeles Mora Pla. Outpatient Nursing Supervisor 

• Dr. José Luis Trillo Mata. Pharmaceutical Primary Care 

• Dr. Mª José Fabiá Valls. Specialist of the Internal Medicine 

Department 

• Ms. Mª José Tarin Blasco. Graduated in Law 

• Prof. Esteban Morcillo Sánchez. Rector of the University of 

Valencia. Professor of Pharmacology 

• Dr. Julio Palmero Da Cruz. Head of the Radiology Department 

• Dr. Francisco Tosca Flores. Specialist doctor in Obstetrics and 

Gynecology Department 

• Dr. José Álvaro Bonet Pla. Hospital Chief Executive Officer 

• Ms. Cristina Pérez Moreno. Graduated in Law 

• Dr. Ricardo Ruiz Granell. Head of Section of Cardiostimulation 

Department 

• D. Diego V. Cano Blanquer. Primary Health Care 

Pharmaceutics. Graduated in Nursing 

• Prof. Miguel Mínguez Pérez. Head of Section of 

Gastroenterology Department 

• Dr. Francisco Dasí Fernández. Stabilized Miguel Servet 

Researcher 

• Prof. Andrés Cervantes Ruipérez. Head of Hematology and 

Oncology Department 

• Prof. Joaquín Ortega Serrano. Head of the General Surgery 

Department 

• Dr. Luis González Luján. Specialist doctor in Primary Health 

Care 

• Dr. Mª Jesús Puchades Montesa. Specialist doctor in 

Nephrology Department 

• Dr. Rafael Fernández-Delgado. Head of Section of Pediatrics 

Department 

• Dr. Jorge Navarro Pérez. Medical Director of the Hospital 

Clínico Universitario of Valencia 

2.2.2. Management structure 

In 2013 organization chart which it was approved two subdirectorates, 

economic and scientific, as well as a new area of 

innovation within the latter subdirectorate. 

The first subdirectorate is in charge of the administrative area, 

which deals with the financial and administrative matters as well 

as with human resource management. 

The second, in turn, is in charge of the scientific activity 

management and innovation. It is responsible for the integral 

scientific management that includes controlling and monitoring 

clinical trials and research projects, organizing courses, 

conferences and seminars, and several tasks related to general 

administration. Furthermore, it acts as an administrative 

support to the different scientific committees attached and 

to the Medical Research Central Unit. Finally, it comprises the 

new innovation area that is in charge of quality research and 

planning, innovation management, international programs and 

scientific and innovative culture promotion (UCCI). 

Administrative Area: 

• Financial-Administrative Director: Mr. Juan Luis Huguet 

• Financial-Administrative Subdirector: Ms. Consuelo López 

• Accounting and Invoicing Unit: Ms. Mª José Rosalén 

• Financial Unit: Ms. Consuelo López and Ms. Karen Iglesias 

• Invoicing and Receiving Unit: Ms. Vera Marín 

• Records Unit: Ms. Alicia Belenguer 

• Purchasing Unit: Ms. Isabel Gomis 

• Human Resources Unit: Ms. Ruth Cano and Ms. Vanessa Aznar 

17

2 


Board of Trustees 

Board of Governors 

President of the board: 

Regional Minister of Health 

President of the Governing board: 

Chief Executive Officer of the Hospital Clínico de Valencia 

External Scientific Committee 


General Secretary 

Internal Scientific Committee 

Goverment body 

18 

Financial-Administrative Director 

Scientific Director 

Advisory bodies 

Financial-Administrative Subdirector 

Scientific Subdirector 

Management areas 

Financial-Administrative Area 

Scientific Management Area 

Innovation Area 

Accounting and Invoicing Unit 

Clinical Trials Management Unit 

Quality and Planning Unit 

Human Resources Unit 

Clinical Trial Platform 

Innovation Management Unit 

Records Unit 

Project Management Unit 

International Projects Unit 

Financial Unit 

Invoicing and Receiving Unit 

Training Events Unit 

Scientific and Innovative Culture 

PromotionUnit (UCC+I)


2 

Scientific Management Area: 

• Scientific Subdirector: Dr. Marta Peiró 

• Projects Unit: Ms. Mayca Román and Ms. Noemí Hidalgo 

• Clinical Trials Management Unit: Ms. Dolores Iglesias and Mr. 

Roberto Martínez 

• Clinical Trials Platform: Ms. Ana Portolés, Ms. Laura Silla, Ms. 

Mireia Hernández 

Innovation Area: 

• Coordination: Mr. Enrique Cremades 

• Quality and Planning Unit: Mr. Rafael Barajas 

• Innovation Management Unit: Dr. Pedro Fernández 

• International projects: Ms. Ana Ferrer 

• OPESVAL: Dr. Ana Levin 

• Scientific and innovative culture promotion (UCCI): Mr. Justo 

Giner, Ms. Clara Badenas 

General Secretary: Ms. Maite Sáez 

2.2.3. Scientific structure 

2.2.3.1 Research areas, programs and platforms 

INCLIVA articulates its research as it follows: 

4 areas of research as a basis on which to articulate the 

scientific work of the groups: 

• Research area in oncology 

• Research area in cardiovascular 

• Research area in metabolism and organ damage 

• Research area in reproductive medicine 

7 scientific programs aimed at specific diseases from a translational 

perspective: 

• Program in overweight and cardiovascular and renal risk 

• Program in myocardial ischemic damage 

• Program in rare diseases 

• Program in neurological impairment 

• Translational oncology program 

• Program in reproductive medicine 

• Program in aging and its associated diseases 

3 platforms based on the provision of services to the whole institute: 

• Inflammation Platform 

• Metabolomics Platform 

• Genomics, Epigenomics and Transcriptomics Platform 

2.2.3.2 Core facilities 

In 2004 INCLIVA and the Central Service for Experimental Research 

Support (SCIE) at the University of Valencia signed a collaboration 

agreement. Whose aim is to boost cooperation between 

both institutions, with special emphasis in the execution of 

research projects and collective research activities. It allows the 

access, stay and use of the Central Unit for Medical Research facilities 

to Hospital Clínico Universitario of Valencia research staff. 

The Central Unit for Medical Research (UCIM) was created 

thanks to FEDER funds in 1990. From its inception, it has been 

granted with several infrastructure coming from both University 

of Valencia and INCLIVA funds, as well as from external funds 

(Comisión Interministerial de Ciencia y Tecnología, Generalitat 

Valenciana and Fondo de Investigaciones Sanitarias). 

In addition to these support units, INCLIVA has three additional 

platforms: the Biobank, the Cytogenetics lab and the Bioinformatics 

Unit. The latter was created as such in 2013, through a Carlos 

III Health Institute (Instituto de Salud Carlos III) grant program to 

improve infrastructure, the so called PROMIIS grant. 

These laboratories count on several research technicians and 

technical assistants who have been included in the organization 

structure thanks to diverse public grants or directly to the 

University’s budget. 

The research support platforms are: 

• Cell culture unit 

• Flow cytometric unit 

• Multigenic analysis unit 

• Confocal microscopy unit 

• Sequenom platform 

• Laboratory of molecular imaging and metabolomics 

• Animal housing and experimental operating theaters unit 

• Proteomics unit 

19

2 

INCLIVA 

Health Research Institute 

• Small animals PET/CT camera and laboratory for radioactive 

isotopes 

• Personal autonomy, dependence and severe mental disorders 

assessment unit 

INCLIVA Platforms 

20 

• Biobank 

• Bioinformatics unit 

• Genotyping and genetic diagnosis unit 

• Cytogenetics laboratory

INCLIVA 

global 

analysis 

3

INCLIVA Global analysis 

3 

3.1 Scientific production global analysis 

INCLIVA Health Research Institute continue in 2015 with the 

gradual increase in the number of scientific publications produced 

every year. Key indicators of research quality such as the 

publications of research results in international journals or the 

impact factor of these journals have improved. The number of 

indexed works in Medline database reached 635 in 2015. 

2.579 

Cumulative 

Impact 

Factor (IF) 

4,06 

Average 

Impact 

Factor 

635 

Publications 

80 

Publications 

with 

IF>7 

154 

First decile 

publications 

The following figures show the trend in the last years, with the number and quality of the published manuscripts expressed in terms 

of total and cumulative impact factor. 

25 

Number of publications 

Cumulative impact factor

3 

INCLIVA 

Global analysis 

This year the 73% of the papers published in indexed journals belong to the first and second quartiles of their corresponding 

thematic categories. The distribution by quartiles within their thematic categories is shown below: 

Quartile distribution 

26 

One of the key factors of a biomedical research institution is 

the development of scientific collaborations. The number of national 

and international collaborations, which lead to scientific 

publications, it is listed below. 

Another success factor is the leadership role in scientific 

publications. The graphic below shows the number of articles in 

which INCLIVA researcher signs as last author, corresponding author 

or both of them at the same time. 

Collaborations 

Leadership in scientific production


3 

3.2. Financial resources 

INCLIVA’s funding during 2015 totalled 7.685.591€. The funds raised from competitive sources in 2015 were higher than the average 

of recent years. 

27 

The found source in the indicated period is shown below.

3 

INCLIVA 


Evolution of the last five periods is shown in the chart below. 

The remaining income corresponds to private sources of funding, clinical trial revenues and grants among others. The graph below 

shows this distribution of the year 2015. 

28


3 

3.3 Cooperative research networks 

The Carlos III Health Institute (Instituto de Salud Carlos III) develops – through the General Subdirection of Networks and Centers 

for the Cooperative Research – the creation of stable research network structures such as RETICS (Thematic Networks of Cooperative 

Research) and CIBER (Network of Centres for Biomedical Research). INCLIVA participates in many of these research structures through 

its associated groups. 

The following table shows the participation in scientific networks according to the prioritized research area, the center and its 

principal investigator. 

Research Area INCLIVA PI Scientific Network Reference 

Carlos Hermenegildo Caudevilla Red RIC RD12/0042/0052 

Rafael Carmena Rodríguez CIBERdem CB07/08/0018 

29 

Cardiovascular 

Juan Sanchis Forés Red RIC RD12/0042/0010 

Francisco Javier Chorro Gascó Red RIC RD12/0042/0048 

Empar Lurbe i Ferrer CIBERobn CB06/03/0039 

Oncology 

Ana Lluch Hernández RETICC RD12/0036/0070 

Samuel Navarro Fos RETICC RD12/0036/0020 

Esteban Morcillo Sánchez CIBERes CB06/06/0027 

Federico V. Pallardó Catalayud CIBERrer CB06/07/0073 

José Viña Ribes Red RETICEF RD12/0043/0029 

Metabolism and 

Organ Damage 

Julio Sanjuán Arias CIBERsam CB07/09/006 

Juan Vicente Esplugues Mota CIBERehd CB06/04/0071 

Guillermo Sáez Tormo CIBERobn CB12/03/30016 

Rafael Tabarés Seisdedos CIBERsam CB07/09/0021 

Others Rafael Peris Bonet RETICC RD12/0036/0053

3 

INCLIVA 


30 

Besides research network structures, INCLIVA joined three 

additional research platforms promoted by Carlos III Health Institute 

which started their activities in 2014. These platforms are 

Biobank, Clinical research and trials and Innovation. 

Reference: PT13/0010/0004 

Title: Biobank Platform 

Principal Investigator: Josep Redón I Mas 

Funding Body: Instituto de Salud Carlos III 

Beneficiary Institution: Fundación Investigación Hospital Clínico 

Universitario de Valencia 

Duration: 2014 - 2016 

Total budget: 46.500€ 


Title: Clinical Research and Trials Platform 

Principal Investigator: Andrés Cervantes Ruipérez 




Duration: 2014 - 2016 



Title: Innovation Platform 

Principal Investigator: Josep Redón I Mas 




Duration: 2014 - 2016 


3.4 Knowledge transfer to the National 

Health System 

INCLIVA Health Research Institute is fully committed to 

innovation in health and to transfer knowledge to both the 

National Health System and the industrial sector in order to fulfil 

its organizational mission. 

3.4.1 Knowledge transfer to the Health System 

Clinical guidelines and consensus documents are one of the 

best indicators of transference from research to clinical practice 

improvement. The following table shows guidelines published 

in indexed journals in which authors attached to INCLIVA have 

participated. 

Clinical guidelines 

IF 

21 117,67 

1. Grupo de expertos del Grupo de Estudio sobre Alteraciones 

Metabólicas (GEAM), de la Secretaría del Plan Nacional 

sobre el Sida (SPNS) y del Grupo de Estudio de Sida 

(GeSIDA), Polo Rodríguez R, Galindo Puerto MJ, Dueñas C, 

Gómez Candela C, Estrada V, Villar NG, Locutura J, Mariño A, 

Pascua J, Palacios R, von Wichmman MÁ, Álvarez J, Asensi 

V, López Aldeguer J, Lozano F, Negredo E, Ortega E, Pedrol E, 

Gutiérrez F, Sanz Sanz J, Martínez Chamorro E. [Consensus 

statement on metabolic disorders and cardiovascular risks 

in patients with human immunodeficiency virus].Enferm 

Infecc Microbiol Clin. 2015 Jan ;33(1):40.e1-40.e16.IF: 1,881 

2. Panel of experts from the Metabolic Disorders Study Group 

(GEAM), National Aids Plan (SPNS), Aids Study Group 

(GeSIDA), Polo Rodríguez R, Galindo Puerto MJ, Dueñas C, 

Gómez Candela C, Estrada V, Villar NG, Locutura J, Mariño A, 

Pascua J, Palacios R, Von Wichmman MÁ, Álvarez J, Asensi 

V, López Aldeguer J, Lozano F, Negredo E, Ortega E, Pedrol 

E, Gutiérrez F, Sanz Sanz J, Martínez Chamorro E. Executive 

summary of the consensus document on metabolic disorders 

and cardiovascular risk in patients with HIV infection.Enferm 

Infecc Microbiol Clin. 2015 Jan; 33(1):41-7.IF: 1,881 

3. Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans 

P, Rutgers E, Zackrisson S, Cardoso F, ESMO Guidelines


3 

Committee. Primary breast cancer: ESMO Clinical Practice 

Guidelines for diagnosis, treatment and follow-up.Ann 

Oncol. 2015 Sep ;26 Suppl 5:v8-30.IF: 7,04 

4. Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, 

Hallek M, Buske C, ESMO Guidelines Committee. Chronic 

lymphocytic leukaemia: ESMO Clinical Practice Guidelines 

for diagnosis, treatment and follow-up.Ann Oncol. 2015 

Sep; 26 Suppl 5:v78-84.IF: 7,04 

5. Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin 

P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, 

Conroy T, Arnold D, ESMO Guidelines Committee. Cancer 

of the pancreas: ESMO Clinical Practice Guidelines for 

diagnosis, treatment and follow-up.Ann Oncol. 2015 Sep; 

26 Suppl 5:v56-68.IF: 7,04 

6. Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S, ESMO 

Guidelines Committee. Thymic epithelial tumours: ESMO 

Clinical Practice Guidelines for diagnosis, treatment and 

follow-up.Ann Oncol. 2015 Sep ;26 Suppl 5:v40-55.IF: 7,04 

7. Kloke M, Cherny N, ESMO Guidelines Committee. Treatment 

of dyspnoea in advanced cancer patients: ESMO Clinical 

Practice Guidelines.Ann Oncol. 2015 Sep ;26 Suppl 5:v169- 

73.IF: 7,04 

8. Sousa B, Furlanetto J, Hutka M, Gouveia P, Wuerstlein R, Mariz 

JM, Pinto D, Cardoso F, ESMO Guidelines Committee. Central 

venous access in oncology: ESMO Clinical Practice Guidelines. 

Ann Oncol. 2015 Sep ;26 Suppl 5:v152-68.IF: 7,04 

9. Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, 

Pentheroudakis G, ESMO Guidelines Committee. Cancers 

of unknown primary site: ESMO Clinical Practice Guidelines 

for diagnosis, treatment and follow-up.Ann Oncol. 2015 Sep 

;26 Suppl 5:v133-8.IF: 7,04 

10. Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis 

G, Keilholz U, ESMO Guidelines Committee. Cutaneous 

melanoma: ESMO Clinical Practice Guidelines for diagnosis, 

treatment and follow-up.Ann Oncol. 2015 Sep ;26 Suppl 

5:v126-32.IF: 7,04 

11. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, 

López-Guillermo A, Walewski J, André M, Johnson PW, 

Pfreundschuh M, Ladetto M, ESMO Guidelines Committee. 

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical 

Practice Guidelines for diagnosis, treatment and follow-up. 


12. d’Amore F, Gaulard P, Trümper L, Corradini P, Kim WS, Specht 

L, Bjerregaard Pedersen M, Ladetto M, ESMO Guidelines 

Committee. Peripheral T-cell lymphomas: ESMO Clinical 



13. Robak T, Matutes E, Catovsky D, Zinzani PL, Buske C, ESMO 

Guidelines Committee. Hairy cell leukaemia: ESMO Clinical 



14. Vannucchi AM, Barbui T, Cervantes F, Harrison C, 

Kiladjian JJ, Kröger N, Thiele J, Buske C, ESMO Guidelines 

Committee. Philadelphia chromosome-negative chronic 

myeloproliferative neoplasms: ESMO Clinical Practice 

Guidelines for diagnosis, treatment and follow-up.Ann 


15. Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters 

S, ESMO Guidelines Committee. Malignant pleural 

mesothelioma: ESMO Clinical Practice Guidelines for 

diagnosis, treatment and follow-up.Ann Oncol. 2015 Sep ;26 

Suppl 5:v31-9.IF: 7,04 

16. Parker C, Gillessen S, Heidenreich A, Horwich A, ESMO 

Guidelines Committee. Cancer of the prostate: ESMO 


follow-up.Ann Oncol. 2015 Sep ;26 Suppl 5:v69-77.IF: 7,04 

17. Peterson DE, Boers-Doets CB, Bensadoun RJ, Herrstedt J, 

ESMO Guidelines Committee. Management of oral and 

gastrointestinal mucosal injury: ESMO Clinical Practice 

Guidelines for diagnosis, treatment, and follow-up.Ann 


18. Llort G, Chirivella I, Morales R, Serrano R, Sanchez AB, 

Teulé A, Lastra E, Brunet J, Balmaña J, Graña B, SEOM 

Hereditary Cancer Working Group. SEOM clinical guidelines 

in Hereditary Breast and ovarian cancer.Clin Transl Oncol. 

2015 Dec ;17(12):956-61.IF: 2,077 

19. Guillén-Ponce C, Serrano R, Sánchez-Heras AB, Teulé A, 

Chirivella I, Martín T, Martínez E, Morales R, Robles L. 

Clinical guideline seom: hereditary colorectal cancer.Clin 

Transl Oncol. 2015 Dec ;17(12):962-71.IF: 2,077 

20. García-Saenz JA, Bermejo B, Estevez LG, Palomo AG, 

González-Farre X, Margeli M, Pernas S, Servitja S, Rodriguez 

CA, Ciruelos E. SEOM clinical guidelines in early-stage breast 

cancer 2015.Clin Transl Oncol. 2015 Oct 26 ;.IF: 2,077 

21. García-Alfonso P, García-Foncillas J, Salazar R, Pérez-Segura 

P, García-Carbonero R, Musulén-Palet E, Cuatrecasas M, 

31

3 

INCLIVA 


32 

Landolfi S, Ramón Y Cajal S, Navarro S, Spanish Society of 

Pathology, Spanish Society of Medical Oncology. Updated 

guidelines for biomarker testing in colorectal carcinoma: a 

national consensus of the Spanish Society of Pathology and 

the Spanish Society of Medical Oncology.Clin Transl Oncol. 

2015 Apr ;17(4):264-73.IF: 2,077 

Consensus documents 

IF 

5 18,50 

1. Cantón R, Máiz L, Escribano A, Olveira C, Oliver A, Asensio 

O, Gartner S, Roma E, Quintana-Gallego E, Salcedo A, Girón 

R, Barrio MI, Pastor MD, Prados C, Martínez-Martínez MT, 

Barberán J, Castón JJ, Martínez-Martínez L, Poveda JL, 

Vázquez C, de Gracia J, Solé A, en representación del Grupo 

Español de Consenso del Tratamiento Antimicrobiano en el 

Paciente con Fibrosis Quística. Spanish consensus on the 

prevention and treatment of Pseudomonas aeruginosa 

bronchial infections in cystic fibrosis patients.Arch 

Bronconeumol. 2015 Mar ;51(3):140-50.IF: 1,816 

2. Ascaso JF, Mata P, Arbona C, Civeira F, Valdivielso P, Masana 

L. [Homozygous familial hypercholesterolaemia: Spanish 

adaptation of the position paper from the Consensus 

Panel on Familial Hypercholesterolaemia of the European 

Atherosclerosis Society. Consensus document of the 

Spanish Society of Arteriosclerosis (SEA) and Familial 

Hypercholesterolaemia Foundation (FHF)].Clin Investig 

Arterioscler. 2015 Mar-Apr ;27(2):80-96.IF: 0 

3. Mahfoud F, Böhm M, Azizi M, Pathak A, Durand Zaleski 

I, Ewen S, Tsioufis K, Andersson B, Blankestijn PJ, Burnier 

M, Chatellier G, Gafoor S, Grassi G, Joner M, Kjeldsen SE, 

Lüscher TF, Lobo MD, Lotan C, Parati G, Redon J, Ruilope L, 

Sudano I, Ukena C, van Leeuwen E, Volpe M, Windecker S, 

Witkowski A, Wijns W, Zeller T, Schmieder RE. Proceedings 

from the European clinical consensus conference for renal 

denervation: considerations on future clinical trial design. 

Eur Heart J. 2015 Sep 1 ;36(33):2219-27.IF: 14,723 

4. Moreno-Pérez D, Andrés Martín A, Tagarro García A, Escribano 

Montaner A, Figuerola Mulet J, García García JJ, Moreno- 

Galdó A, Rodrigo Gonzalo de Lliria C, Saavedra Lozano J. 

[Community acquired pneumonia in children: Treatment of 

complicated cases and risk patients. Consensus statement by 

the Spanish Society of Paediatric Infectious Diseases (SEIP) 

and the Spanish Society of Paediatric Chest Diseases (SENP)]. 

An Pediatr (Barc). 2015 Sep ;83(3):217.e1-11.IF: 0,722 

5. Llau JV, Acosta FJ, Escolar G, Fernández-Mondéjar E, Guasch 

E, Marco P, Paniagua P, Páramo JA, Quintana M, Torrabadella 

P. Multidisciplinary consensus document on the management 

of massive haemorrhage (HEMOMAS document).Med 

Intensiva. 2015 Nov ;39(8):483-504.IF: 1,24 

In addition to those published in indexed journals, INCLIVA has 

generated other guidelines promoted by different agencies. The 

following list collects these practice guidelines and the researcher 

involved in its preparation: 

1. María Ferrer Civeira, Juan Pedro-Botet, Xavier Pintó, Manuel 

Zúñiga, Alipio Mangas, Antonio Hernandez-Mijares, Emili 

Corbella, and Jesus Millan Nuñez-Cortes. Atherogenic 

Ratios in Patients with Recurrent Acute Coronary Syndrome 

and Receiving Statin Therapy: Clinical Usefullness as 

Cardiovascular Predictors. Journal Clinical & Experimental 

Cardiology Vol.6. Núm: 2. Pág: 358 – 362. 

2. Millán Núñez-Cortés J; Mantilla Morató T; Toro R, Millán 

Pérez J; Mangas Rojas A; Comité Científico del Registro de 

Hipertrigliceridemias de la Sociedad Española de Arteriosclerosis. 

Síndrome metabólico en pacientes con fenotipo 

clínico de “cintura hipertrigliceridémica”. Nutrición Hospitalaria 

Integrante del Registro de Hipertrigigeridemia de la SE 

de Arteriosclerosis. Vol: 32. Núm: 3 .Pág: 1145-1152. 

3. Villar del Moral JM, Soria Aledo V, Colina Alonso A, Flores 

Pastor B, Gutiérrez Rodríguez MT, Ortega Serrano J, Parra 

Hidalgo P, Ros López S. Vía Clínica para Tiroidectomía. 

Asociación Española de Cirujanos. Cir Esp. 2015 May; 

93(5):283-99. 

4. Navarro S, Musulén-Palet E, Cuatrecasas M, Landolfi S, Ramón 

Y Cajal S, García-Carbonero R, García-Foncillas J, Pérez- 

Segura P, Salazar R, García-Alfonso P. Actualización de la recomendación 

para la determinación de biomarcadores en 

el carcinoma colorrectal. Consenso Nacional de la Sociedad 

Española de Anatomía Patológica y de la Sociedad Española 

de Oncología Médica. Sociedad Española de Anatomía Patológica 

y de la Sociedad Española de Oncología Médica. 

Revista Española de Patología. Vol. 294; Pág: 11.


3 

3.4.2 Knowledge transfer to industry 

One of the foundational missions of INCLIVA is the translation 

of the research carried out to the society. Giving a medical need, 

researchers and clinicians use their knowledge to make ideas 

that can be taken in products or processes that overcome this 

existing problem through research and development. 

INCLIVA Innovation Unit gives support in this process, detecting 

ideas, assessing them and paving the way for their transformation 

in products or services that can be transferred to the society. 

This track is known as the innovation funnel since it starts with 

a broad range of ideas and gradually refines and selects from 

among them, creating a handful of formal development projects 

that can be pushed to completion and transfer. 

Plot of the INCLIVA innovation funnel in 2015 (please, note the 

attached plot is a suggestion) 

33 

Detection: 35 Assessment: 7 Development: 4 Transfer: 5 Market: 3 

Organizational ITC Device Imaging Pharma Bio

3 

INCLIVA 


3.4.3 Patents 

34 

The knowledge protection is the first step to move scientific 

findings and ideas from researchers to the industry and the most 

common way to protect technologies that are new, inventive and 

have industrial application are patents. Research institutions can 

exploit the patents they hold by licensing them to companies. 

At the moment, the following patent applications have been requested 

and/or granted: 

Granted patents 

Title: Ex-vivo method for the early diagnosis of minimal hepatic 

encephalopathy by means of the determination of 3-nitrotyrosine 

in serum 

Inventors: Vicente Felipo Orts; Omar Caulí; Carmina Montoliu 

Félix 

Applicants: INCLIVA, CIPF 

Publication number: EP20110806343 

Priority Date: 2010/07/12 

Territory: Europe (registered in Spain, United Kingdom, France, 

Germany and Italy). 

Title: Maxillomandibular prosthesis and production method 

Inventors: M. Puche, V. Petrovic, JA. Gómez, JR. Blasco, L. Portolés, 

J. Ferrís, C. Atienza. 

Applicant: INCLIVA, Instituto de Biomecánica de Valencia y Asociación 

de Investigación dela Industria Metal Mecánica, Afines y 

Conexas. 

Publication number: ES20130030734 


Territory: Spain 

Patent application extensions 

Title: Compound for treatment of myotonic dystrophy type 2 

Inventors: R. Artero, A. Bargiela, B. Llamusí, JM. Fernández Costa, 

M. Pérez 

Applicant: Universidad de Valencia 

Application number: PCT/EP2015/080508 


Territory: PCT 

Title: Early detection of preeclampsia 

Inventors: C. Simón C, T. Garrido, A. Pellicer 

Applicant: IVI 

Application number: WO2015166353 


Territory: PCT 

Software 

Title: HADA: diagnostic tool for angina pectoris. 

Authors: Joan Vila Francés, Emilio Soria, Antonio Serrano López 

(Universitat de Valencia), Juan Sanchís Forés and Julio Núñez Villota 

(INCLIVA). 

Register date: 19/01/2015. 

Title: ANGIOPATHSW software for morphometric detection and 

characterization of blood and lymphatic vessels. 

Authors: María Gloria Bueno García, D. Óscar Déniz Suárez (Universidad 

de Castilla la Mancha) María Rosa Noguera Salvá, Irene 

Tadeo Cervera (INCLIVA) and Marcial García Rojo (Servicio Andaluz 

de Salud) 

Register date: 02/18/2015 

Title: Maxillomandibular prosthesis and method of manufacture 

Inventors: M. Puche, V. Petrovic, JA. Gomez, JR. Blasco, L. Portolés, 

J. Ferrís, C. Atienza 

Applicant: INCLIVA, Instituto de Biomecánica de Valencia y Asociación 

de Investigación dela Industria Metal Mecánica, Afines y 

Conexas. 

Application number: EP14800737.0 


Territory: Europe (EPC)

Scientific 

activity 

4

Scientific activity 

4 

4.1. Research areas 

INCLIVA Health Research Institute has four research areas to organize its scientific activity. Despite their independence, there have 

a common objective: meeting health needs and improving R&D&i system. 

Their main aim is to establish a common reference framework to promote collaboration between the attached researchers. Each of 

the lines counts on the participation of one or several advisers from the External Scientific Committee, and these lines are led by the 

following coordinators: 

Cardiovascular Area. 

• Coordinator: Dr. Francisco Javier Chorro Gascó 

• Mission: to contribute to the study of different aspects of cardiovascular disease (CVD) from its origins to its consequences 

Oncology Area. 

• Coordinator: Dr. Andrés Cervantes Ruipérez 

• Mission: to contribute to the study of different aspects of oncological diseases, at the stage of diagnosis and molecular characterization 

and selection of specific molecular targets of therapeutic interest 

Metabolism and Organic Damage Area. 

• Coordinator: Dr. José Viña Ribes 

• Mission: to contribute to the study of the etiology, pathophysiology and diagnosis mechanisms or treatment of various metabolic 

diseases; or those that generate organ damage as a fundamental link of its trigger action 

39 

Reproductive Medicine Area. 

• Coordinator: Dr. Carlos Simón Vallés 

• Mission: to advance in knowledge of human reproduction for translational application, improving the efficiency of assisted reproduction 

treatment and reducing adverse effects

4 

Scientific 

activity 

Scientific production analysis by research area 

To give an overview of the scientific production per area it shows several indicators. 

The following figure shows the main key performance indicators of INCLIVA’s four research areas and other scientific contributions 

from the Hospital Clínico of Valencia. 

Number of articles 

Impact Factor 

40 

Since there are some scientific articles which are shared by two or more areas, it is worth mentioning that the sum of the number 

of publications by area exceeds INCLIVA’s total scientific output. 

Additionally, the next table shows scientific publications distribution by area in terms of number of articles and impact factor. 

Number of articles 


Metabolism 

Oncology 

Reproductive medicine 

Hospital divisions 

IF 


Metabolism 

Oncology 

Reproductive medicine 

Hospital divisions


4 

4.1.1 Cardiovascular Area 

Research Group on Cardiometabolic Risk 42 

Genotyping and Genetic Diagnosis Unit (UGDG) 46 

Research Group on Cardiac Experimental Electrophysiology 50 

Research Group on Endothelial Cells (LINCE) 55 

Research Group on Clinical Cardiology 58 

Research Group on the Study of Cardiovascular Risk in Children and Adolescents 62 

Cardiometabolic Research Group on Primary Care 65 

Research Group on the Study of Cardiometabolic and Renal Risk 68 

Research Group on Vascular Function 73 

Research Group on Pedriatric Nutrition 75 

Group on Translational Research in Ischemic Heart Disease 78 

41 

Impact 

Factor (IF) 

Total: 464,60 

Average: 3,83 

121 

Publications 

18 

International 

collaborations 

JCR: 

15 in D1 

59 in Q1 

22 in Q2 

Author: 

49 first author 

56 last author 

47 corresponding 

author

4 

Scientific 

activity 

Research Group on Cardiometabolic Risk. 

Consolidated group 

42 

“Tenemos mucho que hacer contra esta enfermedad y todos tenemos la posibilidad de cambiar 

hábitos de vida para prevenir el desarrollo de la diabetes” 

Dr. Juan Ascaso. Elperiodic.com 13/11/2015 

Team involved in 

Group members 

Principal investigator 

Juan Francisco Ascaso Gimilio. 

Hospital. University 

H Index: 25 

Collaborating researchers 

Rafael Carmena Rodríguez. University. 

José Tomás Real Collado. Hospital. University 

José Francisco Martínez Valls. Hospital. University 

Mª Antonia Priego Serrano. Hospital. University 

Miguel Civera Andrés. Hospital. 

Marta Peiró Signes. INCLIVA. CIBERdem 

Esther Benito Casado. Hospital. CIBERdem 

Francisco Javier Ampudia Blasco. Hospital 

PhD students 

Griselda de Marco Solar. INCLIVA 

Technicians 

Cristina Pérez Soriano. INCLIVA 

Ana Albert Viguer. INCLIVA 

Emerging researchers 

Sergio Martínez Hervás. Hospital. University 

Ana Bárbara García García. CIBERdem


4 

Strategic aims 

• Study of autosomal dominant hypercholesterolemias and 

familial combined hyperlipidemia. An analysis of inflammation 

markers has been performed, as well as a comprehensive 

biochemical profile and a collection of clinical and 

genetic characteristics 

• Effect of postprandial lipidemia on cardiovascular system, 

mainly on lipid profile, inflammation markers and oxidative 

stress and the response of circulanting cells to stress 

caused by lipidemia. Studies of oral lipid overload in obese 

diabetic patients have been carried out to study cell response 

to fatty acid delivery. Expression of all genes present 

in the lymphomonocytes of these patients has been examined 

comparing with control subjects and the results are 

currently being analyzed 

• Study of insulin resistance and diabetes. The aim is to early 

detect insulin-resistance, identifying early detection markers 

and risk and inflammatory factors linked to this condition 

• Diagnosis and treatment of diabetic foot. Confirmation of 

the connection between plasma homocysteine levels and 

risk for diabetic foot ulceration 

• Genetic factors involved in the regulation of Body Mass Index 

(BMI), waist circumference, obesity development and 

central obesity. Study of oxidative stress and other aspects 

of metabolism as factors able to modulate development of 

obesity. Levels of certain free radicals and oxidative stress 

regulate metabolism and energy homeostasis 

Main lines of research 

• Genetic diagnosis of primary hyperlipidemias and cardiovascular 

risk 

• Combination of primary hyperlipidemias with insulin resistance 

and diabetes mellitus 

• Postprandial lipidemia and atherosclerosis in states of insulin 

resistance 

• Insulin resistance, inflammation and oxidative stress 

• Diagnosis, prevention and treatment of diabetic foot 

• Genetic factors involved in the regulation of Body Mass 

Index and abdominal obesity 

Emerging researcher 

Sergio Martínez Hervás 

The line of research is based on 

cardiovascular risk, essentially on 

insulin resistance and diabetes, 

familial combined hyperlipidemia, 

inflammation, vitamin D, and atherosclerosis, 

just like new markers of 

cardiovascular risk. 


Ana Bárbara García García 

The research is mainly focused 

on DM2, one of the most frequent 

diseases of Western societies. On 

this subject, the work has several 

lines: an SREBF2 variant and its 

possible association with DM2, 

gene expression alterations in postprandial lipemia after an oral 

fat challenge in obese and diabetic populations, and identification 

of markers of β-cell destruction using circulating DNA. 

On the other hand, other line of research is the identification 

of new genes responsible for abetalipoproteinemia using exome 

sequencing. 

• PUBLICATIONS 

Number of articles IF Average IF 

12 49,202 4,10 

National 


Original articles 

International 


Corresponding 

author 

5 2 6 

1. Masana L, Cabré A, Heras M, Amigó N, Correig X, Martínez- 

Hervás S, Real JT, Ascaso JF, Quesada H, Julve J, Palomer 

X, Vázquez-Carrera M, Girona J, Plana N, Blanco-Vaca F. Remarkable 

quantitative and qualitative differences in HDL after 

niacin or fenofibrate therapy in type 2 diabetic patients. 

Atherosclerosis. 2015 Feb ;238(2):213-9.IF: 3,994 

2. Martínez-Barquero V, de Marco G, Martínez-Hervas S, Rentero 

P, Galán-Chilet I, Blesa S, Morchon D, Morcillo S, Rojo 

G, Ascaso JF, Real JT, Martín-Escudero JC, Chaves FJ. Polymorphisms 

in endothelin system genes, arsenic levels and 

obesity risk.PLoS One. 2015 ;10(3):e0118471.IF: 3,234 

43

4 

Scientific 

activity 

44 









4. Amor AJ, Masana L, Soriguer F, Goday A, Calle-Pascual A, 

Gaztambide S, Rojo-Martínez G, Valdés S, Gomis R, Ortega 

E, Di@bet.es study group. Estimating Cardiovascular Risk 

in Spain by the European Guidelines on Cardiovascular 

Disease Prevention in Clinical Practice.Rev Esp Cardiol (Engl 

Ed). 2015 May ;68(5):417-25.IF: 3,792 

5. Martínez-Hervas S, Martínez-Barquero V, Nuñez Savall 

E, Lendínez V, Olivares L, Benito E, Real JT, Chaves FJ, 

Ascaso JF. [Plasma IL-18 levels are related to insulin and 

are modulated by IL-18 gene polymorphisms].Clin Investig 

Arterioscler. 2015 Nov-Dec ;27(6):265-71.IF: 0 

6. Mendez MM, Folgado J, Tormo C, Artero A, Ascaso M, 

Martínez-Hervás S, Chaves FJ, Ascaso JF, Real JT. Altered 

glutathione system is associated with the presence of 

distal symmetric peripheral polyneuropathy in type 2 

diabetic subjects.J Diabetes Complications. 2015 Sep-Oct 

;29(7):923-7.IF: 3,005 

7. Lahoz C, Mostaza JM, Pintó X, de la Cruz JJ, Banegas JR, 

Pedro-Botet J, grupo de investigadores EDICONDIS- 

ULISEA. [LDL-cholesterol control in patients with genetic 

dyslipidemia followed up by Lipid and Vascular Risk Units 

of the Spanish Society of Arteriosclerosis].Clin Investig 

Arterioscler. 2015 Jan-Feb ;27(1):1-8.IF: 0 

8. Onengut-Gumuscu S, Chen WM, Burren O, Cooper NJ, 

Quinlan AR, Mychaleckyj JC, Farber E, Bonnie JK, Szpak 

M, Schofield E, Achuthan P, Guo H, Fortune MD, Stevens 

H, Walker NM, Ward LD, Kundaje A, Kellis M, Daly MJ, 

Barrett JC, Cooper JD, Deloukas P, Type 1 Diabetes Genetics 

Consortium, Todd JA, Wallace C, Concannon P, Rich SS. Fine 

mapping of type 1 diabetes susceptibility loci and evidence 

for colocalization of causal variants with lymphoid gene 

enhancers.Nat Genet. 2015 Apr ;47(4):381-6.IF: 29,352 

9. Ampudia-Blasco FJ, Benhamou PY, Charpentier G, Consoli 

A, Diamant M, Gallwitz B, Khunti K, Mathieu C, Ridderstrale 

M, Seufert J, Tack C, Vilsbøll T, Phan TM, Stoevelaar H. A 

decision support tool for appropriate glucose-lowering 

therapy in patients with type 2 diabetes.Diabetes Technol 

Ther. 2015 Mar ;17(3):194-202.IF: 2,106 

10. Andrés-Blasco I, Herrero-Cervera A, Vinué Á, Martínez- 

Hervás S, Piqueras L, Sanz MJ, Burks DJ, González-Navarro 

H. Hepatic lipase deficiency produces glucose intolerance, 

inflammation and hepatic steatosis.J Endocrinol. 2015 Dec 

;227(3):179-91.IF: 3,718 

11. Ascaso JF, Carmena R. [Importance of dyslipidaemia in 

cardiovascular disease: A point of view]. Clin Investig 


Editorial 

12. Ascaso JF. [Recommendations guide for diagnosis and 

treatment of abdominal aortic aneurysm].Clin Investig Arterioscler. 

2015 May-Jun ;27(3):136-7.IF: 0 

• THESIS 

Thesis title: Sobrecarga oral con grasa insaturada y estrés 

oxidativo en sujetos con obesidad abdominal 

Doctoral candidate: María Inmaculada Navarro Hidalgo 

Director(s): Sergio Martínez Hervás, Rafael Carmena Rodríguez 

Date of the defense: 16/10/2015 

Grade: Sobresaliente “cum laude” 

Thesis title: Identificación de variantes exómicas en diabetes tipo 2 

Doctoral candidate: Vanessa Martínez Barquero 

Director(s): Juan F. Ascaso Gimilio, Mª Antonia Noguera 

Romero, Felipe Javier Chaves Martínez 



Thesis title: Análisis de la relación del genotipado y 

marcadores de estrés oxidativo con la presencia y grado de 

vasculopatía periférica en pacientes con diabetes tipo 2 

Doctoral candidate: José Francisco Folgado Montesinos 

Director(s): José Tomás Real Collado, Juan F. Ascaso Gimilio 



Thesis title: Estudio del estrés oxidativo en la polineuropatía 

diabética 

Doctoral candidate: Mercedes Molina Méndez 



Grade: Sobresaliente “cum laude”


4 

Thesis title: Efecto del género y parámetros antropométricos 

en marcadores de estrés oxidativo e inflamación en situación 

postprandial 

Doctoral candidate: Jordi Ferri Císcar 




• RESEARCH PROJECTS AND GRANTS FOR 

RESEARCH 

Reference: PROMETEOII/2014/002 

Title: Estudio de la relación del patrón de metilación del 

ADN de adipocitos con la diabetes y su remisión tras by-pass 

gastointestinal en sujetos con obesidad grave-mórbida 

Principal Investigator: Rafael Carmena Rodríguez 

Funding Body: Conselleria de Educación, Cultura y Deporte 

Beneficiary Institution: Fundación Investigación Hospital 

Clínico Universitario de Valencia 

Duration: 2014-2018 

Total Budget: 48.000€ 




Reference: SAF2014-57845-R 

Title: Modulación inmunofarmacológica de la inflamación 

sistémica asociada a desórdenes metabólicos. Búsqueda de 

nuevas dianas terapéuticas y síntesis de fármacos novedosos 

Principal Investigator: Juan F. Ascaso Gimilio, M. J. Sanz 

Funding Body: Ministerio de Economía y Competitividad 





45 

Reference: ISIC/2012/018 

Title: Instituto Superior de Investigaciones Científicas INCLIVA 







Reference: CB07/08/0018 

Title: CIBER de Diabetes y Enfermedades Metabólicas 

Asociadas (CIBERdem) 






Reference: PI12/01978 

Title: Association of insulin resistance and oral fat load test 

with DNA methylation of adipocytes and hepatocytes in 

subjects with morbid obesity 

Principal Investigator: José Tomás Real Collado 


Beneficiary Institution: Fundación Investigación Hospital

4 

Scientific 

activity 

Research Group of the Genotyping and Genetic Diagnosis Unit (UGDG) 


46 

Group members 


Felipe Javier Chaves Martínez. 

INCLIVA 

H Index: 19 


Alba Sanchís Juan. INCLIVA 

Jesús Rodríguez Díaz. University. 

José Miguel Juanes Tébar. INCLIVA 

PhD students 

Pilar Rentero Garrido. INCLIVA 

Inmaculada Galán Chilet. INCLIVA 

Daniel Pérez Gil. INCLIVA 

Verónica Lendínez Tortajada. INCLIVA 

Post-doctoral researchers 

Raquel Cortés Vergaz. INCLIVA 

Technicians 

Sebastián Blesa Lujan. INCLIVA 

Verónica González Albert. INCLIVA 

Victoria Adam Felici. INCLIVA 

Azahara Mª Fuentes Trillo. INCLIVA


4 


• Detection of more polymorphisms with 250 functional 

and infrequent strong effect on the population potentially 

related to the development of type 2 diabetes 

• Identification of different genes and polymorphisms involved 

in the development of obesity through different metabolic 

and functional pathways 

• To determine the changes in gene expression in different 

groups of patients after oral lipid overload 

• To determine the relationship between different genes, 

essential metals and pollutants in relation to diseases with 

high cardiovascular risk 

• To determine the relationship between different polymorphisms 

in genes involved in the regulation of oxidative 

stress and the risk of breast cancer 

• To improve methodology for different genetic studies 

• To develop procedures for obtaining libraries 


• To detect genetic changes (mutations or polymorphisms) 

involved in the development of complex diseases with 

high cardiovascular risk, particularly related to oxidative 

stress, lipid metabolism, genes, etc. 

• To study genetic variants in the exome in relation to the 

development of type 2 diabetes and its consequences 

• To study the importance of environmental pollutants in 

the development of human diseases, mainly about heavy 

metals in relation to complex diseases with high cardiovascular 

risk 



15 51,60 3,44 

National 



International 


Corresponding 

author 

8 - 9 

1. Suárez-Varela MM, Llopis-González A, González Albert V, 

López-Izquierdo R, González-Manzano I, Chaves J, Biosca 

VH, Martín-Escudero JC. Zinc and smoking habits in the 

setting of hypertension in a Spanish populations.Hypertens 

Res. 2015 Feb ;38(2):149-54.IF: 2,658 

2. Galán-Chilet I, Guallar E, Martín-Escudero JC, De Marco G, 

Dominguez-Lucas A, González-Manzano I, López-Izquierdo 

R, Redon J, Chaves FJ, Téllez-Plaza M. Do genes modify the 

association of selenium and lipid levels?Antioxid Redox 

Signal. 2015 May 20 ;22(15):1352-62.IF: 7,407 

3. Ivorra C, Fraga MF, Bayón GF, Fernández AF, García-Vicent 

C, Chaves F, Redon J, Lurbe E. DNA methylation patterns in 

newborns exposed to tobacco in utero.J Transl Med. 2015 

Jan 27 ;13(1):25.IF: 3,93 

4. Martínez-Barquero V, de Marco G, Martínez-Hervas S, Rentero 

P, Galán-Chilet I, Blesa S, Morchon D, Morcillo S, Rojo 

G, Ascaso JF, Real JT, Martín-Escudero JC, Chaves FJ. Polymorphisms 

in endothelin system genes, arsenic levels and 

obesity risk.PLoS One. 2015 ;10(3):e0118471.IF: 3,234 

5. Morales-Suárez-Varela M, Llopis-González A, González- 

Albert V, López-Izquierdo R, González-Manzano I, Chaves 

J, Huerta-Biosca V, Martín-Escudero JC. Correlation of zinc 

with oxidative stress biomarkers.Int J Environ Res Public 

Health. 2015 Mar 12 ;12(3):3060-76.IF: 0 

6. Llopis-González A, Rubio-López N, Pineda-Alonso M, Martín- 

Escudero JC, Chaves FJ, Redondo M, Morales-Suárez-Varela 

M. Hypertension and the fat-soluble vitamins A, D and E.Int J 

Environ Res Public Health. 2015 Mar 4 ;12(3):2793-809.IF: 0 

7. Alonso R, Salavert F, García-García F, Carbonell-Caballero 

J, Bleda M, García-Alonso L, Sanchís-Juan A, Perez-Gil D, 

Marin-García P, Sanchez R, Cubuk C, Hidalgo MR, Amadoz A, 

Hernansaiz-Ballesteros RD, Alemán A, Tarraga J, Montaner 

D, Medina I, Dopazo J. Babelomics 5.0: functional interpretation 

for new generations of genomic data.Nucleic Acids 

Res. 2015 Jul 1 ;43(W1):W117-21.IF: 9,112 

47

4 

Scientific 

activity 

48 

8. Martínez-Hervas S, Martínez-Barquero V, Nuñez Savall 

E, Lendínez V, Olivares L, Benito E, Real JT, Chaves FJ, 

Ascaso JF. [Plasma IL-18 levels are related to insulin and 

are modulated by IL-18 gene polymorphisms].Clin Investig 


9. Mendez MM, Folgado J, Tormo C, Artero A, Ascaso M, 

Martínez-Hervás S, Chaves FJ, Ascaso JF, Real JT. Altered 

glutathione system is associated with the presence of distal 

symmetric peripheral polyneuropathy in type 2 diabetic 

subjects.J Diabetes Complications. 2015 Sep-Oct ;29(7):923- 

7.IF: 3,005 

10. Marrachelli V, Monleón D, Morales JM, Rentero P, 

Martínez F, Chaves FJ, Martín-Escudero JC, Redon J. 6C.04: 

INTEGRATED SNP ANALYSIS AND METABOLOMIC PROFILES 

OF METABOLIC SYNDROME.J Hypertens. 2015 Jun ;33 Suppl 

1:e80.IF: 4,72 

11. Mansego ML, De Marco G, Ivorra C, López-Izquierdo R, 

Morcillo S, Rojo-Martínez G, González-Albert V, Martínez 

F, Soriguer F, Martín-Escudero JC, Redon J, Chaves FJ. The 

nutrigenetic influence of the interaction between dietary 

vitamin E and TXN and COMT gene polymorphisms on waist 

circumference: a case control study.J Transl Med. 2015 Sep 

2 ;13:286.IF: 3,93 

12. Mar Rodríguez M, Pérez D, Javier Chaves F, Esteve E, Marin- 

García P, Xifra G, Vendrell J, Jové M, Pamplona R, Ricart W, 

Portero-Otin M, Chacón MR, Fernández Real JM. Obesity 

changes the human gut mycobiome.Sci Rep. 2015 Oct 12 

;5:14600.IF: 5,578 

13. Perez-Hernandez J, Forner MJ, Pinto C, Chaves FJ, Cortes R, 

Redon J. Increased Urinary Exosomal MicroRNAs in Patients 

with Systemic Lupus Erythematosus.PLoS One. 2015 

;10(9):e0138618.IF: 3,234 

14. Mora M, Adam V, Palomera E, Blesa S, Díaz G, Buquet X, 

Serra-Prat M, Martín-Escudero JC, Palanca A, Chaves JF, 

Puig-Domingo M, Mataró Aging Study Group. Ghrelin Gene 

Variants Influence on Metabolic Syndrome Components in 

Aged Spanish Population.PLoS One. 2015 ;10(9):e0136931. 

IF: 3,234 

Review 

15. Perez-Hernandez J, Cortes R. Extracellular Vesicles as 

Biomarkers of Systemic Lupus Erythematosus.Dis Markers. 

2015 ;2015:613536.IF: 1,562 


RESEARCH 


Title: Podocitos y sus componentes como biomarcadores de 

lesión en hipertensión arterial, diabetes y obesidad 

Principal Investigator: Josep Redón i Mas (Pablo Marin, 

Raquel Cortés, Verónica González and Pilar Rentero as 

collaborating researchers) 



Clínico Universitario Valencia 




Title: Association of insulin resistance and oral fat load test 

with DNA methylation of adipocytes and hepatocytes in 

subjects with morbid obesity 

Principal Investigator: José Tomás Real Collado (Verónica 

González and Victoria Adam as collaborating researchers) 







Title: Identification of exome sequence changes, methylation 

and hydroxymethylation associated in the development of 

type 2 diabetes principal. 

Principal Investigator: Felipe Javier Chaves Martínez 






• THESIS 

Thesis title: Identificación de variantes exómicas en diabetes 

tipo 2 

Doctoral candidate: Vanessa Martínez Barquero 

Director(s): Juan F. Ascaso Gimilio, Mª Antonia Noguera 

Romero, Felipe Javier Chaves Martínez 




4 

Thesis title: Identificación de los perfiles de expresión en el 

adenocarcinoma ductal de páncreas. Implicaciones clínicas. 

Doctoral candidate: María Del Carmen Gómez Mateo 

Director(s): Felipe Javier Chaves Martínez, Antonio Ferrández 

Izquierdo, Luis Sabater Ortí 



49

4 

Scientific 

activity 

Research Group on Cardiac Experimental Electrophysiology 


50 

Group members 



Francisco Javier Chorro Gascó. 


H Index: 22 


Luis Such Belenguer. University. 

Antonio M. Alberola Aguilar. University 

Luis Such Miquel. University 

Isabel Trapero Gimeno. University 

Luis Mainar Latorre. Hospital 

Joaquín Cánoves Femenía. Hospital 

Laura López Bueno. Hospital. University 

Manuel Zarzoso Muñoz. University 

Óscar Julián Arias Mutis. INCLIVA 

PhD students 

Laia Brines Ferrando. INCLIVA 

Irene del Canto Serrano. INCLIVA 

Carlos Soler López. University


4 


• Publication of the results obtained by modifying the electrophysiological 

effects of myocardial stretching by EIPA, losartan, 

BQ-123, and ranolazine 

• Continuation of the experimental series to analyze the 

effects of JTV519, KN-93, Carvedilol and analogues 

• Continuation of the analysis of the effects of modifications 

of the basic electrophysiological properties on the processes 

involved in the initiation, perpetuation and the cessation of 

ventricular fibrillation 

• It has continued the analysis of the electrophysiological 

effects of chronic physical exercise and its protective effect 

against arrhythmias, the influence of the cardiac nervous 

system and mitochondrial oxidative stress and the involvement 

of the IKATP current 

• Development of instruments for recording, processing and 

analysis of cardiac electrophysiological signals obtained with 

mapping systems 

• Home of the research aimed to study the mechanisms involved 

in the deterioration of the systolic function, fibrosis and 

the inducibility of arrhythmias in a chronic model of infarction 

in rabbit hearts 


• Myocardial stress: analysis of electrophysiological changes 

induced by mechanical stretching. Autocrine/paracrine infuences 

and study of protective actions by means of drugs 

• Clinical and basic research on heart failure: role of calcium 

homeostasis in arrhythmogenesis. Study on the effects of 

drugs acting on intracellular Ca 2+ dynamics 

• Analysis of the effects of modifications in basic electrophysiological 

properties on the processes involved in beginning, 

perpetuation and cessation of ventricular fibrillation 

• Study of electrophysiological effects of chronic physical activity 

by: a) analysis of the protection against arrhythmias or 

scientific activity facilitation of its reversion; b) study of the 

influence of heart’s nervous system and mitochondrial oxidative 

stress; and c) analysis of the effects on the electrical 

instability induced by myocardial ischemia and the implication 

of IKATP current 

• Development and extension of tools for the registration, 

processing and analysis of cardiac electrophysical signals based 

on multielectrodes and optical cartography systems able 

to analyze voltage and calcium signals 

• Study the mechanisms involved in the deterioration of the 

systolic function, fibrosis and the inducibility of arrhythmias 

in a chronic model of infarction in rabbit hearts 



25 67,76 2,71 

National 



International 


Corresponding 

author 

16 4 12 

1. Del-Canto I, López-Lereu MP, Monmeneu JV, Croisille P, 

Clarysse P, Chorro FJ, Bodí V, Moratal D. Characterization of 

normal regional myocardial function by MRI cardiac tagging.J 

Magn Reson Imaging. 2015 Jan ;41(1):83-92.IF: 3,21 

2. Villanueva MP, Mollar A, Palau P, Carratalá A, Núñez E, 

Santas E, Bodí V, Chorro FJ, Miñana G, Blasco ML, Sanchís 

J, Núñez J. Procalcitonin and long-term prognosis after an 

admission for acute heart failure.Eur J Intern Med. 2015 Jan 

;26(1):42-8.IF: 2,891 

3. Serra-Añó P, Montesinos LL, Morales J, López-Bueno 

L, Gomis M, García-Massó X, González LM. Heart rate 

variability in individuals with thoracic spinal cord injury. 

Spinal Cord. 2015 Jan ;53(1):59-63.IF: 1,804 

4. Filgueiras-Rama D, Calvo CJ, Salvador-Montañés Ó, Cádenas 

R, Ruiz-Cantador J, Armada E, Rey JR, Merino JL, Peinado 

R, Pérez-Castellano N, Pérez-Villacastín J, Quintanilla 

JG, Jiménez S, Castells F, Chorro FJ, López-Sendón JL, 

Berenfeld O, Jalife J, de Sá EL, Millet J. Spectral analysisbased 

risk score enables early prediction of mortality and 

cerebral performance in patients undergoing therapeutic 

hypothermia for ventricular fibrillation and comatose 

status.Int J Cardiol. 2015 Mar 14 ;186:250-258.IF: 4,036 

5. Santas E, Chorro FJ, Miñana G, Méndez J, Muñoz J, Escribano 

D, García-Blas S, Valero E, Bodí V, Núñez E, Sanchís J, Núñez 

J. Tricuspid Regurgitation and Mortality Risk Across Left 

Ventricular Systolic Function in Acute Heart Failure.Circ J. 

2015 ;79(7):1526-33.IF: 3,94 

6. Chorro FJ, Canto ID, Brines L, Such-Miquel L, Calvo C, Soler 

C, Zarzoso M, Trapero I, Tormos Á, Such L. Experimental 

51

4 

Scientific 

activity 

52 

Study of the Effects of EIPA, Losartan, and BQ-123 on 

Electrophysiological Changes Induced by Myocardial 

Stretch.Rev Esp Cardiol (Engl Ed). 2015 Dec ;68(12):1101- 

10.IF: 0 

7. Chorro FJ, del Canto I, Brines L, Such-Miquel L, Calvo C, Soler 

C, Parra G, Zarzoso M, Trapero I, Tormos Á, Alberola A, Such 

L. Ranolazine Attenuates the Electrophysiological Effects of 

Myocardial Stretch in Langendorff-Perfused Rabbit Hearts. 

Cardiovasc Drugs Ther. 2015 Jun ;29(3):231-41.IF: 3,189 

8. Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, 

Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, 

Zile M, Andersen K, Arango JL, Arnold JM, B?lohlávek J, 

Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen 

CH, Dukat A, Duarte YC, Erglis A, Fu M, Gómez E, Gonzàlez- 

Medina A, Hagège AA, Huang J, Katova T, Kiatchoosakun S, 

Kim KS, Kozan Ö, Llamas EB, Martínez F, Merkely B, Mendoza 

I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires 

FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva- 

Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, 

Vinereanu D, Wong RC, PARADIGM-HF Investigators and 

Coordinators. Angiotensin receptor neprilysin inhibition 

compared with enalapril on the risk of clinical progression 

in surviving patients with heart failure.Circulation. 2015 Jan 

6 ;131(1):54-61.IF: 14,43 

9. Fauchier L, Greenlaw N, Ferrari R, Ford I, Fox KM, Tardif 

JC, Tendera M, Steg PG, CLARIFY Investigators. Use 

of Anticoagulants and Antiplatelet Agents in Stable 

Outpatients with Coronary Artery Disease and Atrial 

Fibrillation. International CLARIFY Registry.PLoS One. 2015 

;10(4):e0125164.IF: 3,234 

10. Santas E, García-Blas S, Miñana G, Sanchís J, Bodí V, Escribano 

D, Muñoz J, Chorro FJ, Núñez J. Prognostic implications of 

tissue Doppler imaging-derived e/ea ratio in acute heart 

failure patients.Echocardiography. 2015 Feb ;32(2):213-20. 

IF: 1,254 

11. Hervas A, de Dios E, Forteza MJ, Miñana G, Nuñez J, Ruiz-Sauri 

A, Bonanad C, Perez-Sole N, Chorro FJ, Bodí V. Intracoronary 

Infusion of Thioflavin-S to Study Microvascular Obstruction 

in a Model of Myocardial Infarction.Rev Esp Cardiol (Engl 

Ed). 2015 Nov ;68(11):928-34.IF: 0 

12. Valero E, Ferrero JA, López-Lereu MP, Chorro FJ. Symptomatic 

Partial Congenital Absence of the Pericardium Revealed 

Using Cardiac Magnetic Resonance.Can J Cardiol. 2015 Oct 

;31(10):1303.e5-7.IF: 3,711 

13. García-Blas S, Núñez J, Mainar L, Muñoz J, Martín I, 

Domenech A, Guillen A, Larman M, Sanchís J. A suspicious 

calcium spike.EuroIntervention. 2015 Aug 22 ;11(4):e1.IF: 

3,769 

14. García-Blas S, Núñez J, Mainar L, Miñana G, Bonanad C, 

Racugno P, Rodríguez JC, Moyano P, Sanchís J. Usefulness 

and safety of a guide catheter extension system for the 

percutaneous treatment of complex coronary lesions by a 

transradial approach.Med Princ Pract. 2015 ;24(2):171-7.IF: 

1,34 

15. Sanchís J, Núñez E, Ruiz V, Bonanad C, Fernández J, Cauli O, 

García-Blas S, Mainar L, Valero E, Rodríguez-Borja E, Chorro 

FJ, Hermenegildo C, Núñez J. Usefulness of Clinical Data 

and Biomarkers for the Identification of Frailty After Acute 

Coronary Syndromes.Can J Cardiol. 2015 Dec ;31(12):1462- 

8.IF: 3,711 

16. Valero E, Santas E, Chorro FJ. Right atrial mass.Rev Clin Esp. 

2015 Aug-Sep ;215(6):357-8.IF: 1,063 

17. Alonso JJ, Muñiz J, Gómez-Doblas JJ, Rodríguez-Roca G, 

Lobos JM, Permanyer-Miralda G, Anguita M, Chorro FJ, Roig 

E, OFRECE study researchers. Prevalence of Stable Angina 

in Spain. Results of the OFRECE Study.Rev Esp Cardiol (Engl 

Ed). 2015 Aug ;68(8):691-9.IF: 0 

18. Sanchís J, Abellán L, García-Blas S, Mainar L, Mollar A, Valero 

E, Consuegra-Sánchez L, Roqué M, Bertomeu-González V, 

Chorro FJ, Núñez E, Núñez J. Usefulness of delta troponin 

for diagnosis and prognosis assessment of non-ST-segment 

elevation acute chest pain.Eur Heart J Acute Cardiovasc 

Care. 2015 Jul 1 ;.IF: 0 

19. Núñez J, Rabinovich GA, Sandino J, Mainar L, Palau P, Santas 

E, Villanueva MP, Núñez E, Bodí V, Chorro FJ, Miñana G, 

Sanchís J. Prognostic value of the interaction between 

galectin-3 and antigen carbohydrate 125 in acute heart 

failure.PLoS One. 2015 ;10(4):e0122360.IF: 3,234 

20. Valero E, Bondanza L, Mainar L. Aborted sudden death in a 

cocaine consumer.Rev Clin Esp. 2015 Nov 3 ;.IF: 1,063 

21. Balasch I Bernat M, Balasch I Parisi S, Sebastián EN, 

Moscardó LD, Ferri Campos J, López Bueno L. Determining 

cut-off points in functional assessment scales in stroke. 

NeuroRehabilitation. 2015 Oct 14 ;37(2):165-72.IF: 1,124 

22. Balasch I Bernat M, Balasch I Parisi S, Noé Sebastián E, 

Dueñas Moscardó L, Ferri Campos J, López-Bueno L. Study 

of the Recovery Patterns of Elderly Subacute Stroke Patients


4 

in an Interdisciplinary Neurorehabilitation Unit.J Stroke 

Cerebrovasc Dis. 2015 Oct ;24(10):2213-8.IF: 1,669 

23. Serra-Añó P, López-Bueno L, García-Massó X, Pellicer-Chenoll 

MT, González LM. POSTURAL CONTROL MECHANISMS IN 

HEALTHY ADULTS IN SITTING AND STANDING POSITIONS. 

Percept Mot Skills. 2015 Aug ;121(1):119-34.IF: 0,546 

24. Izquierdo M, Sánchez-Gómez JM, Ferrero de Loma-Osorio 

A, Martínez A, Bellver A, Peláez A, Núñez J, Núñez C, Chorro 

J, Ruiz-Granell R. Endo-epicardial versus only-endocardial 

ablation as a first line strategy for the treatment of ventricular 

tachycardia in patients with ischemic heart disease.Circ 

Arrhythm Electrophysiol. 2015 Aug ;8(4):882-9.IF: 4,513 

Letter 

25. Santas E, Sandino J, Chorro FJ, Méndez J, Miñana G, Núñez 

E, Sanchís J, Núñez J. Prognostic implications of pericardial 

effusion in acute heart failure: Does size matter?Int J 

Cardiol. 2015 Apr 1 ;184:259-61.IF: 4,036 

• THESIS 

Thesis title: Estudio de las modificaciones farmacológicas de 

los efectos electrofisiológicos producidos por el estiramiento 

local miocárdico a partir de técnicas dinámicas de cartografía 

eléctrica en un modelo experimental de corazón aislado de 

conejo. 

Doctoral candidate: Irene del Canto Serrano 

Director(s): Francisco J. Chorro Gascó, David Moratal 



Thesis title: Diagnóstico precoz de la neumonía asociada 

al ventilador. Evaluación seriada de biomarcadores en 

minilavado broncoalveolar y monitorización microbiológica, 

complementada con condensado de aire exhalado y sangre. 

Doctoral candidate: Santiago Borrás Pallé 

Director(s): José Blanquer Olivas, Francisco Javier Chorro 

Gascó, Manuel Mata Roig 



Thesis title: Beneficios de la terapia de resincronización 

cardíaca en pacientes con severa disfunción y dilatación 

ventricular izquierda en la insuficiencia cardíaca leve respecto 

a la avanzada. 

Doctoral candidate: Mónica Giménez Alcalá 

Director(s): Francisco Javier Chorro Gascó, Aurelio Quesada 

Dorador 



Thesis title: Estudio de la posible participación de la 

corriente ikatp en las modificaciones que sobre estabilidad y 

heterogeneidad miocárdica produce el ejercicio físico crónico, 

en corazón aislado, normalmente oxigenado y tras isquemia 

regional aguda. 

Doctoral candidate: Manuel Koninckx Cañada 

Director(s): Luís Such Belenguer, Germán Parra Giraldo, Luis 

Such Miquel 




RESEARCH 


Title: Utilidad de la estabilización de la homeostasis del calcio 

intracelular en el control de los procesos fibrilatorios 

Principal Investigator: Francisco Javier Chorro Gascó 

Funding body: Instituto de Salud Carlos III 

Beneficiary Institution: Fundación Investigación del Hospital 




Reference: RD12/0042/0048 

Title: Red de Investigación Cardiovascular (RIC) 








Title: Estudio mediante técnicas cartográficas avanzadas de 

los mecanismos básicos implicados en las arritmias malignas y 

en su control. 


Funding body: Generalitat Valenciana 


53

4 

Scientific 

activity 



Total budget: 33.000€ (this year) 

Reference: UV-INV-PRECOMP14-206372 

Title: Estudio del remodelado eléctrico cardíaco producido 

en un modelo experimental de síndrome metabólico y su 

implicación en la génesis de arritmias. 

Principal Investigator: Manuel Zarzoso Muñoz 

Funding body: Universitat de Valencia 





54


4 

Research Group on Endothelial Cells (LINCE) 


55 

http://www.uv.es/lince/SP/index.html 

Group members 



Carlos Hermenegildo Caudevilla. 

University 

H Index: 26 


Elena Monsalve Villalba. University 

PhD students 

Daniel Bernardo Pérez Cremades. University 

Xavier Vidal Gómez. INCLIVA 

Ana Mompeón Campos. University 


Susana Novella del Campo. University

4 

Scientific 

activity 

56 


• The advance of the FIS PI13/00617 research project has 

solved the difficulty on the array analysis of miRNA profile 

in endothelial cells and the main results were checked. 

The recruitment of patients is ongoing and the follow up 

was enlarged up to one year 

• To complete the effects induced by oxidized low density 

lipoprotein on endothelial transcriptomic profile and to 

publish 

• To complete and to publish the first part of the Procell study 

in collaboration with 8 different groups of the Red de 

Investigación Cardiovascular on the time-course of mobilization 

of endothelial progenitor cells in acute cardiovascular 

events (acute myocardial infarction and stroke) 

• In the murine model of senescence, we have demonstrated 

a decreased availability of nitric oxide in aorta from 

ovariectomized senescence mice involving cyclooxygenases 

(manuscript is in press) 


• Gender difference in cardiovascular area 

• Vascular effects of sex hormones 

• Identification of new hormone-regulated signalling 

pathways in endothelium 

• Interaction of sex hormones with pro-atherogenic factors 

• Determination of circulating endothelial progenitor cells 

and their link with hormone treatment 

• miRNA profile in vascular cells under estrogen exposure 


Susana Novella del Campo 

The research is focused in the study of 

endothelial dysfunction associated with 

aging and lack of estrogen. During aging 

are produced mechanical and functional 

alterations in the arterial wall wich leads to the occurrence 

of cardiovascular diseases. These alterations are conditioned 

by gender differences. Our main goal is to determine the 

mechanisms by which the main endothelial mediators, nitric 

oxide and prostanoids are affected during aging. We also studied 

the regulatory role of miRNAs associated with acute coronary 

syndrome and the estrogen-dependent vascular function and 

aging. 



7 32,08 4,5 

National 



International 


Corresponding 

author 

6 - 3 

1. Regueiro A, Cuadrado-Godia E, Bueno-Betí C, Díaz-Ricart M, 

Oliveras A, Novella S, Gené GG, Jung C, Subirana I, Ortiz- 

Pérez JT, Roqué M, Freixa X, Núñez J, Escolar G, Marrugat 

J, Hermenegildo C, Valverde MA, Roquer J, Sanchís J, Heras 

M. Mobilization of endothelial progenitor cells in acute cardiovascular 

events in the PROCELL study: Time-course after 

acute myocardial infarction and stroke. J Mol Cell Cardiol. 

2015 Jan 22 ;80C:146-155.IF: 4,655 

2. Escudero P, Martínez de Marañón A, Collado A, González- 

Navarro H, Hermenegildo C, Peiró C, Piqueras L, Sanz MJ. 

Combined sub-optimal doses of rosuvastatin and bexarotene 

impair angiotensin II-induced arterial mononuclear 

cell adhesion through inhibition of Nox5 signaling pathways 

and increased RXR/PPAR? and RXR/PPAR? interactions. Antioxid 

Redox Signal. 2015 Apr 10 ;22(11):901-20.IF: 7,407 

3. Toral M, Gómez-Guzmán M, Jiménez R, Romero M, 

Zarzuelo MJ, Utrilla MP, Hermenegildo C, Cogolludo Á, 

Pérez-Vizcaíno F, Gálvez J, Duarte J. Chronic peroxisome 

proliferator-activated receptor?/? agonist GW0742 prevents 

hypertension, vascular inflammatory and oxidative status, 

and endothelial dysfunction in diet-induced obesity. J 

Hypertens. 2015 Sep ;33(9):1831-1844.IF: 4,72 

4. Vidal-Gómez X, Perez-Monzo I, Mompeon A, Segarra G, Dantas 

AP, Hermenegildo C, Medina P, Novella S. 2C.04: TIMING 

OF BLOOD PRESSURE AND VASCULAR CHANGES INDUCED 

BY AGEING IN AORTA AND SMALL MESENTERIC ARTERIES 

FROM FEMALE SENESCENCE-ACCELERATED MOUSE PRONE 

(SAMP8). J Hypertens. 2015 Jun ;33 Suppl 1:e26.IF: 4,72 

5. Laguna-Fernández A, Novella S, Bueno-Betí C, Marrugat 

J, Hermenegildo C. Endothelial transcriptomic changes 

induced by oxidized low density lipoprotein disclose an upregulation 

of Jak-Stat pathway. Vascul Pharmacol. 2015 Oct 

;73:104-14.IF: 3,635 

6. Cuadrado-Godia E, Regueiro A, Núñez J, Díaz-Ricard M, 

Novella S, Oliveras A, Valverde MA, Marrugat J, Ois A,


4 

Giralt-Steinhauer E, Sanchís J, Escolar G, Hermenegildo 

C, Heras M, Roquer J. Endothelial Progenitor Cells Predict 

Cardiovascular Events after Atherothrombotic Stroke and 

Acute Myocardial Infarction. A PROCELL Substudy. PLoS 

One. 2015 ;10(9):e0132415.IF: 3,234 





Coronary Syndromes. Can J Cardiol. 2015 Dec ;31(12):1462- 

8.IF: 3,711 

• AWARDS 

The Investigator Carlos Hermenegildo was awarded “Alberto 

Ferrari prize” to the best poster in 25 th European Meeting on 

Hypertension and Cardiovascular Protection celebrated in 

Milan in 2015. 


RESEARCH 


Title: Nodo de la red de investigación cooperativa (RETIC) de 

Enfermedades Cardiovasculares. 

Principal Investigator: Carlos Hermenegildo Caudevilla 


Beneficiary institution: Fundación Investigación del Hospital 




57 


Title: miRNA endothelial profile modification in response to 

estradiol and aging. Relationship to clinical course of coronary 

restenosis 

Principal Investigator: Carlos Hermenegildo Caudevilla 






Fig. 1 Ang1-7 expression in cultured 

human endothelial cells 

Reference: COST Action BM1402 

Title: Development of a European network for preclinical 

testing of interventions in mouse models of age and agerelated 

diseases (MouseAGE) 

Principal Investigator: Ilaria Bellantuono (Susana Novella as 

collaborating researcher) 

Funding body: European Commission 

Beneficiary institution: Fundación Investigación Hospital 



Fig 2: Superoxide production in 

murine arteries

4 

Scientific 

activity 

Research Group on Clinical Cardiology 


58 

“Realizar un artículo supone un gran esfuerzo e implica dedicarle mucho tiempo. Desde luego, 

hace falta una gran capacidad de trabajo.” 

Juan Sanchis. CardioTeca. 7 -6-2015 

http://www.cardioteca.com/blogs/cardionews/sec2014/entry/sec2014/juan-sanchis-fores-la-calidad-de-losarticulos-publicados-en-revista-espanola-de-cardiologia.html 

Group members 



Juan Sanchis Forés. 


H Index: 30 


Vicente Ruiz Ros. Hospital. University 

Sergio García Blas. Hospital. University 

Ernesto Valero Picher. Hospital 

Gemma Miñana Escrivá. Hospital 

PhD students 

Estefanía Montalvo Torró. INCLIVA 

Anna Mollar Fernández. INCLIVA 


Julio Núñez Villota. Hospital. University


4 


• To consolidate the research in acute coronary syndromes 

and heart failure 


• Therapeutic and prognostic assessment of acute coronary 

syndromes and secondary prevention 

• Acute heart failure. New strategies for risk assessment 

and treatment and new control programs 



33 74,32 2,25 

National 


International 


Corresponding 

author 

23 2 12 


1. Villanueva MP, Mollar A, Palau P, Carratalá A, Núñez E, Santas 

E, Bodí V, Chorro FJ, Miñana G, Blasco ML, Sanchís J, 

Núñez J. Procalcitonin and long-term prognosis after an admission 

for acute heart failure. Eur J Intern Med. 2015 Jan 

;26(1):42-8.IF: 2,891 

2. Regueiro A, Cuadrado-Godia E, Bueno-Betí C, Díaz-Ricart M, 

Oliveras A, Novella S, Gené GG, Jung C, Subirana I, Ortiz- 

Pérez JT, Roqué M, Freixa X, Núñez J, Escolar G, Marrugat 

J, Hermenegildo C, Valverde MA, Roquer J, Sanchís J, Heras 

M. Mobilization of endothelial progenitor cells in acute cardiovascular 

events in the PROCELL study: Time-course after 

acute myocardial infarction and stroke. J Mol Cell Cardiol. 

2015 Jan 22 ;80C:146-155.IF: 4,655 

59 


Julio Núñez Villota (Department 

of Cardiology - Hospital Clínico Universitario 

of Valencia) 

Our research team has focused 

in the development of new clinical 

tools for improving diagnosis, risk 

stratification and treatment of patients 

with ischemic heart disease 

and heart failure. 

Along this line, we are conducting several clinical studies, many 

of them investigator-initiated clinical trials, aimed to evaluate: a) 

new therapies/strategies to improve prognosis, and, b) new biomarkers/devices 

useful for monitoring and guiding therapy after 

an episode of acute coronary and acute heart failure episode. 

More specifically, we are focused on the potential utility of 

peritoneal dialysis for patients with refractory congestive heart 

failure, the development of new algorithms for monitoring patients, 

the efficacy of physical therapies in heart failure, the development 

of a multimarker and dynamic approach for risk stratification. 

3. Carrizo S, Sanchez-Recalde A, García-Blas S, Moreno R. 

Subacute left main coronary stent thrombosis secondary 

to a large calcium spicule that produced stent malapposition: 

OCT and IVUS findings. EuroIntervention. 2015 Nov 22 

;11(8):781.IF: 3,769 

4. Núñez J, Bonanad C, Navarro JP, Bondanza L, Artero A, Ventura 

S, Núñez E, Miñana G, Sanchís J, Real J. Differential 

Effect of Glycosylated Hemoglobin Value and Antidiabetic 

Treatment on the Risk of 30-day Readmission Following a 

Hospitalization for Acute Heart Failure. Rev Esp Cardiol (Engl 

Ed). 2015 Oct ;68(10):852-60.IF: 3,342 

5. Santas E, Chorro FJ, Miñana G, Méndez J, Muñoz J, Escribano 

D, García-Blas S, Valero E, Bodí V, Núñez E, Sanchís J, 

Núñez J. Tricuspid Regurgitation and Mortality Risk Across 

Left Ventricular Systolic Function in Acute Heart Failure. Circ 

J. 2015 ;79(7):1526-33.IF: 3,94 

6. de la Torre Hernández JM, Oteo Domínguez JF, Hernández F, 

García Camarero T, Abdul-Jawad Altisent O, Rivero Crespo 

F, Cascón JD, Zavala G, Gimeno F, Arrebola Moreno AL, 

Andraka L, Gómez Menchero A, Bosa F, Carrillo X, Sánchez 

Recalde Á, Alfonso F, Pérez de Prado A, López Palop R,

4 

Scientific 

activity 

60 

Sanchís J, Diarte de Miguel JA, Jiménez Navarro M, Muñoz 

L, Ramírez Moreno A, Tizón Marcos H, ESTROFA-DAPT 

and ESTROFA-2 study groups. Dual Antiplatelet Therapy 

for 6 Months vs 12 Months After New-generation Drugeluting 

Stent Implantation: Matched Analysis of ESTROFA- 

DAPT and ESTROFA-2.Rev Esp Cardiol (Engl Ed). 2015 Oct 

;68(10):838-45.IF: 0 

7. Bertomeu-González V, Anguita M, Moreno-Arribas J, Cequier 

Á, Muñiz J, Castillo-Castillo J, Sanchís J, Roldán I, Marin F, 

Bertomeu-Martínez V, FANTASIIA Study Investigators. 

Quality of Anticoagulation With Vitamin K Antagonists. Clin 

Cardiol. 2015 Jun ;38(6):357-64.IF: 2,586 

8. Santas E, García-Blas S, Miñana G, Sanchís J, Bodí V, 

Escribano D, Muñoz J, Chorro FJ, Núñez J. Prognostic 

implications of tissue Doppler imaging-derived e/ea ratio 

in acute heart failure patients. Echocardiography. 2015 Feb 

;32(2):213-20.IF: 1,254 

9. Escolar G, Arellano-Rodrigo E, López-Vilchez I, Molina P, 

Sanchís J, Reverter JC, Carne X, Cid J, Villalta J, Tassies D, 

Galán AM, Díaz-Ricart M. Reversal of rivaroxaban-induced 

alterations on hemostasis by different coagulation factor 

concentrates – in vitro studies with steady and circulating 

human blood. Circ J. 2015 ;79(2):331-8.IF: 3,94 

10. García-Blas S, Núñez J, Mainar L, Muñoz J, Martín I, Domenech 

A, Guillen A, Larman M, Sanchís J. A suspicious calcium spike. 

EuroIntervention. 2015 Aug 22 ;11(4):e1.IF: 3,769 

11. Bayés-Genís A, Barallat J, Pascual D, Nuñez J, Miñana 

G, Sánchez-Mas J, Galán A, Sanchís J, Zamora E, Pérez- 

Martínez MT, Lupón J. Prognostic Value and Kinetics of 

Soluble Neprilysin in Acute Heart Failure: A Pilot Study. JACC 

Heart Fail. 2015 Aug ;3(8):641-4.IF: 0 

12. García-Blas S, Núñez J, Mainar L, Miñana G, Bonanad C, 

Racugno P, Rodríguez JC, Moyano P, Sanchís J. Usefulness 

and safety of a guide catheter extension system for the 

percutaneous treatment of complex coronary lesions by a 

transradial approach. Med Princ Pract. 2015 ;24(2):171-7. 

IF: 1,34 

13. Cuadrado-Godia E, Regueiro A, Núñez J, Díaz-Ricard M, 

Novella S, Oliveras A, Valverde MA, Marrugat J, Ois A, 

Giralt-Steinhauer E, Sanchís J, Escolar G, Hermenegildo 

C, Heras M, Roquer J. Endothelial Progenitor Cells Predict 

Cardiovascular Events after Atherothrombotic Stroke and 

Acute Myocardial Infarction. A PROCELL Substudy. PLoS 

One. 2015 ;10(9):e0132415.IF: 3,234 

14. Buigues C, Padilla-Sánchez C, Garrido JF, Navarro-Martínez 

R, Ruiz-Ros V, Cauli O. The relationship between depression 

and frailty syndrome: a systematic review. Aging Ment 

Health. 2015 ;19(9):762-72.IF: 1,751 

15. Santas E, Núñez J. Prognostic implications of pericardial 

effusion: The importance of underlying etiology. Int J 

Cardiol. 2015 Sep 25 ;202:407.IF: 4,036 



FJ, Hermenegildo C, Núñez J. Usefulness of Clinical Data and 

Biomarkers for the Identification of Frailty After Acute Coronary 

Syndromes. Can J Cardiol. 2015 Dec ;31(12):1462-8.IF: 3,711 


E, Consuegra-Sánchez L, Roqué M, Bertomeu-González V, 

Chorro FJ, Núñez E, Núñez J. Usefulness of delta troponin 


elevation acute chest pain. Eur Heart J Acute Cardiovasc 

Care. 2015 Jul 1 ;.IF: 0 





failure. PLoS One. 2015 ;10(4):e0122360.IF: 3,234 

19. Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, García Del Blanco 

B, García-Touchard A, López-Minguéz JR, Rivero F, Masotti 

M, Zueco J, Cequier A, Morís C, Fernández-Ortíz A, Escaned 

J, Jiménez-Quevedo P, Gonzalo N, Fernández C, Macaya C, 

Restenosis Intra-stent: drug-eluting Balloon vs. everolimuseluting 

Stent (RIBS IV) Study Investigators (under the 

auspices of the Working Group on Interventional Cardiology 

of the Spanish Society of Cardiology). Rationale and design 

of the RIBS IV randomised clinical trial (drug-eluting 

balloons versus everolimus-eluting stents for patients with 

drug-eluting stent restenosis). EuroIntervention. 2015 Jul 

;11(3):336-42.IF: 3,769 

20. Núñez J, Merlos P, Fácila L, Llàcer P, Bosch MJ, Bertomeu- 

Martínez V, García-Blas S, Montagud V, Pedrosa V, Mendizábal 

A, Cordero A, Miñana G, Sanchís J, Bertomeu-González V, 

CHANCE-HF Investigators. Prognostic effect of carbohydrate 

antigen 125-guided therapy in patients recently discharged 

for acute heart failure (CHANCE-HF). Study design.Rev Esp 

Cardiol (Engl Ed). 2015 Feb ;68(2):121-8.IF: 0 

21. Palau P, Domínguez E, Núñez E, Sanchís J, Santas E, Núñez 

J. Six-minute walk test in moderate to severe heart failure


4 

with preserved ejection fraction: Useful for functional 

capacity assessment? Int J Cardiol. 2015 Nov 10 ;203:800- 

802.IF: 4,036 

22. Alfonso F, Sanchís J. [Editorial and scientific excellence of 

biomedical journals: Is the impact factor everything?] .Arch 

Cardiol Mex. 2015 Oct-Dec ;85(4):265-9.IF: 0 





tachycardia in patients with ischemic heart disease. Circ 


24. Iglesias D, Salinas P, Moreno R, García-Blas S, Calvo L, 

Jiménez-Valero S, Sánchez-Recalde Á, Galeote G, Mesa 

JM, Plaza I, López-Sendón JL. Prognostic impact of 

decisions taken by the heart team in patients evaluated for 

transcatheter aortic valve implantation. Rev Port Cardiol. 

2015 Oct ;34(10):587-95.IF: 0,454 

25. Carrizo S, Peinado RP, Sanchez-Recalde A, Ruiz-García J, 

Jimenez-Valero S, Galeote G, García-Blas S, Trucco G, Orbe 

LC, López-De-Sa E, Moreno R, López-Sendon JL. Clinical and 

angiographic characteristics of patients with acute coronary 

syndrome associated with sudden cardiac death. Hellenic J 

Cardiol. 2015 Mar-Apr ;56(2):136-41.IF: 1,229 

26. de la Torre Hernández JM, Moreno R, Lee DH, García Del 

Blanco B, San Martín JC, Serra García V, Gaviria K, García 

Blas S, Garcia I, Zueco J. The routine use of a surgical 

exposure approach for trans-femoral implantation of the 

balloon expandable aortic prosthesis is associated to a low 

rate of vascular complications. Results from a multicenter 

registry. J Cardiovasc Surg (Torino). 2015 Feb 12 ;.IF: 1,461 

Letters 

27. Bayes-Genis A, Avanzas P, Pérez de Isla L, Sanchís J. Acute 

heart failure: the unrecognized epidemic. Rev Esp Cardiol 

(Engl Ed). 2015 Mar ;68(3):243-4.IF: 0 

28. Avanzas P, Bayes-Genis A, Pérez de Isla L, Sanchís J, Heras 

M. Fate of original articles rejected by Revista Española de 

Cardiología. Rev Esp Cardiol (Engl Ed). 2015 Mar ;68(3):263- 

4.IF: 0 

29. Cordero A, Fácila L, García-Carrilero M, Gunturiz C, Montagud 

V, Núñez J. Breakfast Habits in Patients Hospitalized for 

Acute Coronary Syndrome. Rev Esp Cardiol (Engl Ed). 2015 

Sep ;68(9):814-5.IF: 0 

30. García-Blas S, Valero E, Escribano D, Bonanad C, Sanchís J, 

Núñez J. Guideliner use for the percutaneous treatment of 

right coronary artery arising from the left circumflex (L-type 

single coronary artery). Int J Cardiol. 2015 Apr 15 ;185:2-3. 

IF: 4,036 

31. Santas E, Sandino J, Chorro FJ, Méndez J, Miñana G, Núñez 

E, Sanchís J, Núñez J. Prognostic implications of pericardial 

effusion in acute heart failure: Does size matter? Int J 

Cardiol. 2015 Apr 1 ;184:259-61.IF: 4,036 

Editorial 

32. Sanchís J, Avanzas P, Bayes-Genis A, Pérez de Isla L, Heras 

M. 2014 annual summary and new projects in Revista 

Española de Cardiología. Rev Esp Cardiol (Engl Ed). 2015 

Mar ;68(3):265-72.IF: 0 

Review 

33. Núñez J, Miñana G, Santas E, Bertomeu-González V. Cardiorenal 

Syndrome in Acute Heart Failure: Revisiting Paradigms. 

Rev Esp Cardiol (Engl Ed). 2015 May ;68(5):426-35.IF: 3,342 


RESEARCH 


Title: Red de Investigación Cardiovascular (RIC) 

Principal Investigator: Juan Sanchis Forés 







Title: Loop diuretics dosage in patients with acute heart 

failure and renal failure: conventional strategy versus strategy 

guided by CA125 plasma levels 

Principal Investigator: Julio Núñez Villota 






61

4 

Scientific 

activity 

Research Group on the Study of Cardiovascular Risk in Children and Adolescents 


62 

Group members 



Empar Lurbe i Ferrer. 

University 

H Index: 24 


Isabel Torró Doménech. University 

Julio Álvarez Pitti. University 

Francisco Aguilar Bacallado. University 

Consuelo García Vicent. University 

Nuria García Carbonell. University 

Pau Redón Lurbe. CIBERobn 

Laura Cantero Milán. CIBERobn 

Technician 

Francisco Ponce Zanón. CIBERobn 

Administrative assistant 

Rachael Dix. CIBERobn


4 


• To work in UNIT PEDITEC which co-localizes in the daily 

work of health personnel with engineers who develop 

software for capturing signals via mobile devices. The study 

of physiological parameters that allow the therapeutic 

individualization has been a priority during 2015 and 

meant an advance in clinical practice in obese pediatric 

patients in the unit 

• To expand PAIDO personalized health care program that 

with the development of actions involving family, educators, 

nutritionist, physical education teachers and other 

social actors. The intervention on the pathology transcends 

the hospital space and involves also the environment 

and the individual sphere of children. 

• To develop a prospective study in more than 200 children. 

The study collects information and material cord 

with epigenetic studies and metabolomics, and monitoring 

clinical parameters and cardiometabolic phenotype 

• To coordinate a new document of the European Guidelines 

on Hypertension in Children and Adolescents 


• New technologies applied to the detection of congenital 

heart diseases and sepsis in asymptomatic newborn babies 

• Childhood obesity 

• New technologies applied to the treatment of obesity 

• Impact of intrauterine life in the development of cardiometabolic 

disease 

• Arterial hypertension in children 

• Cardiovascular and renal risk in diabetes 



8 23,78 2,97 

National 



International 


Corresponding 

author 

5 - 7 

1. Pichler G, Martínez F, Vicente A, Solaz E, Calaforra O, Lurbe 

E, Redon J. Influence of obesity in central blood pressure. J 

Hypertens. 2015 Feb ;33(2):308-13.IF: 4,72 



newborns exposed to tobacco in utero. J Transl Med. 2015 

Jan 27 ;13(1):25.IF: 3,93 

3. Redon J, Lurbe E. The kidney in obesity.Curr Hypertens Rep. 

2015 Jun ;17(6):555.IF: 3,435 

4. Torro MI, Alvarez J, Aguilar F, Redon P, Lurbe E. 2B.04: 

FACTORS RELATED TO THE LINK BETWEEN URIC ACID AND 

SYSTOLIC BLOOD PRESSURE IN YOUTHS. J Hypertens. 2015 

Jun ;33 Suppl 1:e23.IF: 4,72 

5. Bermúdez L, García-Vicent C, López J, Torró MI, Lurbe E. Assessment 

of ten trace elements in umbilical cord blood and 

maternal blood: association with birth weight. J Transl Med. 

2015 Sep 7 ;13:291.IF: 3,93 

6. Lisón JF, Cebolla A, Guixeres J, Álvarez-Pitti J, Escobar P, 

Bruñó A, Lurbe E, Alcañiz M, Baños R. Competitive active 

video games: Physiological and psychological responses in 

children and adolescents. Paediatr Child Health. 2015 Oct 

;20(7):373-6.IF: 1,388 

Letter 

7. Lurbe I Ferrer E, Alsina Manrique de Lara L, Rodríguez 

Fernández LM, Solís Sánchez G. [Need for the gender 

perspective in the Anales de Pediatría yearbook. Author’s 

response]. An Pediatr (Barc). 2015 Sep ;83(3):226.IF: 0,833 

63 

Editorial 

8. Lurbe i Ferrer E, Manrique de Lara LA, Rodríguez Fernández LM, 

Solís Sánchez G. [Editors’ corner: Anales de Pediatria annual report]. 

An Pediatr (Barc). 2015 Jun ;82(6):375-7.IF: 0,833

4 

Scientific 

activity 

64 


RESEARCH 

Reference: IPT-2011-0824-900000 

Title: INNPACTO Plataforma IntegNeo 

Principal Investigator: Empar Lurbe i Ferrer 

Funding body: Ministerio de Ciencia e Innovación 

Beneficiary institution: Consorcio Hospital General 




Reference: InTecMedic 

Title: Investigación clínica y tecnología médica personalizada 

para prevención, diagnóstico y terapia 


Funding body: Microcluster 





Title: ISITIC: Instituto Superior de Investigación, Traslación 

e Innovación Cooperativas Orientadas al Bienestar del Ser 

Humano 

Principal Investigator: Cristina Botella Arbona (Empar Lurbe 

as collaborating researcher) 

Funding body: Consellería de Educación, Formación y 

Ocupación 





Funding Body: FIPSE 



Duration: 2015 - 2016 



Title: Impacto del peso al nacer y la ganancia ponderal 

postnatal en la disfunción endotelial e inflamación vascular 





Duration: 2015 - 2017 


• AWARDS 

In 2015 Empar Lurbe received the Pronokal award to support 

the research to prevent childhood obesity. Another member 

of the group, Francisco Aguilar, was awarded with the López 

Trigo Prize. 


Title: CIBER de la Obesidad y Nutrición (CIBERobn) 



Beneficiary Institution: Universidad de Valencia 



Reference: 120022/14 

Title: Desarrollo de un plan de transferencia de un prototipo 

de análisis de la capacidad cardiorrespiratoria y su aplicación 

en la prevención y el tratamiento de la obesidad infantil 

Principal Investigator: Empar Lurbe i Ferrer


4 

Cardiometabolic Research Group on Primary Care 


65 

Group members 


Jorge Navarro Pérez. 

Clínico-Malvarrosa Health Department 

H Index: 24 


Jose Vicente Lozano Vidal. Clínico-Malvarrosa Health 

Department 

Alvaro Bonet Pla. Clínico-Malvarrosa Health Department 

Victoria Gosalbes Soler. Clínico-Malvarrosa Health 

Department 

Carlos Fluixá Carrascosa. Clínico-Malvarrosa Health 

Department 

Nidia Ruiz Varea. Clínico-Malvarrosa Health Department 

Pilar Roca Navarro. University. Clínico-Malvarrosa Health 

Department 

Gaspar Sánchez Vela. Clínico-Malvarrosa Health 

Department 

José Sanfélix-Genovés. Clínico-Malvarrosa Health 

Department

4 

Scientific 

activity 

66 


• Consolidation of various lines of cardiometabolic research 

• Consolidation of a network of partners in the area of 

primary care 


• Epidemiological studies: 

- Valencian cardiometabolic study (ESCARVAL project) 

• Intervention studies: 

- Euroaction Plus 

- Secondary Prevention Program (PROPRESE program) 

• Cost-effectiveness qualitative studies: 

- Antiaggregation 

• Systematic reviews of Cardiovascular Interventions 



11 19,55 1,77 

National 



International 


Corresponding 

author 

9 1 4 

1. Martínez MT, González I, Tarazona N, Roselló S, Saiz R, Sanmartín 

A, Martínez-Agulló Á, Caballero A, Mas P, Franco J, 

Martínez-Jabaloyas J, García-Callejo J, Martín V, Navarro 

J, Teruel A, Lluch A, Chirivella I. Implementation and assessment 

of a fast-track programme to improve communication 

between primary and specialized care in patients 

with suspected cancer: how to shorten time between initial 

symptoms of cancer, diagnosis and initiation of treatment. 

Clin Transl Oncol. 2015 Feb ;17(2):167-72.IF: 2,077 

2. Gil-Guillén V, Hermida E, Pita-Fernandez S, Palazon-Bru 

A, Durazo-Arvizu R, Pallares-Carratala V, Orozco-Beltran 

D, Carratala-Munuera C, López-Pineda A, Navarro J. A 

cardiovascular educational intervention for primary care 

professionals in Spain: positive impact in a quasi-experimental 

study. Br J Gen Pract. 2015 Jan ;65(630):e32-40.IF: 2,294 

3. Darocas M, Ruiz N, Bergoglio MT, Cano A. A decision dilemma: 

Cushing syndrome during pregnancy. J Obstet Gynaecol. 

2015 Jan ;35(1):93-4.IF: 0,551 

4. Arrieta F, Iglesias P, Pedro-Botet J, Tébar FJ, Ortega E, Nubiola 

A, Pardo JL, Maldonado GF, Obaya JC, Matute P, Petrecca 

R, Alonso N, Sarabia E, Sánchez-Margalet V, Alemán JJ, 

Navarro J, Becerra A, Duran S, Aguilar M, Escobar-Jiménez F, 

Grupo de Trabajo Diabetes y Enfermedad Cardiovascular de 

la Sociedad Española de Diabetes (SED). [Diabetes mellitus 

and cardiovascular risk: Working group recommendations 

of Diabetes and Cardiovascular Disease of the Spanish 

Society of Diabetes (SED, 2015)]. Clin Investig Arterioscler. 

2015 Jul-Aug ;27(4):181-92.IF: 0 

5. Ferrando C, Soro M, Canet J, Unzueta MC, Suárez F, Librero 

J, Peiró S, Llombart A, Delgado C, León I, Rovira L, Ramasco 

F, Granell M, Aldecoa C, Diaz O, Balust J, Garutti I, de la 

Matta M, Pensado A, González R, Durán ME, Gallego L, 

Del Valle SG, Redondo FJ, Diaz P, Pestaña D, Rodríguez A, 

Aguirre J, García JM, García J, Espinosa E, Charco P, Navarro 

J, Rodríguez C, Tusman G, Belda FJ, iPROVE investigators 

(Appendices 1 and 2). Rationale and study design for an 

individualized perioperative open lung ventilatory strategy 

(iPROVE): study protocol for a randomized controlled trial. 

Trials. 2015 Apr 27 ;16(1):193.IF: 1,731 

6. Téllez-Plaza M, Orozco-Beltran D, Gil-Guillen V, Navarro- 

Pérez J, Pallares V, Valls F, Fernandez A, Martín-Moreno 

JM, Sanchis C, Dominguez-Lucas A, Redon J. 3A.05: 

HYPERTENSION AND RISK OF EVENTS ASSOCIATED TO 

REDUCED EGFR. THE ESCARVAL-RISK STUDY. J Hypertens. 

2015 Jun ;33 Suppl 1:e32-3.IF: 4,72 

7. Morillas P, Pallarés V, Fácila L, Llisterri JL, Sebastián ME, Gómez 

M, Castilla E, Camarasa R, Sandin M, García-Honrubia 

A, FAPRES registry investigators. The CHADS2 Score to Predict 

Stroke Risk in the Absence of Atrial Fibrillation in Hypertensive 

Patients Aged 65 Years or Older. Rev Esp Cardiol 

(Engl Ed). 2015 Jun ;68(6):485-91.IF: 0 

8. Sanfélix-Gimeno G, Hurtado I, Sanfélix-Genovés J, Baixauli-Pérez 

C, Rodríguez-Bernal CL, Peiró S. Overuse and 

Underuse of Antiosteoporotic Treatments According to 

Highly Influential Osteoporosis Guidelines: A Population-Based 

Cross-Sectional Study in Spain. PLoS One. 2015 

;10(8):e0135475.IF: 3,234 

9. Morillas C, Feliciano R, Catalina PF, Ponte C, Botella M, 

Rodrigues J, Esmatjes E, Lafita J, Lizán L, Llorente I, Morales C,


4 

Navarro-Pérez J, Orozco-Beltran D, Paz S, Ramirez de Arellano 

A, Cardoso C, Tribaldos Causadias M. Patients’ and physicians’ 

preferences for type 2 diabetes mellitus treatments in Spain 

and Portugal: a discrete choice experiment. Patient Prefer 

Adherence. 2015 ;9:1443-58.IF: 1,676 

10. Hurtado I, Sanfélix-Gimeno G, Peiró S, Sanfélix-Genovés J. 

Primary Non-Adherence to Antiosteoporotic Treatment and 

Associated Factors: A Prospective Cohort Study in Spain. 

Value Health. 2015 Nov ;18(7):A650.IF: 3,279 

11. Benítez Camps M, Egocheaga Cabello MI, Dalfó Baqué 

A, Bajo García J, Vara González L, Sanchis Doménech C, 

Martín Rioboo E, Ureña Fernández T, Domínguez Sardiña 

M, Bonet Pla A, nombre del equipo investigador del 

trabajo. [Knowledge level of hypertensive patients about 

hypertension. Relationship between knowledge level and 

hypertension control]. Hipertens Riesgo Vasc. 2015 Jan-Mar 

;32(1):12-20.IF: 0 

67 


RESEARCH 

Title: CIBER de Epidemiología y Salud Pública (CIBERESP) 

Principal Investigator: María Manuela Morales (Jorge Navarro 

Pérez as a Collaborating researcher) 



Duration: 2007 – 2015

4 

Scientific 

activity 

Research Group on the Study of Cardiometabolic and Renal Risk 


68 

“Hacer investigación y desarrollar tratamientos que curan o, cuando menos, que mejoran la 

calidad de vida de estos enfermos es el principal objetivo de nuestros investigadores.” 

Josep Redon i Más. Bioval.org . 21-02-2015 

http://www.bioval.org/2015/02/24/incliva-y-la-universitat-de-valencia-crean-el-primer-centro-deenfermedades-raras-de-ambito-autonomico-2/ 

Group members 


Josep Redón i Mas. 


H Index: 50 


Mª José García-Fuster González-Alegre. Hospital 

Mª José Galindo Puerto. Hospital. University 

Mª José Forner Giner. Hospital. University 

Gernot Helmut Pichler. INCLIVA 

María José Fabiá Valls. Hospital 

Elena Solaz Moreno. Hospital 

Carlos Sánchez Sánchez. INCLIVA 

PhD students 

Óscar Calaforra Juan. CIBERobn 

Javier Pérez Hernández. INCLIVA 


Fernando Martínez García. Hospital. University 

María Téllez Plaza. INCLIVA


4 


• To start-up the laboratory for the analysis of podocytes 

(identification, cultivation and phenotyping) and its derivatives: 

micro-RNA, exosomes 

• The integration of metabolomics and genomics in the 

study of factors related to the development of kidney 

damage 

• Development of studies for noninvasive hemodynamic 

characterization in vascular pathology 

• Analysis of morbidity and mortality linked to the presence 

of hypertension and renal injury 

• Development of in vitro studies of platelet and leukocyte 

adhesion in venous thromboembolism 

• Genetic studies related to obesity and overweight and venous 

thromboembolism 

• Development of phase III and IV clinical trials 


Fernando Martínez García 

During the last year we have focused 

our research activity in those 

mechanisms, which are involved in 

the development of microalbuminuria 

and kidney damage in hypertensive 

patients. In this sense we 

have been studying the role of the 

podocytes in the regulation of urine albumin excretion not only 

in hypertension but also in obesity and diabetes. 

We are also studying the role of new image techniques for the 

early diagnosis of atherosclerosis and the potential value of markers 

of vascular stiffness for risk prediction. Jointly with other research 

groups we are also performing some collaborative studies 

in metabolic syndrome and insulin resistance. Finally we are also 

taking advantage of the new Electronic Health Recordings system 

to analyse cardiovascular risk factors and events in real world. 

All of our research is aimed to improve the prevention and the 

consequences of cardiovascular disease, especially those related 

with essential hypertension. 

69 


• Mechanisms of development of renal damage associated 

with hypertension with special emphasis on the podocyte 

damage 

• Impact of cardiovascular risk factors and renal function in 

absolute morbidity and mortality in high-risk population 

and in the general population 

• Inflammation and oxidative stress in the development of 

cardiovascular disease 

• Genomics, proteomics and metabolomics of early cardiometabolic 

and renal disorders 

• Impact of environmental toxins (metals) in cardiometabolic 

risk 

• Identification of polymorphisms and related to the control 

of BMI and waist circumference and the risk of obesity 

genes 

• Venous thrombosis in young patients: factors associated 

with its development 

• The relationship between risk of venous thromboembolic 

disease and arteriosclerosis 


María Téllez Plaza 

Dr. Téllez-Plaza’s research interest 

is in the health consequences of widespread 

exposure to environmental 

toxicants. In recent years, her 

research has built expertise in population-based 

studies of the chronic 

cardiovascular effects of cadmium, 

arsenic and other toxic metals. Her 

current focus is on the use of DNA-methylation alterations as a 

tool for studying gene-environment interaction. The epigenetic 

epidemiology field is moving towards high-throughput platforms 

that allow genome-wide arrays and next-generation sequencing, 

and an important area of work involves the development of data 

analysis methods that can be applied to genome-wide DNAmethylation 

data in population-based studies. The simultaneous 

assessment of environmental exposures, genetic and epigenetic 

profiles and cardiovascular end-points can have important clinical 

and public health implications for cardiovascular disease prevention 

and control, while also developing novel research areas.

4 

Scientific 

activity 

70 



31 147,59 4,76 

National 



International 


Corresponding 

author 

11 8 16 

1. Pichler G, Martínez F, Vicente A, Solaz E, Calaforra O, Lurbe 

E, Redon J. Influence of obesity in central blood pressure. J 

Hypertens. 2015 Feb ;33(2):308-13.IF: 4,72 

2. Galán-Chilet I, Guallar E, Martín-Escudero JC, De Marco G, 

Dominguez-Lucas A, González-Manzano I, López-Izquierdo 

R, Redon J, Chaves FJ, Téllez-Plaza M. Do genes modify the 

association of selenium and lipid levels? Antioxid Redox Signal. 

2015 May 20 ;22(15):1352-62.IF: 7,407 

3. Böhm M, Schumacher H, Leong D, Mancia G, Unger T, 

Schmieder R, Custodis F, Diener HC, Laufs U, Lonn E, 

Sliwa K, Teo K, Fagard R, Redon J, Sleight P, Anderson C, 

O’Donnell M, Yusuf S. Systolic blood pressure variation and 

mean heart rate is associated with cognitive dysfunction in 

patients with high cardiovascular risk. Hypertension. 2015 

Mar ;65(3):651-61.IF: 6,48 



newborns exposed to tobacco in utero. J Transl Med. 2015 

Jan 27 ;13(1):25.IF: 3,93 

5. Redon J. Different strategies from monotherapies to dual 

or triple fixed dose combination therapies to achieve blood 

pressure goals: a summary of a satellite symposium from 

the European Society of Hypertension, June 13-16, 2014 

Athens, Greece. Introduction. High Blood Press Cardiovasc 

Prev. 2015 Jul ;22 Suppl 1:S3-4.IF: 0 

6. Redón J, Monleón D. Combining -omics in the search for 

mechanisms in complex trait diseases. J Hypertens. 2015 

Apr ;33(4):698-9.IF: 4,72 

7. Redon J, Lurbe E. The kidney in obesity.Curr Hypertens Rep. 

2015 Jun ;17(6):555.IF: 3,435 

8. Mahfoud F, Böhm M, Azizi M, Pathak A, Durand Zaleski 

I, Ewen S, Tsioufis K, Andersson B, Blankestijn PJ, Burnier 

M, Chatellier G, Gafoor S, Grassi G, Joner M, Kjeldsen SE, 

Lüscher TF, Lobo MD, Lotan C, Parati G, Redon J, Ruilope L, 

Sudano I, Ukena C, van Leeuwen E, Volpe M, Windecker S, 

Witkowski A, Wijns W, Zeller T, Schmieder RE. Proceedings 

from the European clinical consensus conference for renal 

denervation: considerations on future clinical trial design. 

Eur Heart J. 2015 Sep 1 ;36(33):2219-27.IF: 15,203 

9. Ruiz-Hernandez A, Kuo CC, Rentero-Garrido P, Tang WY, 

Redon J, Ordovas JM, Navas-Acien A, Téllez-Plaza M. 

Environmental chemicals and DNA methylation in adults: 

a systematic review of the epidemiologic evidence. Clin 

Epigenetics. 2015 ;7(1):55.IF: 0 

10. Marrachelli V, Monleón D, Morales JM, Rentero P, Martínez F, 

Chaves FJ, Martín-Escudero JC, Redon J. 6C.04: INTEGRATED 

SNP ANALYSIS AND METABOLOMIC PROFILES OF METABOLIC 

SYNDROME. J Hypertens. 2015 Jun ;33 Suppl 1:e80.IF: 4,72 

11. Téllez-Plaza M, Orozco-Beltran D, Gil-Guillen V, Navarro- 

Pérez J, Pallares V, Valls F, Fernandez A, Martín-Moreno 

JM, Sanchis C, Dominguez-Lucas A, Redon J. 3A.05: 

HYPERTENSION AND RISK OF EVENTS ASSOCIATED TO 

REDUCED EGFR. THE ESCARVAL-RISK STUDY. J Hypertens. 

2015 Jun ;33 Suppl 1:e32-3.IF: 4,72 

12. Kotsis V, Nilsson P, Grassi G, Mancia G, Redon J, Luft F, 

Schmieder R, Engeli S, Stabouli S, Antza C, Pall D, Schlaich M, 

Jordan J, WG on Obesity, Diabetes, the High Risk Patient, European 

Society of Hypertension. New developments in the 

pathogenesis of obesity-induced hypertension. J Hypertens. 

2015 Aug ;33(8):1499-508.IF: 4,72 

13. Pichler G, Martínez F, Vicente A, Solaz E, Calaforra O, Redon 

J. Carotid-femoral pulse wave velocity assessment by 

two different methods: implications for risk assessment. J 

Hypertens. 2015 Sep ;33(9):1868-75.IF: 4,72 

14. Redon J, Team MD. 2A.06: COMPARATIVE STUDY OF THE 

EFFICACY OF OLMESARTAN/AMLODIPINE VERSUS PERIN- 

DOPRIL/AMLODIPINE IN PERIPHERAL AND CENTRAL BP 

PARAMETERS AFTER MISSED DOSE IN TYPE 2 DIABETES. J 

Hypertens. 2015 Jun ;33 Suppl 1:e20-1.IF: 4,72 

15. Patiño Galindo JA, Torres-Puente M, Gimeno C, Ortega E, 

Navarro D, Galindo MJ, Navarro L, Navarro V, Juan A, Belda 

J, Bracho MA, González-Candelas F, CRIVIH. Expansion 

of the CRF19_cpx Variant in Spain. J Clin Virol. 2015 Aug 

;69:146-9.IF: 3,016 

16. Casadellà M, van Ham PM, Noguera-Julian M, van Kessel A, 

Pou C, Hofstra LM, Santos JR, García F, Struck D, Alexiev I, 

Bakken Kran AM, Hoepelman AI, Kostrikis LG, Somogyi S,


4 

Liitsola K, Linka M, Nielsen C, Otelea D, Paraskevis D, Poljak 

M, Puchhammer-Stöckl E, Staneková D, Stanojevic M, Van 

Laethem K, Zidovec Lepej S, Clotet B, Boucher CA, Paredes 

R, Wensing AM, SPREAD programme. Primary resistance to 

integrase strand-transfer inhibitors in Europe. J Antimicrob 

Chemother. 2015 Oct ;70(10):2885-8.IF: 5,313 

17. Aldámiz-Echevarría T, González-García J, Von Wichmann MA, 

Crespo M, López-Aldeguer J, Quereda C, Téllez MJ, Galindo 

MJ, Sanz J, Santos I, Guardiola JM, Bellón JM, Montes M, 

Berenguer J. Association of baseline CD4+ cell count and 

HIV-RNA on sustained virologic response to interferonribavirin 

in HIV/HCV coinfected patients. Ann Hepatol. 2015 

Jul-Aug ;14(4):464-9.IF: 2,065 

18. Gribble MO, Voruganti VS, Cole SA, Haack K, Balakrishnan 

P, Laston SL, Téllez-Plaza M, Francesconi KA, Goessler W, 

Umans JG, Thomas DC, Gilliland F, North KE, Franceschini 

N, Navas-Acien A. Linkage Analysis of Urine Arsenic Species 

Patterns in the Strong Heart Family Study. Toxicol Sci. 2015 

Nov ;148(1):89-100.IF: 3,854 

19. Berenguer J, Zamora FX, Aldámiz-Echevarría T, Von 

Wichmann MA, Crespo M, López-Aldeguer J, Carrero A, 

Montes M, Quereda C, Téllez MJ, Galindo MJ, Sanz J, 

Santos I, Guardiola JM, Barros C, Ortega E, Pulido F, Rubio 

R, Mallolas J, Tural C, Jusdado JJ, Pérez G, Díez C, Álvarez- 

Pellicer J, Esteban H, Bellón JM, González-García J, Grupo de 

Estudio del SIDA (GESIDA) HIV/HCV Cohort Study Group. 

Comparison of the prognostic value of liver biopsy and FIB-4 

index in patients coinfected with HIV and hepatitis C virus. 

Clin Infect Dis. 2015 Mar 15 ;60(6):950-8.IF: 8,886 

20. Mansego ML, De Marco G, Ivorra C, López-Izquierdo R, 

Morcillo S, Rojo-Martínez G, González-Albert V, Martínez 

F, Soriguer F, Martín-Escudero JC, Redon J, Chaves FJ. The 

nutrigenetic influence of the interaction between dietary 

vitamin E and TXN and COMT gene polymorphisms on waist 

circumference: a case control study. J Transl Med. 2015 Sep 

2 ;13:286.IF: 3,93 

21. Pichler G, Martínez F, Fernandez C, Redon J. Unusual Case 

of Severe Hypertension in a 20-Year-Old Woman. Hypertension. 

2015 Dec ;66(6):1093-7.IF: 6,48 

22. Perez-Hernandez J, Forner MJ, Pinto C, Chaves FJ, Cortes 

R, Redon J. Increased Urinary Exosomal MicroRNAs in Patients 

with Systemic Lupus Erythematosus. PLoS One. 2015 

;10(9):e0138618.IF: 3,234 

23. Grassi G, Seravalle G, Maloberti A, Facchetti R, Cuspidi C, 

Bombelli M, Laurent S, Redon J, Mancia G. Within-visit BP 

variability, cardiovascular risk factors, and BP control in central 

and eastern Europe: findings from the BP-CARE study. J 

Hypertens. 2015 Nov ;33(11):2250-6.IF: 4,72 

24. NCD Risk Factor Collaboration (NCD-RisC). Effects of diabetes 

definition on global surveillance of diabetes prevalence 

and diagnosis: a pooled analysis of 96 population-based 

studies with 331,288 participants. Lancet Diabetes Endocrinol. 

2015 Aug ;3(8):624-37.IF: 9,185 

25. Viciana-Fernández P, Falcó V, Castaño M, de los Santos-Gil I, 

Olalla-Sierra J, Hernando A, Deig E, Clotet B, Knobel H, Podzamczer 

D, Pedrol PD, Grupo de trabajo Bridgap. [Barriers 

to ART initiation in HIV infected subjects and with treatment 

indication in Spain. Why don’t they start their treatment? 

Bridgap Study]. Enferm Infecc Microbiol Clin. 2015 Jun-Jul 

;33(6):397-403.IF: 2,172 

26. Rojo D, Gosalbes MJ, Ferrari R, Pérez-Cobas AE, Hernández 

E, Oltra R, Buesa J, Latorre A, Barbas C, Ferrer M, Moya A. 

Clostridium difficile heterogeneously impacts intestinal 

community architecture but drives stable metabolome responses. 

ISME J. 2015 Oct;9(10):2206-20. IF: 9,302 

Review 

27. Apostolova N, Funes HA, Blas-García A, Galindo MJ, Alvarez 

A, Esplugues JV. Efavirenz and the CNS: what we already 

know and questions that need to be answered. J Antimicrob 


28. Perez-Hernandez J, Cortes R. Extracellular Vesicles as Biomarkers 

of Systemic Lupus Erythematosus. Dis Markers. 

2015 ;2015:613536.IF: 1,562 

Letter 

29. Pichler G, Martínez F, Redon J. Reply.J Hypertens. 2015 Dec 

;33(12):2551.IF: 4,72 

Guidelines 

30. Grupo de expertos del Grupo de Estudio sobre Alteraciones 

Metabólicas (GEAM), de la Secretaría del Plan Nacional sobre 

el Sida (SPNS) y del Grupo de Estudio de Sida (GeSIDA), 

Polo Rodríguez R, Galindo Puerto MJ, Dueñas C, Gómez 

Candela C, Estrada V, Villar NG, Locutura J, Mariño A, Pascua 

J, Palacios R, von Wichmman MÁ, Álvarez J, Asensi V, López 

Aldeguer J, Lozano F, Negredo E, Ortega E, Pedrol E, Gutié- 

71

4 

Scientific 

activity 

72 

rrez F, Sanz Sanz J, Martínez Chamorro E. [Consensus statement 

on metabolic disorders and cardiovascular risks in 

patients with human immunodeficiency virus]. Enferm Infecc 

Microbiol Clin. 2015 Jan ;33(1):40.e1-40.e16.IF: 2,172 

31. Panel of experts from the Metabolic Disorders Study Group 

(GEAM), National Aids Plan (SPNS), Aids Study Group (Ge- 

SIDA), Polo Rodríguez R, Galindo Puerto MJ, Dueñas C, Gómez 

Candela C, Estrada V, Villar NG, Locutura J, Mariño A, 

Pascua J, Palacios R, Von Wichmman MÁ, Álvarez J, Asensi 

V, López Aldeguer J, Lozano F, Negredo E, Ortega E, Pedrol 

E, Gutiérrez F, Sanz Sanz J, Martínez Chamorro E. Executive 

summary of the consensus document on metabolic disorders 

and cardiovascular risk in patients with HIV infection. 

Enferm Infecc Microbiol Clin. 2015 Jan ;33(1):41-7.IF: 2,172 


RESEARCH 

Reference: HEALTH 2011.2.4.2-2 

Title: Markers for Subclinical Cardiovascular Risk Assessment 

Principal Investigator: Josep Redón i Mas 







Title: CIBER de obesidad y trastornos de la nutrición 

Principal Investigator: Empar Lurbe i Ferrer (Josep Redón i 

Mas as collaborating research) 



General Universitario de Valencia 



Title: Podocitos y sus componentes como biomarcadores de 

lesión en hipertensión arterial, diabetes y obesidad 







Reference: CP12/03080 

Título: DNA Methylation and Hydroxymethylation, Metal 

Exposure and Cardiovascular Risk: an Epidemiologic Study 

Principal Investigator: María Téllez Plaza 






Reference: COST Action TD0905 

Title: Epigenetics: Epigenetics: Bench to Bedside 

Principal Investigator: Arasu Ganesan (María Téllez as 



Beneficiary institution: University of East Anglia, Norwich 

Research Park (UK) 


Reference: AFI 

Title: Desarrollo de la Unidad de Gestión de Proyectos 

Internacionales 


Funding Body: Conselleria de Sanidad 




Title: Estudio metabolómico de lípidos intra-miocelulares en 

preobesidad. 

Principal Investigator: Fernando Martínez García 

Funding Body: Fundación ERESA 





Title: Deterioro neurocognitivo (DNC) en mujeres VIH positivo. 

(Parte II) 

Principal Investigator: Mª José Galindo Puerto 

Funding Body: Janssen - Cilag S.A. 

Program: Research Fellowship Program 

Fellow: Ramón Ferrando Vilalta 



Duration: 2014 - 2015


4 

Research Group on Vascular Function 


73 

Group members 


José Mª Vila Salinas. 

University 

H Index: 18 


Salvador Lluch López. University 

Martín Aldasoro Celaya. University 

Pascual Medina Besso. University 

Gloria Segarra Irles. University 

Mª Dolores Mauricio Aviñó. University

4 

Scientific 

activity 


• Vascular changes associated with experimental cirrhosis 

and portal hypertension 

• The involvement of VEGF in tumor growth 

Review 

4. Lluch P, Segarra G, Medina P. Asymmetric dimethylarginine 

as a mediator of vascular dysfunction in cirrhosis. World J 

Gastroenterol. 2015 Aug 28 ;21(32):9466-75.IF: 2,369 


• Characterization of alterations in the control of vascular 

tone and endothelial function induced by aging 

• Alterations of ADMA-NO and EDHF system in obese patients 

with steatosis and steatohepatitis 

• The effects of exercise training on the vascular response 

• Vascular effects of ranolazine 

• Effects of ranolazine extravascular 

74 



4 12,32 3,08 

National 


International 


Corresponding 

author 

2 - 2 


1. Aguirre-Rueda D, Guerra-Ojeda S, Aldasoro M, Iradi A, Obrador 

E, Ortega A, Mauricio MD, Vila JM, Valles SL. Astrocytes 

Protect Neurons from A?1-42 Peptide-Induced Neurotoxicity 

Increasing TFAM and PGC-1 and Decreasing PPAR-? and 

SIRT-1. Int J Med Sci. 2015 ;12(1):48-56.IF: 2,003 

2. Vidal-Gómez X, Perez-Monzo I, Mompeon A, Segarra G, 

Dantas AP, Hermenegildo C, Medina P, Novella S. 2C.04: 

TIMING OF BLOOD PRESSURE AND VASCULAR CHANGES 

INDUCED BY AGEING IN AORTA AND SMALL MESENTER- 

IC ARTERIES FROM FEMALE SENESCENCE-ACCELERATED 

MOUSE PRONE (SAMP8). J Hypertens. 2015 Jun ;33 Suppl 

1:e26.IF: 4,72 

3. Aguirre-Rueda D, Guerra-Ojeda S, Aldasoro M, Iradi A, 

Obrador E, Mauricio MD, Vila JM, Marchio P, Valles SL. WIN 

55,212-2, agonist of cannabinoid receptors, prevents amyloid? 

1-42 effects on astrocytes in primary culture. PLoS 

One. 2015 ;10(4):e0122843.IF: 3,234


4 

Research Group on Pedriatric Nutrition 


75 

Group members 


Cecilia Martínez Costa. 


H Index: 13 


Francisco Núñez Gómez. Hospital. University 

Javier Buesa Gómez. Hospital. University 

Carmen Collado Amores. IATA-CSIC Valencia 

Mª Ángeles Montal Navarro. Hospital. University 

Pablo García Molina. Hospital. University 

Evelin Balaguer López. Hospital. University 

Elena Crehuá Gaudiza. Hospital 

Bibiana Bertua Ríos. INCLIVA 

Ana Paula Grattarola. OMS 

Izaskun García-Mantrana. IATA-CSIC Valencia 

Julia Sánchez Zahonero. Hospital 

Inmaculada Tarazona Casany. Hospital 

Elena Martínez Arias. Hospital 

Virtudes Molina Sevilla. Hospital 

Javier Estañ Capell. Hospital. University 

Laura Martínez Rodríguez. Hospital

4 

Scientific 

activity 

76 


• To measure the vascular changes by Doppler ultrasound 

and its correlation with the metabolic alterations in cardiovascular 

risk children 

• To quantify norovirus-specific antibodies and their blocking 

activity on the binding of norovirus-like particles of 

Caco-2 and / or saliva cells. To relate it with the results 

with the ABO blood group, the secretory phenotype 

mother and Lewis antigen. To analyze the composition 

of the microbiota in human milk longitudinal samples in 

term and preterm infants 

• To analyze the nutritional response of home support and 

to apply validated systems to measure their impact on 

the quality of life of patients and their caregivers 


Cardiovascular area: 

• Study of early markers of vascular damage in dyslipidemic 

obese children by Doppler ultrasonography to establish 

a correlation with insulin resistance and other 

metabolic markers 

• Monitoring exercise and energy consumption in obese 

schoolchildren and teenagers to adjust nutritional intervention 

Area of human milk: 

• Analysis of defensive factors against norovirus infections 

and its relationship with histo-blood group antigens 

and FUT genotype 

• Analysis of mother-fetal microbiome and cold preservation 

methods 

Area of hospital malnutrition and artificial nutrition: 

• Screening procedures for detecting the risk of malnutrition 

linked to chronic disease and pediatric hospitalization 

• Multicenter study of acceptance and quality of life in 

children treated with home enteral nutrition 



7 21,062 3 

National 



International 


Corresponding 

author 

6 1 1 

1. Wanden-Berghe C, Cuerda Compes JC, Burgos Peláez R, 

Gómez Candela C, Virgili Casas N, Pérez de la Cruz A, Moreno 

Villares JM, Carabaña Pérez F, Garde Orbaiz C, Martínez 

Faedo C, Penacho Lázaro MÁ, Gonzalo Marín M, García Luna 

PP, Matía Martín P, Sanz Paris A, Luengo Pérez LM, Martín 

Folgueras T, García Zafra MV, Hernández Á, Campos Martín 

C, Suárez Llanos JP, Zugasti A, Apezetxea Celaya A, Urgeles 

Planella JR, Laborda González L, Sánchez-Vilar Burdiel O, 

Joaquín Ortiz C, Martínez Costa C, Vidal Casariego A, Leyes 

García P, Ponce González MA, Gil Martínez MC, Sánchez 

Martos EÁ, del Olmo García MD, Díaz Guardiola P, Grupo 

NADYA-SENPE. A Home and Ambulatory Artificial Nutrition 

(NADYA) group report, Home Parenteral Nutrition in Spain, 

2013. Nutr Hosp. 2015 Jun 1 ;31(6):2533-8.IF: 1,04 

2. Carmona-Vicente N, Fernández-Jiménez M, Ribes JM, Téllez- 

Castillo CJ, Khodayar-Pardo P, Rodríguez-Diaz J, Buesa J. 

Norovirus infections and seroprevalence of genotype GII.4- 

specific antibodies in a Spanish population.J Med Virol. 

2015 Apr ;87(4):675-82.IF: 2,347 

3. Collado MC, Santaella M, Mira-Pascual L, Martínez-Arias E, 

Khodayar-Pardo P, Ros G, Martínez-Costa C. Longitudinal 

Study of Cytokine Expression, Lipid Profile and Neuronal 

Growth Factors in Human Breast Milk from Term and Preterm 

Deliveries. Nutrients. 2015 Oct 19 ;7(10):8577-91.IF: 3,27 

4. González Jiménez D, Muñoz Codoceo R, Garriga García 

M, Molina Arias M, Alvarez Beltran M, García Romero R, 

Martínez Costa C, Meavilla Olivas SM, Peña Quintana L, 

Gallego Gutierrez S, Marugan de Miguelsanz JM, Suárez 

Cortina L, Castejón Ponce EN, Leis Trabazo R, Martín Cruz 

F, Díaz Martín JJ, Bousoño García C. [VITAMIN D AND 

CHRONIC LUNG COLONIZATION IN PEDIATRIC AND YOUNG 

ADULTS CYSTIC FIBROSIS PATIENTS]. Nutr Hosp. 2015 Oct 1 

;32(4):1629-35.IF: 1,04 

5. Wanden-Berghe C, Pereira Cunill JL, Cuerda Compes C, 

Moreno Villares JM, Pérez de la Cruz A, Burgos Peláez R, 

Gómez Candela C, Virgili Casas N, Penacho Lázaro MA,


4 

Martínez Faedo C, Garde Orbaiz C, Gonzalo Marín M, Sanz 

Paris A, Álvarez J, Sánchez Martos EA, Martín Folgueras T, 

Campos Martín C, Matía Martín P, Zugasti A, Carabaña Pérez 

F, García Zafra MV, Ponce González MA, Suárez Llanos 

JP, Martínez Costa C, De Luis D, Apezetxea Celaya A, Luengo 

Pérez LM, Díaz Guardiola P, Gil Martínez MC, Del Olmo 

García MD, Leyes García P, Vidal Casariego A, Joaquín Ortiz 

C, Sánchez-Vilar Burdiel O, Laborda González L. [HOME 

AND AMBULATORY ARTIFICIAL NUTRITION (NADYA) GROUP 

REPORT, HOME PARENTERAL NUTRITION IN SPAIN, 2014]. 

Nutr Hosp. 2015 Dec 1 ;32(6):2380-4.IF: 1,04 

6. Poelman R, Schuffenecker I, Van Leer-Buter C, Josset L, 

Niesters HG, Lina B, ESCV-ECDC EV-D68 study group. 

European surveillance for enterovirus D68 during the 

emerging North-American outbreak in 2014. J Clin Virol. 

2015 Oct ;71:1-9.IF: 3,016 




community architecture but drives stable metabolome 

responses. ISME J. 2015 Oct;9(10):2206-20. IF: 9,302 


RESEARCH 

Reference: SAF2012-38368 

Title: Especificidad de receptores y antigenicidad de variantes 

epidémicas de norovirus genotipo GII.4 causantes de 

gastroenteritis aguda 

Principal Investigator: Javier Buesa Gómez (Cecilia Martínez 

Costa as collaborating researcher) 

Funding body: Ministerio de Economía y Competitividad 

Beneficiary institution: Universidad de Valencia 



Title: Búsqueda de las bases genéticas no descritas hasta el 

momento en la abetalipoproteinemia mediante secuenciación 

de exoma 

Principal Investigator: Ana Bárbara García García (Cecilia 

Martínez Costa as collaborating researcher) 

Funding body: Fundación Mutua Madrileña 

Beneficiary institution: CIBERdem 



Title: Atlas de los nutrientes en la leche materna 

Principal Investigator: Cecilia Martínez-Costa 

Funding body: Nestec 





Reference: I-LINK0679 

Title: Impact of diet, nutrition and geographical location on 

host-microbe interactions. 

Principal Investigator: María Carmen Collado (Cecilia 


Funding body: ILINK-2013 CSIC 





Reference: ERC Starting Grant 2014 

Title: The power of maternal microbes on infant health. 

Principal Investigator: María Carmen Collado (Cecilia 


Funding body: ERC (European Research Council) 




Total budget: 

• THESIS 

Thesis title: Análisis de los factores epidemiológicos y clínicos 

implicados en el desarrollo de la enterocolitis necrosante 

Doctoral candidate: Laura Martínez Rodríguez 

Director(s): Cecilia Martínez Costa, Javier Estañ Capell, Juan 

Brines 



Thesis title: Adaptación cultural y validación de la escala de 

valoración de riesgo de desarrollar úlceras por presión en 

neonatos hospitalizados (Neonatal Skin Risk Assessment Scale). 

Doctoral candidate: Pablo García Molina 

Director(s): José Verdú Soriano, Francisco Pedro García- 

Fernández. 



77

4 

Scientific 

activity 

Group on Translational Research in Ischemic Heart Disease 


78 

Group members 


Vicente Bodí Peris. 


H Index: 24 


Clara Bonanad Lozano. INCLIVA. Hospital 

Amparo Ruiz Saurí. University 

Jose Vicente Monmeneu Menadas. Eresa 

Eva Rumiz Gónzález. Hospital 

David Moratal Pérez. UPV 

José Gavara Doñate. INCLIVA 

Nerea Pérez Solé. INCLIVA 

Predoctoral researchers 

Arantxa Hervás Lorente. INCLIVA 

Technicians 

Ana Díaz Cuevas. University 

Elena de Dios Lluc. INCLIVA


4 


• To focus into a translational approach 

• To continue dilucidating the physiological role of the immune 

dysregulation. Indeed we have deeply elucidated 

the macroscopic, microscopic and molecular changes in 

the fibrotic process after a myocardial infarction by using 

a swine model 

• To develop new tools to study patients with myocardial 

infarction using magnetic resonance imaging 

• To advance in basic mechanisms, diagnosis, prediction 

and prevention of cardiac damage in reperfused acute 

myocardial infarction 


• Prospective registry of patients with first ST-segment elevation 

myocardial infarction studied with cardiac MRI 

• Multicenter registry of patients with myocardial ischemia 

studied with stress cardiac MRI 

• Porcine model of experimental myocardial ischemia and 

myocardial infarction. To achieve a better understanding 

of the pathophysiology of ischemia, necrosis, fibrosis and 

reperfussion injury and test novel 

• Involvement in several large international multicenter clinical 

trials in the field of acute coronary syndromes 



13 90,22 8,20 

National 



International 


Corresponding 

author 

9 4 4 

1. Del-Canto I, López-Lereu MP, Monmeneu JV, Croisille P, 

Clarysse P, Chorro FJ, Bodí V, Moratal D. Characterization 

of normal regional myocardial function by MRI cardiac tagging. 

J Magn Reson Imaging. 2015 Jan ;41(1):83-92.IF: 3,21 

2. Núñez-Gil IJ, Almendro-Delia M, Andrés M, Sionis A, Martín 

A, Bastante T, Córdoba-Soriano JG, Linares JA, González Sucarrats 

S, Sánchez-Grande-Flecha A, Fabregat-Andrés O, Pérez 

B, Escudier-Villa JM, Martín-Reyes R, Pérez-Castellanos 

A, Rueda Sobella F, Cambeiro C, Piqueras-Flores J, Vidal-Perez 

R, Bodí V, García de la Villa B, Corbí-Pascua M, Biagioni 

C, Mejía-Rentería HD, Feltes G, Barrabés J, RETAKO investigators. 

Secondary forms of Takotsubo cardiomyopathy: 

A whole different prognosis. Eur Heart J Acute Cardiovasc 

Care. 2015 Jun 4 ;.IF: 0 

3. Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, 

Dickstein K, Gerstein HC, Johnston P, Køber LV, Lawson F, 

Lewis EF, Maggioni AP, McMurray JJ, Ping L, Probstfield JL, 

Solomon SD, Tardif JC, Wu Y, Pfeffer MA, ELIXA Investigators. 

Rationale, design, and baseline characteristics in Evaluation 

of LIXisenatide in Acute Coronary Syndrome, a long-term 

cardiovascular end point trial of lixisenatide versus placebo. 

Am Heart J. 2015 May ;169(5):631-638.e7.IF: 4,463 

4. Santas E, García-Blas S, Miñana G, Sanchís J, Bodí V, Escribano 

D, Muñoz J, Chorro FJ, Núñez J. Prognostic implications of 

tissue Doppler imaging-derived e/ea ratio in acute heart failure 

patients. Echocardiography. 2015 Feb ;32(2):213-20.IF: 1,254 

5. Hervas A, de Dios E, Forteza MJ, Miñana G, Nuñez J, Ruiz- 

Sauri A, Bonanad C, Perez-Sole N, Chorro FJ, Bodí V. 

Intracoronary Infusion of Thioflavin-S to Study Microvascular 

Obstruction in a Model of Myocardial Infarction. Rev Esp 

Cardiol (Engl Ed). 2015 Nov ;68(11):928-34.IF: 3,792 





failure. PLoS One. 2015 ;10(4):e0122360.IF: 3,792 

7. Barrabés JA, Bardají A, Jiménez-Candil J, del Nogal Sáez F, 

Bodí V, Basterra N, Marco E, Melgares R, Cuñat de la Hoz J, 

Fernández-Ortiz A, investigators of DIOCLES study. Prognosis 

and management of acute coronary syndrome in Spain 

in 2012: the DIOCLES study. Rev Esp Cardiol (Engl Ed). 2015 

Feb ;68(2):98-106.IF: 0 

8. Ortiz R, Morales JM, Ruiz-Espana S, Bodí V, Monleón D, 

Moratal D. Magnetic resonance microimaging of a swine 

infarcted heart: Performing cardiac virtual histologies. Conf 

Proc IEEE Eng Med Biol Soc. 2015 Aug ;2015:1584-7.IF: 0 

9. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, 

Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, 

McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif 

JC, ELIXA Investigators. Lixisenatide in Patients with Type 2 

Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015 

Dec 3 ;373(23):2247-57.IF: 55,873 

79

4 

Scientific 

activity 

80 

10. Santas E, Chorro FJ, Miñana G, Mendez J, Muñoz J, Escribano 

D, García-Blas S, Valero E, Bodí V, Nuñez E, Sanchís J, Nuñez 

J. Tricuspid Regurgitation and mortality risk across left ventricular 

systolic function in acute heart failure. Circ J. 2015; 

79:1526-33. IF: 3.940 

11. Núñez J, Merlos P, Fácila L, Llacer P, Bosch MJ, Bertomeu- 

Martínez V, Blas-García S, Montagud V, Pedrosa V, Mendizábal 

A, Cordero A, Miñana G, Sanchís J, Bertomeu-González 

V; CHANCE-HF Investigators. Prognostic effect of carbohydrate 


for acute heart failure (CHANCE-HF). Study design. 

Rev Esp Cardiol. 2015 Feb;68(2)_121-8. IF: 3.792. 

12. Villanueva MP, Mollar A, Palau P, Carratala A, Núñez E, Santas 

E, Bodí V, Chorro FJ, Miñana G, Blasco ML, Sanchís J, 

Núñez J. Procalcitonin and long-term prognosis after an 

admission for acute heart failure. Eur J Intern Med. 2015 

Jan;26(1):42-8. IF: 2.300 

Letter 

13. Núñez-Gil IJ, Sionis A, Andrés M, Almendro Delia M, Martín 

A, Lozano Á, Córdoba Soriano JG, Linares Vicente JA, González 

Sucarrats S, Sánchez Grande Flecha A, Mejía-Rentería 

HD, Biagioni C, Feltes G, Barrabés JA, RETAKO investigators. 

Takotsubo cardiomyopathy and elderly adults: still a benign 

condition?J Am Geriatr Soc. 2015 Feb ;63(2):404-7.IF: 4,572 

Principal Investigator: Vicente Bodí Peris 






Reference: Beca Cátedra ERESA 

Title: Estudio prospectivo para el análisis de la fibrosis 

cardíaca mediante resonancia magnética cardíaca usando la 

secuencia T1 mapping 


Funding Body: Fundación Grupo ERESA 




Reference: PIE15/00013 

Title: A multidisciplinary Project to advance in basic 

mechanisms, diagnosis, prediction, and prevention of cardiac 

damage in reperfused acute myocardial infarction 





Duration: 2015 - 2018 



RESEARCH 

Reference: PROMETEO/2013/007 

Title: Inmunidad y metabolismo: exploración de nuevas vías 

fisiopatológicas y oportunidades terapéuticas en el infarto 

agudo de miocardio 








Title: Fibrosis miocárdica tras un infarto de miocardio. Estudio 

traslacional para la innovación diagnóstica con resonancia 

magnética y para el entendimiento de los mecanismos 

reguladores 

Reference: FPU12/01140 

Title: Diagnóstico y pronóstico de enfermedades 

cardiovasculares mediante el análisis de la señal de 

espectroscopia por resonancia magnética nuclear de suero 

sanguíneo y su determinación metabolómica 






• THESIS 

Thesis title: Estudio de la afectación del ventrículo derecho en 

el infarto anterior reperfundido. 

Doctoral candidate: Eva Rumiz González 

Director(s): Vicente Bodí Peris 




4 

• AWARDS 

On 2015, Vicente Bodí was awarded by the Cardiac Imaging 

Section of the Valencian Society of Cardiology for his work 

“Predicción de eventos cardíacos mayores a largo plazo 

mediante resonancia magnética cardíaca tras un infarto agudo 

de miocardio con elevación del segmento ST”. Moreover, 

he was also awarded by the Real Academia de Medicina de 

la Comunidad Valenciana for the scientific work “Proof-ofconcept 

methodology for studying the effect of ischemicreperfusion 

injury on microvascular obstruction in myocardial 

samples of an in vivo model of myocardial infarction”. 

81 

Fig 1: The group led by Dr. Bodí has developed a model of 

acute myocardial infarction in which a transient occlusion 

of the left anterior descending artery is induced. With 

these samples, you can simulate events that occur in 

the pathophysiology of myocardial regeneration after 

myocardial 

Fig 2: In samples obtained in patients with acute 

myocardial infarction and in an in vivo myocardial 

infarction model, you can study the inflammatory process 

and the degree of fibrosis at different levels: macroscopic, 

microscopic, cell, gene expression and protein and through 

by magnetic resonance microimage

4 

Scientific 

activity 

4.1.2 Oncology Area 

Research Group on Histopathology and Tissue Engineering 83 

Research Group on Central Nervous System Tumours 86 

Research Group on Colorectal Cancer and New Therapeutical Developments in Solid Tumours 89 

Research Group on Breast Cancer Biology 95 

Research Group on Skin Cancer 102 

Translational Research Group on Pediatric Solid Tumours 105 

Research Group on Hematopoietic Transplantation 109 

Research Group on Lymphoproliferative Disorders 114 

Research Group on Myeloid Neoplasms 117 

Research Group on Epigenetics and Chromatin 121 

Research Group on Molecular Imaging and Metabolomics 124 

82 

Impact 

Factor (IF) 

Total: 1.019,80 

Average: 6,18 

165 

Publications 

69 

International 


JCR: 

61 in D1 

93 in Q1 

31 in Q2 

Author: 




author


4 

Research Group on Histopathology and Tissue Engineering 


83 

Group members 


Carmen Carda Batalla 

University 

H Index: 20 


Amando Peydró Olaya. Hospital. University 

Amparo Ruiz Sauri. University 

María Sancho-Tello Valls. University 

José Javier Martín de Llano. University 

Manuel Mata Roig. University 

Lara Milian Medina. INCLIVA 

Teresa Sagrado Vives. University 

Miguel Armengot Carceller. University 

Carlos Tejerina Botella. Hospital 

Miguel Puche Torres. Hospital 

Mari Fe Minguez Rey. Hospital 

Genaro Galán Gil. Hospital 

Antonio Silvestre Muñoz. Hospital 

Francisco Forriol Brocal. University 

Antonio Fons Font. University 

Rosa María Cibrian Ortiz de Anda. University 

Santiago Peydró Tomas. University 

PhD students 

Esperanza Núñez Benito. University 

María Oliver Ferrándiz. University 

Javier Alcácer Fernández-Coronado. University

4 

Scientific 

activity 

84 


• In relation to the line of Tissue Engineering we have secured 

funding to continue working on regeneration techniques 

cartilage and bone 

• A project in relation to micro-cluster of Dentistry was also 

secured in order to investigate possible modifications of 

titanium as a biomaterial in different dental therapies 

• We provide publications, theses and attending conferences 

of which are derived that guarantee the trajectory in 

this annuity 


Regenerative medicine: 

• Study of cartilage regeneration 

• Study of bone regeneration 

• Study of use of pulpal precursors in regenerative therapies 

• Study of regeneration of dental and periodontal tissues 

• Study of corneal induction and regeneration 

• Study of tracheal regeneration 

Histopathology: 

• Study of recurrent myocardial infarction and its determinants 

• Study of vascularization in renal tumours 

• Study of ciliary pathology 

• Study of endometriosis 



11 27,84 2,53 

National 



International 


Corresponding 

author 

7 2 4 

1. Solá-Ruiz MF, Pérez-Martínez C, Martín-Del-Llano JJ, Carda- 

Batalla C, Labaig-Rueda C. In vitro preliminary study of 

osteoblast response to surface roughness of titanium discs 

and topical application of melatonin. Med Oral Patol Oral 

Cir Bucal. 2015 Jan 1 ;20(1):e88-93.IF: 0 

2. Sarrion I, Milian L, Juan G, Ramon M, Furest I, Carda 

C, Cortijo Gimeno J, Mata Roig M. Role of Circulating 

miRNAs as Biomarkers in Idiopathic Pulmonary Arterial 

Hypertension: Possible Relevance of miR-23a. Oxid Med 

Cell Longev. 2015 ;2015:792846.IF: 3,516 

3. Sancho-Tello M, Forriol F, Gastaldi P, Ruiz-Saurí A, Martín de 

Llano JJ, Novella-Maestre E, Antolinos-Turpín CM, Gómez- 

Tejedor JA, Gómez Ribelles JL, Carda C. Time evolution of 

in vivo articular cartilage repair induced by bone marrow 

stimulation and scaffold implantation in rabbits. Int J Artif 

Organs. 2015 Apr ;38(4):210-23.IF: 0,962 

4. Giner F, López-Guerrero JA, Machado I, García-Casado 

Z, Peydró-Olaya A, Llombart-Bosch A. The early stages 

of tumor angiogenesis in human osteosarcoma: a nude 

mice xenotransplant model. Virchows Arch. 2015 Aug 

;467(2):193-201.IF: 2,651 

5. Giménez-Garzó C, Salhi D, Urios A, Ruíz-Sauri A, Carda 

C, Montoliu C, Felipo V. Rats with mild bile duct ligation 

show hepatic encephalopathy with cognitive and motor 

impairment in the absence of cirrhosis: effects of alcohol 

ingestion. Neurochem Res. 2015 Feb ;40(2):230-40.IF: 2,593 

6. Hervas A, de Dios E, Forteza MJ, Miñana G, Nuñez J, Ruiz-Sauri 

A, Bonanad C, Perez-Sole N, Chorro FJ, Bodí V. Intracoronary 

Infusion of Thioflavin-S to Study Microvascular Obstruction 

in a Model of Myocardial Infarction. Rev Esp Cardiol (Engl 

Ed). 2015 Nov ;68(11):928-34.IF: 0 

7. Castangia I, Caddeo C, Manca ML, Casu L, Latorre AC, Díez- 

Sales O, Ruiz-Saurí A, Bacchetta G, Fadda AM, Manconi M. 

Delivery of liquorice extract by liposomes and hyalurosomes 

to protect the skin against oxidative stress injuries. 

Carbohydr Polym. 2015 Dec 10 ;134:657-63.IF: 4,074 

8. Alió del Barrio JL, Chiesa M, Gallego Ferrer G, Garagorri 

N, Briz N, Fernandez-Delgado J, Sancho-Tello Valls M, 

Botella CC, García-Tuñón I, Bataille L, Rodriguez A, Arnalich- 

Montiel F, Gómez Ribelles JL, Antolinos-Turpín CM, Gómez- 

Tejedor JA, Alió JL, De Miguel MP. Biointegration of corneal 

macroporous membranes based on poly(ethyl acrylate) 

copolymers in an experimental animal model. J Biomed 

Mater Res A. 2015 Mar ;103(3):1106-18.IF: 3,369 

9. Conejos-Sánchez I, Cardoso I, Oteo-Vives M, Romero- 

Sanz E, Paul A, Sauri AR, Morcillo MA, Saraiva MJ, Vicent 

MJ. Polymer-doxycycline conjugates as fibril disrupters: 

an approach towards the treatment of a rare amyloidotic 

disease. J Control Release. 2015 Jan 28 ;198:80-90.IF: 7,705 

10. Calzada D, Aguerri M, Baos S, Montaner D, Mata M, Dopazo 

J, Quiralte J, Florido F, Lahoz C, Cárdaba B. Therapeutic 

targets for olive pollen allergy defined by gene markers


4 

modulated by Ole e 1-derived peptides. Mol Immunol. 2015 

Apr ;64(2):252-61.IF: 2,973 

11. Fabregat-Andrés Ó, Ridocci-Soriano F, Estornell-Erill J, Corbí- 

Pascual M, Valle-Muñoz A, Berenguer-Jofresa A, Barrabés 

JA, Mata M, Monsalve M. Blood PGC-1? Concentration 

Predicts Myocardial Salvage and Ventricular Remodeling 

After ST-segment Elevation Acute Myocardial Infarction. 

Rev Esp Cardiol (Engl Ed). 2015 May ;68(5):408-16.IF: 0 


RESEARCH 

Reference: MAT2013-46467-C4-4-R. 

Title: Estimulación mecánica local de células mesenquimales de 

cara a su diferenciación osteogénica y condrogénica en medicina 

regenerativa 

Principal Investigator: Carmen Carda Batalla and María Sancho-Tello 

Valls 





Reference: Redes Excelencia 

Title: Red de investigación para el desarrollo de implantes de 

titanio funcionalizados, BIOIMPLANT 

Principal Investigator: José Luis Gómez Ribelles (Carmen Carda 





Reference: Intramural BBN 

Title: Biofunctionalization of titanium implant surfaces: protein 

conformation, osseointegration and antimicrobial activity (BIO- 

SURFACES) 

Principal Investigator: José Luis Gómez Ribelles (Carmen Carda 


Funding Body: CIBERBbn 



Principal Investigator: Carmen Carda Batalla 

Funding Body: Ministerio de Educación, Cultura y Deporte 


Duration: 2015 

Reference: Programa VLC-BIOCLINIC Subprograma A 

Title: Soportes tridimensionales biodegradables basados en microparticulas 

para la regeneración del cartílago articular. 


Funding Body: Fundación Investigación Hospital Clínico Universitario 

de Valencia 




• THESIS 

Thesis title: Diagnóstico precoz de la neumonía asociada al 

ventilador. Evaluación seriada de biomarcadores en minilavado 

broncoalveolar y monitorización microbiológica, complementada 

con condensado de aire exhalado y sangre 


Director(s): José Blanquer Olivas, Francisco Javier Chorro Gascó, 

Manuel Mata Roig 



Thesis title: Regeneración tisular: estudio de la diferenciación 

in vitro de las células madre de la pulpa dental 

Doctoral candidate: Santiago Peydró Tomas 

Director(s): Carmen Carda Batalla, Javier Martín de Llano y 

Amando Peydró Olaya 



• AWARDS 

On December, Carmen Carda Batalla received the “Premio Real 

Academia de Medicina de Andalucia Oriental”. 

85 

Reference: 07_EQ-BIO-2015 

Title: Diseño de una plataforma experimental basada en la microbalanza 

electroquímica de cristal de cuarzo (EQCM) para el 

desarrollo y ensayo in-vivo de nuevas aleaciones biomédicas 

VLC- Bioclinic Project: articular 

cartilage regeneration 

using biodegradable 

microparticles

4 

Scientific 

activity 

Research Group on Central Nervous System Tumours 


86 

Group members 


Miguel Cerdá Nicolás 


H Index: 24 


Rosario Gil Benso. University 

Concepción López Ginés. University 

Teresa San Miguel Díez. University 

José Manuel Almerich Silla. University 

Robert Callaghan Pitlik. University 

M. Aurelia Gregori Romero. University 

Pablo Cerdá Durán. University 

Pedro Roldán Badía. Hospital. University 

Javier Megías Vericat. University 

PhD students 

Lisandra Muñoz Hidalgo. INCLIVA 

Technicians 

Ana María Clari Pérez. University 

Lara Navarro Cerveró. University


4 


• Clinicopathological study of 20 patients with primary 

GBM. To collect samples (formol, freezing, crop pickup 

means). To conduct tissue arrays of 20 tumors; neuropathological, 

inmunohistoquimic and FISH study matrix 

according to established methodology 

• To realize tissue cultures of short duration and feasibility 

analysis; FISH analysis of EGFR status and freezing of the 

different countries according to established methodology 

• To study molecular genomic analysis of the 20 tumours 

(frozen samples) MLPA techniques, sequencing and 

RT-qPCR analysis of gene alterations and mRNA expression 

and miRNAs is performed according to established 

methodology 

• To do proteomic analysis of 20 tumors (frozen samples) 

by Western blot methodology 

• To start an experimental study. Analysis of situations 


• Primary GBM. Amplification status of EGFR and angiogenic/infiltrative 

phenotype. Molecular networks responsible 

for tumor modulation and reprogramming processes 

• Role of microRNA in the regulation of EGFR-dependent 

signalling pathways in high-grade astrocytic gliomas 

• Development of a model for analyzing the modulation of 

microRNA gene activity in cell cultures of primary GBM 

and GBM cell lines 

• Development of a model of population analysis and spatial 

distribution of these neoplasias 

• Metabolomics and microvascular environment characterization 

of aggressive human glioma by DCE-MRI and genetic 

study of biopsies 



13 18,53 1,42 

National 


International 


Corresponding 

author 

5 5 4 


1. Maraver F, Vitoria I, Almerich-Silla JM, Armijo F. [Fluoride 

content of bottled natural mineral waters in Spain and 

prevention of dental caries]. Aten Primaria. 2015 Jan 

;47(1):15-24.IF: 0,953 

2. Bellot-Arcís C, Ferrer-Molina M, Carrasco-Tornero Á, 

Montiel-Company JM, Almerich-Silla JM. Differences in 

psychological traits between lingual and labial orthodontic 

patients: Perfectionism, body image, and the impact of 

dental esthetics. Angle Orthod. 2015 Jan ;85(1):58-63.IF: 

1,225 

3. Tarazona N, Navarro L, Cejalvo JM, Gambardella V, Pérez- 

Fidalgo JA, Sempere A, Navarro S, Cervantes A. Primary 

paraesophageal Ewing’s sarcoma: an uncommon case 

report and literature review. Onco Targets Ther. 2015 

;8:1053-9.IF: 2,311 

4. Navarro L, Gil-Benso R, Megías J, Muñoz-Hidalgo L, San- 

Miguel T, Callaghan RC, González-Darder JM, López-Ginés 

C, Cerdá-Nicolás MJ. Alteration of major vault protein in 

human glioblastoma and its relation with EGFR and PTEN 

status. Neuroscience. 2015 Jun 25 ;297:243-51.IF: 3,357 

5. San-Miguel T, Pinto S, Navarro L, Callaghan RC, Monteagudo 

C, López-Ginés C, Cerdá-Nicolás M, Gil-Benso R. Expression 

of the Chemokine Receptors CXCR3, CXCR4, CXCR7 and 

Their Ligands in Rhabdomyosarcoma. Pathol Oncol Res. 

2015 Sep ;21(4):1191-9.IF: 1,855 

6. Machado I, López-Soto MV, Rubio L, Navarro L, Llombart- 

Bosch A. Soft tissue myoepithelial carcinoma with rhabdoidlike 

features and EWSR1 rearrangement: Fine needle 

aspiration cytology with histologic correlation. Diagn 

Cytopathol. 2015 May ;43(5):421-6.IF: 1,121 

7. García March G, Bordes V, Roldán P, Real L, González 

Darder JM. [Spinal cord stimulation and failed back surgery 

syndrome. Clinical results with laminectomy electrodes]. 

Neurocirugia (Astur). 2015 Mar-Apr ;26(2):78-83.IF: 0,293 

8. Almerich-Silla JM, Montiel-Company JM, Pastor S, Serrano 

F, Puig-Silla M, Dasí F. Oxidative Stress Parameters in Saliva 

and Its Association with Periodontal Disease and Types of 

Bacteria. Dis Markers. 2015 ;2015:653537.IF: 1,562 

9. García-Moya EJ, Montiel-Company JM, Almerich-Silla 

JM. Case-control study of craniomandibular disorders 

in patients with fibromyalgia. J Clin Exp Dent. 2015 Apr 

;7(2):e293-8.IF: 0 

87

4 

Scientific 

activity 

88 

10. Fernández-Ferrer L, Montiel-Company JM, Pinho T, 

Almerich-Silla JM, Bellot-Arcís C. Effects of mandibular 

setback surgery on upper airway dimensions and their 

influence on obstructive sleep apnoea - a systematic review. 

J Craniomaxillofac Surg. 2015 Mar ;43(2):248-53.IF: 2,933 

11. Bellot-Arcís C, Montiel-Company JM, Pinho T, Almerich-Silla 

JM. Relationship between perception of malocclusion and 

the psychological impact of dental aesthetics in university 

students. J Clin Exp Dent. 2015 Feb ;7(1):e18-22.IF: 0 

12. Tardío JC, Machado I, Navarro L, Idrovo F, Sanz-Ortega J, 

Pellín A, Llombart-Bosch A. Ewing-like sarcoma with CIC- 

DUX4 gene fusion in a patient with neurofibromatosis type 

1. A hitherto unreported association. Pathol Res Pract. 2015 

Nov ;211(11):877-82.IF: 1,397 

Letter 

13. San-Miguel T, Cerdá-Nicolás M, Gil-Benso R, Callaghan RC, 

Muñoz-Hidalgo L, López-Ginés C. Evolution to malignancy: 

A genetic stepwise study of tumor suppressor genes loss in 

a recurrent meningioma. Clin Neuropathol. 2015 Jul-Aug 

;34(4):237-9.IF: 1,528 

• THESIS 

Thesis title: Papel del nf-K946 Y miRNA-34A en la patogénesis 

de la osteoartritis y como posible diana de las nuevas terapias 

biológicas. 

Doctoral candidate: Francisco Argüelles Linares 

Director(s): Antonio Silvestre Muñoz, José Miguel Cerdá 

Nicolás 


Grade: Sobresaliente “cum laude 

Thesis title: Impacto de la variación en el número de copias y 

del estado de metilación de genes supresores de tumor en las 

vías de progresión del meningioma. 

Doctoral candidate: Teresa San Miguel Díez 

Director(s): Rosario Gil Benso, José Miguel Cerdá Nicolás, 

María Concepción López Ginés 




RESEARCH 


Title: Papel de los microRNA en la regulación de las vías de 

señalización dependientes de EGFR en gliomas astrocitarios 

de alto grado. Desarrollo de un modelo poblacional de análisis 

poblacional y de distribución espacial de estas neoplasias. 

Principal Investigator: Miguel Cerdá Nicolás 

Funding body: Conselleria de Educación, Cultura y Deporte 


Universitario Valencia 




Title: Implication of selected miRNAs in tumor progression of 

curaneous malignant melanoma, and their value as prognostic 

and therapeutic biomarkers. 

Principal Investigator: José Carlos Monteagudo Castro (Rosario 

Gil Benso as collaborating researcher) 







Title: Interacción de miRNA-200 y miRNA-138 en la infiltración 

y perfiles de MMMI del Glioblastoma Multiforme primario. 

Utilidad como biomarcadores en el diagnóstico, pronóstico y 

terapéutico. 

Principal Investigator: Miguel Cerdá Nicolás 






• AWARDS 

Lisandra Muñoz Hidalgo had received the Innovation Award 

Genetics, an award given each year for the Cátedra Universitat 

de Valencia/Fundación Sistemas Genómicos. L. Muñoz: “This 

prize gives me strength to continue investigating”.


4 

Research Group on Colorectal Cancer and New Therapeutical Developments in Solid 

Tumours 


“Los oncólogos deben estar preparados para afrontar problemas muy complejos cada día. Es su 

responsabilidad encontrar la luz en la oscuridad y hacer fácil lo difícil”. Andrés Cervantes. Innovando 

es posible. Septiembre 2015. http://www.innovandoesposible.es/historias/dr-andres-cervantes/ 

89 

Group members 


Andrés Cervantes Ruipérez 


H Index: 40 

PhD students 

Marta Llorca Cardeñosa. INCLIVA 

Sara Oltra Sanchís. INCLIVA 


Jose. A. Pérez Fidalgo. Hospital 

Amelia Insa Mollá. Hospital 

Susana Roselló Keranen. Hospital 

Desamparados Roda Pérez. INCLIVA 

Inma Blasco Blasco. INCLIVA 

Estefania García Botello. Hospital 

Alejandro Espí Macías. Hospital. University 

Maider Ibarrola Villava. INCLIVA 

Josefa Castillo Aliaga. INCLIVA 

Ana Isabel Gil Tébar. INCLIVA 

Marcelino Telechea Fernández. INCLIVA 

Marisol Huerta Álvaro. Hospital 

Noelia Tarazona Llavero. Hospital 

Gema Bruixola Campos. Hospital 

María Carolina Martínez Ciarpaglini. INCLIVA 


Gloria Ribas Despuig. INCLIVA 

Technicians 

Cristina Mongort Sanchis. INCLIVA 


Gabriela Perez Garity. INCLIVA

4 

Scientific 

activity 

90 


Gloria Ribas Despuig 

My scientific interests are based 

both on the study of the genetic 

susceptibility to complex diseases 

as well as on the study of genomics 

deregulation in solid tumours. 

In relation to genetic susceptibility, we have unraveled new 

variants associated to sporadic melanoma susceptibility. The 

group has contributed to the study of variants in pathways 

related to pigmentation, DNA repair after UV irradiation and 

oxidative stress. Some of the more relevant results are the study 

of the genetic variation of MC1R (melanocortin receptor 1, the 

most important gene predisposing to susceptibility to sporadic 

melanoma) and the identification of new genes associated to 

this disease, the most important has been SLC45A2. 

During 2015 we have investigated the role of genetic variation 

in TERT related genes and their association to telomerase 

length and to melanoma. We have several ongoing studies in 

collaboration with international groups and the consortium 

M-SKIP. 

As for the genomic deregulation in solid tumours, I am 

interested in the identification and characterization of the 

genetic distinctiveness of breast cancer in very young women 

(35 years or younger). In order to do so, we carried out several 

studies with microRNA expression, methylation, IHQ staining and 

bioinformatics analysis to validate our data. The main objective is 

to find out whether new markers could be more suitable to treat 

these patients and would improve their response to therapy. 

In collaboration with Dr. Cervantes we have set up the 

mutational screening of solid tumours in 25 oncogenes (287 

hotspots) with the Mass Array-Sequenom platform at the 

Faculty of Medicine. Up to now we have screened more than 

150 tumours from several oncologic pathologies: colorectal, 

breast, ovarian, gastric, melanoma, etc. 


• To implement strategies in order to facilitate precision 

medicine development in solid tumours with innovative 

therapeutic approaches 

• To provide knowledge on how to approach precision medicine 

in colorectal and gastric cancer: molecular classification, 

predictive biomarkers and innovative therapeutic 

approaches 


• To develop first-in-human Phase I trials of antineoplastic 

agents with innovative designs 

• To develop liquid biopsies (ctDNA, cmicroRNAs) for early 

diagnosis, monitoring and the prediction of therapeutic 

effects in patients with gastro-intestinal malignancies 

• To study the role of acetylated nuclear ribonucleoproteins 

in predicting resistance to anti-EFGR antibodies 



43 441,28 10,26 

National 



International 


Corresponding 

author 

5 35 8 

1. Martínez MT, González I, Tarazona N, Roselló S, Saiz R, 

Sanmartín A, Martínez-Agulló Á, Caballero A, Mas P, 

Franco J, Martínez-Jabaloyas J, García-Callejo J, Martín V, 

Navarro J, Teruel A, Lluch A, Chirivella I. Implementation 

and assessment of a fast-track programme to improve 

communication between primary and specialized care 

in patients with suspected cancer: how to shorten time 

between initial symptoms of cancer, diagnosis and initiation 

of treatment. Clin Transl Oncol. 2015 Feb ;17(2):167-72.IF: 

2,077 

2. Di Cosimo S, Sathyanarayanan S, Bendell JC, Cervantes A, 

Stein MN, Braña I, Roda D, Haines BB, Zhang T, Winter CG, 

Jha S, Xu Y, Frazier J, Klinghoffer RA, Leighton-Swayze A, 

Song Y, Ebbinghaus S, Baselga J. Combination of the mTOR 

Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal 

Antibody Dalotuzumab: Preclinical Characterization and


4 

Phase I Clinical Trial. Clin Cancer Res. 2015 Jan 1 ;21(1):49- 

59.IF: 8,722 

3. Rafii S, Roda D, Geuna E, Jimenez B, Rihawi K, Capelan M, 

Yap TA, Molife LR, Kaye SB, de Bono JS, Banerji U. Higher 

Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors 

in Patients with Advanced Solid Tumours on Phase I Clinical 

Trials. Clin Cancer Res. 2015 Apr 15 ;21(8):1869-76.IF: 8,722 




report and literature review. Onco Targets Ther. 2015; 8: 

1053-9.IF: 2,311 

5. Macarulla T, Cervantes A, Tabernero J, Roselló S, Van 

Cutsem E, Tejpar S, Prenen H, Martínelli E, Troiani T, 

Laffranchi B, Jego V, von Richter O, Ciardiello F. Phase I 

study of FOLFIRI plus pimasertib as second-line treatment 

for KRAS-mutated metastatic colorectal cancer. Br J Cancer. 

2015 Jun 9 ;112(12):1874-81.IF: 4,836 

6. Dienstmann R, Patnaik A, García-Carbonero R, Cervantes A, 

Benavent M, Roselló S, Tops BB, van der Post RS, Argilés G, 

Skartved NJ, Hansen UH, Hald R, Pedersen MW, Kragh M, 

Horak ID, Braun S, Van Cutsem E, Tolcher AW, Tabernero J. 

Safety and Activity of the First-in-Class Sym004 Anti-EGFR 

Antibody Mixture in Patients with Refractory Colorectal 

Cancer. Cancer Discov. 2015 Jun ;5(6):598-609.IF: 19,453 

7. Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann 

JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, 

Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, 

Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart 

AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ, ICON7 trial 

investigators. Standard chemotherapy with or without 

bevacizumab for women with newly diagnosed ovarian 

cancer (ICON7): overall survival results of a phase 3 

randomised trial. Lancet Oncol. 2015 Aug ;16(8):928-36.IF: 

24,69 

8. Roda D, Castillo J, Telechea-Fernández M, Gil A, López- 

Rodas G, Franco L, González-Rodríguez P, Roselló S, Pérez- 

Fidalgo JA, García-Trevijano ER, Cervantes A, Zaragozá 

R. EGF-Induced Acetylation of Heterogeneous Nuclear 

Ribonucleoproteins Is Dependent on KRAS Mutational Status 

in Colorectal Cancer Cells. PLoS One. 2015 ;10(6):e0130543. 

IF: 3,234 

9. Sclafani F, Peckitt C, Cunningham D, Tait D, Giralt J, Glimelius 

B, Keränen SR, Bateman A, Hickish T, Tabernero J, Thomas 

J, Brown G, Oates J, Chau I. Short- and Long-Term Quality 

of Life and Bowel Function in Patients With MRI-Defined, 

High-Risk, Locally Advanced Rectal Cancer Treated With an 

Intensified Neoadjuvant Strategy in the Randomized Phase 

2 EXPERT-C Trial. Int J Radiat Oncol Biol Phys. 2015 Oct 1; 

93(2): 303-12.IF: 4,258 

10. Frenel JS, Carreira S, Goodall J, Roda D, Perez-López R, Tunariu 

N, Riisnaes R, Miranda S, Figueiredo I, Nava-Rodrigues D, 

Smith A, Leux C, García-Murillas I, Ferraldeschi R, Lorente D, 

Mateo J, Ong M, Yap TA, Banerji U, Gasi Tandefelt D, Turner 

N, Attard G, de Bono JS. Serial Next-Generation Sequencing 

of Circulating Cell-Free DNA Evaluating Tumour Clone 

Response To Molecularly Targeted Drug Administration. 

Clin Cancer Res. 2015 Oct 15 ;21(20):4586-96.IF: 8,722 

11. Roselló S, Cervantes A. Extending neoadjuvant chemotherapy 

in rectal cancer. Lancet Oncol. 2015 Aug; 16(8): 

880-1.IF: 24,69 

12. Sclafani F, Chau I, Cunningham D, Peckitt C, Lampis A, 

Hahne JC, Braconi C, Tabernero J, Glimelius B, Cervantes 

A, Begum R, González De Castro D, Hulkki Wilson S, Eltahir 

Z, Wotherspoon A, Tait D, Brown G, Oates J, Valeri N. 

Prognostic role of the LCS6 KRAS variant in locally advanced 

rectal cancer: results of the EXPERT-C trial. Ann Oncol. 2015 

Sep ;26(9):1936-41.IF: 7,04 

13. Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith 

W, Blumenschein GR Jr, Tabernero J, Roda D, Calles A, 

Jimeno A, Wang X, Bohórquez SS, Leddy C, Littman C, Kapp 

AV, Shames DS, Penuel E, Amler LC, Pirzkall A, Baselga J. 

Safety and Pharmacokinetics/Pharmacodynamics of the 

First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A 

in Locally Advanced or Metastatic Epithelial Tumours. Clin 

Cancer Res. 2015 Jun 1 ;21(11):2462-70.IF: 8,722 

14. Marinello FG, Frasson M, Baguena G, Flor-Lorente B, 

Cervantes A, Roselló S, Espí A, García-Granero E. Selective 

approach for upper rectal cancer treatment: total 

mesorectal excision and preoperative chemoradiation are 

seldom necessary. Dis Colon Rectum. 2015 Jun ;58(6):556- 

65.IF: 3,749 

15. Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, García- 

Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, 

Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, 

Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen 

H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A, 

RECOURSE Study Group. Randomized trial of TAS-102 for 

91

4 

Scientific 

activity 

92 

refractory metastatic colorectal cancer. N Engl J Med. 2015 

May 14 ;372(20):1909-19.IF: 55,873 

16. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, 

Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn 

MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, 

Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford 

JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, 

Gandhi L, KEYNOTE-001 Investigators. Pembrolizumab for 

the treatment of non-small-cell lung cancer. N Engl J Med. 

2015 May 21 ;372(21):2018-28.IF: 55,873 

17. Karachaliou N, Mayo-de Las Casas C, Queralt C, de Aguirre I, 

Melloni B, Cardenal F, García-Gómez R, Massuti B, Sánchez 

JM, Porta R, Ponce-Aix S, Moran T, Carcereny E, Felip E, 

Bover I, Insa A, Reguart N, Isla D, Vergnenegre A, de Marinis 

F, Gervais R, Corre R, Paz-Ares L, Morales-Espinosa D, Viteri 

S, Drozdowskyj A, Jordana-Ariza N, Ramirez-Serrano JL, 

Molina-Vila MA, Rosell R, Spanish Lung Cancer Group. 

Association of EGFR L858R Mutation in Circulating Free 

DNA With Survival in the EURTAC Trial. JAMA Oncol. 2015 

May 1 ;1(2):149-57.IF: 0 

18. Ibarrola-Villava M, Kumar R, Nagore E, Benfodda M, Guedj 

M, Gazal S, Hu HH, Guan J, Rachkonda PS, Descamps V, 

Basset-Seguin N, Bensussan A, Bagot M, Saiag P, Schadendorf 

D, Martín-González M, Mayor M, Grandchamp B, Ribas G, 

Soufir N. Genes involved in the WNT and vesicular trafficking 

pathways are associated with melanoma predisposition. Int 

J Cancer. 2015 May 1 ;136(9):2109-19.IF: 5,085 

19. Geva R, Vecchione L, Kalogeras KT, Jensen BV, Lenz HJ, 

Yoshino T, Paez D, Montagut C, Souglakos J, Cappuzzo F, 

Cervantes A, Frattini M, Fountzilas G, Johansen JS, Høgdall 

EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D, 

Vincenzi B, Macarulla T, Loupakis F, De Schutter J, Spindler 

KL, Pfeiffer P, Ciardiello F, Piessevaux H, Tejpar S. FCGR 

polymorphisms and cetuximab efficacy in chemorefractory 

metastatic colorectal cancer: an international consortium 

study. Gut. 2015 Jun ;64(6):921-8.IF: 14,66 

20. Ibarrola-Villava M, Llorca-Cardeñosa MJ, Tarazona N, 

Mongort C, Fleitas T, Perez-Fidalgo JA, Roselló S, Navarro 

S, Ribas G, Cervantes A. Deregulation of ARID1A, CDH1, 

cMET and PIK3CA and target-related microRNA expression 

in gastric cancer. Oncotarget. 2015 Sep 29 ;6(29):26935-45. 

IF: 6,359 

21. Peeters M, Oliner KS, Price TJ, Cervantes A, Sobrero AF, 

Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, 

Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem 

E, He P, Yu H, Koukakis R, Terwey JH, Jung AS, Sidhu R, 

Patterson SD. Analysis of KRAS/NRAS Mutations in a Phase III 

Study of Panitumumab with FOLFIRI Compared with FOLFIRI 

Alone as Second-line Treatment for Metastatic Colorectal 

Cancer. Clin Cancer Res. 2015 Dec 15 ;21(24):5469-79.IF: 

8,722 

22. Marinello FG, Baguena G, Lucas E, Frasson M, Hervás 

D, Flor-Lorente B, Esclapez P, Espí A, García-Granero E. 

Anastomotic leaks after colon cancer resections: Does the 

individual surgeon matter? Colorectal Dis. 2015 Nov 12 ;.IF: 

2,351 

23. Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, 

Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, 

Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD, 

LUX-Lung 8 Investigators. Afatinib versus erlotinib as 

second-line treatment of patients with advanced squamous 

cell carcinoma of the lung (LUX-Lung 8): an open-label 

randomised controlled phase 3 trial. Lancet Oncol. 2015 

Aug ;16(8):897-907.IF: 24,69 

24. Tagliabue E, Fargnoli MC, Gandini S, Maisonneuve P, Liu 

F, Kayser M, Nijsten T, Han J, Kumar R, Gruis NA, Ferrucci 

L, Branicki W, Dwyer T, Blizzard L, Helsing P, Autier P, 

García-Borrón JC, Kanetsky PA, Landi MT, Little J, Newton- 

Bishop J, Sera F, Raimondi S, M-SKIP Study Group. MC1R 

gene variants and non-melanoma skin cancer: a pooledanalysis 

from the M-SKIP project. Br J Cancer. 2015 Jul 14 

;113(2):354-63.IF: 4,836 

Letter 

25. Cervantes A, Pentheroudakis G, Arnold D. Critical evaluation 

of the scientific content in clinical practice guidelines. Cancer. 

2015 Jun 1 ;121(11):1907-8.IF: 4,889 

Editorial 

26. Cervantes A, Glynne-Jones R. Adjuvant chemotherapy for 

rectal cancer after preoperative radiation or chemoradiation: 

one size does not fit all. Ann Oncol. 2015 Apr ;26(4):617-9. 

IF: 7,04 

27. Dienstmann R, Cervantes A. Heterogeneity of driver genes 

and therapeutic implications in colorectal cancer. Ann 

Oncol. 2015 Aug ;26(8):1523-5.IF: 7,04 

28. Pentheroudakis G, Cardoso F, Arnold D, Sessa C, Peters


4 

S, Horwich A, Pavlidis N, Stahel R, Cervantes A, ESMO 

Guidelines Committee. The ESMO guideline strategy: an 

identity statement and reflections on improvement. Ann 

Oncol. 2015 Sep ;26 Suppl 5:v1-v7.IF: 7,04 


29. Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans 

P, Rutgers E, Zackrisson S, Cardoso F, ESMO Guidelines 

Committee. Primary breast cancer: ESMO Clinical Practice 

Guidelines for diagnosis, treatment and follow-up. Ann 


30. Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, 

Hallek M, Buske C, ESMO Guidelines Committee. Chronic 

lymphocytic leukaemia: ESMO Clinical Practice Guidelines 

for diagnosis, treatment and follow-up. Ann Oncol. 2015 

Sep ;26 Suppl 5:v78-84.IF: 7,04 

31. Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin 

P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, 

Conroy T, Arnold D, ESMO Guidelines Committee. Cancer 

of the pancreas: ESMO Clinical Practice Guidelines for 

diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep 

;26 Suppl 5:v56-68.IF: 7,04 

32. Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S, ESMO 

Guidelines Committee. Thymic epithelial tumours: ESMO 


follow-up. Ann Oncol. 2015 Sep ;26 Suppl 5:v40-55.IF: 7,04 

33. Kloke M, Cherny N, ESMO Guidelines Committee. Treatment 

of dyspnoea in advanced cancer patients: ESMO Clinical 

Practice Guidelines. Ann Oncol. 2015 Sep ;26 Suppl 5:v169- 

73.IF: 7,04 

34. Sousa B, Furlanetto J, Hutka M, Gouveia P, Wuerstlein R, 

Mariz JM, Pinto D, Cardoso F, ESMO Guidelines Committee. 

Central venous access in oncology: ESMO Clinical Practice 

Guidelines. Ann Oncol. 2015 Sep ;26 Suppl 5:v152-68.IF: 

7,04 

35. Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, 

Pentheroudakis G, ESMO Guidelines Committee. Cancers 

of unknown primary site: ESMO Clinical Practice Guidelines 

for diagnosis, treatment and follow-up. Ann Oncol. 2015 

Sep ;26 Suppl 5:v133-8.IF: 7,04 

36. Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis 

G, Keilholz U, ESMO Guidelines Committee. Cutaneous 

melanoma: ESMO Clinical Practice Guidelines for diagnosis, 

treatment and follow-up. Ann Oncol. 2015 Sep ;26 Suppl 

5:v126-32.IF: 7,04 

37. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, 

López-Guillermo A, Walewski J, André M, Johnson PW, 

Pfreundschuh M, Ladetto M, ESMO Guidelines Committee. 

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical 



38. d’Amore F, Gaulard P, Trümper L, Corradini P, Kim WS, Specht 

L, Bjerregaard Pedersen M, Ladetto M, ESMO Guidelines 

Committee. Peripheral T-cell lymphomas: ESMO Clinical 



39. Robak T, Matutes E, Catovsky D, Zinzani PL, Buske C, ESMO 

Guidelines Committee. Hairy cell leukaemia: ESMO Clinical 



40. Vannucchi AM, Barbui T, Cervantes F, Harrison C, 

Kiladjian JJ, Kröger N, Thiele J, Buske C, ESMO Guidelines 

Committee. Philadelphia chromosome-negative chronic 

myeloproliferative neoplasms: ESMO Clinical Practice 

Guidelines for diagnosis, treatment and follow-up. Ann 


41. Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters 

S, ESMO Guidelines Committee. Malignant pleural 

mesothelioma: ESMO Clinical Practice Guidelines for 

diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep 

;26 Suppl 5:v31-9.IF: 7,04 

42. Parker C, Gillessen S, Heidenreich A, Horwich A, ESMO 

Guidelines Committee. Cancer of the prostate: ESMO 


follow-up. Ann Oncol. 2015 Sep ;26 Suppl 5:v69-77.IF: 7,04 

43. Peterson DE, Boers-Doets CB, Bensadoun RJ, Herrstedt J, 

ESMO Guidelines Committee. Management of oral and 

gastrointestinal mucosal injury: ESMO Clinical Practice 

Guidelines for diagnosis, treatment, and follow-up. Ann 


• THESIS 

Thesis Title: Resonancia magnética pélvica dinámica versus 

videodefecografía en el estudio del síndrome de defecación 

obstrutiva. 

Doctoral candidate: Gonzalo Martín Martín 

93

4 

Scientific 

activity 

94 

Director(s): Alejandro Espí Macías, José Vicente Roig Vila, 

Juan García Armengol 



Thesis Title: Cirugía del cáncer de colon. Análisis de los 

resultados en una unidad especializada. 

Doctoral candidate: Gloria Gema Báguena Requena 

Director(s): Eduardo García Granero Ximenez, Alejandro Espí 

Macías, Andrés Cervantes Ruipérez 




RESEARCH 


Title: Hyperacetylation of heterogeneous nuclear riboproteins 

(hnRNPs) as a final pathway to resistance to antiEGFR agents 

in colorectal cancer 








Title: Estudio traslacional sobre la hiperacetilación de 

proteínas como vía final de resistencia a fármacos anti-EGFR 

en cánceres de alta incidencia clínica 







Title: Hiperacetilación de riboproteinas heterogéneas 

nucleares (hnRNPs) como vía final de resistencia a fármacos 

anti-EGFR en cáncer de próstata 

Principal Investigator: Ana Isabel Gil 

Funding Body: Fundación de la Asociación Española contra el 

Cáncer 




Reference: 635342 - MoTriColor 

Title: Molecularly guided trials with specific treatment 

strategies in patients with advanced newly molecular defined 

subtypes of colorectal cancer (MoTriColor) 

Principal Investigator: Dr. Josep Tabernero 

Funding Body: Comisión Europea 


Clínico Universitario de Valencia. 


Total budget: 5.996.992€ 

• AWARDS: 

The oncologist Andrés Cervantes received several awards 

during 2015. He entered the Royal Academy of Medicine of Valencia. 

He was appointed honorary member of the European 

Society for Therapeutic Radiology and Oncology and received a 

Recognition of Service for its special contribution to the success 

of the program “ESMO Fellowship Programme”. 


Title: Clinical Research and Trials Platform 





Duration: 2014 - 2017 

Total budget: 65.550€


4 

Research Group on Breast Cancer Biology 


“Mis pacientes me han enseñado a vivir.” 

Ana Lluch. Levante. 21.12.2015. 

95 

Group members 


Ana Lluch Hernández 


H Index: 41 



Begoña Bermejo De Las Heras. Hospital 

Octavio Burgues Gasion. Hospital 

Antonio Caballero Garate. Hospital 

Angel Martínez Agullo. Hospital 

Estela Contel Martín. INCLIVA 

Isabel Catoira Domenech. INCLIVA 

Patricia Martínez Belenguer. INCLIVA 

Antonio Millet Serrano. Hospital. University 

Vicenta Garcés Honrubia. Hospital 

Begoña Pineda Merlo. INCLIVA 


Isabel Chirivella González. Hospital 

Pilar Eroles Asensio. INCLIVA 

Joan Climent Bataller. INCLIVA 

PhD students 

Eduardo Tormo Martín. INCLIVA 

María Peña Chilet. INCLIVA 

Technicians 

Elisa Alonso Yuste. INCLIVA 


Yolanda De La Cruz Robles. INCLIVA

4 

Scientific 

activity 

96 


• Identification of methylated areas in DNA (triple negative 

breast cancer pts) that differentiate responders and nonresponders 

to treatment 

• Pattern of miRNAs and mRNAs: modification of expression 

by chemotherapy 

• Evaluation of the role of miR-26a and miR-30b in the development 

of resistance in HER2+ breast cancer 

• Assessment of the PI3K/Akt pathway in resistance to 

anti-HER2 + therapies 

• Determination of the association PP2A inhibition and 

poor outcome and doxorubicin resistance in early breast 

cancer 

• Validation of a differential microRNA expression of breast 

cancer in very young women using METABRIC and TCGA 

public databases in addition to our own data. We have 

also characterized cell lines from young women and identified 

two as good models for functional studies. 


• Study of methylation as a prognostic and predictive factor 

of treatment response in triple negative breast cancer 

• Evaluation of microRNAs and mRNAs differentially expressed 

after chemotherapy treatment 

• Involvement of miRNAs in cancer processes in breast 

cancer 

• Role of tumor heterogeneity and dynamic reprogramming 

of tumor cell resistance to anti-HER2 

• Evaluation of the involvement of stem cells and epithelial 

mesenchymal transition in the mechanisms of resistance 

to treatment in HER2 + breast cancer 

• Primary and secondary resistance in HER2 + breast cancer: 

search for new treatments 

• Interaction between estrogen receptors, tumor angiogenesis 

and breast cancer metabolism 

• Molecular and clinical characterization of breast tumours 

from very young women 


Isabel Chirivella González 

The research line suggests a possible 

relation between mammographic 

density as a genetic susceptibility 

marker and the risk to suffer breast 

cancer in women with a mutation in 

BRCA (hereditary breast cancer). Women 

with a mutation in genes BRCA1 or BRCA2 have a higher risk 

of developing breast cancer (40-70%) and the risk could possibly 

be modified by genetic variations related to mammographic 

density. 

We also have a project to evaluate a set of endometrial cancer 

risk markers in Lynch syndrome patients. The study will prospectively 

analyze these markers and the progression to endometrial 

cancer in a series of endometrial biopsies taken from a prominent 

cohort of Lynch syndrome carriers during the follow-up 

period. The ultimate goal of this research is to achieve the minimum 

required clinical evidence to use these markers to improve 

the medical decision process towards a customized recommendation 

on the management options (surveillance vs. prophylactic 

hysterectomy) in these patients. 


Pilar Eroles Asensio 

The lines of research aim at deepening 

the knowledge of some of the 

molecular subtypes of breast cancer, 

especially HER2+ and triple negative, 

through studies of expression 

and epigenetic changes (microRNAs, 

methylation) to decipher the possible mechanisms of resistance 

to current treatments. We intend to develop new strategies for 

diagnostic and therapeutic intervention to reverse the identified 

resistance, based on combinations with other biologic agents 

and the use of predictive biomarkers of resistance. 


Joan Climent Bataller 

The research area of Dr. Climent 

lab is focused in exploiting “systems” 

approaches to the understanding of 

susceptibility to cancer and its related 

sub-phenotypes, and to apply 

this knowledge to the problems po-


4 

sed by the increasing human cancer burden. The main expertise 

is focused in breast cancer research and it covers the use of novel 

mathematical tools for comprehensive analysis of genetic and 

gene expression data, with the purpose of optimizing predictive 

responses to targeted drug treatment. 

These algorithms are based on mathematical methods of 

network analysis for determining not whether single specific 

genes are deregulated in tumours, but for identifying the 

combinations of the many possible gene expression changes 

that are most commonly associated with a particular outcome. 

Outcomes can be either patient or cell line responses to a 

particular treatment, levels of expression or polymorphic 

variants from specific genes. 

Advances in technology have allowed us to construct a global 

view of tissue architecture, filtered through the lens of genetic 

control of gene expression and now could be used to generate 

copy-number profiles based on breast cancer patients response 

to chemotherapy treatments. Novel network analysis tools can 

be used to identify critical signaling hubs that may reflect underlying 

susceptibility of different individuals to cancer development, 

progression or therapeutic responses. The same signaling 

hubs may also be targets for chemoprevention or therapeutic 

intervention, in addition to informing basic questions in cancer 

biology. 



34 256,45 7,54 

National 



International 


Corresponding 

author 

18 13 9 

1. Pasquali E, García-Borrón JC, Fargnoli MC, Gandini S, 

Maisonneuve P, Bagnardi V, Specchia C, Liu F, Kayser M, 

Nijsten T, Nagore E, Kumar R, Hansson J, Kanetsky PA, 

Ghiorzo P, Debniak T, Branicki W, Gruis NA, Han J, Dwyer T, 

Blizzard L, Landi MT, Palmieri G, Ribas G, Stratigos A, Council 

ML, Autier P, Little J, Newton-Bishop J, Sera F, Raimondi 

S, M-SKIP Study Group. MC1R variants increased the risk 

of sporadic cutaneous melanoma in darker-pigmented 

Caucasians: a pooled-analysis from the M-SKIP project.Int J 

Cancer. 2015 Feb 1 ;136(3):618-31.IF: 5,085 


Sanmartín A, Martínez-Agulló Á, Caballero A, Mas P, Franco 

J, Martínez-Jabaloyas J, García-Callejo J, Martín V, Navarro J, 

Teruel A, Lluch A, Chirivella I. Implementation and assessment 


between primary and specialized care in patients with 

suspected cancer: how to shorten time between initial 



3. Stanisavljevic J, Loubat-Casanovas J, Herrera M, Luque 

T, Peña R, Lluch A, Albanell J, Bonilla F, Rovira A, Peña C, 

Navajas D, Rojo F, García de Herreros A, Baulida J. Snail1- 

expressing fibroblasts in the tumor microenvironment 

display mechanical properties that support metastasis. 

Cancer Res. 2015 Jan 15 ;75(2):284-95.IF: 9,329 

4. Martín M, Martínez N, Ramos M, Calvo L, Lluch A, Zamora P, 

Muñoz M, Carrasco E, Caballero R, García-Sáenz JÁ, Guerra 

E, Caronia D, Casado A, Ruíz-Borrego M, Hernando B, Chacón 

JI, De la Torre-Montero JC, Jimeno MÁ, Heras L, Alonso R, De 

la Haba J, Pita G, Constenla M, González-Neira A. Standard 

versus continuous administration of capecitabine in 

metastatic breast cancer (GEICAM/2009-05): a randomized, 

noninferiority phase II trial with a pharmacogenetic analysis. 

Oncologist. 2015 Feb ;20(2):111-2.IF: 4,865 

5. Forés-Martos J, Cervera-Vidal R, Chirivella E, Ramos- 

Jarero A, Climent J. A genomic approach to study down 

syndrome and cancer inverse comorbidity: untangling the 

chromosome 21.Front Physiol. 2015 ;6:10.IF: 3,534 

6. Tormo E, Pineda B, Serna E, Guijarro A, Ribas G, Fores J, 

Chirivella E, Climent J, Lluch A, Eroles P. MicroRNA Profile in 

Response to Doxorubicin Treatment in Breast Cancer.J Cell 

Biochem. 2015 Sep ;116(9):2061-73.IF: 3,263 

7. Rincón R, Cristóbal I, Zazo S, Arpí O, Menéndez S, Manso 

R, Lluch A, Eroles P, Rovira A, Albanell J, García-Foncillas J, 

Madoz-Gúrpide J, Rojo F. PP2A inhibition determines poor 

outcome and doxorubicin resistance in early breast cancer 

and its activation shows promising therapeutic effects. 

Oncotarget. 2015 Feb 28 ;6(6):4299-314.IF: 6,359 

8. Zaragozá R, García-Trevijano ER, Lluch A, Ribas G, Viña 

JR. Involvement of Different networks in mammary gland 

involution after the pregnancy/lactation cycle: Implications 

in breast cancer.IUBMB Life. 2015 Apr ;67(4):227-38.IF: 3,143 

9. Alés-Martínez JE, Ruiz A, Chacón JI, Lluch Hernández 

A, Ramos M, Córdoba O, Aguirre E, Barnadas A, Jara C, 

97

4 

Scientific 

activity 

98 

González S, Plazaola A, Florián J, Andrés R, Sánchez Rovira 

P, Frau A. Preventive treatments for breast cancer: recent 

developments.Clin Transl Oncol. 2015 Apr ;17(4):257-63.IF: 

2,077 

10. Sonnenblick A, Francis PA, Azim HA Jr, de Azambuja E, 

Nordenskjöld B, Gutiérez J, Quinaux E, Mastropasqua MG, 

Ameye L, Anderson M, Lluch A, Gnant M, Goldhirsch A, 

Di Leo A, Barnadas A, Cortes-Funes H, Piccart M, Crown J. 

Final 10-year results of the Breast International Group 2-98 

phase III trial and the role of Ki67 in predicting benefit of 

adjuvant docetaxel in patients with oestrogen receptor 

positive breast cancer.Eur J Cancer. 2015 Aug ;51(12):1481- 

9.IF: 5,417 

11. Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, 

Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino 

S, Davidson NE, Geyer CE Jr, Walley BA, Coleman R, Kerbrat P, 

Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach 

R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale 

G, Coates AS, Goldhirsch A, Gelber RD, SOFT Investigators, 

International Breast Cancer Study Group. Adjuvant ovarian 

suppression in premenopausal breast cancer.N Engl J Med. 

2015 Jan 29 ;372(5):436-46.IF: 55,873 

12. Vicario R, Peg V, Morancho B, Zacarias-Fluck M, Zhang J, 

Martínez-Barriocanal Á, Navarro Jiménez A, Aura C, Burgues 

O, Lluch A, Cortés J, Nuciforo P, Rubio IT, Marangoni E, Deeds 

J, Boehm M, Schlegel R, Tabernero J, Mosher R, Arribas J. 

Patterns of HER2 Gene Amplification and Response to Anti- 

HER2 Therapies.PLoS One. 2015 ;10(6):e0129876.IF: 3,234 

13. Castelló A, Martín M, Ruiz A, Casas AM, Baena-Cañada JM, 

Lope V, Antolín S, Sánchez P, Ramos M, Antón A, Muñoz 

M, Bermejo B, De Juan-Ferré A, Jara C, Chacón JI, Jimeno 

MA, Rosado P, Díaz E, Guillem V, Lluch A, Carrasco E, Pérez- 

Gómez B, Vioque J, Pollán M, EpiGEICAM Researchers. 

Lower Breast Cancer Risk among Women following the 

World Cancer Research Fund and American Institute for 

Cancer Research Lifestyle Recommendations: EpiGEICAM 

Case-Control Study.PLoS One. 2015 ;10(5):e0126096.IF: 

3,234 

14. Ramón Y Cajal T, Chirivella I, Miranda J, Teule A, Izquierdo 

Á, Balmaña J, Sánchez-Heras AB, Llort G, Fisas D, Lope V, 

Hernández-Agudo E, Juan-Fita MJ, Tena I, Robles L, Guillén- 

Ponce C, Pérez-Segura P, Luque-Molina MS, Hernando-Polo 

S, Salinas M, Brunet J, Salas-Trejo MD, Barnadas A, Pollán M. 

Mammographic density and breast cancer in women from 

high risk families.Breast Cancer Res. 2015 Jul 11 ;17:93.IF: 0 

15. de Juan I, Palanca S, Domenech A, Feliubadaló L, Segura Á, 

Osorio A, Chirivella I, de la Hoya M, Sánchez AB, Infante M, 

Tena I, Díez O, García-Casado Z, Vega A, Teulé À, Barroso 

A, Pérez P, Durán M, Carrasco E, Juan-Fita MJ, Murria R, 

Llop M, Barragan E, Izquierdo Á, Benítez J, Caldés T, Salas 

D, Bolufer P. BRCA1 and BRCA2 mutations in males with 

familial breast and ovarian cancer syndrome. Results of a 

Spanish multicenter study.Fam Cancer. 2015 Dec ;14(4):505- 

13.IF: 1,977 

16. Murria R, Palanca S, de Juan I, Egoavil C, Alenda C, García- 

Casado Z, Juan MJ, Sánchez AB, Santaballa A, Chirivella 

I, Segura Á, Hervás D, Llop M, Barragán E, Bolufer P. 

Methylation of tumor suppressor genes is related with copy 

number aberrations in breast cancer.Am J Cancer Res. 2015 

;5(1):375-85.IF: 4,165 

17. Ibarrola-Villava M, Kumar R, Nagore E, Benfodda M, Guedj 

M, Gazal S, Hu HH, Guan J, Rachkonda PS, Descamps V, 

Basset-Seguin N, Bensussan A, Bagot M, Saiag P, Schadendorf 

D, Martín-González M, Mayor M, Grandchamp B, Ribas G, 

Soufir N. Genes involved in the WNT and vesicular trafficking 

pathways are associated with melanoma predisposition.Int 

J Cancer. 2015 May 1 ;136(9):2109-19.IF: 5,085 

18. González-Martín A, Alba E, Ciruelos E, Cortés J, Llombart 

A, Lluch A, Andrés R, Álvarez I, Aramendía JM, de la Peña 

FA, Barnadas A, Batista N, Calvo L, Galve E, García-Palomo 

A, García-Sáenz JÁ, de la Haba J, López R, López-Vivanco G, 

Martínez-Jáñez N, de Dueñas EM, Plazaola A, Rodríguez- 

Lescure Á, Ruiz M, Sánchez-Rovira P, Santaballa A, Seguí MÁ, 

Tusquets I, Zamora P, Martín M. Nab-Paclitaxel in Metastatic 

Breast Cancer: Defining the Best Patient Profile.Curr Cancer 

Drug Targets. 2015 Aug 17 ;.IF: 3,522 

19. Martín M, Ruiz Simón A, Ruiz Borrego M, Ribelles N, 

Rodríguez-Lescure Á, Muñoz-Mateu M, González S, Margelí 

Vila M, Barnadas A, Ramos M, Del Barco Berron S, Jara C, 

Calvo L, Martínez-Jáñez N, Mendiola Fernández C, Rodríguez 

CA, Martínez de Dueñas E, Andrés R, Plazaola A, de la 

Haba-Rodríguez J, López-Vega JM, Adrover E, Ballesteros 

AI, Santaballa A, Sánchez-Rovira P, Baena-Cañada JM, 

Casas M, Del Carmen Cámara M, Carrasco EM, Lluch A. 

Epirubicin Plus Cyclophosphamide Followed by Docetaxel 

Versus Epirubicin Plus Docetaxel Followed by Capecitabine 

As Adjuvant Therapy for Node-Positive Early Breast Cancer: 

Results From the GEICAM/2003-10 Study.J Clin Oncol. 2015 

Nov 10 ;33(32):3788-95.IF: 18,428 

20. Bianchini G, Pusztai L, Pienkowski T, Im YH, Bianchi GV,


4 

Tseng LM, Liu MC, Lluch A, Galeota E, Magazzù D, de la 

Haba-Rodríguez J, Oh DY, Poirier B, Pedrini JL, Semiglazov 

V, Valagussa P, Gianni L. Immune modulation of pathologic 

complete response after neoadjuvant HER2-directed 

therapies in the NeoSphere trial.Ann Oncol. 2015 Dec 

;26(12):2429-36.IF: 7,04 

21. Guillem V, Amat P, Collado M, Cervantes F, Alvarez-Larrán A, 

Martínez J, Tormo E, Eroles P, Solano C, Hernández-Boluda 

JC. BCL2 gene polymorphisms and splicing variants in 

chronic myeloid leukemia.Leuk Res. 2015 Aug 28 ;.IF: 2,351 

22. Pavlovic M, Arnal-Estapé A, Rojo F, Bellmunt A, Tarragona M, 

Guiu M, Planet E, García-Albéniz X, Morales M, Urosevic J, 

Gawrzak S, Rovira A, Prat A, Nonell L, Lluch A, Jean-Mairet J, 

Coleman R, Albanell J, Gomis RR. Enhanced MAF Oncogene 

Expression and Breast Cancer Bone Metastasis.J Natl Cancer 

Inst. 2015 Dec ;107(12).IF: 12,583 

23. Murria R, Palanca S, de Juan I, Alenda C, Egoavil C, Seguí FJ, 

García-Casado Z, Juan MJ, Sánchez AB, Segura Á, Santaballa 

A, Chirivella I, Llop M, Pérez G, Barragán E, Salas D, Bolufer 

P. Immunohistochemical, genetic and epigenetic profiles of 

hereditary and triple negative breast cancers. Relevance in 

personalized medicine.Am J Cancer Res. 2015 ;5(7):2330- 

43.IF: 4,165 

24. Núñez J, Merlos P, Fácila L, Llàcer P, Bosch MJ, Bertomeu- 

Martínez V, García-Blas S, Montagud V, Pedrosa V, Mendizábal 

A, Cordero A, Miñana G, Sanchís J, Bertomeu-González V, 

CHANCE-HF Investigators. Prognostic effect of carbohydrate 


for acute heart failure (CHANCE-HF). Study design.Rev Esp 

Cardiol (Engl Ed). 2015 Feb ;68(2):121-8.IF: 0 

25. Panach L, Pineda B, Mifsut D, Tarín JJ, Cano A, García-Pérez 

MÁ. The role of CD40 and CD40L in bone mineral density 

and in osteoporosis risk: A genetic and functional study. 

Bone. 2015 Nov 7 ;83:94-103.IF: 3,973 

26. Llombart-Cussac A, Bermejo B, Villanueva C, Delaloge S, 

Morales S, Balmaña J, Amillano K, Bonnefoi H, Casas A, 

Manso L, Roché H, González-Santiago S, Gavilá J, Sánchez- 

Rovira P, Di Cosimo S, Harbeck N, Charpentier E, García-Ribas 

I, Radosevic-Robin N, Aura C, Baselga J. SOLTI NeoPARP: a 

phase II randomized study of two schedules of iniparib plus 

paclitaxel versus paclitaxel alone as neoadjuvant therapy in 

patients with triple-negative breast cancer.Breast Cancer 

Res Treat. 2015 Nov ;154(2):351-7.IF: 3,94 

27. Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, 

Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, 

Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, 

Peintinger F, von Minckwitz G, White J, Yang W, Symmans 

WF, Residual Disease Characterization Working Group of 

the Breast International Group-North American Breast 

Cancer Group Collaboration. Standardization of pathologic 

evaluation and reporting of postneoadjuvant specimens 

in clinical trials of breast cancer: recommendations from 

an international working group.Mod Pathol. 2015 Sep 

;28(9):1185-201.IF: 6,187 

28. Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini 

BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola 

K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, 

Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, 

Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ, 

METEOR Investigators. Cabozantinib versus Everolimus in 

Advanced Renal-Cell Carcinoma.N Engl J Med. 2015 Nov 5 

;373(19):1814-23.IF: 55,873 

29. Tagliabue E, Fargnoli MC, Gandini S, Maisonneuve P, Liu 

F, Kayser M, Nijsten T, Han J, Kumar R, Gruis NA, Ferrucci 

L, Branicki W, Dwyer T, Blizzard L, Helsing P, Autier P, 

García-Borrón JC, Kanetsky PA, Landi MT, Little J, Newton- 

Bishop J, Sera F, Raimondi S, M-SKIP Study Group. MC1R 

gene variants and non-melanoma skin cancer: a pooledanalysis 

from the M-SKIP project.Br J Cancer. 2015 Jul 14 

;113(2):354-63.IF: 4,836 

Letter 

30. Seguí MA, Crespo C, Cortés J, Lluch A, Brosa M, Becerra 

V, Chiavenna S, Gracia A. In response: Genomic profile of 

breast cancer. Expert Rev Pharmacoecon Outcomes Res. 

2015 Jun ;15(3):395-7.IF: 1,669 

Editorial 

31. García-Saenz JA, Bermejo B, Estevez LG, Palomo AG, 

González-Farre X, Margeli M, Pernas S, Servitja S, Rodriguez 

CA, Ciruelos E. SEOM clinical guidelines in early-stage breast 

cancer 2015.Clin Transl Oncol. 2015 Dec ;17(12):939-45.IF: 

2,077 

Review 

32. Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles 

C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn 

T, Peintinger F, von Minckwitz G, White J, Yang W, Badve S, 

99

4 

Scientific 

activity 

Denkert C, MacGrogan G, Penault-Llorca F, Viale G, Cameron 

D, of the Breast International Group-North American 

Breast Cancer Group (BIG-NABCG) collaboration, of the 

Breast International Group-North American Breast Cancer 

Group BIG-NABCG collaboration. Recommendations for 

standardized pathological characterization of residual disease 

for neoadjuvant clinical trials of breast cancer by the 

BIG-NABCG collaboration.Ann Oncol. 2015 Jul ;26(7):1280- 

91.IF: 7,04 


Title: Red Temática de Investigación Cooperativa en Cáncer 

(RTICC) 

Principal Investigator: Ana Lluch Hernández 






100 


33. Llort G, Chirivella I, Morales R, Serrano R, Sanchez AB, 

Teulé A, Lastra E, Brunet J, Balmaña J, Graña B, SEOM 

Hereditary Cancer Working Group. SEOM clinical guidelines 

in Hereditary Breast and ovarian cancer.Clin Transl Oncol. 

2015 Dec ;17(12):956-61.IF: 2,077 

34. Guillén-Ponce C, Serrano R, Sánchez-Heras AB, Teulé A, 

Chirivella I, Martín T, Martínez E, Morales R, Robles L. 

Clinical guideline seom: hereditary colorectal cancer.Clin 

Transl Oncol. 2015 Dec ;17(12):962-71.IF: 2,077 

Reference: Convocatoria 2012 de ayudas intramurales para 

grupos emergentes 

Title: Papel del reloj molecular circadiano en la progresión y 

tratamiento del cáncer de mama 

Principal Investigator: Joan Bataller Climent 

Funding body: Fundación Investigación Hospital Clínico 






• THESIS 

Thesis Title: Expresión diferencial de microRNAs en tumores 

de mujeres jóvenes con cáncer de mama: Cribado de dianas 

moleculares 

Doctoral candidate: María del Carmen Peña Chilet 

Director(s): Ana Lluch Hernández, Gloria Ribas Despuig 




RESEARCH 


Title: Identificación de mecanismos de resistencia a nuevos 

anticuerpos anti-HER2 en cáncer de mama 








Title: Transcriptional deregulation in tumoral tissue from very 

young women with breast cancer and functional Implications 

Principal Investigator: Gloria Ribas Despuig 








Title: ¿Tiene el cáncer de mama en mujeres jóvenes una 

entidad genética diferente? Análisis de tejido tumoral de 

mujeres jóvenes mediante el estudio de la expresión de 

miRNAS 

Principal Investigator: Gloria Ribas Despuig 

Funding body: Fundación Investigación Hospital Clínico 







4 


Title: Genomic architecture of triple negative breast cancer. 

A systems genetics analysis of cancer risk progression and 

therapeutic response 

Principal Investigator: Joan Climent Bataller 








Title: Mecanismos de resistencia al tratramiento en cancer de 

mama triple negativo 

Principal Investigator: Pilar Eroles Asensio 

Funding Body: Fundación Investigación Hospital Clínico 






101 

Reference: Programa VLC-BIOCLINIC 

Title: Nuevas estrategias dirigidas a pacientes con cáncer de 

mama con tumores triples negativos. 





Clínico Universitario de Valencia, Fundación CETIR 

Duration: 9 months 


• AWARDS: 

The oncologist Ana Lluch was awarded with several awards during 

2015. The “Premio ABC Salud 2015”, the “Premio Valencianos 

para el Siglo XXI” and the “Premio Clara Campoamor”.

4 

Scientific 

activity 

Research Group on Skin Cancer 


102 

Group members 


José Carlos Monteagudo Castro 


H Index: 23 


Antonio Pellín Pérez. University 

Esperanza Jordá Cuevas. Hospital. University 

David Ramos Soler. Hospital (La Fe). University 

José Mª Martín Hernández. Hospital. University 

Miguel Martínez Rodríguez. Telemark Hospital, Skien,Noruega 

Ana Pellín Carcelén. European University of Valencia 

Liria Terrádez Más. Hospital 

Verónica López Castillo. Quirón Hospital 

Lara Navarro Cerveró. INCLIVA


4 


• PhD thesis on spontaneous regression of melanocytic 

neoplasms. Main results: 1) demonstration that an increase 

in telomere length variation (TLV) correlates with spontaneous 

regression in cutaneous melanomas. 2) A prediction 

equation including lamellar fibrosis, melanophage, 

blood vessel and granzyme B+ lymphocyte density, as well 

as the age of the patient can correctly identify malignancy 

in 87% of melanocytic lesions with partial regression. 

Completion of 4 additional PhD theses at the end of 2015 

• Modification of endogenous levels of miRNA-205 in melanoma 

cell lines A375 and SKMEL147 by lentiviral vectors. 

Transcriptomic study of the differential gene expression 

between cells with low and high miRNA-205 expresion, 

and experimental xenograft study in immunodeficient 

mice of both types of cells 

• First demonstration that CD34 nuclear immunoexpression, 

as well as CD133, SPARC and ABCG2 expression in 

melanoma correlates with the development of distant 

metastases (paper under review) 


• Expression of epithelial–mesenchymal transition markers 

and tumor initiating cells (tumourstem cells) in tumour 

progression of human skin melanoma and in xenotransplantation 

in immunodeficient mice 

• Epidemiology and genetics of Birt-Hogg-Dubé familial 

cancer syndrome 

• Implication of certain microRNAs in tumor progression of 

melanoma 



13 17,01 1,30 

National 



International 


Corresponding 

author 

5 1 9 

1. Ramos D, Pellín-Carcelén A, Agustí J, Murgui A, Jordá E, 

Pellín A, Monteagudo C. Deregulation of glyceraldehyde- 

3-phosphate dehydrogenase expression during tumor 

progression of human cutaneous melanoma.Anticancer 

Res. 2015 Jan ;35(1):439-44.IF: 1,826 

2. San-Miguel T, Pinto S, Navarro L, Callaghan RC, Monteagudo 

C, López-Ginés C, Cerdá-Nicolás M, Gil-Benso R. Expression 

of the Chemokine Receptors CXCR3, CXCR4, CXCR7 and 

Their Ligands in Rhabdomyosarcoma.Pathol Oncol Res. 

2015 Sep ;21(4):1191-9.IF: 1,855 

3. González Rodríguez AJ, Jordá Cuevas E. Idiopathic facial 

aseptic granuloma.Clin Exp Dermatol. 2015 Apr ;40(3):298- 

300.IF: 1,092 

4. Gavrilova M, Cabezas Macian M, Martín-Gorgojo A, Beteta 

LG, Posadas V, Jordá-Cuevas E. A rapidly enlarging mass on 

the right leg.Pediatr Dermatol. 2015 Jan-Feb ;32(1):143-4. 

IF: 1,015 

5. Monteagudo C, Llombart B, Burgués O, Rubio L, 

Calabuig S, Sanmartín O, López-Guerrero JA. Biphasic 

dermatofibrosarcoma protuberans with a labyrinthine 

plexiform high-grade fibrosarcomatous transformation.J 

Cutan Pathol. 2015 Mar ;42(3):206-12.IF: 1,582 

6. Saravia M, Pellicer Z, Martín JM, Monteagudo C. Clinically 

atypical spitzoid lesions: semi-quantitative histologic 

index correlation with dermoscopic scores (ABCD rule, 

7-point checklist and pattern analysis).J Eur Acad Dermatol 

Venereol. 2015 Apr ;29(4):668-72.IF: 2,826 

7. Gómez-Mateo Mdel C, Compañ-Quilis A, Monteagudo 

C. Microcystic pseudoglandular plexiform cutaneous 

neurofibroma.J Cutan Pathol. 2015 Nov ;42(11):884-8.IF: 

1,582 

8. Martín JM, Beteta G, Allende A, Jordá E. Parvovirus B19- 

Associated Microvesicular Eruption.Pediatr Dermatol. 2015 

Nov ;32(6):e303-4.IF: 1,015 




1. A hitherto unreported association.Pathol Res Pract. 2015 

Nov ;211(11):877-82.IF: 1,397 

10. Ayala D, Ramón MD, Cabezas M, Jordá E. Primary Cutaneous 

CD4+ Small/Medium-Sized Pleomorphic T-Cell Lymphoma With 

Expression of Follicular T-Helper Cell Markers and Spontaneous 

Remission.Actas Dermosifiliogr. 2015 Dec 24 ;.IF: 0 

11. Ayala D, Ramón MD, Martín JM, Jordá E. Atypical 

Phacomatosis Pigmentokeratotica as the Expression of a 

Mosaic RASopathy With the BRAF-Glu586Lys Mutation. 

Actas Dermosifiliogr. 2015 Dec 15 ;.IF: 0 

103

4 

Scientific 

activity 

104 

12. Díaz-Corpas T, Morales-Suárez-Varela M, Rausell Fontestad 

N, Fuertes Prósper A, Marquina-Vila A, Jordá-Cuevas 

E. Squamous Cell Carcinoma: Clinical and Pathological 

Features and Associated Risk Factors in an Observational 

Study of 118 Patients.Actas Dermosifiliogr. 2015 Dec; 

106(10): 806-815.IF: 0 

Letter 

13. Escandell I, Cabezas M, Martín JM, Terrádez L, Pinazo MI. 

Effective treatment with Dabrafenib and Trametinib for 

a BRAF-mutated metastatic dedifferentiated malignant 

spindle cell neoplasm. J Eur Acad Dermatol Venereol. 2015 

Apr 27;.IF: 2,826 

• THESIS 

Thesis title: Determinación de parámetros clínico-patológicos 

y moleculares implicados en la regresión espontánea de 

neoplasias melanocíticas cutáneas. 

Doctoral candidate: José María Martín Hernández 

Director(s): Carlos Monteagudo Castro, Esperanza Jordá 

Cuevas 



Thesis title: Carcinoma epidermoide cutáneo: relación con los 

trastornos respiratorios del sueño y definición de la variante 

alto riesgo 

Doctoral candidate: Tania Díaz Corpas 

Director(s): Esperanza Jordá Cuevas, María Manuela Morales 

Suárez-Varela, Estrella Fernández Fabrellas 




RESEARCH 



curaneous malignant melanoma, and their value as prognostic 

and therapeutic biomarkers 

Principal Investigator: José Carlos Monteagudo Castro 






Reference: Programa VLC-BIOCLINIC 

Title: Biosensor molecular para la detección espacio-temporal 

de miRNAS 

Principal Investigator: Carlos Monteagudo Castro 






Reference: PROMETEO II 2015/009 

Title: Análisis transcriptómico y proteómico de los cambios 

condicionados por miRNAs en el melanoma cutáneo: 

identificación de nuevos biomarcadores proteicos con 

significación pronóstica 




Clínico Universitario de Valencia- INCLIVA 


Total Budget: 167.010€ (2015: 51.100€) 

• AWARDS 

José María Martín, Esperanza Jordá and Carlos Monteagudo 

received the grant “Premio Campaña Euromelanoma” awarded 

by the Spanish Academy of Dermatology and Venereology for 

the scientific work: The heterogeneity of telomere length influences 

the spontaneous regression of melanoma. 

In addition they received the prize “Pierre Fabre Dermatology 

about Acne” in the category: care process, organized by the 

Spanish Academy of Dermatology and Venereology and sponsored 

by Pierre Fabre Dermatology Laboratory for the work 

entitled “Differences in treatment efficacy and quality of life 

patients with moderate and severe acne comparing different 

doses of isotretinoin”.


4 

Translational Research Group on Pediatric Solid Tumours 


“Micromecenazgo para lograr imágenes en 3D para el diagnóstico de tumores infantiles”. 

Rosa Noguera. Levante. 10.11.2015 

https://www.aecc.es/RedSocial/Blogs%20investigadores/Paginas/RosaNoguera.aspx 

105 

Group members 



Samuel Navarro Fos 


H Index: 26 


Rosa Noguera Salvá. University 

Antonio Llombart Bosch. University 

Ana Pilar Berbegall Beltrán. University 

Irene Tadeo Cervera. INCLIVA 

Maite Blanquer Maceiras. INCLIVA 

PhD students 

Susana Martín Vañó. University 

Víctor Zúñiga Zaragoza. University 

Technicians 

Alejo Miguel Sempere Crespo. University 

Rebeca Brugos Panadero. INCLIVA

4 

Scientific 

activity 

106 


• Genetic analyses of neuroblastoma. At a European level, 

the group is participating in the establishment of a 

standardized nomenclature, a standard operating procedure 

and studies of quality validation, critical tools to 

maintain high quality in FISH, MLPA y SNPs results used 

in therapeutic stratification 

• Identification of new genetic factors with prognostic value 

in malignant pediatric neuroblastic and skeletogenic 

tumours 

• Obtention and characterization of cell lines from fresh 

pediatric skeletogenic tumours 

• Establishment and characterization of in vivo models of 

malignant skeletogenic tumours 

• Expression studies of markers in colorectal carcinoma 

and pediatric solid tumours 

• To analyze histopathologic and genetic studies in uterine 

mesenchymal tumours 

• To study genetic and immunohistochemical characterization 

of renal clear cell carcinoma 


• Analysis of histopathological and genetic prognostic factors 

in neuroblastoma (NB) 

• Development of high-throughput pan-genomic techniques 

in NB and sarcomas 

• Study of apoptosis, proliferation, angiogenesis and hypoxia 

in pediatric tumours, soft-tissue sarcomas, skeletogenic 

tumours and gynecologic mesenchymal tumours 

• ALK as a prognostic factor in NB 

• Identification and isolation of stem cells in NB 

• Establishment and characterization of in vitro and in 

vivo models of malignant skeletogenic tumours. Cell line 

extraction in these tumours 

• Expression study of immunohistochemistry and Western 

blot markers in these tumours in order to identify 

possible therapeutic targets 

• Study of NB hyperstructure 



16 61,03 3,81 

National 



International 


Corresponding 

author 

4 9 6 

1. Kunz P, Fellenberg J, Moskovszky L, Sápi Z, Krenacs T, 

Machado I, Poeschl J, Lehner B, Szendrõi M, Ruef P, 

Bohlmann M, Bosch AL, Ewerbeck V, Kinscherf R, Fritzsching 

B. Improved survival in osteosarcoma patients with atypical 

low vascularization.Ann Surg Oncol. 2015 Feb ;22(2):489- 

96.IF: 3,93 

2. Defferrari R, Mazzocco K, Ambros IM, Ambros PF, Bedwell 

C, Beiske K, Bénard J, Berbegall AP, Bown N, Combaret V, 

Couturier J, Erminio G, Gambini C, Garaventa A, Gross N, 

Haupt R, Kohler J, Jeison M, Lunec J, Marques B, Martinsson 

T, Noguera R, Parodi S, Schleiermacher G, Tweddle DA, 

Valent A, Van Roy N, Vicha A, Villamon E, Tonini GP. Influence 

of segmental chromosome abnormalities on survival in 

children over the age of 12 months with unresectable 

localised peripheral neuroblastic tumours without MYCN 

amplification.Br J Cancer. 2015 Jan 20 ;112(2):290-5.IF: 

4,836 

3. Fransson S, Hansson M, Ruuth K, Djos A, Berbegall A, 

Javanmardi N, Abrahamsson J, Palmer RH, Noguera R, 

Hallberg B, Kogner P, Martinsson T. Intragenic anaplastic 

lymphoma kinase (ALK) rearrangements: Translocations 

as a novel mechanism of ALK activation in neuroblastoma 

tumours.Genes Chromosomes Cancer. 2015 Feb ;54(2):99- 

109.IF: 4,041 

4. Braekeveldt N, Wigerup C, Gisselsson D, Mohlin S, Merselius 

M, Beckman S, Jonson T, Börjesson A, Backman T, Tadeo I, 

Berbegall AP, Ora I, Navarro S, Noguera R, Påhlman S, Bexell 

D. Neuroblastoma patient-derived orthotopic xenografts 

retain metastatic patterns and geno- and phenotypes of 

patient tumours.Int J Cancer. 2015 Mar 1 ;136(5):E252-61. 

IF: 5,085 




report and literature review.Onco Targets Ther. 2015 

;8:1053-9.IF: 2,311


4 

6. Zhang W, Yu Y, Hertwig F, Thierry-Mieg J, Zhang W, Thierry- 

Mieg D, Wang J, Furlanello C, Devanarayan V, Cheng J, 

Deng Y, Hero B, Hong H, Jia M, Li L, Lin SM, Nikolsky Y, 

Oberthuer A, Qing T, Su Z, Volland R, Wang C, Wang 

MD, Ai J, Albanese D, Asgharzadeh S, Avigad S, Bao W, 

Bessarabova M, Brilliant MH, Brors B, Chierici M, Chu TM, 

Zhang J, Grundy RG, He MM, Hebbring S, Kaufman HL, 

Lababidi S, Lancashire LJ, Li Y, Lu XX, Luo H, Ma X, Ning B, 

Noguera R, Peifer M, Phan JH, Roels F, Rosswog C, Shao S, 

Shen J, Theissen J, Tonini GP, Vandesompele J, Wu PY, Xiao 

W, Xu J, Xu W, Xuan J, Yang Y, Ye Z, Dong Z, Zhang KK, Yin Y, 

Zhao C, Zheng Y, Wolfinger RD, Shi T, Malkas LH, Berthold 

F, Wang J, Tong W, Shi L, Peng Z, Fischer M. Comparison 

of RNA-seq and microarray-based models for clinical 

endpoint prediction.Genome Biol. 2015 Jun 25 ;16:133.IF: 

10,288 

7. von Stedingk K, De Preter K, Vandesompele J, Noguera 

R, Øra I, Koster J, Versteeg R, Påhlman S, Lindgren D, 

Axelson H. Individual patient risk stratification of high-risk 

neuroblastomas using a two-gene score suited for clinical 

use.Int J Cancer. 2015 Aug 15 ;137(4):868-77.IF: 5,085 

8. Yáñez Y, Grau E, Rodríguez-Cortez VC, Hervás D, Vidal E, 

Noguera R, Hernández M, Segura V, Cañete A, Conesa A, 

Font de Mora J, Castel V. Two independent epigenetic 

biomarkers predict survival in neuroblastoma.Clin 

Epigenetics. 2015 ;7(1):16.IF: 0 

9. Machado I, Mayordomo-Aranda E, Giner F, Llombart- 

Bosch A. The Role of Immunohistochemistry in 

Rhabdomyosarcoma Diagnosis Using Tissue Microarray 

Technology and a Xenograft Model.Fetal Pediatr Pathol. 

2015 ;34(5):271-81.IF: 0,481 

10. Giner F, López-Guerrero JA, Machado I, García-Casado 

Z, Peydró-Olaya A, Llombart-Bosch A. The early stages 

of tumor angiogenesis in human osteosarcoma: a nude 

mice xenotransplant model.Virchows Arch. 2015 Aug 

;467(2):193-201.IF: 2,651 

11. Machado I, López-Soto MV, Rubio L, Navarro L, Llombart- 

Bosch A. Soft tissue myoepithelial carcinoma with 

rhabdoid-like features and EWSR1 rearrangement: Fine 

needle aspiration cytology with histologic correlation.Diagn 

Cytopathol. 2015 May ;43(5):421-6.IF: 1,121 

12. Oberthuer A, Juraeva D, Hero B, Volland R, Sterz C, Schmidt 

R, Faldum A, Kahlert Y, Engesser A, Asgharzadeh S, Seeger 

R, Ohira M, Nakagawara A, Scaruffi P, Tonini GP, Janoueix- 

Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, 

Speleman F, Noguera R, Piqueras M, Bénard J, Valent A, 

Avigad S, Yaniv I, Grundy RG, Ortmann M, Shao C, Schwab 

M, Eils R, Simon T, Theissen J, Berthold F, Westermann F, 

Brors B, Fischer M. Revised risk estimation and treatment 

stratification of low- and intermediate-risk neuroblastoma 

patients by integrating clinical and molecular prognostic 

markers.Clin Cancer Res. 2015 Apr 15 ;21(8):1904-15.IF: 

8,722 

13. Ibarrola-Villava M, Llorca-Cardeñosa MJ, Tarazona N, 

Mongort C, Fleitas T, Perez-Fidalgo JA, Roselló S, Navarro 

S, Ribas G, Cervantes A. Deregulation of ARID1A, CDH1, 

cMET and PIK3CA and target-related microRNA expression 

in gastric cancer.Oncotarget. 2015 Sep 29 ;6(29):26935-45. 

IF: 6,359 




1. A hitherto unreported association.Pathol Res Pract. 2015 

Nov ;211(11):877-82.IF: 1,397 

15. Machado I, Cruz J, Lavernia J, Llombart-Bosch A. Solitary, 

multiple, benign, atypical, or malignant: the “Granular Cell 

Tumor” puzzle.Virchows Arch. 2015 Dec 5 ;.IF: 2,651 


16. García-Alfonso P, García-Foncillas J, Salazar R, Pérez-Segura 

P, García-Carbonero R, Musulén-Palet E, Cuatrecasas M, 

Landolfi S, Ramón Y Cajal S, Navarro S, Spanish Society of 

Pathology, Spanish Society of Medical Oncology. Updated 

guidelines for biomarker testing in colorectal carcinoma: a 

national consensus of the Spanish Society of Pathology and 

the Spanish Society of Medical Oncology.Clin Transl Oncol. 

2015 Apr ;17(4):264-73.IF: 2,077 

• THESIS 

Thesis title: Estudio clínico, histopatológico, 

inmunohistoquímico y citigenético de los tumores 

mesenquimales uterinos de musculo liso. Búsqueda de dianas 

terapéuticas. 

Doctoral candidate: Nuria Santonja López 

Director(s): Samuel Navarro Fos, José Juan Santonja Lucas, 

Rosa Noguera Salvá 



107

4 

Scientific 

activity 

108 

Thesis title: Integración de la genómica en la modelización de 

los tumores neuroblásticos 

Doctoral candidate: Ana Pilar Berbegall Beltrán 

Director(s): Samuel Navarro Fos, Rosa Noguera Salvá 



Thesis title: Estudio del armazón arquitectónico y del sistema 

vascular de los tumores neuroblásticos 

Doctoral candidate: Irene Tadeo Cervera 

Director(s): Samuel Navarro Fos, Rosa Noguera Salvá 




RESEARCH 

Reference: 261474 

Title: European network for cancer in children and adolescent 

(ENCCA) 

Principal Investigator: Ruth Landenstein (Rosa Noguera as 



Beneficiary institution: Universitat de València 



Reference: FAECC2015 

Title: Búsqueda de dianas terapéuticas en los puntos de 

contacto de la célula tumoral en el neuroblastoma infantil con 

su matriz extracelular 

Principal Investigator: Rosa Noguera 

Funding body: AECC-Asociación Española Contra el Cáncer 






Title: Estudio de la biotensegridad en los tumores 

neuroblásticos 


Funding body: Ministerio de Economia y Competitividad 






Title: Red temática de investigación cooperativa en cáncer 

(RTICC) 

Principal Investigator: Samuel Navarro Fos 




Total budget: 73.000€/year 

Title: Prospective Validation of alterations in 1q and 16q as 

Biomarkers in Ewing Sarcoma 

Principal Investigator: Enrique de Álava Casado (Rosa 

Noguera and Samuel Navarro as collaborating researchers) 

Funding body: Fundación CRIS-FISEVI 





Overlapping images obtained after staining a tumor sample of neuroblastoma 

with different histochemical and immunohistochemical markers, 

in order to perform topological studies. Legend: CD163 + (green), 

CD45 + (blue), CD11c + (purple), CD8 + (red) and reticulin fibers of the 

matrix (white) Cells.


4 

Research Group on Hematopoietic Transplantation 


109 

Group members 


Carlos Solano Vercet 


H Index: 26 


Cristina Arbona Castaño. Hospital 

María José Remigia Pellicer. Hospital 

Rosa Goterris Viciedo. Hospital 

David Navarro Ortega. Hospital. University 

Julia Peláez González. INCLIVA 

Joana Hernández Martín. INCLIVA 

Paula Amat Martínez. Hospital 

Estela Giménez Quiles. Hospital

4 

Scientific 

activity 

110 


• To advance in translational research in biology and 

treatment of graft versus host disease after allogeneic 

hematopoietic progenitor cells 

• To study the Infection and immune reconstitution after 

hematopoietic transplantation 

• To investigate in biology implant in hematopoietic 

transplantation 

• To research cell therapy with adult stem cells in the context 

of hematopoietic transplantation 


• Biology of hematopoietic implant 

• Cell therapy with adult stem cells in relation with hematopoietic 


• Translational research on complications of allogeneic 

hematopoietic transplantation: graft-versus-host disease 

• Infection and immune reconstitution after hematopoietic 




34 114,92 3,38 

National 



International 


Corresponding 

author 

25 5 12 

1. Corrales I, Giménez E, Solano C, Amat P, de la Cámara 

R, Nieto J, García-Noblejas A, Navarro D. Incidence and 

dynamics of active cytomegalovirus infection in allogeneic 

stem cell transplant patients according to single nucleotide 

polymorphisms in donor and recipient CCR5, MCP-1, IL-10, 

and TLR9 genes.J Med Virol. 2015 Feb ;87(2):248-55.IF: 

2,347 

2. Aguado JM, Vázquez L, Fernández-Ruiz M, Villaescusa T, 

Ruiz-Camps I, Barba P, Silva JT, Batlle M, Solano C, Gallardo 

D, Heras I, Polo M, Varela R, Vallejo C, Olave T, López- 

Jiménez J, Rovira M, Parody R, Cuenca-Estrella M, PCRAGA 

Study Group, Spanish Stem Cell Transplantation Group, the 

Study Group of Medical Mycology of the Spanish Society 

of Clinical Microbiology and Infectious Diseases, and the 

Spanish Network for Research in Infectious Diseases. Serum 

galactomannan versus a combination of galactomannan 

and polymerase chain reaction-based Aspergillus DNA 

detection for early therapy of invasive aspergillosis in highrisk 

hematological patients: a randomized controlled trial. 

Clin Infect Dis. 2015 Feb 1 ;60(3):405-14.IF: 8,886 

3. Corrales I, Giménez E, Aguilar G, Delgado C, Puig J, Izquierdo 

A, Belda J, Navarro D. Detection of fungal DNA in peritoneal 

fluids by a PCR DNA low-density microarray system and 

quantitation of serum (1-3)-?-D-glucan in the diagnosis of 

peritoneal candidiasis.Med Mycol. 2015 Feb 1 ;53(2):199- 

204.IF: 2,335 

4. Costa E, Rodríguez-Domínguez M, Clari MÁ, Giménez E, 

Galán JC, Navarro D. Comparison of the performance of 

2 commercial multiplex PCR platforms for detection of 

respiratory viruses in upper and lower tract respiratory 

specimens.Diagn Microbiol Infect Dis. 2015 May ;82(1):40- 

3.IF: 2,457 

5. Giménez E, Solano C, Amat P, de la Cámara R, Nieto J, 

López J, García-Noblejas A, Navarro D. Enumeration of 

NKG2C+ natural killer cells early following allogeneic stem 

cell transplant recipients does not allow prediction of the 

occurrence of cytomegalovirus DNAemia.J Med Virol. 2015 

Sep ;87(9):1601-7.IF: 2,347 









7. Bow EJ, Vanness DJ, Slavin M, Cordonnier C, Cornely OA, 

Marks DI, Pagliuca A, Solano C, Cragin L, Shaul AJ, Sorensen 

S, Chambers R, Kantecki M, Weinstein D, Schlamm H. 

Systematic review and mixed treatment comparison metaanalysis 

of randomized clinical trials of primary oral antifungal 

prophylaxis in allogeneic hematopoietic cell transplant 

recipients.BMC Infect Dis. 2015 Mar 17 ;15(1):128.IF: 2,613 

8. Giménez E, Muñoz-Cobo B, Solano C, Amat P, de la Cámara 

R, Nieto J, López J, Remigia MJ, García-Noblejas A, Navarro


4 

D. Functional patterns of cytomegalovirus (CMV) pp65 and 

immediate early-1-specific CD8(+) T cells that are associated 

with protection from and control of CMV DNAemia after 

allogeneic stem cell transplantation.Transpl Infect Dis. 2015 

Jun ;17(3):361-70.IF: 2,064 

9. San-Juan R, Navarro D, García-Reyne A, Montejo M, Muñoz 

P, Carratala J, Len O, Fortun J, Muñoz-Cobo B, Gimenez E, 

Eworo A, Sabe N, Meije Y, Martín-Davila P, Andres A, Delgado 

J, Jimenez C, Amat P, Fernández-Ruiz M, López-Medrano F, 

Lumbreras C, Aguado JM, REIPI Network. Effect of long-term 

prophylaxis in the development of cytomegalovirus-specific 

T-cell immunity in D+/R- solid organ transplant recipients. 

Transpl Infect Dis. 2015 Oct ;17(5):637-46.IF: 2,064 

10. Patiño Galindo JA, Torres-Puente M, Gimeno C, Ortega E, 

Navarro D, Galindo MJ, Navarro L, Navarro V, Juan A, Belda 

J, Bracho MA, González-Candelas F, CRIVIH. Expansion 

of the CRF19_cpx Variant in Spain.J Clin Virol. 2015 Aug 

;69:146-9.IF: 3,016 

11. Solano C, de la Cámara R, Vázquez L, López J, Giménez E, 

Navarro D. Cytomegalovirus Infection Management in 

Allogeneic Stem Cell Transplant Recipients: a National 

Survey in Spain.J Clin Microbiol. 2015 Aug ;53(8):2741-4.IF: 

3,993 

12. Giménez E, Blanco-Lobo P, Muñoz-Cobo B, Solano C, Amat 

P, Pérez-Romero P, Navarro D. Role of cytomegalovirus 

(CMV)-specific polyfunctional CD8+ T-cells and antibodies 

neutralizing virus epithelial infection in the control of CMV 

infection in an allogeneic stem-cell transplantation setting.J 

Gen Virol. 2015 Sep ;96(9):2822-31.IF: 3,183 

13. Parody R, López-Corral L, Godino OL, Cadenas IG, Martínez 

AP, Vazquez L, Martino R, Martínez C, Solano C, Barba P, 

Valcarcel D, Caballero-Velazquez T, Marquez-Malaver FJ, 

Sierra J, Caballero D, Perez-Simón JA. GVHD prophylaxis 

with sirolimus-tacrolimus may overcome the deleterious 

effect on survival of HLA mismatch after reduced-intensity 

conditioning allo-SCT.Bone Marrow Transplant. 2015 Jan 

;50(1):121-6.IF: 3,57 

14. Sánchez-Castro J, Marco-Betés V, Gómez-Arbonés X, García- 

Cerecedo T, López R, Talavera E, Fernández-Ruiz S, Ademà 

V, Marugan I, Luño E, Sanzo C, Vallespí T, Arenillas L, Marco 

Buades J, Batlle A, Buño I, Martín Ramos ML, Blázquez Rios B, 

Collado Nieto R, Vargas MT, González Martínez T, Sanz G, Solé 

F, Spanish Group for Mds Study (GESMD) and the Spanish 

Group for Clinical Cytogenetics (Gcecgh). Fluorescence in 

situ hybridization of TP53 for the detection of chromosome 

17 abnormalities in myelodysplastic syndromes.Leuk 

Lymphoma. 2015 Nov ;56(11):3183-8.IF: 2,891 

15. González-Gascón Y Marín I, Hernández-Sánchez M, Rodríguez-Vicente 

AE, Sanzo C, Aventín A, Puiggros A, Collado R, 

Heras C, Muñoz C, Delgado J, Ortega M, González MT, Marugán 

I, de la Fuente I, Recio I, Bosch F, Espinet B, González 

M, Hernández-Rivas JM, Hernández JÁ, On behalf of Grupo 

Español de Leucemia Linfática Crónica (GELLC), Grupo Cooperativo 

Español de Citogenética Hematológica (GCECGH). A 

high proportion of cells carrying trisomy 12 is associated with 

a worse outcome in patients with chronic lymphocytic leukemia.Hematol 

Oncol. 2015 Feb 17 ;.IF: 3,084 

16. Chen-Liang TH, Martín-Santos T, Jerez A, Senent L, Orero MT, 

Remigia MJ, Muiña B, Romera M, Fernandez-Muñoz H, Raya 

JM, Fernandez-González M, Lancharro A, Villegas C, Carlos 

Herrera J, Frutos L, Luis Navarro J, Uña J, Igua C, Sanchez- 

Vaño R, Cozar Mdel P, Contreras J, Sanchez-Blanco JJ, Perez- 

Ceballos E, Ortuño FJ. The role of bone marrow biopsy and 

FDG-PET/CT in identifying bone marrow infiltration in the 

initial diagnosis of high grade non-Hodgkin B-cell lymphoma 

and Hodgkin lymphoma. accuracy in a multicenter series of 

372 patients.Am J Hematol. 2015 Aug ;90(8):686-90.IF: 3,798 

17. San-Juan R, Navarro D, García-Reyne A, Montejo M, Muñoz 

P, Carratala J, Len O, Fortun J, Muñoz-Cobo B, Gimenez 

E, Eworo A, Sabe N, Meije Y, Martín-Davila P, Andres A, 

Delgado J, Jimenez C, Amat P, Fernández-Ruiz M, López- 

Medrano F, Lumbreras C, Aguado JM, REIPI Network, Spain, 

GESITRA Study Group from the SEIMC. Effect of delaying 

prophylaxis against CMV in D+/R- solid organ transplant 

recipients in the development of CMV-specific cellular 

immunity and occurrence of late CMV disease.J Infect. 2015 

Nov ;71(5):561-70.IF: 4,441 

18. Fernández-Ruiz M, Corrales I, Arias M, Campistol JM, 

Giménez E, Crespo J, López-Oliva MO, Beneyto I, Martín- 

Moreno PL, Llamas-Fuente F, Gutiérrez A, García-Álvarez 

T, Guerra-Rodríguez R, Calvo N, Fernández-Rodríguez A, 

Tabernero-Romo JM, Navarro MD, Ramos-Verde A, Aguado 

JM, Navarro D, OPERA Study Group. Association between 

individual and combined SNPs in genes related to innate 

immunity and incidence of CMV infection in seropositive 

kidney transplant recipients.Am J Transplant. 2015 May 

;15(5):1323-35.IF: 5,683 

19. Fernández-Ruiz M, Arias M, Campistol JM, Navarro D, 

Gómez-Huertas E, Gómez-Márquez G, Díaz JM, Hernández 

111

4 

Scientific 

activity 

112 

D, Bernal-Blanco G, Cofan F, Jimeno L, Franco-Esteve A, 

González E, Moreso FJ, Gómez-Alamillo C, Mendiluce 

A, Luna-Huerta E, Aguado JM, OPERA Study Group. 

Cytomegalovirus prevention strategies in seropositive 

kidney transplant recipients: an insight into current clinical 

practice.Transpl Int. 2015 Sep ;28(9):1042-54.IF: 2,599 

20. Ferrà C, Sanz J, Díaz-Pérez MA, Morgades M, Gayoso J, 

Cabrera JR, Villaescusa T, Sampol MA, Fernández-Avilés F, 

Solano C, Ortín M, Duarte R, Cuesta M, Heras I, de la Serna 

J, Moraleda JM, Barrenetxea C, González-Vicent M, Sanz G, 

Ribera JM, Grupo Español de Trasplante Hematopoyético 

(Geth) Spanish Society of Hematology. Outcome of graft 

failure after allogeneic stem cell transplant: study of 89 

patients.Leuk Lymphoma. 2015 Mar ;56(3):656-62.IF: 2,891 

21. Monleón D, Giménez E, Muñoz-Cobo B, Morales JM, Solano 

C, Amat P, Navarro D. Plasma metabolomics profiling for 

the prediction of cytomegalovirus DNAemia and analysis 

of virus–host interaction in allogeneic stem cell transplant 

recipients.J Gen Virol. 2015 Nov ;96(11):3373-81.IF: 3,183 

22. Noriega V, Martínez-Laperche C, Buces E, Pion M, Sánchez- 

Hernández N, Martín-Antonio B, Guillem V, Bosch-Vizcaya 

A, Bento L, González-Rivera M, Balsalobre P, Kwon M, 

Serrano D, Gayoso J, de la Cámara R, Brunet S, Rojas- 

Contreras R, Nieto JB, Martínez C, Gónzalez M, Espigado 

I, Vallejo JC, Sampol A, Jiménez-Velasco A, Urbano-Ispizua 

A, Solano C, Gallardo D, Díez-Martín JL, Buño I, Spanish 

Hematopoietic Stem Cell Transplantation and Cell Therapy 

Group (GETH). The Genotype of the Donor for the (GT) 

n Polymorphism in the Promoter/Enhancer of FOXP3 Is 

Associated with the Development of Severe Acute GVHD 

but Does Not Affect the GVL Effect after Myeloablative HLA- 

Identical Allogeneic Stem Cell Transplantation.PLoS One. 

2015 ;10(10):e0140454.IF: 3,234 



JC. BCL2 gene polymorphisms and splicing variants in chronic 

myeloid leukemia.Leuk Res. 2015 Aug 28 ;.IF: 2,351 




emerging North-American outbreak in 2014.J Clin Virol. 

2015 Oct ;71:1-9.IF: 3,016 

25. Aguilar G, Delgado C, Corrales I, Izquierdo A, Gracia E, 

Moreno T, Romero E, Ferrando C, Carbonell JA, Borrás R, 

Navarro D, Belda FJ. Epidemiology of invasive candidiasis in 

a surgical intensive care unit: an observational study.BMC 

Res Notes. 2015 Sep 29 ;8:491.IF: 0 

26. Lupiañez CB, Canet LM, Carvalho A, Alcazar-Fuoli L, Springer 

J, Lackner M, Segura-Catena J, Comino A, Olmedo C, Ríos 

R, Fernández-Montoya A, Cuenca-Estrella M, Solano C, 

López-Nevot MÁ, Cunha C, Oliveira-Coelho A, Villaescusa T, 

Fianchi L, Aguado JM, Pagano L, López-Fernández E, Potenza 

L, Luppi M, Lass-Flörl C, Loeffler J, Einsele H, Vazquez L, 

PCRAGA Study Group, Jurado M, Sainz J. Polymorphisms 

in Host Immunity-Modulating Genes and Risk of Invasive 

Aspergillosis: Results from the AspBIOmics Consortium. 

Infect Immun. 2015 Dec 14 ;84(3):643-57.IF: 3,731 

27. Solano C, Giménez E, Piñana JL, Vinuesa V, Poujois S, 

Zaragoza S, Calabuig M, Navarro D. Preemptive antiviral 

therapy for CMV infection in allogeneic stem cell transplant 

recipients guided by the viral doubling time in the blood. 

Bone Marrow Transplant. 2015 Dec 7 ;.IF: 3,57 

28. Grau S, Solano C, García-Vidal C, Jarque I, Barrueta J, 

Peral C, Rodríguez I, Rubio-Rodríguez D, Rubio-Terrés C. 

Pharmacoeconomic Analysis of The Use of Voriconazole, 

Posaconazole And Micafungin In The Primary Prophylaxis 

of Invasive Fungal Infections In Recipients of Allogeneic 

Hematopoietic Stem Cell Transplants In Spain.Value Health. 

2015 Nov ;18(7):A581.IF: 3,279 

29. López-Labrador FX, Berenguer M, Navarro D. Overcoming 

drug resistance in HSV, CMV, HBV and HCV infection.Future 

Microbiol. 2015 Nov ;10:1759-66.IF: 4,275 

30. Cuervo G, Puig-Asensio M, García-Vidal C, Fernández-Ruiz 

M, Pemán J, Nucci M, Aguado JM, Salavert M, González- 

Romo F, Guinea J, Zaragoza O, Gudiol C, Carratalà J, 

Almirante B, CANDIPOP Project, Validation Cohort Project. 

A simple prediction score for estimating the risk of 

candidaemia caused by fluconazole non-susceptible strains. 

Clin Microbiol Infect. 2015 Jul ;21(7):684.e1-9.IF: 5,768 

Review 

31. Navarro D. [Optimization strategies in management of CMV 

infection in transplant patients].Rev Esp Quimioter. 2015 

Sep ;28 Suppl 1:52-3.IF: 0,797 

Letters 

32. Falcón R, Madrid S, Tormo N, Casañ C, Albert E, Gimeno C, 

Navarro D. Intra- and Interinstitutional Evaluation of an 

Etest for Vancomycin Minimum Inhibitory Concentration


4 

Measurement in Staphylococcus aureus Blood Isolates.Clin 

Infect Dis. 2015 Nov 1 ;61(9):1490-2.IF: 8,886 

33. Saumell S, Florensa L, Rodríguez-Rivera M, Pedro C, 

Hernández-Rivas JM, Lumbreras E, Abáigar M, Collado R, 

Ivars D, Carbonell F, Marugán I, Tormo M, Botia M, Piñan 

MÁ, Ancín I, González T, Varela ND, Grau J, Granada I, Ruiz 

N, Martín ML, Fernández-Guijarro M, Duarte JJ, Calasanz 

MJ, Larrayoz MJ, Solé F. Fluorescence in situ hybridization 

analysis does not increase detection rate for trisomy 8 in 

chronic myelomonocytic leukemia.Leuk Lymphoma. 2015 

Jan ;56(1):242-3.IF: 2,891 

• AWARDS 

Carlos Solano received the Van Bekkum Award 2015, award 

for best paper presented at the 41 st Congress of the European 

Society of Transplant Blood and Marrow Transplant (EBMT). 

34. Fernández-Ruiz M, Corrales I, Amat P, González E, Andrés 

A, Navarro D, Aguado JM. Influence of Age and HLA Alleles 

on the CMV-Specific Cell-Mediated Immunity Among CMV- 

Seropositive Kidney Transplant Candidates.Am J Transplant. 

2015 Sep ;15(9):2525-6.IF: 5,683 


RESEARCH 

113 


Title: Estudio integral de biomarcadores de la enfermedad 

injerto contra huésped (EICH) en el trasplante alogénico de 

células hematopoyéticas (TPH-ALO) 

Principal Investigator: Carlos Solano Vercet 







Title: Infección activa por el citomegalovirus (CMV) en el 

trasplante alogénico de precursores hematopoyéticos: 

investigación de nuevos factores biológicos para la estimación 

del riesgo y análisis integral de los mecanismos inmunitarios 

que previenen y controlan 

Principal Investigator: David Navarro Ortega 






4 

Scientific 

activity 

Research Group on Lymphoproliferative Disorders 


114 

Group members 


Mª José Terol Casterá 


H Index: 26 


Antonio Ferrández Izquierdo. Hospital. University 

Ana Isabel Teruel Casaús. Hospital 

Sandra Ballester García. INCLIVA 

Lucía Brines Sirerol. INCLIVA 

Blanca Ferrer Lores. INCLIVA 

Ariadna Pérez Martínez. Hospital


4 


• VEGF/VEGF-R increases migration of B-CLL cells through 

an increased in expressión and functional activation of 

CXCR-4/CCR7 pathway. Increment in expression and migration 

correlates with adverse clinical features such as 

CD38/ZAP-70 expression, advanced Binet/RAi stage 

• The 936T allele at SNP rs3025039 of the VEGF gene is 

associated with a lower risk of B-CLL while variant genotype 

T/- SNP rs1449683 in the bFGF gene contributes to 

disease initiation and progression, showing a reduction 

in survival 

• Haplotype CGAC +/+ of the SNPs rs3025039, rs1109324, 

rs1547651 y rs833052 VEGF gene, associates with a lowe 

survival of CLL patients compared with the rest. This is 

especially relevant in the CD38/ZAP-70 positive Group 

• Both therapeutic approaches based on VMP and Rd, in 

an alternating or sequential schedules are associated 

with high efficacy and acceptable toxicity profile with no 

differences between them 


• Analysis of the interactions of CLL cells with their cellular 

microenvironment: further study of the intracellular mechanisms 

triggered by VEGF. Analysis of the possible correlation 

with CXCR4/CCR7 cytokinespathway. Transactivation 

mechanisms of the aforementioned receptors 

• Development of new ex-vivo co-culture models of the 

cells of CLL with bone marrow stroma and dendritic cells 

for the efficacy analysis of new kinase inhibitor drugs. 

Drug resistance effect mediated by microcellular environment 

• Identification and analysis of VEGF polymorphisms in CLL 

progression: study of samples from CLL patients obtained 

at diagnosis and controlled at the institution 

• Study of polymorphisms in folate pathway genes (MTHFR, 

DHFR, TS) and predisposition to develop lymphomas. Correlation 

with the clinical and biological characteristics of 

the disease, response to treatment, toxicity and survival 

• Study of polymorphisms of circadian rhythm-regulating 

genes in follicular lymphomas: correlation with the clinical 

and biological characteristics of the disease, response 

to treatment, toxicity and survival 

• New therapeutic options for CLL/MM patients who are 

resistant to chemoimmunotherapy 



4 64,08 16,02 

National 



International 


Corresponding 

author 

4 - - 

1. Puente XS, Beà S, Valdés-Mas R, Villamor N, Gutiérrez- 

Abril J, Martín-Subero JI, Munar M, Rubio-Pérez C, Jares 

P, Aymerich M, Baumann T, Beekman R, Belver L, Carrio A, 

Castellano G, Clot G, Colado E, Colomer D, Costa D, Delgado 

J, Enjuanes A, Estivill X, Ferrando AA, Gelpí JL, González B, 

González S, González M, Gut M, Hernández-Rivas JM, López- 

Guerra M, Martín-García D, Navarro A, Nicolás P, Orozco 

M, Payer ÁR, Pinyol M, Pisano DG, Puente DA, Queirós AC, 

Quesada V, Romeo-Casabona CM, Royo C, Royo R, Rozman 

M, Russiñol N, Salaverría I, Stamatopoulos K, Stunnenberg 

HG, Tamborero D, Terol MJ, Valencia A, López-Bigas N, 

Torrents D, Gut I, López-Guillermo A, López-Otín C, Campo 

E. Non-coding recurrent mutations in chronic lymphocytic 

leukaemia.Nature. 2015 Oct 22 ;526(7574):519-24.IF: 

41,456 

2. Martínez-López J, Paiva B, López-Anglada L, Mateos MV, 

Cedena T, Vidríales MB, Sáez-Gómez MA, Contreras T, Oriol 

A, Rapado I, Teruel AI, Cordón L, Blanchard MJ, Bengoechea 

E, Palomera L, de Arriba F, Cueto-Felgueroso C, Orfao 

A, Bladé J, San Miguel JF, Lahuerta JJ, Spanish Multiple 

Myeloma Group / Program for the Study of Malignant Blood 

Diseases Therapeutics (GEM / PETHEMA) Cooperative Study 

Group. Critical analysis of the stringent complete response 

in multiple myeloma: contribution of sFLC and bone marrow 

clonality.Blood. 2015 Aug 13 ;126(7):858-62.IF: 10,452 

3. García-Sanz R, Oriol A, Moreno MJ, de la Rubia J, Payer 

AR, Hernández MT, Palomera L, Teruel AI, Blanchard MJ, 

Gironella M, Ribas P, Bargay J, Abellá E, Granell M, Ocio EM, 

Ribera JM, San Miguel JF, Mateos MV, Spanish Myeloma 

Group (GEM/PETHEMA). Zoledronic acid as compared with 

observation in multiple myeloma patients at biochemical 

relapse: results of the randomized AZABACHE Spanish trial. 

Haematologica. 2015 Sep ;100(9):1207-13.IF: 5,814 

4. Amigo-Jiménez I, Bailón E, Aguilera-Montilla N, Terol MJ, 

García-Marco JA, García-Pardo A. Bone marrow stromainduced 

resistance of chronic lymphocytic leukemia 

115

4 

Scientific 

activity 

cells to arsenic trioxide involves Mcl-1 upregulation and 

is overcome by inhibiting the PI3K? or PKC? Signaling 

pathways.Oncotarget. 2015 Dec 29 ;6(42):44832-48.IF: 

6,359 


RESEARCH 


Title: Papel de la vía de señalización NOTCH1/FBXW7/PI3K/ 

PTEN/AKT en la progresión de la Leucemia Linfocítica Crónica B 

(LLC-B) a formas avanzadas. 

Principal Investigator: Mª José Terol Casterá 






116


4 

Research Group on Myeloid Neoplasms 


117 

http://www.esmo.org/Profiles/Juan-Carlos-Hernandez-Boluda 

Group members 


Mar Tormo Díaz 


H Index: 27 


Vicente Martín Guillem Primo. INCLIVA 

Blanca Navarro Cubells. Hospital 

Marisa Calabuig Muñoz. Hospital 

Montserrat Gómez Calafaz. Hospital 


Juan Carlos Hernández Boluda. Hospital

4 

Scientific 

activity 

118 


• To study the involvement of VEGF / VEGFR pathway in 

AML and their relation to different clinical, cytogenetic 

and molecular variables with established prognostic value 

• To study the role of complex RUNX1 / CBF-beta / p300 / 

HIPK2 in leukemic progression of chronic myeloproliferative 

neoplasms 

• To study the influence of SNPs involved in the synthesis 

and repair of DNA in toxicity and survival (SRV) patients 

diagnosed with LAL treated with therapeutic regimens 

containing MTX 


• Studies of new biological prognostic factors in acute myelogenous 

leukemia 

• Study of mechanisms of the leukemic chronic myeloproliferative 

neoplasms progression 

• Clinical guidelines for diagnosis, prognosis and treatment 

of myelodysplastic syndromes 

• Study the influence of SNPs involved in the synthesis and 

repair of DNA in toxicity and survival patients diagnosed 

with LAL treated with therapeutic regimens containing 

MTX 

• Clinical guidelines for assessment of response in chronic 

myeloid leukemia 

• Studies inside of CETLAM registry 

• Studies inside of PETHEMA registry 

• Studies inside of Spanish registry of myelofibrosis 

• Spanish inside of registry of Myelodysplastic syndromes 


Juan Carlos Hernández Boluda 

The research is focused on the 

molecular mechanisms involved 

in the progression of the chronic 

myeloproliferative neoplasms 

from the chronic phase to the 

leukemic phase. 



19 59,43 3,12 

National 



International 


Corresponding 

author 

13 4 3 

1. Bernal T, Martínez-Camblor P, Sánchez-García J, de Paz R, 

Luño E, Nomdedeu B, Ardanaz MT, Pedro C, Amigo ML, 

Xicoy B, del Cañizo C, Tormo M, Bargay J, Valcárcel D, Brunet 

S, Benlloch L, Sanz G, Spanish Group on Myelodysplastic 

Syndromes, PETHEMA Foundation, Spanish Society of 

Hematology. Effectiveness of azacitidine in unselected highrisk 

myelodysplastic syndromes: results from the Spanish 

registry.Leukemia. 2015 Sep ;29(9):1875-81.IF: 10,431 

2. Morillas P, Pallarés V, Fácila L, Llisterri JL, Sebastián ME, 

Gómez M, Castilla E, Camarasa R, Sandin M, García- 

Honrubia A, FAPRES registry investigators. The CHADS2 

Score to Predict Stroke Risk in the Absence of Atrial 

Fibrillation in Hypertensive Patients Aged 65 Years or Older. 

Rev Esp Cardiol (Engl Ed). 2015 Jun ;68(6):485-91.IF: 0 

3. Ribera J, Morgades M, Zamora L, Montesinos P, Gómez- 

Seguí I, Pratcorona M, Sarrà J, Guàrdia R, Nomdedeu J, 

Tormo M, Martínez-López J, Hernández-Rivas JM, González- 

Campos J, Barba P, Escoda L, Genescà E, Solé F, Millá 

F, Feliu E, Ribera JM, Spanish PETHEMA Group and the 

Spanish Society of Hematology. Prognostic significance of 

copy number alterations in adolescent and adult patients 

with precursor B acute lymphoblastic leukemia enrolled in 

PETHEMA protocols.Cancer. 2015 Nov 1 ;121(21):3809-17. 

IF: 4,889 

4. Ramos F, Thépot S, Pleyer L, Maurillo L, Itzykson R, Bargay 

J, Stauder R, Venditti A, Seegers V, Martínez-Robles V, 

Burgstaller S, Récher C, Debén G, Gaidano G, Gardin C, 

Musto P, Greil R, Sánchez-Guijo F, Fenaux P, European 

ALMA Investigators. Azacitidine frontline therapy for unfit 

acute myeloid leukemia patients: clinical use and outcome 

prediction.Leuk Res. 2015 Mar ;39(3):296-306.IF: 2,351 

5. Falantes J, Delgado RG, Calderón-Cabrera C, Márquez- 

Malaver FJ, Valcarcel D, de Miguel D, Bailén A, Bargay J, 

Bernal T, González-Porras JR, Tormo M, Ramos F, Andreu 

R, Xicoy B, Nomdedeu B, Brunet S, Sánchez J, Jurado AF,


4 

Bonanad S, Pérez-Simón JA, Sanz G, Spanish Group of 

Myelodysplastic Syndromes (GESMD). Multivariable timedependent 

analysis of the impact of azacitidine in patients 

with lower-risk myelodysplastic syndrome and unfavorable 

specific lower-risk score.Leuk Res. 2015 Jan ;39(1):52-7.IF: 

2,351 

6. Cervantes F, Isola IM, Alvarez-Larrán A, Hernández-Boluda 

JC, Correa JG, Pereira A. Danazol therapy for the anemia of 

myelofibrosis: assessment of efficacy with current criteria 

of response and long-term results.Ann Hematol. 2015 Nov 

;94(11):1791-6.IF: 2,634 

7. Hernández-Boluda JC, Gómez M. Target hematologic values 

in the management of essential thrombocythemia and 

polycythemia vera.Eur J Haematol. 2015 Jan ;94(1):4-11.IF: 

2,066 

8. García-Dabrio MC, Hoyos M, Brunet S, Tormo M, Ribera 

JM, Esteve J, Gallardo D, Duarte RF, de Llano MP, Bargay J, 

Martí-Tutusaus JM, Heras I, García A, Salamero O, Aventin 

A, Lecrevisse Q, Orfao A, Sierra J, Nomdedéu JF. Complex 

Measurements May Be Required to Establish the Prognostic 

Impact of Immunophenotypic Markers in AML.Am J Clin 

Pathol. 2015 Sep ;144(3):484-92.IF: 2,514 

9. Hernández-Boluda JC, Arellano-Rodrigo E, Cervantes F, 

Alvarez-Larrán A, Gómez M, Barba P, Mata MI, González- 

Porras JR, Ferrer-Marín F, García-Gutiérrez V, Magro E, 

Moreno M, Kerguelen A, Pérez-Encinas M, Estrada N, Ayala 

R, Besses C, Pereira A, Grupo Español de Enfermedades 

Mieloproliferativas Filadelfia Negativas (GEMFIN). Oral 

anticoagulation to prevent thrombosis recurrence in 

polycythemia vera and essential thrombocythemia.Ann 

Hematol. 2015 Jun ;94(6):911-8.IF: 2,634 



JC. BCL2 gene polymorphisms and splicing variants in 

chronic myeloid leukemia.Leuk Res. 2015 Aug 28 ;.IF: 2,351 

11. Díaz-Beyá M, Brunet S, Nomdedéu J, Pratcorona M, Cordeiro 

A, Gallardo D, Escoda L, Tormo M, Heras I, Ribera JM, 

Duarte R, de Llano MP, Bargay J, Sampol A, Nomdedeu M, 

Risueño RM, Hoyos M, Sierra J, Monzo M, Navarro A, Esteve 

J, Cooperative AML group CETLAM. The lincRNA HOTAIRM1, 

located in the HOXA genomic region, is expressed in acute 

myeloid leukemia, impacts prognosis in patients in the 

intermediate-risk cytogenetic category, and is associated 

with a distinctive microRNA signature.Oncotarget. 2015 Oct 

13 ;6(31):31613-27.IF: 6,359 

12. Díaz-Beyá M, Brunet S, Nomdedéu J, Cordeiro A, Tormo M, 

Escoda L, Ribera JM, Arnan M, Heras I, Gallardo D, Bargay 

J, Queipo de Llano MP, Salamero O, Martí JM, Sampol A, 

Pedro C, Hoyos M, Pratcorona M, Castellano JJ, Nomdedeu 

M, Risueño RM, Sierra J, Monzó M, Navarro A, Esteve J. The 

expression level of BAALC-associated microRNA miR-3151 

is an independent prognostic factor in younger patients 

with cytogenetic intermediate-risk acute myeloid leukemia. 

Blood Cancer J. 2015 Oct 2 ;5:e352.IF: 3,467 

13. Sanz MA, Montesinos P, Kim HT, Ruiz-Argüelles GJ, Undurraga 

MS, Uriarte MR, Martínez L, Jacomo RH, Gutiérrez- 

Aguirre H, Melo RA, Bittencourt R, Pasquini R, Pagnano 

K, Fagundes EM, Vellenga E, Holowiecka A, González- 

Huerta AJ, Fernández P, De la Serna J, Brunet S, De Lisa E, 

González-Campos J, Ribera JM, Krsnik I, Ganser A, Berliner 

N, Ribeiro RC, Lo-Coco F, Löwenberg B, Rego EM, IC-APL and 

PETHEMA and HOVON Groups. All-trans retinoic acid with 

daunorubicin or idarubicin for risk-adapted treatment of 

acute promyelocytic leukaemia: a matched-pair analysis of 

the PETHEMA LPA-2005 and IC-APL studies.Ann Hematol. 

2015 Aug ;94(8):1347-56.IF: 2,634 

14. Codoñer-Franch P, Carrasco-Luna J, Allepuz P, Codoñer- 

Alejos A, Guillem V. Association of RBP4 genetic variants 

with childhood obesity and cardiovascular risk factors. 

Pediatr Diabetes. 2015 Nov 26 ;.IF: 2,569 

15. Valcárcel D, Sanz G, Ortega M, Nomdedeu B, Luño E, Díez- 

Campelo M, Ardanaz MT, Pedro C, Montoro J, Collado R, 

Andreu R, Marco V, Cedena MT, de Paz R, Tormo M, Xicoy 

B, Ramos F, Bargay J, González B, Brunet S, Muñoz JA, 

Gómez V, Bailén A, Sanchez J, Merchán B, Del Cañizo C, 

Vallespí T, Grupo Español de Síndromes Mielodisplásicos 

(GESMD). Use of newer prognostic indices for patients with 

myelodysplastic syndromes in the low and intermediate-1 

risk categories: a population-based study.Lancet Haematol. 

2015 Jun ;2(6):e260-6.IF: 0 

16. Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, 

Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, 

Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, 

Harrison C, Verstovsek S, COMFORT Investigators. A pooled 

analysis of overall survival in COMFORT-I and COMFORT-II, 

2 randomized phase III trials of ruxolitinib for the treatment 

of myelofibrosis.Haematologica. 2015 Sep ;100(9):1139-45. 

IF: 5,814 

119

4 

Scientific 

activity 

120 

17. Xicoy B, Germing U, Jimenez MJ, García O, García R, 

Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp 

C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, 

Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, 

Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente 

A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, 

Sanz G. Response to erythropoietic-stimulating agents 

in patients with chronic myelomonocytic leukemia.Eur J 

Haematol. 2015 Sep 5 ;.IF: 2,066 

Letter 

18. Saumell S, Florensa L, Rodríguez-Rivera M, Pedro C, 

Hernández-Rivas JM, Lumbreras E, Abáigar M, Collado R, 

Ivars D, Carbonell F, Marugán I, Tormo M, Botia M, Piñan 

MÁ, Ancín I, González T, Varela ND, Grau J, Granada I, Ruiz 

N, Martín ML, Fernández-Guijarro M, Duarte JJ, Calasanz 

MJ, Larrayoz MJ, Solé F. Fluorescence in situ hybridization 

analysis does not increase detection rate for trisomy 8 in 

chronic myelomonocytic leukemia.Leuk Lymphoma. 2015 

Jan ;56(1):242-3.IF: 2,891 

Editorial 

19. Hernández Boluda JC. [Risk assessment for trombosis and 

survival in essential thrombocythemia].Med Clin (Barc). 

2015 Mar 15 ;144(6):257-8.IF: 1,417 


RESEARCH 


Title: Role of the RUNX1/CBF-beta/p300/HIPK2 complex in 

the leukemic progression of the chronic myeloproliferative 

neoplasms 

Principal Investigator: Juan Carlos Hernández Boluda 





Total Budget: 79.860€


4 

Research Group on Epigenetics and Chromatin 


121 

http://www.bioeticaweb.com/byline/luis-franco-vera/ 

Group members 


Luis Franco Vera 

University 

H Index: 19 


Gerardo López Rodas. University 

Technician 

Josefa Castillo Aliaga. INCLIVA

4 

Scientific 

activity 

122 


• We have finished and published the analysis of the changes 

in structure and epigenetic regulation of the murine 

Egr1 gene during the induction-repression cycle at a mononucleosomal 

resolution 

• The influence of liver transfection with Gas1 gene in mice 

bearing hepatocellular carcinoma has been published. 

The results show a significant decrease in the size of tumours 

and metastasis and a reversal of the expression of 

genes which are altered in tumours 

• We have gone on analysing the consequences of KRAS 

G13D mutation in gene splicing and expression in colorectal 

cancer cells, to find that ZNF518B and EPDR1 genes 

show a clear differential behavior. The results were 

incorporated in a Ph. D. Thesis, as it was the influence 

of that mutation in the alternative splicing of the KRAS 

gene itself 

• A collaboration of Prof. López Rodas with other groups 

working on epigenetics of multiple sclerosis has also given 

rise to several papers published 


• Involvement of chromatin in the regulation of Egr1. Study 

of chromatin changes associated with Egr1 expression 

during phorbol esters-induced proliferation in a cell line 

and in vivo mouse liver after partial hepatectomy 

• Gas1 overexpression effects in reducing the size of liver 

tumours. Study of the effects of overexpression of Gas1 

in mice bearing HCC in reducing the size of tumours and 

their metastatic potential and normalization of the expression 

levels of genes involved in cell proliferation 

• Analysis of differential expression and splicing of genes 

in relation with KRAS mutational activation in colorectal 

cancer (CRC). The study is specially centred in ZNF518B 

and EPDR1 genes and it covers as well the consequences 

of knocking down these genes on the malignant properties 

of CRC cells. We are also studying the differential isoform 

expression of these genes in CRC patients 

• Regulation of the ZNF518B expression at a chromatin level 

• Study of the alternative splicing of KRAS in CRC cells at 

a chromatin level. The research covers the nucleosomal 

organization and epigenetic modifications in the regions 

involved in alternative splicing 



5 20,15 4,03 

National 



International 


Corresponding 

author 

2 2 5 

1. Riffo-Campos ÁL, Castillo J, Tur G, González-Figueroa P, 

Georgieva EI, Rodríguez JL, López-Rodas G, Rodrigo MI, 

Franco L. Nucleosome-specific, Time-dependent Changes 

in Histone Modifications during Activation of the Early 

Growth Response 1 (Egr1) Gene.J Biol Chem. 2015 Jan 2 

;290(1):197-208.IF: 4,573 

2. Haines JD, Vidaurre OG, Zhang F, Riffo-Campos ÁL, Castillo 

J, Casanova B, Casaccia P, López-Rodas G. Multiple sclerosis 

patient-derived CSF induces transcriptional changes in 

proliferating oligodendrocyte progenitors.Mult Scler. 2015 

Nov ;21(13):1655-69.IF: 4,822 

3. Roda D, Castillo J, Telechea-Fernández M, Gil A, López- 

Rodas G, Franco L, González-Rodríguez P, Roselló S, Pérez- 

Fidalgo JA, García-Trevijano ER, Cervantes A, Zaragozá 

R. EGF-Induced Acetylation of Heterogeneous Nuclear 

Ribonucleoproteins Is Dependent on KRAS Mutational Status 

in Colorectal Cancer Cells.PLoS One. 2015 ;10(6):e0130543. 

IF: 3,234 

4. Sacilotto N, Castillo J, Riffo-Campos ÁL, Flores JM, Hibbitt 

O, Wade-Martins R, López C, Rodrigo MI, Franco L, 

López-Rodas G. Growth Arrest Specific 1 (Gas1) Gene 

Overexpression in Liver Reduces the In Vivo Progression 

of Murine Hepatocellular Carcinoma and Partially Restores 

Gene Expression Levels.PLoS One. 2015 ;10(7):e0132477.IF: 

3,234 

5. Mathur D, Urena-Peralta JR, López-Rodas G, Casanova 

B, Coret-Ferrer F, Burgal-Marti M. Bypassing hazard of 

housekeeping genes: their evaluation in rat granule neurons 

treated with cerebrospinal fluid of multiple sclerosis 

subjects.Front Cell Neurosci. 2015 ;9:375.IF: 4,289


4 


RESEARCH 


Title: Acetilación de hnRNP-L y modificaciones epigenéticas 

de la cromatina: hacia una aplicación traslacional en cáncer 

colorrectal 

Principal Investigator: Gerardo López Rodas 





• THESIS 

Thesis title: Chromatin regulatory mechanisms of gene 

expression at mononucleosomal level: nucleosome occupancy 

and epigenetic modifications 

Doctoral candidate: Angela Leticia Riffo Campos 

Director(s): Luis Franco Vera, Gerardo López Rodas, Josefa 

Castillo Aliaga 




Title: Estudio traslacional sobre la hiperacetilación de 

proteínas como vía final de resistencia a fármacos anti-EGFR 

en cánceres de alta incidencia clínica 

Principal Investigator: Andrés Cervantes Ruipérez (Gerardo 

López-Rodas and Luis Franco as collaborating researchers) 



Clínico Universitario Valencia 



123 

Fig. 1. Model of the structural changes and histone modifications 

during the activation and repression of the Egr1 gene. The 

position of nucleosomes -2, -1, and +1 is given at four different 

times after TPA addition. The partial eviction of nucleosomes 

is symbolized by increasing the transparency of the ovals. The 

location of transcription factors serum-response factor, ELK1, 

SP1, and CREB and the phosphorylation of the latter is based on 

previous results (78). The tentative positions of the BRM-containing 

remodeler and the preinitiation complex (PIC) are also 

shown. The transcriptional rate is symbolized by placing more 

or less arrows over the RNA pol II molecule. The relative level of 

histone modifications is given according to the color code depicted 

at the top. 

Fig. 2. Differential expression of KRAS isoforms in two human 

colorectal cáncer cell lines.

4 

Scientific 

activity 

Research Group on Molecular Imaging and Metabolomics 

Emerging group 

124 

Group members 


Daniel Monleón Salvadó 

INCLIVA 

H Index: 21 


Vannina González Marrachelli. INCLIVA 

Remedios Segura Sabater. University 

Antonio Pellín Carcelén. University 

Mercedes Pardo Tendero. INCLIVA 

Technician 

José Manuel Morales Tatay. University


4 


• Development of new diagnostic tools, prognostic and 

predictive based on NMR metabolomic profiles for patient 

stratification in cardiometabolic disease 



stratification in glioblastoma multiforme 



stratification in sepsis 


• Study of intestinal microbiota metabolic interaction-host 

in cardiometabolic disease 

• Identification of new markers of cardiometabolic risk by 

metabolomic profiles in blood and urine 

• Study of the interaction between tumor metabolism, 

angiogenesis, hypoxia and estrogen receptors in breast 

cancer 

• Study of the interaction between tumor metabolism, hypoxia 

and invasion in glioblastoma multiforme 



8 23,78 2,97 

National 



International 


Corresponding 

author 

6 - 5 

1. Mayordomo-Febrer A, López-Murcia M, Morales-Tatay JM, 

Monleón-Salvado D, Pinazo-Durán MD. Metabolomics of 

the aqueous humor in the rat glaucoma model induced by 

a series of intracamerular sodium hyaluronate injection.Exp 

Eye Res. 2015 Feb ;131:84-92.IF: 2,709 

2. Redón J, Monleón D. Combining -omics in the search for 

mechanisms in complex trait diseases.J Hypertens. 2015 

Apr ;33(4):698-9.IF: 4,72 

3. Galbis-Estrada C, Pinazo-Durán MD, Martínez-Castillo S, 

Morales JM, Monleón D, Zanon-Moreno V. A metabolomic 

approach to dry eye disorders. The role of oral supplements 

with antioxidants and omega 3 fatty acids.Mol Vis. 2015 

;21:555-67.IF: 1,986 

4. Marrachelli V, Monleón D, Morales JM, Rentero P, 

Martínez F, Chaves FJ, Martín-Escudero JC, Redon J. 6C.04: 

INTEGRATED SNP ANALYSIS AND METABOLOMIC PROFILES 

OF METABOLIC SYNDROME.J Hypertens. 2015 Jun ;33 Suppl 

1:e80.IF: 4,72 

5. Milara J, Morcillo E, Monleón D, Tenor H, Cortijo J. 

Roflumilast Prevents the Metabolic Effects of Bleomycin- 

Induced Fibrosis in a Murine Model.PLoS One. 2015 

;10(7):e0133453.IF: 3,234 

6. Monleón D, Giménez E, Muñoz-Cobo B, Morales JM, Solano 

C, Amat P, Navarro D. Plasma metabolomics profiling for 

the prediction of cytomegalovirus DNAemia and analysis 

of virus–host interaction in allogeneic stem cell transplant 

recipients.J Gen Virol. 2015 Nov ;96(11):3373-81.IF: 3,183 

7. Ortiz R, Morales JM, Ruiz-Espana S, Bodí V, Monleón D, 

Moratal D. Magnetic resonance microimaging of a swine 

infarcted heart: Performing cardiac virtual histologies.Conf 

Proc IEEE Eng Med Biol Soc. 2015 Aug ;2015:1584-7.IF: 0 

8. García-Simón M, Morales JM, Modesto-Alapont V, González- 

Marrachelli V, Vento-Rehues R, Jorda-Miñana A, Blanquer- 

Olivas J, Monleón D. Prognosis Biomarkers of Severe Sepsis 

and Septic Shock by 1H NMR Urine Metabolomics in the 

Intensive Care Unit.PLoS One. 2015 ;10(11):e0140993.IF: 

3,234 


RESEARCH 

Reference: HEALTH 2011.2.4.2-2 

Title: Markers for Subclinical Cardiovascular Risk Assessment 

(EU MASCARA) 

Principal Investigator: Josep Redón i Mas (Daniel Monleón, 

Vannina González and José Manuel Morales as a collaborating 

researchers) 

Funding Body: European Commission 





125

4 

Scientific 

activity 

Reference: SAF2014-52875R 

Title: Estudio metabolómico de la interacción huéspedmicrobiota 

intestinal en la enfermedad cardiometabólica. 

Detección temprana, prevención y tratamiento. 

Principal Investigator: Daniel Monleón Salvadó 

Funding Body: Ministerio de Economia y Competitividad 





126 



Title: Interacción entre receptores de estrógenos, hipoxia, 

angiogénesis y metabolismo tumoral en células de cáncer de 

mama 

Principal Investigator: Daniel Monleón Salvadó 








4 

4.1.3 Metabolism and organic damage area 

Research Group on Genetics of Osteoporosis 128 

Translational Research Group on Nutrition and Metabolism 131 

Research Group on Neurological Impairment 135 

Research Group on Inflammation 139 

Research Group on Cellular and Organic Physiopathology of Oxidative Stress 144 

Research Group on Oxidative Pathology 148 

Research Group on Psychiatry and Neurodegenerative Diseases 151 

Research Group on Respiratory Problems in Neuromuscular Diseases 155 

Research Group on Tissular Biochemistry 158 

Research Group on Aging and Physical Activity 161 

Research Group on Anesthesiology and Reanimation 166 

Research Group on Translational Genomics 171 

Research Group on General and Digestive Surgery 174 

Research Group on Personal Autonomy, Dependence and Severe Mental Disorders (TMAP) 177 

127 

Impact 

Factor (IF) 

Total: 745,04 

Average: 4,04 

184 

Publications 

52 

International 


JCR: 

30 in D1 

81 in Q1 

42 in Q2 

Author: 




author

4 

Scientific 

activity 

Research Group on Genetics of Osteoporosis 


128 

Group members 


Miguel Ángel García Pérez. 

University 

H Index: 16 

Collaborating researchers: 

Rosa María Aliaga Corachán. University 

Damian Mifsut Miedes. Hospital. University 

PhD students 

Layla Panach González. INCLIVA


4 


• To continue with the studies of genetic association between 

candidate genes and bone phenotypes 

• Characterization of the association CD40 / CD40L in bone 

mass by genetic and epigenetic techniques 

• To study the profile of miRNAs and cytokines in osteoporotic 

hip fracture. Also the analysis of SNPs in genes 

of miRNAs precursors and bone phenotypes in a collaborative 

study 

• To analyze the role of B lymphocytes in bone loss associated 

with estrogen deficiency by microarray studies and 

association studies to bone phenotypes 

• To analyze the state of the transcriptome in osteoporotic 

bone fracture to detect and identify candidate genes for 

population studies 

• To do collaborations in areas related to bone metabolism 

during pregnancy and fertility related issues 


• Research and analysis of polymorphisms in estrogenregulated, 

the immune system of the Wnt / beta-catenin 

pathway and B cell associated with postmenopausal osteoporosis 

genes 

• Identification of new genes regulated by estrogen via microarray 

in murine models of accelerated bone loss 

• Analysis of miRNAs profile and circulating cytokines in 

osteoporotic hip fracture 

• Role of B cell and CD40 / CD40L system in postmenopausal 

bone loss 

• The role of B cells in the production of osteoprotegerin in 

the bone marrow 

• Functional characterization via genetic and epigenetic 

variants associated with bone phenotypes techniques 



5 15,76 3,15 

National 



International 


Corresponding 

author 

3 1 5 

1. Sanz-Salvador L, García-Pérez MÁ, Tarín JJ, Cano A. 

Endocrinology in Pregnancy: Bone metabolic changes during 

pregnancy: a period of vulnerability to osteoporosis and 

fracture.Eur J Endocrinol. 2015 Feb ;172(2):R53-R65.IF: 4,069 

2. Tarín JJ, García-Pérez MA, Hamatani T, Cano A. Infertility 

etiologies are genetically and clinically linked with other 

diseases in single meta-diseases.Reprod Biol Endocrinol. 

2015 Apr 15 ;13(1):31.IF: 2,226 

3. Panach L, Mifsut D, Tarín JJ, Cano A, García-Pérez MÁ. 

Serum Circulating MicroRNAs as Biomarkers of Osteoporotic 

Fracture.Calcif Tissue Int. 2015 Nov ;97(5):495-505.IF: 3,272 




Bone. 2015 Nov 7 ;83:94-103.IF: 3,973 

Review 

5. Tarín JJ, García-Pérez MA, Cano A. Deficiencies in reporting 

results of lesbians and gays after donor intrauterine insemination 

and assisted reproductive technology treatments: a 

review of the first emerging studies.Reprod Biol Endocrinol. 

2015 May 29 ;13(1):52.IF: 2,226 


RESEARCH 


Title: Identificación de polimorfismos y genes asociados a la 

osteoporosis posmenopáusica: análisis genético y funcional 

Principal Investigator: Miguel Ángel García Pérez 






129

4 

Scientific 

activity 

Reference: FOCUS 

Title: Frailty management Optimisation though EIP AHA 

Commitments and Utilisation of Stakeholders input 

Principal Investigator: Antonio Cano Sánchez (Juan José Tarín 

and Miguel Ángel García Pérez as collaborating researchers) 

Funding body: Comisión Europea- DG SANCO 




130 

Research on genetics of human postmenopausal osteoporosis through a translational approach from animal models. To do this, 

initially its identified genes differentially expressed in B lymphocyte of mouse bone marrow ovariectomized (OVX, red) and compared to 

control animals (SHAM, blue). A) Analysis of Principal Component (PCA mapping) of microarray both types of mice and B) Hierarchical 

Clustering of differentially expressed genes. C) Analysis of functional pathways KEGG overrepresented in OVX B lymphocytes has 

shown that osteoclast differentiation pathway is one of the most affected (19 genes, p = 3.5x10-8). Later it was studied the genetic 

association to bone phenotypes of SNPs selected candidate genes after genotyping in human cohort studies. Microarray experiments 

were performed in the facilities of INCLIVA.


4 

Translational Research Group on Nutrition and Metabolism 


131 

http://www.farmacologiavalencia.es/index.php/inv-ppales/victor-gonzalez-victor-m-phd 


Group members 


Antonio Hernández Mijares. 

University 

H Index: 20 


Milagros Rocha Barajas. FISABIO 

Víctor Manuel Víctor González. University 

Juan Vicente Esplugues Mota. University 

Carlos Morillas Ariño. University 

Eva Solá Izquierdo. University 

Celia Bañuls Morant. University 

Ana Jover Fernández. Hospital Dr. Peset 

Marcelino Gómez Balaguer. Hospital Dr. Peset 

Nadezda Apostolova Atanasovska. CIBERehd 

Silvia Veses Martín. Hospital Dr. Peset 

Susana Rovira Llopis. Hospital Dr. Peset

4 

Scientific 

activity 

132 


• To determine the implication of the stress of endoplasmic 

reticulum (RE), mitochondrial and endothelial dysfunction 

in the underlying mechanisms associated with 

insulin resistance in diseases such as type 2 diabetes, 

obesity and polycystic ovary syndrome, and its relationship 

with the risk of cardiovascular disease. In addition, 

we evaluated possible therapeutic targets that could 

help to understand the mechanism and source of stress 

of RE in different cell models 

• To develop various projects that focus on the efficacy 

of functional foods with properties of health, for the 

reduction of risks of chronic diseases 


• Diabetes mellitus and cardiovascular risk 

• Obesity, inflammation and endothelial dysfunction 

• Polycystic ovary syndrome and insulin resistance 

• Dyslipidemia and residual cardiovascular risk 

• Functional foods and their influence on cardiovascular 

risk factors 

• Endoplasmic reticulum stress, mitochondrial dysfunction 

and oxidative stress 

• Characterization of new cellular mechanisms of antiretroviral 

hepatotoxicity 



18 75,26 4,18 

National 



International 


Corresponding 

author 

16 1 12 

1. Rubio-Puchol O, Garzón-Pastor S, Cortés-Vizcaíno V, Luna- 

Boquera I, Gómez-Balaguer M, Hernández-Mijares A. 

Hodgkin’s lymphoma of the thyroid in a woman with 

autoimmune thyroiditis.Rev Clin Esp. 2015 Oct ;215(7):405- 

8.IF: 1,063 

2. Víctor VM, Rovira-Llopis S, Saiz-Alarcón V, Sangüesa 

MC, Rojo-Bofill L, Bañuls C, de Pablo C, Álvarez Á, Rojo L, 

Rocha M, Hernández-Mijares A. Involvement of leucocyte/ 

endothelial cell interactions in anorexia nervosa.Eur J Clin 

Invest. 2015 Jul ;45(7):670-8.IF: 2,734 

3. Rovira-Llopis S, Díaz-Morales N, Bañuls C, Blas-García A, 

Polo M, López-Domenech S, Jover A, Rocha M, Hernández- 

Mijares A, Víctor VM. Is Autophagy Altered in the 

Leukocytes of Type 2 Diabetic Patients? Antioxid Redox 

Signal. 2015 Nov 1 ;23(13):1050-6.IF: 7,407 

4. Victor VM, Rovira-Llopis S, Bañuls C, Díaz-Morales N, 

López-Domenech S, Escribano-López I, Rios-Navarro C, 

Alvarez A, Gómez M, Rocha M, Hernandez-Mijares A. 

Metformin modulates human leukocyte/endothelial cell 

interactions and proinflammatory cytokines in polycystic 

ovary syndrome patients.Atherosclerosis. 2015 Jul 10 

;242(1):167-173.IF: 3,994 

5. Bañuls C, Rovira-Llopis S, Falcón R, Veses S, Monzó N, Víctor 

VM, Rocha M, Hernández-Mijares A. Chronic consumption 

of an inositol-enriched carob extract improves postprandial 

glycaemia and insulin sensitivity in healthy subjects: A 

randomized controlled trial.Clin Nutr. 2015 May 23 ;.IF: 4,476 

6. Funes HA, Blas-García A, Esplugues JV, Apostolova N. 

Efavirenz alters mitochondrial respiratory function in 

cultured neuron and glial cell lines.J Antimicrob Chemother. 

2015 Aug ;70(8):2249-54.IF: 5,313 

7. Miova B, Dinevska-Kjovkarovska S, Esplugues JV, Apostolova 

N. Heat Stress Induces Extended Plateau of Hsp70 

Accumulation--A Possible Cytoprotection Mechanism in 

Hepatic Cells.J Cell Biochem. 2015 Oct ;116(10):2365-74.IF: 

3,263 

8. Polo M, Alegre F, Funes HA, Blas-García A, Victor VM, 

Esplugues JV, Apostolova N. Mitochondrial (dys)function 

- a factor underlying the variability of efavirenz-induced 

hepatotoxicity?Br J Pharmacol. 2015 Apr ;172(7):1713-27. 

IF: 4,842 

9. Apostolova N, Victor VM. Molecular strategies for targeting 

antioxidants to mitochondria: therapeutic implications. 

Antioxid Redox Signal. 2015 Mar 10 ;22(8):686-729.IF: 7,407 

10. Apostolova N, Funes HA, Blas-García A, Alegre F, Polo 

M, Esplugues JV. Involvement of nitric oxide in the 

mitochondrial action of efavirenz: a differential effect 

on neurons and glial cells.J Infect Dis. 2015 Jun 15 

;211(12):1953-8.IF: 5,997 

11. Victor VM, Rovira-Llopis S, Bañuls C, Díaz-Morales N,


4 

Castelló R, Falcón R, Gómez M, Rocha M, Hernández- 

Mijares A. Effects of metformin on mitochondrial function 

of leukocytes from polycystic ovary syndrome patients with 

insulin resistance.Eur J Endocrinol. 2015 Nov ;173(5):683- 

91.IF: 4,069 

12. Morillas C, Feliciano R, Catalina PF, Ponte C, Botella M, 

Rodrigues J, Esmatjes E, Lafita J, Lizán L, Llorente I, Morales C, 

Navarro-Pérez J, Orozco-Beltran D, Paz S, Ramirez de Arellano 

A, Cardoso C, Tribaldos Causadias M. Patients’ and physicians’ 

preferences for type 2 diabetes mellitus treatments in Spain 

and Portugal: a discrete choice experiment.Patient Prefer 

Adherence. 2015 ;9:1443-58.IF: 1,676 

13. Vayá A, Rivera L, Hernández-Mijares A, Bautista D, Solá 

E, Romagnoli M, Alis R, Laiz B. Association of metabolic 

syndrome and its components with hyperuricemia in a 

Mediterranean population.Clin Hemorheol Microcirc. 2015 

Jul 27 ;60(3):327-34.IF: 2,242 

14. Millán Núñez-Cortés J, Mantilla Morató T, Toro R, Millán 

Pérez J, Mangas Rojas A, Comité Científico del Registro 

de Hipertrigliceridemias de la Sociedad Española de 

Arteriosclerosis. [METABOLIC SYNDROME IN PATIENTS 

WITH CLINICAL PHENOTYPE “HYPERTRIGLYCERIDEMIC 

WAIST”].Nutr Hosp. 2015 Sep 1 ;32(3):1145-52.IF: 1,04 

15. Cosín-Roger J, Ortiz-Masiá D, Calatayud S, Hernández 

C, Esplugues JV, Barrachina MD. The activation of Wnt 

signaling by a STAT6-dependent macrophage phenotype 

promotes mucosal repair in murine IBD.Mucosal Immunol. 

2015 Nov 25 ;.IF: 7,374 

16. Hernández C, Barrachina MD, Vallecillo-Hernández J, Álvarez 

Á, Ortiz-Masiá D, Cosín-Roger J, Esplugues JV, Calatayud S. 

Aspirin-induced gastrointestinal damage is associated with 

an inhibition of epithelial cell autophagy.J Gastroenterol. 

2015 Nov 3 ;.IF: 4,523 

17. Ríos-Navarro C, de Pablo C, Collado-Diaz V, Orden S, Blas- 

García A, Martínez-Cuesta MÁ, Esplugues JV, Alvarez A. 

Differential effects of anti-TNF-? And anti-IL-12/23 agents 

on human leukocyte-endothelial cell interactions.Eur J 

Pharmacol. 2015 Oct 15 ;765:355-65.IF: 2,532 

Review 

18. Apostolova N, Funes HA, Blas-García A, Galindo MJ, Alvarez 

A, Esplugues JV. Efavirenz and the CNS: what we already 

know and questions that need to be answered.J Antimicrob 



RESEARCH 


Title: Implicación del estrés de retículo endoplasmático en la 

fisiopatología del síndrome de ovario poliquístico: Posibles 

aplicaciones terapeúticas de los sensibilizadores de la insulina 

Principal Investigator: Antonio Hernández Mijares 


Beneficiary institution: Fundación para la investigación 

Hospital Dr. Peset 




Title: Efecto de la pérdida de peso sobre marcadores de 

estrés de retículo endoplasmático en la obesidad mórbida: 

Implicaciones fisiopatológicas y nuevas dianas terapéuticas 

Principal Investigator: Milagros Rocha Barajas 


Beneficiary Institution: Fundación para el Fomento de 

la Investigación Sanitaria y Biomédica de la Comunitat 

Valenciana (FISABIO) 




Title: Disfunción endotelial-mitocondrial, estrés de retículo y 

autofagia en la diabetes tipo 2: Implicaciones fisiopatológicas, 

clínicas y terapeúticas 

Principal Investigator: Víctor Manuel Víctor González 








Title: Caracterización de nuevos mecanismos celulares de 

hepatoxicidad por antiretrovirales 

Principal Investigator: Juan Vicente Esplugues Mota 







133

4 

Scientific 

activity 


Title: CIBER de Enfermedades Hepáticas y Digestivas 

(CIBERehd) 

Principal Investigator: Juan Vicente Esplugues Mota 




Thesis title: Alteraciones metabólicas de la Hiperlipemia 

Familiar Combinada y su asociación con la obesidad 

abdominal y la inflamación de bajo grado. 

Doctoral candidate: María Díaz Ruiz 

Director(s): Antonio Hernández Mijares 



134 

Reference: UGP14-095 

Title: Disfunción endotelial-mitocondrial, estrés de retículo y 

autofagia en la diabetes tipo 2: Implicaciones fisiopatológicas, 

clínicas y terapeúticas 

Principal Investigator: Víctor Manuel Víctor González 

Funding Body: Fundación para el Fomento de la Investigación 

Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) 






Reference: UGP14-093 

Title: Efecto de la pérdida de peso sobre marcadores de 

estrés de retículo endoplasmático en la obesidad mórbida: 

Implicaciones fisiopatológicas y nuevas dianas terapéuticas 

Principal Investigator: Milagros Rocha Barajas 

Funding Body: Fundación para el Fomento de la Investigación 

Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) 






Thesis title: Estudio de los mecanismos moleculares de 

estrés oxidativo, disfunción mitocondrial, estrés de retículo 

endoplasmático y autogamia en leucocitos de pacientes con 

diabetes tipo 2. 

Doctoral candidate: Susana Rovira Llopis 




• THESIS 

Thesis title: Estudio clínico de la correlación de los niveles de 

glucosa en sangre y saliva; y la importancia de las citoquinas 

proinflamatorias en la enfermedad periodontal de los 

pacientes diabéticos. 

Doctoral candidate: Esther Carramolino Cuéllar 





4 

Research Group on neurological impairment 


135 

http://www.neurocipf.es/web/montoliu.car/pagina-personal 

Group members 


Carmina Montoliu Félix. 

INCLIVA. University 

H Index: 30 


Ana Agustí Feliu. INCLIVA 

Miguel Ángel Serra Desfilis. Hospital. University 

Amparo Escudero García. Hospital. University 

María Luisa García Torres. Hospital 

Paloma Lluch García. Hospital 

Joan Tosca Cuquerella. Hospital 

José Ballester Fayos. Hospital 

PhD students 

Alba Mangas Losada. INCLIVA 

Isidro Torregrosa. Hospital 

Technicians 

Remedios González Ballesteros. Hospital 

Laura Puchades. INCLIVA

4 

Scientific 

activity 

136 


• To analyze the contribution of oxidative and nitrosative 

stress and of inflammation to MHE and to specific neuropsychological 

alterations. To study by fMRI: 

• The pattern of activation of brain areas while performing 

tests of attention and “mismatch negativity” 

• The neuronal connectivity of the default mode network 

• The cerebral mechanisms of alterations in cognitive 

and motor tasks in patients with MHE 


• Minimal Hepatic encephalopathy (MHE), clinical and 

biochemical diagnostics 

• Detection of the presence of MHE in cirrhotic patients. 

Comparison of psychometric tests and critical flicker 

frequency. Study of peripheral parameters related 

with cGMP homeostasis and inflammation as possible 

indicators of the presence of MHE 

• Identification of metabolites to be use in the diagnosis 

of MHE 

• Study of brain disorders using magnetic resonance 

imaging (including edema, cerebral atrophy, abnormal 

neural tracts) in patients with liver cirrhosis. Useful in 

the diagnosis of MHE 

• Study of alterations in attention, quality and sleep 

patterns in patients with liver cirrhosis with or without 

minimal hepatic encephalopathy 

• Study of impaired driving ability in patients with liver 

cirrhosis. Correlation with the presence of MHE 

• Analysis of synergistic effect between hyperammonemia 

and inflammation in the induction of MHE cognitive 

impairment 

• Minimal Hepatic Encephalopathy and Critical Flicker 

Frequency are Associated With Survival of Patients 

With Cirrhosis 

• Rats with Mild Bile Duct Ligation Show Hepatic 

Encephalopathy with Cognitive and Motor Impairment 

in the Absence of Cirrhosis: Effects of Alcohol Ingestion 

• Modulation of GABAA receptors by neurosteroids. 

A new concept to improve cognitive and motor 

alterations in hepatic encephalopathy 

• Real-time cytometric assay of nitric oxide and 

superoxide interaction in peripheral blood monocytes: 

A no-wash, no-lyse kinetic method 

• About the hepatitis, to study the epidemiological and 

therapeutic aspects of immunoprophylaxis 

• Development and characterization of an animal model 

of alcohol-induced hepatic encephalopathy 

• Molecular and cellular mechanisms of liver injury 

in obesity: pathogenic, diagnostic and therapeutic 

implications 

• Valor de NGAL, KIM-1, l-FABP e Interleukina-18 como 

marcadores precoces de insuficiencia renal aguda en 

pacientes críticos y tras cirugía y cateterismo cardiacos. 

• ELISA-measured urinary Klotho as an early biomarker 

of acute kidney failure in patients undergoing heart 

surgery or coronary angiography. 



14 69,50 4,96 

National 



International 


Corresponding 

author 

12 2 1 

1. Torregrosa I, Montoliu C, Urios A, Andrés-Costa MJ, 

Giménez-Garzó C, Juan I, Puchades MJ, Blasco ML, Carratalá 

A, Sanjuán R, Miguel A. Urinary KIM-1, NGAL and L-FABP 

for the diagnosis of AKI in patients with acute coronary 

syndrome or heart failure undergoing coronary angiography. 

Heart Vessels. 2015 Nov ;30(6):703-11.IF: 2,065 

2. Gimenez-Garzó C, Urios A, Agustí A, González-López O, 

Escudero-García D, Escudero-Sanchis A, Serra MA, Giner- 

Durán R, Montoliu C, Felipo V. Is cognitive impairment 

in cirrhotic patients due to increased peroxynitrite 

and oxidative stress?Antioxid Redox Signal. 2015 Apr 1 

;22(10):871-7.IF: 7,407 

3. Johansson M, Agusti A, Llansola M, Montoliu C, Strömberg 

J, Malinina E, Ragagnin G, Doverskog M, Bäckström T, 

Felipo V. GR3027 antagonizes GABAA receptor-potentiating 

neurosteroids and restores spatial learning and motor 

coordination in rats with chronic hyperammonemia and 

hepatic encephalopathy.Am J Physiol Gastrointest Liver


4 

Physiol. 2015 Sep 1 ;309(5):G400-9.IF: 3,798 

4. Crespo J, Diago M, Cabezas J, Berenguer M, Broquetas 

T, Serra MÁ, Morillas R, García-Samaniego J, Calleja JL, 

Sánchez JJ, Lens S, Soto-Fernández S, Sacristán B, Fernández 

I, López-Núñez C, Buti M, Romero-Gómez M, Sáez-Royuela 

F, Fernández C, Jorquera F, Sánchez-Antolín G, Pascasio JM, 

Cuadrado A, Hernández-Guerra M. High efficacy and safety 

of triple therapy in HCV genotype 1 and moderate fibrosis: a 

multicenter study of clinical practice in Spain.Ann Hepatol. 

2015 Jul-Aug ;14(4):477-86.IF: 2,065 

5. Castells L, Rimola A, Manzardo C, Valdivieso A, Montero 

JL, Barcena R, Abradelo M, Xiol X, Aguilera V, Salcedo M, 

Rodriguez M, Bernal C, Suárez F, Antela A, Olivares S, Del 

Campo S, Laguno M, Fernandez JR, de la Rosa G, Agüero F, 

Perez I, González-García J, Esteban-Mur JI, Miro JM, FIPSE 

LT-HIV Investigators. Pegylated interferon plus ribavirin in 

HIV-infected patients with recurrent hepatitis C after liver 

transplantation: a prospective cohort study.J Hepatol. 2015 

Jan ;62(1):92-100.IF: 11,336 

6. Giménez-Garzó C, Salhi D, Urios A, Ruíz-Sauri A, Carda 

C, Montoliu C, Felipo V. Rats with mild bile duct ligation 

show hepatic encephalopathy with cognitive and motor 

impairment in the absence of cirrhosis: effects of alcohol 

ingestion.Neurochem Res. 2015 Feb ;40(2):230-40.IF: 2,593 

7. Torregrosa I, Montoliu C, Urios A, Giménez-Garzó C, Tomás 

P, Solís MÁ, Ramos C, Juan I, Puchades MJ, Saez GT, Blasco 

ML, Miguel A. ELISA-measured urinary Klotho as an early 

biomarker of acute kidney failure in patients undergoing 

heart surgery or coronary angiography.Nefrologia. 2015 

Mar-Apr ;35(2):172-178.IF: 1,223 

8. Ampuero J, Simón M, Montoliú C, Jover R, Serra MÁ, Córdoba 

J, Romero-Gómez M. Minimal Hepatic Encephalopathy and 

Critical Flicker Frequency Are Associated With Survival 

of Patients With Cirrhosis.Gastroenterology. 2015 Nov 

;149(6):1483-9.IF: 16,716 

9. Salmerón J, Vinaixa C, Berenguer R, Pascasio JM, Sánchez 

Ruano JJ, Serra MÁ, Gila A, Diago M, Romero-Gómez M, 

Navarro JM, Testillano M, Fernández C, Espinosa D, Carmona 

I, Pons JA, Jorquera F, Rodriguez FJ, Pérez R, Montero JL, 

Granados R, Fernández M, Martín AB, Muñoz de Rueda 

P, Quiles R, Alhambra Spanish Study Group. Effectiveness 

and safety of first-generation protease inhibitors in clinical 

practice: Hepatitis C virus patients with advanced fibrosis. 

World J Gastroenterol. 2015 Aug 14 ;21(30):9163-74.IF: 2,369 

10. Llansola M, Montoliu C, Agusti A, Hernandez-Rabaza V, 

Cabrera-Pastor A, Gómez-Gimenez B, Malaguarnera M, 

Dadsetan S, Belghiti M, García-García R, Balzano T, Taoro L, 

Felipo V. Interplay between glutamatergic and GABAergic 

neurotransmission alterations in cognitive and motor 

impairment in minimal hepatic encephalopathy.Neurochem 

Int. 2015 Sep ;88:15-9.IF: 3,092 

11. Hernandez-Rabaza V, Agusti A, Cabrera-Pastor A, Fustero S, 

Delgado O, Taoro-González L, Montoliu C, Llansola M, Felipo 

V. Sildenafil reduces neuroinflammation and restores spatial 

learning in rats with hepatic encephalopathy: underlying 

mechanisms.J Neuroinflammation. 2015 Oct 29 ;12(1):195. 

IF: 5,408 

12. Tenorio-Laranga J, Montoliu C, Urios A, Hernandez- 

Rabaza V, Ahabrach H, García-Horsman JA, Felipo V. The 

expression levels of prolyl oligopeptidase responds not only 

to neuroinflammation but also to systemic inflammation 

upon liver failure in rat models and cirrhotic patients.J 

Neuroinflammation. 2015 Sep 30 ;12:183.IF: 5,408 

13. Balaguer S, Diaz L, Gomes A, Herrera G, O’Connor JE, Urios 

A, Felipo V, Montoliu C. Real-time cytometric assay of 

nitric oxide and superoxide interaction in peripheral blood 

monocytes: A no-wash, no-lyse kinetic method.Cytometry B 

Clin Cytom. 2015 Mar 11 ;.IF: 2,398 

Review 

14. Agusti A, Llansola M, Hernández-Rabaza V, Cabrera-Pastor 

A, Montoliu C, Felipo V. Modulation of GABAA receptors 

by neurosteroids. A new concept to improve cognitive 

and motor alterations in hepatic encephalopathy.J Steroid 

Biochem Mol Biol. 2015 Aug 22 ;.IF: 3,628 

• THESIS 

Thesis title: Biomarcadores precoces de fracaso renal agudo 

tras angiografía coronaria o cirugía cardiaca en pacientes con 

síndrome coronario o fallo cardiaco agudo 

Doctoral candidate: Isidro Antonio Torregrosa Maicas 

Director(s): Juan Alfonso Miguel Carrasco, Guillermo Sáez 

Tormo y Carmina Montoliu Felix 



137

4 

Scientific 

activity 

138 

Thesis title: Enfermedad hepática grasa no alcohólica en la 

obesidad mórbida: Implicaciones patogénicas y diagnosticas 

Doctoral candidate: María Luisa García Torres 

Director(s): Desamparados Escudero García 




RESEARCH 


Title: Caracterización de las alteraciones neurológicas 

con encefalopatía hepática mínima y de las alteraciones 

cerebrales responsables. Contribución del estrés oxidativo y la 

inflamación 

Principal Investigator: Carmina Montoliu Félix 






Title: Desarrollo de una herramienta para el diagnóstico 

temprano, monitorización y seguimiento, por imagen cerebral, 

del deterioro cognitivo leve (encefalopatía hepática mínima) 

en pacientes cirróticos. 

Principal Investigator: Carmina Montoliu Félix 

Funding Body: PROGRAMA VLC-BIOCLINIC 





Title: Evaluación de la eficacia y costes del tratamiento 

antiviral de los enfermos con hepatitis crónicas por virus C. 

(Parte II) 

Principal Investigator: Miguel Ángel Serra Desfilis 



Fellow: Laura Puchades Lanza 



Duration: 2014 - 2015 

Reference: Proyect Number 282957 

Title: DENAMIC—Developmental neurotoxicity assessment of 

mixtures in children 

Call (part) identifier FP7-ENV-2011 

Principal Investigator: Vicente Felipo Orts (Carmina Montoliu 



Beneficiary institution: Centro de Investigación Príncipe Felipe 


Title: Caracterización de las alteraciones en resonancia 

magnética funcional en pacientes cirróticos con encefalopatía 

hepática mínima. Correlación con los déficits de atención y 

con otras alteraciones neurológicas. Posibles implicaciones 

diagnósticas. 

Principal Investigator: Carmina Montoliu Felix 

Funding Body: Fundación ERESA 





Figure. Hyperammonemia and inflammation act synergistically 

to induce neurological alterations in chronic liver disease. Chronic 

liver failure induces both hyperammonemia and peripheral 

inflammation, leading to microglial activation and neuroinflammation, 

which alters neurotransmission, leading to cognitive 

and motor impairment


4 

Research Group on Inflammation 


139 

“La Universidad de Valencia crea ciudadanía crítica, es lengua y patrimonio, es plural y abierta, y 

genera riqueza y cohesión social” Esteban Morcillo. El País. 1-5-2015 

http://ccaa.elpais.com/ccaa/2015/04/30/valencia/1430399293_013729.html 

Group members 



Esteban Morcillo Sánchez 

University. Hospital 

H Index: 31 

María Jesús Sanz Ferrando 

University 

H Index: 31 


Laura Piqueras Ruiz. INCLIVA 

Herminia González Navarro. INCLIVA 

PhD students 

Aida Collado Sánchez. INCLIVA 

Patrice Gomes Marques. University 

Technicians 

Ángela Vinué Visús. INCLIVA

4 

Scientific 

activity 


140 


• Study of the anti-inflammatory and anti-angiogenic activity 

of combinations of sub-optimal doses of rosuvastatin 

and bexarotene in atherosclerosis and abdominal 

aortic aneurysm 

• Study of Roflumilast on corticosteroid resistance in 

COPD bronchial epithelial cells stimulated with toll 

like receptor 3 agonist and its metabolic Effects of 

Bleomycin-Induced fibrosis in vivo 

• Molecular mechanisms of neutrophil extracellular 

traps (NET) formation and degradation in the liver 

vasculature in infection with methicillin-resistant Staphylococcus 

aureus 

• Synthesis of hexahydrocyclopenta isoquinolines, new 

potential drugs in the control of dopaminergic disorders 

• Study of the effect of increased expression of the INK4/ 

ARF locus on hepatic steatosis and inflammation associated 

with the glucose metabolism derangement 

• Study of the impact of the hepatic lipase in the development 

of insulin resistance and hepatic steatosis 


• Study of the novel molecular, biochemical, cellular and 

genetic mechanisms involved in the etiopathogenesis 

of chronic obstructive pulmonary disease (COPD). Lung 

and systemic effects 

• Study of the vascular inflammation induced by different 

risk factors of aterosclerosis: angiotensin-II, menopause, 

cigarette smoke, metabolic syndrome, insulin 

resistance or familial hypercholesterolemia 

• Study of the role of retinoid X receptors (RXR) in inflammation 

angiogenesis 

• Study of SuperInk4/Arf locus and hepatic lipase in ageassociated 

insulin resistance and atherosclerosis 

Herminia González Navarro 

Molecular Physiopathology of 

the diabetes and atherosclerosis. 

Our research is focused in the 

study of the molecular mechanisms 

of the diabetes mellitus 

(DM) and its effect on atherosclerosis 

development which is one 

of the main causes of cardiovascular diseases. To this end, we 

perform studies in genetically-modified mice that develop metabolic 

alterations such as diabetes, insulin resistance, fatty liver 

disease and atherosclerosis. To translate our findings into the human 

pathology we also perform investigations in human subjects 

and in human cell cultures. 

Recent studies in our laboratory have shown that insulin resistance 

aggravates atherosclerosis by promoting the death of 

vascular smooth muscle cells present in the atheroma plaques 

which favours plaque rupture and acute events such as myocardial 

infarction. We have also identified some of the inflammatory 

mediators that participate in these processes in the mouse models 

and in human patients. 

In another line of research we are studying the role of the CDK- 

N2A and 2B genes, contained in the Ink4/Arf locus, in the development 

of diabetes. We have found that increased expression 

of these genes, in mice with impaired IRS2-mediated signalling, 

protects the mice from developing glucose intolerance, insulin 

resistance and fatty liver disease. Currently, we are studying 

whether these genes are relevant for the human pathology by 

analysing the expression and functionality of these genes in human 

samples. 


Laura Piqueras Ruiz 

Abdominal aortic aneurysm 

(AAA) is a degenerative disease 

of the aorta that mainly affects 

elderly population over the age 

of 65. Given the high mortality 

rate associated with AAA, it is important 

to find new pharmacological 

approaches to prevent its progression. Our work focuses on 

the study of molecular mechanism associated to AAA develop-


4 

ment and to investigate new pharmacological approaches to halt 

its progression. 

In recent years, angiogenesis and inflammation in aortic aneurysmal 

disease has been related with the risk of rupture and 

complications. In this regard, emerging evidence indicates that 

a single drug may not be sufficient to combat the wide array of 

proangiogenic and proinflammatory factors produced during 

AAA. Thus, we are currently testing potential alternative approach 

with the use of combinations of already available clinical 

drugs that exhibit anti-angiogenic and anti-inflammatory activity 

and whose long-term safety has been proven. 

To carry out our research we are using a model of AAA induced 

by angiotensin-II- in apolipoprotein E deficient mice. This 

experimental model shares many characteristic features of the 

human disease, including chemokine and protease generation, 

leukocyte infiltration and neovascularization. Currently, we are 

also exploring the effect of several nuclear receptors; retinoid 

X receptor (RXR), peroxisome proliferator activating receptors 

(PPAR) and Vitamin D receptor (VDR) ligands on the AAA development. 

We are also interested in characterizing new molecular 

mechanism associated to aneurysm formation in animal models 

and human samples. 



12 45,30 3,77 

National 



International 


Corresponding 

author 

5 3 6 

1. Párraga J, Galán A, Sanz MJ, Cabedo N, Cortes D. Synthesis 

of hexahydrocyclopenta[ij]isoquinolines as a new class of 

dopaminergic agents.Eur J Med Chem. 2015 Jan 27 ;90:101- 

6.IF: 3,447 

2. Escudero P, Martínez de Marañón A, Collado A, González- 

Navarro H, Hermenegildo C, Peiró C, Piqueras L, Sanz MJ. 

Combined sub-optimal doses of rosuvastatin and bexarotene 

impair angiotensin II-induced arterial mononuclear cell 

adhesion through inhibition of Nox5 signaling pathways and 

increased RXR/PPAR? and RXR/PPAR? interactions.Antioxid 

Redox Signal. 2015 Apr 10 ;22(11):901-20.IF: 7,407 

3. Ferrando C, Suárez-Sipmann F, Gutierrez A, Tusman G, 

Carbonell J, García M, Piqueras L, Compañ D, Flores S, Soro 

M, Llombart A, Belda F. Adjusting tidal volume to stress 

index in an open lung condition optimizes ventilation and 

prevents overdistension in an experimental model of lung 

injury and reduced chest wall compliance.Crit Care. 2015 

Jan 13 ;19(1):9.IF: 5,035 

4. Escudero P, Navarro A, Ferrando C, Furio E, González-Navarro 

H, Juez M, Sanz MJ, Piqueras L. Combined treatment with 

bexarotene and rosuvastatin reduces angiotensin-II-induced 

abdominal aortic aneurysm in apoE(-/-) mice and angiogenesis. 

Br J Pharmacol. 2015 Jun ;172(12):2946-60.IF: 4,842 

5. Boulangé A, Parraga J, Galán A, Cabedo N, Leleu S, Sanz MJ, 

Cortes D, Franck X. Synthesis and antibacterial activities 

of cadiolides A, B and C and analogues.Bioorg Med Chem. 

2015 Jul 1 ;23(13):3618-28.IF: 2,793 

6. Vinué Á, Andrés-Blasco I, Herrero-Cervera A, Piqueras L, 

Andrés V, Burks DJ, Sanz MJ, González-Navarro H. Ink4/Arf 

locus restores glucose tolerance and insulin sensitivity by 

reducing hepatic steatosis and inflammation in mice with 

impaired IRS2-dependent signalling.Biochim Biophys Acta. 

2015 Sep ;1852(9):1729-42.IF: 0 

7. Milara J, Morell A, Ballester B, Sanz C, Freire J, Qian X, 

Alonso-García M, Morcillo E, Cortijo J. Roflumilast improves 

corticosteroid resistance COPD bronchial epithelial cells 

stimulated with toll like receptor 3 agonist.Respir Res. 2015 

Feb 5 ;16:12.IF: 0 

8. Milara J, Morcillo E, Monleón D, Tenor H, Cortijo J. 

Roflumilast Prevents the Metabolic Effects of Bleomycin- 

Induced Fibrosis in a Murine Model.PLoS One. 2015 

;10(7):e0133453.IF: 3,234 

9. Kolaczkowska E, Jenne CN, Surewaard BG, Thanabalasuriar 

A, Lee WY, Sanz MJ, Mowen K, Opdenakker G, Kubes P. 

Molecular mechanisms of NET formation and degradation 

revealed by intravital imaging in the liver vasculature.Nat 

Commun. 2015 Mar 26 ;6:6673.IF: 11,47 

10. Fernández-Murga ML, Vinué Á, Caeiro JR, Guede D, Tarín JJ, 

Andrés V, Cano A. Impact of estrogens on atherosclerosis 

and bone in the apolipoprotein E-deficient mouse model. 

Menopause. 2015 Apr ;22(4):428-36.IF: 3,361 

11. Vinué Á, González-Navarro H. Glucose and Insulin Tolerance 

Tests in the Mouse.Methods Mol Biol. 2015 ;1339:247-54.IF: 0 

12. Andrés-Blasco I, Herrero-Cervera A, Vinué Á, Martínez- 

141

4 

Scientific 

activity 

142 

Hervás S, Piqueras L, Sanz MJ, Burks DJ, González-Navarro 

H. Hepatic lipase deficiency produces glucose intolerance, 

inflammation and hepatic steatosis.J Endocrinol. 2015 Dec 

;227(3):179-91.IF: 3,718 


RESEARCH 


Title: Estudio de nuevos marcadores inflamatorios en la 

disfuncion endotelial: Papel de los ligandos de PPAR y RXR 

Principal Investigator: Laura Piqueras Ruiz 






Reference: PROMETEO II/2013/ 014 

Title: Nuevas dianas farmacológicas para el tratamiento de la 

EPOC y sus comorbilidades vasculares 

Principal Investigator: Esteban Morcillo Sánchez 







Title: European Network for Translational Immunology 

Research and Education (ENTIRE): From immunomonitoring to 

personalized immunotherapy 

Principal Investigator: Dominique Baeten (María Jesús Sanz 

Ferrando as collaborating researcher) 






Title: Modulación farmacológica de la señalización de 

receptores toll-like por inhibidores de fosfodiesterasa 4 (PDE4) 

y esteroides en modelos experimentales relevantes en EPOC 

Principal Investigator: Esteban Morcillo Sánchez 

Funding Body: Ministerio de Ciencia e Innovación 





Referencia: CB06/06/0027 

Título: CIBER Enfermedades Respiratorias 

Investigador principal: Esteban Morcillo Sánchez 

Fundingbody: Instituto de Salud Carlos III 


Duración: 2007-2015 


Title: Study of the molecular mechanisms of Diabetes Mellitus 

and its role on aterosclerosis 

Principal Investigator: Herminia González Navarro 






Reference: PRV00052 

Title: Estudio del papel del locus Ink4/Arf en la funcionalidad 

de las células β en un modelo murino de diabetes 


Funding Body: Proyecto Paula 



Duration: 2013 - 2016 


Title: The William Harvey International Translational Research 

Academy (WHRI-ACADEMY) 

Principal Investigator: Márta Korbonits (María Jesús Sanz 

Ferrando as collaborating research) 

Funding Body: FP7 Marie Curie Actions 




Total Budget: 6.500.000€ 



Title: Estudio de nuevos marcadores inflamatorios en la 

disfunción endotelial: papel modulador de ligandos de PPAR y 

RXR


4 









Title: Modulación Inmunofarmacológica de la Inflamación 

Sistémica asociada a Desordenes Metabólicos. Búsqueda de 

nuevas dianas terapéuticas y síntesis de fármacos novedosos. 

Principal Investigator: Juan F. Ascaso Gimilio, M. J. Sanz 






Title: Sistema de inclusión en parafina y microtomo. 









Title: Development of a European network for preclinical 

testing of interventions in mouse models of age and agerelated 

diseases (MouseAGE) 

Principal Investigator: Prof Ilaria BELLANTUONO (Herminia 

González Navarro) 

Funding Body: European Union 




Reference: SAF 2011-23777 

Title: Estudio de los mecanismos moleculares y celulares 

en la disfunción endotelial asociada a enfermedades con 

inflamación sistémica que podrían inducir desórdenes 

cardiovasculares 

Principal Investigator: María Jesús Sanz Ferrando 

Funding Body: Ministerio de Ciencia e Innovación 







Title: Estudio del papel de la lipasa hepática en la dislipemia 

de la diabetes y síndroma metabólico en el desarrollo de la 

enfermedad cardiovascular 






Duration: 2013 - 2015 



Title: CIBER de Diabetes y Enfermedades Metabólicas 

Asociadas 

Principal Investigator: Deborah J Burks (Herminia González as 



Beneficiary institution: CIPF 


143

4 

Scientific 

activity 

Research Group on Cellular and Organic Physiopathology of Oxidative Stress 


144 

“Lo que se pretende actualmente es dar vida a los años y no años a la vida” 

Federico Pallardó. 5-2-2015. Revista Genética Médica. 

http://revistageneticamedica.com/2015/02/05/entrevista-federico-pallardo/ 

Group members 



Federico V. Pallardó Calatayud 

University 

H Index: 44 


Amparo Gimeno Monrós. University 

Carlos Romá Mateo. University 

Pilar González Cabo. CIBERer 

Carla Giménez Garzón. INCLIVA 

PhD students 

José Santiago Ibáñez Cabellos. University 

Marta Seco Cervera. INCLIVA 

Technicians 

Isabel Esmoris Méndez. INCLIVA 


Francisco Dasí Fernández. University. INCLIVA 

José Luis García Giménez. CIBERer


4 


• A European patent for the method and kit of diagnosis 

for idiopathic scoliosis by miRNAs (EP15382319.0) was 

approved. New projects are the following: “Identifying 

circulating histones by mass spectrometry methods in 

plasma of patients with severe sepsis and septic shock” 

by INCLIVA, and “Analysis of microRNAs as biomarkers 

of drug monitoring for Lafora disease models”, by the 

micro-cluster of ER (MCI-FER) of VLC / Campus and CI- 

BERER´s spin-off (EpiDisease), other projects initiated in 

2013 and 2014, where founded by an international consortium 

(USAID,UKAID, Melinda and Bill Gates foundation, 

Grand Challenges Canada, Government of Norway). 

• Approval of an optional teaching subject “Rare Diseases” 

(RD) in the curricula of the medical degree being the first 

course in the country. Awarded by FEDER as the best initiative 

to increase the quality of life of people with rare 

diseases. 

• Official agreement for the establishment of the Alliance 

in translational research in Rare Diseases of the Valencian 

Community (DOCV 7654, 10/11/15) was signed between 

the Generalitat Valenciana, CIBERER, FEDER and 

other valencian universities and research institutes to 

develop a common research strategy in Rare Diseases. 

Dr. Pallardó was appointed as president of the scientific 

committee of the Alliance. 

• To analyze the pathophysiological mechanisms of Kindler 

syndrome and Werner syndrome, two progerias that 

help to understand the process of organic aging 

• To build up a new animal model of Charcot-Marie-Tooth 

disease and contribute to better understand the relationship 

between oxidative stress and the mechanisms 

of gene regulation modulated by epigenetic factors 

• To study the Down syndrome from the perspective of 

change in the processes of cell turnover, helping to elucidate 

its pathophysiology 

• To describe the presence of oxidative stress and lack of 

antioxidant defense in Lafora disease 


• Epigenetic regulation of cell proliferation by nuclear glutathione 

• Identifying of new post-translational modifications in 

histones related to cell redox environment. Deleterious 

effects and action as a biomarker in human pathology 

• Physiopathology of oxidative stress in rare neuromuscular 

diseases. Search biomarkers associated 


José Luis García Giménez 

We are interested in understanding 

the role of epigenetics in the physiopathology 

of rare diseases (e.g. Friedreich 

ataxia, dyskeratosis congenita 

and adolescent idiopathic scoliosis). 

Our goal is to identify epigenetic 

marks and mechanisms underlying the natural history of disease. 

Therefore, one of our challenge is the identification of epigenetic 

biomarkers based on DNA methylation, histone variants and posttranslational 

modifications and non-coding RNAs (e.g., microR- 

NAs) which provide us of new tools for diagnostic and prognostic 

of disease. Furthermore, we are investigating the redox-related 

mechanisms controling the sophisticated epigenetic regulation. In 

this regard, we are interested on the impact of several novel histone 

redox-related PTMs on cell physiology and gene regulation. 


Francisco Dasí Hernández 

Research is mainly devoted to the 

study alpha-1 antitrypsin deficiency 

(AATD). Research in other pulmonary 

rare diseases such as primary 

ciliary dyskinesia is currently under 

development. 

The scientific interests of the group are: 

•To characterize the molecular mechanisms (especially those 

aspects related to the REDOX signalling) involved in the development 

of liver and/or lung disease in patients with AATD, in order 

to understand why some patients develop serious liver and/or 

lung disease, while other patients bearing the same of alpha-1 

antitrypsin (AAT) phenotype, are perfectly healthy. 

•To assess cell-free circulating nucleic acids for the diagnosis 

and prognosis of AATD. 

145

4 

Scientific 

activity 

•To develop new therapeutic strategies based on gene therapy. 

•To generate social awareness of pulmonary rare diseases, 

through scientific disclosure of biomedical advances and social 

and health policies to improve the quality of life of patients with 

pulmonary rare diseases. 



8 37,28 4,66 

National 



International 


Corresponding 

author 

5 3 3 

Biol. 2015 Nov 3 ;69:204-214.IF: 4,046 

7. Castillo-González D, Mergny JL, De Rache A, Pérez-Machado 

G, Cabrera-Pérez MA, Nicolotti O, Introcaso A, Mangiatordi 

GF, Guédin A, Bourdoncle A, Garrigues T, Pallardó F, Cordeiro 

MN, Paz-Y-Miño C, Tejera E, Borges F, Cruz-Monteagudo 

M. Harmonization of QSAR Best Practices and Molecular 

Docking Provides an Efficient Virtual Screening Tool for 

Discovering New G-Quadruplex Ligands.J Chem Inf Model. 

2015 Oct 26 ;55(10):2094-110.IF: 3,738 

Letter 

8. Escribano A, Amor M, Pastor S, Castillo S, Sanz F, Codoñer- 

Franch P, Dasí F. Decreased glutathione and low catalase 

activity contribute to oxidative stress in children with ?-1 

antitrypsin deficiency.Thorax. 2015 Jan ;70(1):82-3.IF: 8,29 

146 

1. López Del Amo V, Seco-Cervera M, García-Giménez JL, 

Whitworth AJ, Pallardó FV, Galindo MI. Mitochondrial 

defects and neuromuscular degeneration caused by altered 

expression of Drosophila Gdap1: implications for the 

Charcot-Marie-Tooth neuropathy.Hum Mol Genet. 2015 Jan 

1 ;24(1):21-36.IF: 6,393 

2. Romá-Mateo C, Aguado C, García-Giménez JL, Knecht E, 

Sanz P, Pallardó FV. Oxidative stress, a new hallmark in the 

pathophysiology of Lafora progressive myoclonus epilepsy. 

Free Radic Biol Med. 2015 Nov ;88(Pt A):30-41.IF: 5,736 

3. Pagano G, d’Ischia M, Pallardó FV. Fanconi anemia (FA) 

and crosslinker sensitivity: Re-appraising the origins of FA 

definition.Pediatr Blood Cancer. 2015 Jul ;62(7):1137-43.IF: 

2,386 

4. Romá-Mateo C, Aguado C, García-Giménez JL, Ibáñez- 

Cabellos JS, Seco-Cervera M, Pallardó FV, Knecht E, Sanz 

P. Increased oxidative stress and impaired antioxidant 

response in Lafora disease.Mol Neurobiol. 2015 Jun 

;51(3):932-46.IF: 5,137 

5. Almerich-Silla JM, Montiel-Company JM, Pastor S, Serrano 

F, Puig-Silla M, Dasí F. Oxidative Stress Parameters in Saliva 

and Its Association with Periodontal Disease and Types of 

Bacteria.Dis Markers. 2015 ;2015:653537.IF: 1,562 

6. Sánchez-Martín P, Romá-Mateo C, Viana R, Sanz P. Ubiquitin 

conjugating enzyme E2-N and sequestosome-1 (p62) are 

components of the ubiquitination process mediated by the 

malin-laforin E3-ubiquitin ligase complex.Int J Biochem Cell 

• THESIS 

Thesis title: Perfiles de expresión genómica: nuevo enfoque 

diagnóstico para la sepsis en recién nacidos menores de 1500 

gramos 

Doctoral candidate: María Cernada Badía 

Director(s): Eva Serna García, Federico Pallardó Calatayud 




RESEARCH 


Title: Estudio de miRNAs en pacientes de ataxia de Friedreich. 

Implicaciones diagnósticas y terapéuticas 

Principal Investigator: Federico V Pallardó Calatayud 






Referencia: CB06/07/0073 

Title: CIBER de Enfermedades Raras (CIBERer) 

Principal Investigator: Federico Vicente Pallardó Calatayud 



Duration: 2007-2015


4 

Reference: HIST-BIRTH 

Title: HIST-BIRTH: Innovative and rapid point-of-care histone 

test strips for early diagnosis of sepsis in pregnancy and 

childbirth 

Principal Investigator: Federico V. Pallardó 

Funding body: USAID. USA Agency for Innovation and 

Development Saving Lives at Birth Development Change 




Reference: TREAT-CMT 

Title: Translational Research, Experimental Medicine and 

Therapeutics on Charcot-Marie-Tooth Disease (TREAT-CMT) 

Principal Investigator: Francesc Palau (Federico V. Pallardó, 

José Luis García-Giménez, Amparo Gimeno and Jelena 

Markovic as collaborating researchers) 


Beneficiary institution: CIBERER 







AWARDS 

Federico Pallardó was received the FEDER award to the best 

regional initiative to increase the quality of life to people with 

rare diseases. On the other hand, Francisco Dasí Fernández was 

awarded for the paper presented at the International Congress 

of Respiratory Diseases celebrated in Amsterdam by the European 

Respiratory Society-ERS. 

147 

Reference: HIST-BIRTH 

Title: Bases Fisiopatológicas de la Enfermedad de Lafora 

Principal Investigator: Federico Vicente Pallardó Calatayud 

Funding body: I USAID. USA Agency for Innovation and 

DevelopmentSaving Lives at Birth Development Change 

Beneficiary institution: Universitat de Valencia 



Reference: 03_LDmiRNA-2015 

Title: Análisis de microARNs como biomarcadores de 

monitorización farmacológica en modelos de enfermedad de 

Lafora. 

Principal Investigator: Carlos Roma Mateo 

Funding Body: Ministerio de Educación, Cultura y Deporte 





Title: Evaluación de la function mitochondrial en leucocitos de 

pacientes con déficit de alfa-1 antitripsina 

Principal Investigator: Francisco Dasí Fernández 

Funding body: Fundación Investigación del Hospital Clínico 

Universitario de Valencia

4 

Scientific 

activity 

Research Group on Oxidative Pathology 


148 


Group members 


Guillermo Sáez Tormo 

University 

H Index: 30 


Antonio Iradi Casal. University 

Carmen Tormos Muñoz. University 

Benjamín Climent Díaz. University 

Technicians 

Lidia Monzó Beltrán. University


4 


• To study the role of Mediterranean diet and the individual 

effect of olive oil and dietary polyphenols on hemodynamics, 

endothelial function, abdominal adiposity and gene 

expression in patients at high cardiovascular risk has been 

studied 

• To investigate the systemic levels of inflammatory mediators 

and oxidative stress in verrucous leukoplakia in patients 

with acute renal failure 

• To monitor the morbidly obese patients in terms of 

anthropometric changes, metabolic and oxidative stress 

markers before and after dietary intervention, exercise 

and bariatric surgery 

• To analyze in gastric carcinoma patients the role of DNA 

damage and different markers of oxidative stress in order 

to validate the modified base 8-oxo-dG as a possible tumor 

marker 


• Study of the role of OS as a physiopathological mechanism 

of cardiovascular diseases 

• Study p53-dependent signaling routes in patients with 

cardiovascular evolution pathologies, in order to identify 

differences between grades of expression in different 

genes, especially those in control of repairing the genetic 

material 

• Study of OS role in the pathology of neoplastic diseases, 

as well as the possible validation of their molecular oxidative 

products as clinical markers 



12 37,16 3,09 

National 



International 


Corresponding 

author 

10 2 1 

1. Medina-Remón A, Tresserra-Rimbau A, Pons A, Tur JA, 

Martorell M, Ros E, Buil-Cosiales P, Sacanella E, Covas MI, 

Corella D, Salas-Salvadó J, Gómez-Gracia E, Ruiz-Gutiérrez V, 

Ortega-Calvo M, García-Valdueza M, Arós F, Sáez GT, Serra- 

Majem L, Pinto X, Vinyoles E, Estruch R, Lamuela-Raventos 

RM, PREDIMED Study Investigators. Effects of total dietary 

polyphenols on plasma nitric oxide and blood pressure in a 

high cardiovascular risk cohort. The PREDIMED randomized 

trial.Nutr Metab Cardiovasc Dis. 2015 Jan ;25(1):60-7.IF: 

3,323 

2. Eguaras S, Toledo E, Buil-Cosiales P, Salas-Salvadó J, Corella 

D, Gutierrez-Bedmar M, Santos-Lozano JM, Arós F, Fiol M, 

Fitó M, Ros E, Serra-Majem L, Pintó X, Martínez JA, Sorlí 

JV, Muñoz MA, Basora J, Estruch R, Martínez-González MÁ, 

PREDIMED Investigators. Does the Mediterranean diet 

counteract the adverse effects of abdominal adiposity?Nutr 

Metab Cardiovasc Dis. 2015 Jun ;25(6):569-74.IF: 3,323 


P, Solís MÁ, Ramos C, Juan I, Puchades MJ, Sáez GT, Blasco 




Mar-Apr ;35(2):172-178.IF: 1,223 

4. Storniolo CE, Casillas R, Bulló M, Castañer O, Ros E, Sáez 

GT, Toledo E, Estruch R, Ruiz-Gutiérrez V, Fitó M, Martínez- 

González MA, Salas-Salvadó J, Mitjavila MT, Moreno JJ. A 

Mediterranean diet supplemented with extra virgin olive 

oil or nuts improves endothelial markers involved in blood 

pressure control in hypertensive women.Eur J Nutr. 2015 

Oct 8 ;.IF: 3,467 

5. Benlloch M, Obrador E, Valles S, Rodriguez ML, Sirerol JA, 

Alcácer J, Pellicer JA, Salvador R, Cerdá C, Sáez G, Estrela 

JM. Pterostilbene Decreases the Antioxidant Defenses 

of Aggressive Cancer Cells in Vivo: a Physiological 

Glucocorticoids- and Nrf2-Dependent Mechanism.Antioxid 

Redox Signal. 2015 Dec 9 ;.IF: 7,407 

6. Martín-Peláez S, Castañer O, Konstantinidou V, Subirana I, 

Muñoz-Aguayo D, Blanchart G, Gaixas S, de la Torre R, Farré 

M, Sáez GT, Nyyssönen K, Zunft HJ, Covas MI, Fitó M. Effect 

of olive oil phenolic compounds on the expression of blood 

pressure-related genes in healthy individuals.Eur J Nutr. 

2015 Dec 12 ;.IF: 3,467 

7. Martínez-González MA, Zazpe I, Razquin C, Sánchez-Tainta 

A, Corella D, Salas-Salvadó J, Toledo E, Ros E, Muñoz MÁ, 

Recondo J, Gómez-Gracia E, Fiol M, Lapetra J, Buil-Cosiales 

P, Serra-Majem L, Pinto X, Schröder H, Tur JA, Sorli JV, 

Lamuela-Raventós RM, Estruch R, PREDIMED GROUP. 

149

4 

Scientific 

activity 

150 

Empirically-derived food patterns and the risk of total 

mortality and cardiovascular events in the PREDIMED study. 

Clin Nutr. 2015 Oct ;34(5):859-67.IF: 4,476 

8. Ata-Ali J, Ata-Ali F, Di-Benedetto N, Bagán L, Bagán JV. 

Does HIV infection have an impact upon dental implant 

osseointegration? A systematic review.Med Oral Patol Oral 

Cir Bucal. 2015 May 1 ;20(3):e347-56.IF: 0 

9. Candel-Marti E, Peñarrocha-Oltra D, Bagán L, Peñarrocha- 

Diago M, Peñarrocha-Diago M. Palatal positioned 

implants in severely atrophic maxillae versus conventional 

implants to support fixed full-arch prostheses: Controlled 

retrospective study with 5 years of follow-up.Med Oral 

Patol Oral Cir Bucal. 2015 May 1 ;20(3):e357-64.IF: 0 

10. Bagan JV, Cibrian RM, López J, Leopoldo-Rodado M, 

Carbonell E, Bagán L, Utrilla J, Scully C. Sclerosis in 

bisphosphonate-related osteonecrosis of the jaws and its 

correlation with the clinical stages: study of 43 cases.Br J 

Oral Maxillofac Surg. 2015 Mar ;53(3):257-62.IF: 1,076 

11. Bagan JV, Carbonell F, Gómez MJ, Sánchez M, Navarro A, 

Leopoldo M, Bagán L, Zapater E. Extra-nodal B-cell non- 

Hodgkin’s lymphomas of the head and neck: a study of 68 

cases.Am J Otolaryngol. 2015 Jan-Feb ;36(1):57-62.IF: 0,984 

12. Díaz-López A, Babio N, Martínez-González MA, Corella D, 

Amor AJ, Fitó M, Estruch R, Arós F, Gómez-Gracia E, Fiol 

M, Lapetra J, Serra-Majem L, Basora J, Basterra-Gortari FJ, 

Zanon-Moreno V, Muñoz MÁ, Salas-Salvadó J, PREDIMED 

Study Investigators. Mediterranean Diet, Retinopathy, 

Nephropathy, and Microvascular Diabetes Complications: 

A Post Hoc Analysis of a Randomized Trial.Diabetes Care. 

2015 Nov ;38(11):2134-41.IF: 8,42 

• THESIS 






Tormo, Carmina Montoliu Felix 




RESEARCH 


Title: Factores genéticos y metabolómicos en la obesidad 

mórbida y su modulación tras 

intervención dietética, ejercicio físico y cirugía bariátrica. 

Estudio especial de P53, SIRT1 y sistemas de reparación del 

ADN en la patogenia de sus complicaciones neoplásicas 

Principal Investigator: Guillermo Sáez Tormo 






Title: CIBER de la Obesidad y Nutrición (CIBERObn) 




Duration: 2012-2015


4 

Research Group on Psychiatry and Neurodegenerative Diseases 


151 

“Una app para ayudar a los pacientes con psicosis”. 

Europa Press. 25/11/2015 

Group members 



Julio Sanjuán Arias 


H Index: 19 


José Carlos González Piqueras. Hospital. University 

Eduardo Jesús Aguilar García-Iturrospe. Hospital. University 

Esther Lorente Rovira. Hospital 

María José Escarti Fabra. Hospital 

María Dolores Moltó Ruiz. University 

Marien Gadea Domenech. University 

Gracián García Martí. CIBERSAM 

Manuel Jover Martínez. Hospital 

José Luis Ivorra Martínez. CIBERSAM 

Javier Gilabert Juan. University 

Juan Nácher Roselló. University 

Francisco Olucha Bordonau. University

4 

Scientific 

activity 

152 


• To develop of a mobile application associated with the 

Health Record to improve adherence for treatment of 

patients with first psychotic episodes 

• To enlarge the common data base for multicenter studies 

(CIBERSAM) 

• To apply of EEG-fMRI new techniques for identifying hallucinations 

in psychosis 

• To develop of new patents measurement techniques 

for brain morphometry 

• To develop of animal models in severe mental disorder 

and neurodegenerative diseases 

• Evaluation of brain changes after cognitive therapy in 

persistent hallucinations in psychosis 

• Prediction models and treatment in first psychotic episodes 


• Differential expression of candidate genes in the brains 

of patients with psychosis 

• Animal models for mental illness and degenerative 

• Study of mutations in degenerative diseases mono- 

GENE 

• Identification of the interactions between environmental 

and genetic factors in the risk of early psychotic episodes 

• Identification of abnormal patterns of activation in fMRI 

Psychosis 

• Database Design for multicenter studies in genetics and 

neuroimaging of psychosis 

• Prototyping of mobile applications to improve adherence 

in first psychotic episodes 



20 51,49 2,57 

National 


International 


Corresponding 

author 

16 4 7 


1. Sánchez-Pérez AM, Arnal-Vicente I, Santos FN, Pereira CW, 

ElMlili N, Sanjuán J, Ma S, Gundlach AL, Olucha-Bordonau FE. 

Septal projections to nucleus incertus in the rat: Bidirectional 

pathways for modulation of hippocampal function.J Comp 

Neurol. 2015 Mar 1 ;523(4):565-88.IF: 3,225 

2. Hernández-González S, Ballestín R, López-Hidalgo R, 

Gilabert-Juan J, Blasco-Ibáñez JM, Crespo C, Nácher J, Varea 

E. Altered Distribution of Hippocampal Interneurons in the 

Murine Down Syndrome Model Ts65Dn.Neurochem Res. 

2015 Jan ;40(1):151-64.IF: 2,593 

3. Cuesta MJ, Sánchez-Torres AM, Cabrera B, Bioque M, 

Merchán-Naranjo J, Corripio I, González-Pinto A, Lobo A, 

Bombín I, de la Serna E, Sanjuán J, Parellada M, Saiz-Ruiz 

J, Bernardo M, PEPs Group. Premorbid adjustment and 

clinical correlates of cognitive impairment in first-episode 

psychosis. The PEPsCog Study.Schizophr Res. 2015 May 

;164(1-3):65-73.IF: 3,923 

4. Cuesta MJ, Zarzuela A, Sánchez-Torres AM, Lorente- 

Omeñaca R, Moreno-Izco L, Sanjuán J, Peralta V. Familial 

liability to schizophrenia and mood disorders and cognitive 

impairment in psychosis.Psychiatry Res. 2015 Jun 30 ;227(2- 

3):258-64.IF: 2,467 

5. García-Avilés Á, Albert-Gascó H, Arnal-Vicente I, Elhajj E, 

Sanjuán-Arias J, Sanchez-Perez AM, Olucha-Bordonau F. 

Acute oral administration of low doses of methylphenidate 

targets calretinin neurons in the rat septal area.Front 

Neuroanat. 2015 ;9:33.IF: 3,544 

6. López-Campos G, Gilabert-Juan J, Sebastia-Ortega N, 

González-Martínez R, Nácher J, Sanjuán J, Molto MD. 

Using gene expression and systems biology to interrogate 

auditory hallucinations in schizophrenic patients.Stud 

Health Technol Inform. 2015 ;210:950.IF: 0 

7. Castillo-Gómez E, Coviello S, Perez-Rando M, Curto Y, 

Carceller H, Salvador A, Nácher J. Streptozotocin diabetic 

mice display depressive-like behavior and alterations in 

the structure, neurotransmission and plasticity of medial 

prefrontal cortex interneurons.Brain Res Bull. 2015 Jun 22 

;116:45-56.IF: 2,718 

8. Gutiérrez-Zotes A, Labad J, Martín-Santos R, García-Esteve 

L, Gelabert E, Jover M, Guillamat R, Mayoral F, Gornemann 

I, Canellas F, Gratacós M, Guitart M, Roca M, Costas J, Luis 

Ivorra J, Navinés R, de Diego-Otero Y, Vilella E, Sanjuán J.


4 

Coping strategies and postpartum depressive symptoms: 

A structural equation modelling approach.Eur Psychiatry. 

2015 Sep ;30(6):701-8.IF: 3,439 

9. Rapado-Castro M, Pazos Á, Fañanás L, Bernardo M, Ayuso- 

Mateos JL, Leza JC, Berrocoso E, de Arriba J, Roldán L, 

Sanjuán J, Pérez V, Haro JM, Palomo T, Valdizan EM, Micó 

JA, Sánchez M, Arango C. Building up careers in translational 

neuroscience and mental health research: Education and 

training in the Centre for Biomedical Research in Mental 

Health.Rev Psiquiatr Salud Ment. 2015 Apr-Jun ;8(2):65-74. 

IF: 1,622 

10. Calap-Quintana P, Soriano S, Llorens JV, Al-Ramahi I, Botas 

J, Moltó MD, Martínez-Sebastián MJ. TORC1 Inhibition 

by Rapamycin Promotes Antioxidant Defences in a 

Drosophila Model of Friedreich’s Ataxia.PLoS One. 2015 

;10(7):e0132376.IF: 3,234 

11. Nácher J, Bonfanti L. New neurons from old beliefs in the 

adult piriform cortex? A Commentary on: “Occurrence of 

new neurons in the piriform cortex”.Front Neuroanat. 2015 

;9:62.IF: 3,544 

12. Liberia T, Blasco-Ibáñez JM, Nácher J, Varea E, Lanciego JL, 

Crespo C. Synaptic connectivity of the cholinergic axons 

in the olfactory bulb of the cynomolgus monkey.Front 

Neuroanat. 2015 ;9:28.IF: 3,544 

13. Sanz-Requena R, Prats-Montalbán JM, Martí-Bonmatí L, 

Alberich-Bayarri Á, García-Martí G, Pérez R, Ferrer A. 

Automatic individual arterial input functions calculated from 

PCA outperform manual and population-averaged approaches 

for the pharmacokinetic modeling of DCE-MR images.J 

Magn Reson Imaging. 2015 Aug ;42(2):477-87.IF: 3,21 

14. Picó Aliaga SD, Muro Velilla D, García-Martí G, Sangüesa 

Nebot C, Martí-Bonmatí L. Acoustic radiation force impulse 

imaging elastography is efficacious in detecting hepatic 

fibrosis in children.Radiologia. 2015 Jul-Aug ;57(4):314-320. 

IF: 0 

15. Gilabert-Juan J, Sáez AR, López-Campos G, Sebastiá-Ortega N, 

González-Martínez R, Costa J, Haro JM, Callado LF, Meana JJ, 

Nácher J, Sanjuán J, Moltó MD. Semaphorin and plexin gene 

expression is altered in the prefrontal cortex of schizophrenia 

patients with and without auditory hallucinations.Psychiatry 

Res. 2015 Oct 30 ;229(3):850-7.IF: 2,467 

16. Rubio A, Belles M, Belenguer G, Vidueira S, Fariñas I, Nácher 

J. Characterization and isolation of immature neurons of 

the adult mouse piriform cortex.Dev Neurobiol. 2015 Oct 

21 ;.IF: 3,37 

17. Gutiérrez-Zotes A, Labad J, Martín-Santos R, García-Esteve 

L, Gelabert E, Jover M, Guillamat R, Mayoral F, Gornemann 

I, Canellas F, Gratacós M, Guitart M, Roca M, Costas J, Ivorra 

JL, Navinés R, de Diego-Otero Y, Vilella E, Sanjuán J. Coping 

strategies for postpartum depression: a multi-centric study 

of 1626 women.Arch Womens Ment Health. 2015 Sep 23 

;.IF: 2,164 

18. Gadea M, Aliño M, Garijo E, Espert R, Salvador A. Testing the 

Benefits of Neurofeedback on Selective Attention Measured 

Through Dichotic Listening.Appl Psychophysiol Biofeedback. 

2015 Dec 18 ;.IF: 1,847 

19. Gadea M, Aliño M, Espert R, Salvador A. Deceit and facial 

expression in children: the enabling role of the “poker face” 

child and the dependent personality of the detector.Front 

Psychol. 2015 ;6:1089.IF: 2,56 

20. Curto Y, García-Mompo C, Bueno-Fernandez C, Nácher J. 

Chronic benzodiazepine treatment decreases spine density 

in cortical pyramidal neurons.Neurosci Lett. 2015 Dec 28 

;613:41-46.IF: 2,03 


RESEARCH 


Title: Neuroimaging and genetic markers for language 

disordesrs in psychosis 

Principal Investigator: Julio Sanjuán Arias 







Title: Desarrollo de marcadores biológicos y estrategias 

terapéuticas en el trastorno mental grave 


Funding body: Conselleria de Sanitat. Generalitat Valenciana 





153

4 

Scientific 

activity 

154 


Title: CIBER de Enfermedades Mentales (CIBERsam) 





Title: European brain imaging network for psychosis (EBINP) 








Reference: EU-GEI 241909 

Title: Gene-Environment Interactions (EU-GEI) 

Investigador Principal: Celso Arango López (Julio Sanjuán as 


Entidad Financiadora: European Commission 




Reference: 520785 

Title: Effects of juvenile and chronic stress on the structure 

and connectivity of neural circuits 

Principal Investigator: Juan Salvador Nácher Roselló 

Funding body: Ècole Polytechnique Fédérale de Lausanne 

(Suiza) 





Title: Eficacia del entrenamiento metacognitivo 

individualizado (EMC+) en personas con psicosis de reciente 

evolución. 

Principal Investigator: Susana Ochoa (Esther Lorente and Ana 

Luengo as collaborating researcher) 

Funding body: Ministerio de Ciencia e innovación 




Total budget: 

Reference: BFU2012-32512 

Title: Plasticidad estructural de interneuronas en el cerebro 

adulto. Implicaciones en esquizofrenia. 


Funding body: Ministerio de Ciencia e innovación 






Title: Plasticidad estructural de circuitos inhibitorios. 

Implicación en esquizofrenia 








Title: Utilización de Drosophila como organismo modelo en 

investigación biomédica 

Principal Investigator: Nuria Paricio Ortiz 






• AWARDS 

The Investigator Eduardo Aguilar and its collaborators were 

awarded for the scientific work “normalization of limbic hiperactivity 

trough cognitive behaviour therapy for auditory hallucinations 

assessed using an amotional fmr auditory paradigm” by the 

Reial Acadèmia de Medicina de la Comunitat Valenciana.


4 

Research Group on Respiratory Problems in Neuromuscular Diseases 


155 

Group members 

“Neumología del Clínico ofrece el primer curso en España para cuidadores de pacientes 

neuromusculares con problemas respiratorios”. 

24/11/2015 | elperiodic.com 


Emilio Servera Pieras 


H Index: 15 


Jesús Sancho Chinesta. Hospital 

María Pilar Barreto Martín. University 

José Luís Díaz Cordobés. Hospital 

Pilar Bañuls Polo. Hospital 

Manuela Marín González. Hospital 

Mª Luisa Briones Urtiaga. Hospital 

Mª Jesús Zafra Pirés. University 

María Belén Safont Muñoz. Hospital 

Mª Cruz González Villaescusa. Hospital 

José Vicente Ferreres Franco. Hospital 

Enric Burés Sales. INCLIVA 

Jaime Signes-Costa Miñana. Hospital

4 

Scientific 

activity 

156 


• To identify predictive factors for the failure of non-invasive 

ventilation in patients with amyotrophic lateral 

sclerosis who are suffering from a respiratory infection 

• To identify predictive factors for the tolerance of volume-cycled 

non-invasive ventilation in subjects with amyotrophic 

lateral sclerosis 

• To identify, in clinically stable patients with amyotrophic 

lateral sclerosis, predictors for the need for noninvasive 

mechanical ventilation during an acute respiratory 

infection 

• We have found that a considerable percentage of ALS 

patients suffer from frontal impairment, especially with 

regard to executive function, and that FrSBe is a tool 

which enables the identification of these behavioural 

changes 

• To identify the biological, psychological and social factors 

which impact upon the perception of dyspnoea 

and we have established a interdisciplinary action plan 

which can alleviate this symptom 

• We are aware of the variables at play in the generation 

of complicated grief in relatives of patients suffering 

from respiratory diseases and we have established an 

action plan which can facilitate the adaptation process 

for these people 


• To improve knowledge in the staging of patients with 

neuromuscular diseases to anticipate decisions and to 

adjust respiratory therapeutic measures 

• To improve knowledge in technical assistance and replacement 

of the respiratory muscles in neuromuscular 

diseases, particularly to the life-prolonging without 

adding suffering 

• To improve knowledge in the management of the 

psycho-emotional needs in neuromuscular patients with 

COPD and incapacitating dyspnea and their caregivers 

• To improve knowledge about the role of genetic polymorphisms 

in the predisposition, severity and susceptibility 

to bacteremia in community-acquired pneumonia 

• To evaluate the efficiency of the management of dyspnea 

• To assess cognitive / behavioral signs associated with 

neuromuscular dementia patients and their involvement 

in the decision-making process 

• To evaluate the prevalence of stressful life events, different 

styles of attachment and the proportion of adaptive 

and problem duels present in relatives of patients at the 

end of life 



16 37,51 2,34 

National 



International 


Corresponding 

author 

13 2 4 

1. Sanz F, Dean N, Dickerson J, Jones B, Knox D, Fernández- 

Fabrellas E, Chiner E, Briones ML, Cervera Á, Aguar MC, 

Blanquer J. Accuracy of PaO2 /FiO2 calculated from SpO2 

for severity assessment in ED patients with pneumonia. 

Respirology. 2015 Jul ;20(5):813-8.IF: 3,345 

2. Hsu CH, Reyes LF, Orihuela CJ, Buitrago R, Anzueto A, 

Soni NJ, Levine S, Peters J, Hinojosa CA, Aliberti S, Sibila 

O, Rodriguez A, Chalmers JD, Martín-Loeches I, Bordon J, 

Blanquer J, Sanz F, Marcos PJ, Rello J, Solé-Violán J, Restrepo 

MI. Chromogranin A levels and mortality in patients with 

severe sepsis.Biomarkers. 2015 ;20(3):171-6.IF: 2,26 

3. Lorente L, Martín MM, López-Gallardo E, Blanquer J, Solé- 

Violán J, Labarta L, Díaz C, Jiménez A, Montoya J, Ruiz-Pesini 

E. Decrease of oxidative phosphorylation system function 

in severe septic patients.J Crit Care. 2015 Oct ;30(5):935-9. 

IF: 1,995 

4. Lorente L, Martín MM, Almeida T, Hernández M, Ferreres 

J, Solé-Violán J, Labarta L, Díaz C, Jiménez A. Association 

between serum substance P levels and mortality in patients 

with severe sepsis.J Crit Care. 2015 Oct ;30(5):924-8.IF: 1,995 

5. Lorente L, Martín MM, Borreguero-León JM, Barrios Y, Solé- 

Violán J, Ferreres J, Labarta L, Díaz C, Jiménez A. The 4G/4G 

Genotype of PAI-1 Polymorphism Is Associated with Higher 

Plasma PAI-1 Concentrations and Mortality in Patients with 

Severe Sepsis.PLoS One. 2015 ;10(6):e0129565.IF: 3,234 

6. Lorente L, Martín MM, Abreu-González P, de la Cruz T, 

Ferreres J, Solé-Violán J, Labarta L, Díaz C, Jiménez A, 

Borreguero-León JM. Serum melatonin levels are associated 

with mortality in severe septic patients.J Crit Care. 2015 Aug


4 

;30(4):860.e1-6.IF: 1,995 

7. Lorente L, Martín MM, Almeida T, Abreu-González P, 

Ferreres J, Solé-Violán J, Labarta L, Díaz C, Jiménez A. 

Association between serum total antioxidant capacity and 

mortality in severe septic patients.J Crit Care. 2015 Feb 

;30(1):217.e7-12.IF: 1,995 

8. Sancho J, Servera E, Bañuls P, Marin J. Predictors of need for 

noninvasive ventilation during respiratory tract infections in 

medically stable, non-ventilated subjects with amyotrophic 

lateral sclerosis.Respir Care. 2015 Apr ;60(4):492-7.IF: 1,838 

9. Canadell L, Martín-Loeches I, Díaz E, Trefler S, Grau S, Yebenes 

JC, Almirall J, Olona M, Sureda F, Blanquer J, Rodriguez A, 

GETGAG. Degree of adherence to recommended antiviral 

treatment during the pandemic and post-pandemic periods 

of influenza A(H1N1)pdm09 in 148 intensive care units in 

Spain.Med Intensiva. 2015 May ;39(4):222-33.IF: 1,336 

10. Servera E, Sancho J, Bañuls P, Marín J. Bulbar impairment 

score predicts noninvasive volume-cycled ventilation failure 

during an acute lower respiratory tract infection in ALS.J 

Neurol Sci. 2015 Nov 15 ;358(1-2):87-91.IF: 2,474 

11. Martínez D, Sancho J, Servera E, Marín J. Tolerance of 

Volume Control Noninvasive Ventilation in Subjects With 

Amyotrophic Lateral Sclerosis.Respir Care. 2015 Dec 

;60(12):1765-71.IF: 1,838 



Olivas J, Monleón D. Prognosis Biomarkers of Severe Sepsis and 

Septic Shock by 1H NMR Urine Metabolomics in the Intensive 

Care Unit.PLoS One. 2015 ;10(11):e0140993.IF: 3,234 

13. Rudilla D, Galiana L, Oliver A, Barreto P. Comparing 

counseling and dignity therapies in home care patients: A 

pilot study.Palliat Support Care. 2015 Oct 14 ;:1-9.IF: 1,525 

14. Fombuena M, Galiana L, Barreto P, Oliver A, Pascual A, Soto- 

Rubio A. Spirituality in patients with advanced illness: The 

role of symptom control, resilience and social network.J 

Health Psychol. 2015 May 28 ;.IF: 1,748 

15. Fernández-Ruiz M, Puig-Asensio M, Guinea J, Almirante 

B, Padilla B, Almela M, Díaz-Martín A, Rodríguez-Baño 

J, Cuenca-Estrella M, Aguado JM, CANDIPOP Project, 

GEIH-GEMICOMED (SEIMC), REIPI. Candida tropicalis 

bloodstream infection: Incidence, risk factors and outcome 

in a population-based surveillance.J Infect. 2015 Sep 

;71(3):385-94.IF: 4,441 

16. Torner N, Soldevila N, García JJ, Launes C, Godoy P, Castilla 

J, Domínguez A, Effectiveness of non-pharmaceutical 

measures in preventing pediatric influenza: a case-control 

study.BMC Public Health. 2015 Jun 9 ;15:543.IF: 2,264 


RESEARCH 

Reference: PSI2014-51962R 

Title: Apego, acontecimientos vitales estresantes y duelo 

Principal Investigator: Pilar Barreto 

Funding body: Ministerio de Ciencia e Innovación 




Reference: PROMETEO II/2013/014 

Title: Nuevas dianas farmacológicas para el tratamiento de la 

EPOC y sus comorbilidades vasculares 

Principal Investigator: Esteban Morcillo Sánchez (Emilio 

Servera and María Cruz González as collaborating researchers) 




Title: Efecto de los líquidos del cigarro electrónico 

(propilenglicol, detinenglicol y nicotina) sobre los cultivos 

celulares humanos: células epiteliales pulmonares y células 

endoteliales 

Principal Investigator: Jaime Signes-Costa Mañana 

Funding body: Sociedad Valenciana de Neumología/Fundación 

de neumología de la comunidad Valenciana. 





Title: Physiological and clinical effectiveness of mechanically 

assited coughing techniques using cough assist with 

oscillations in amyotrophic lateral sclerosis patients. 

Principal Investigator: Emilio Servera Pieras. 

Funding body: Philips Respironics 




157

4 

Scientific 

activity 

Research Group on Tissular Biochemistry 


158 

Group members 


Juan R. Viña 

University 

H Index: 26 


Luis Torres Asensi. University 

Elena Ruiz García-Trevijano. University 

Vicente Miralles Fernández. University 

Teresa Barber Ballester. University 

PhD student 

Lucía Rodríguez Fernández. University 

Technicians 

Eva Serna García. University 

Concha García de Mier. University 


Rosa Zaragozá Colom. University


4 


• Calpains, activated in the mammary gland during involution, 

cleave several proteins located in cell membrane, 

lysosomes, mitochondria and nuclei favoring cell 

death. Calpains can be implicated in cell anchoring loss. 

The isoform-specific function of CAPN1 and -2 was explored 

in two models of cell-adhesion disruption: mice 

mammary gland during involution and breast cancer cell 

lines. Both CAPNs were able to cleave adhesion proteins 

from lactating mammary gland in vitro. CAPN2/Ecadherin 

in vivo interaction was dramatically increased 

during involution. Calpain inhibitor administration prevented 

the cytosolic accumulation of truncated E-cadherin 

cleaved by CAPN2. In breast cancer cells, CAPN2 

was restricted to the nuclear compartment, CAPN1 and 

CAPN2 knock-down cells showed that cleavage of adhesion 

proteins and cell migration was mediated by CAPN1 

independently of the breast-cancer subtype. 


• The mammary gland as a physiological model for the 

study of programmed cell death 

• Mammalian tissues metabolism and its regulation 

• Epigenomic and protein acetylation studies in K-ras mutated. 

Colon cancer cell lines 


Rosa Zaragozá Colom 

Research has been focused on the 

pathways that regulate mammary 

gland involution after the pregnancy/lactation 

cycle and how these 

pathways become deregulated in 

breast cancer. Recently, our group has 

demonstrated a dual role for calpains 

in mammary tissue controlling programmed cell death and adipocyte 

redifferentiation. Moreover, these calcium-dependent 

proteases seem to play also a role in cell migration in breast tumours. 



3 9,64 3,21 

National 



International 


Corresponding 

author 

- - 3 

1. Tormo E, Pineda B, Serna E, Guijarro A, Ribas G, Fores J, Chirivella 

E, Climent J, Lluch A, Eroles P. MicroRNA Profile in 

Response to Doxorubicin Treatment in Breast Cancer.J Cell 

Biochem. 2015 Sep ;116(9):2061-73.IF: 3,263 

2. Zaragozá R, García-Trevijano ER, Lluch A, Ribas G, Viña JR. 

Involvement of Different networks in mammary gland involution 

after the pregnancy/lactation cycle: Implications in 

breast cancer.IUBMB Life. 2015 Apr ;67(4):227-38.IF: 3,143 

3. Roda D, Castillo J, Telechea-Fernández M, Gil A, López-Rodas 

G, Franco L, González-Rodríguez P, Roselló S, Pérez-Fidalgo 

JA, García-Trevijano ER, Cervantes A, Zaragozá R. EGF-Induced 

Acetylation of Heterogeneous Nuclear Ribonucleoproteins 

Is Dependent on KRAS Mutational Status in Colorectal 

Cancer Cells.PLoS One. 2015 ;10(6):e0130543.IF: 3,234 

• THESIS 

Thesis title: NF-KB e ID2 como nodos de regulación de redes 

transcripcionales en diferentes modelos biológicos 

Doctoral candidate: Iván Ferrer Vicens 

Director(s): Elena Ruiz García-Trevijano, Juan Viña Ribes 



Thesis title: Perfiles de expresión genómica: nuevo enfoque 

diagnóstico para la sepsis en recién nacidos menores de 1500 

gramos 

Doctoral candidate: María Cernada Badía 

Director(s): Eva Serna García, Federico Pallardó Calatayud 



159

4 

Scientific 

activity 


RESEARCH 


Title: Papel de las metilaciones y acetilaciones en las vías de 

señalización desencadenadas por mutaciones en KRas como 

mecanismo de resistencia a fármacos en cáncer colo-rectal 

Principal Investigator: Elena Ruíz García-Trevijano 





160 

Reference: BFU2013-46434P 

Title: Papel dual de las calpaínas en la involución de la 

glándula mamaria murina tras la lactancia: Implicaciones en 

el desarrollo tumoral post-gestacional 

Principal Investigator: Juan R. Viña and Rosa Zaragozá Colom 







Title: Vías de señalización que controlan la involución de la 

glándula mamaria e importancia en el cáncer de mama postgestacional: 

estudio en modelos murinos y en líneas celulares 

humanas 

Principal Investigator: Juan Viña Ribes 

Funding Body: Consellería de Educación, Cultura y Deporte 



Total Budget: 25.000€ (this year)


4 

Research Group on Aging and Physical Activity 


161 

Group members 



José Viña Ribes 

University 

H Index: 60 


Ana Lloret Alcañíz. University 

Juan Gambini Buchón. University 

Gloria Olaso González. University 

José Viña Almunia. University 

Esther Giraldo Reboloso. INCLIVA 

Marta Inglés de la Torre. University 

PhD students 

Cristina Mas Bargues. University 

Andrea Salvador Pascual. University 


Consuelo Borrás Blasco. University 

Mª Carmen Gómez Cabrera. University

4 

Scientific 

activity 

162 


• To identify a multicomponent exercise intervention to reverse 

frailty (JAMDA, 2016). One of our major aims is to 

prove that exercise can be considered as a drug (we published 

in the Journal of Pharmacology, 2012) and more 

recently considered as a supplement to reach healthy 

ageing and retard frailty. (J Physiol., 2016) 

• Concerning Alzheimer’s disease, during 2015 we identified 

that PTEN is a major protein in controlling synapsis 

and cognitive function in Alzheimer’s (Nature Neuroscience, 

2016). We also identified, using redox proteomics, an 

oxidative signature in cerebrospinal fluid to mark changes 

from cognitive impairment to dementia in Alzheimer’s 

(Free Radical Biology and Medicine, 2016). Moreover, we 

performed extensive studies that led us to determine that 

genistein is a treatment for experimental Alzheimer’s disease. 

(Journal of Alzheimer’s disease, 2016) 

• We have been part of the Frailomics initiative (funded by 

the EU) and to identify biomarkers that predict the risk of 

frailty in older individuals (Gerontology, 2016) 

• We have kept our work on centenarians and have recently 

identified that single nucleotide polymorphism, which is 

associated with exceptional longevity and it was published 

in the Revista de Geriatria y Gerontologia, 2015 


• Aging: identification of genes associated with aging, especially 

genes that are specific in centenary people. Implication 

of the estrogens and phytoestrogens in the prevention 

of age-related damage 

• Physical activity: identification of the mechanisms by 

which physical activity is good for health. Identification 

of the mechanisms by which physical activity helps preventing 

senile sarcopenia. Identification of the possible 

doping agents in professional practice of physical activity 

• Physiopathology of the Alzheimer’s disease: identification 

of the mechanisms by which free radicals, originators of 

the oxidative stress are used to unleash cell signals that 

lead to cell death in Alzheimer disease 


Consuelo Borrás Blasco 

Research is focused on stem cells 

and oxygen concentration in regenerative 

medicine. We are studying 

the role of oxygen concentration 

when culturing stem cells. High rates 

of stem cell proliferation are an important tool in regenerative 

medicine. Ambient oxygen tensions (21% O 2 

) are normally used 

for in vitro culture, but physiological levels in vivo range between 

3-6% O 2 

. Our aim is to compare different parameters such as 

proliferation, pluripotency, senescence or apoptosis culturing 

human Dental Pulp Stem Cells (hDPSC) under physiological or 

environmental oxygen concentrations. The results will be determinant 

to obtain enough cells and with good quality for applying 

them in regenerative medicine 


María Carmen Gómez Cabrera 

The main aim of this research is 

to study the beneficial effects of 

physical activity in prevention and 

treatment of several pathologies and 

more specifically on Alzheimer’s disease, 

senile sarcopenia and frailty. We are also interested in the 

study of the molecular bases of skeletal muscle atrophy during 

periods of immobilization, as well as in its prevention. 



21 70,38 3,35 

National 



International 


Corresponding 

author 

10 8 9 

1. Sanchis-Gomar F, Pareja-Galeano H, Gómez-Cabrera 

MC, Candel J, Lippi G, Salvagno GL, Mann GE, Viña J. 

Allopurinol prevents cardiac and skeletal muscle damage 

in professional soccer players.Scand J Med Sci Sports. 2015 

Feb ;25(1):e110-5.IF: 2,896


4 

2. Lippi G, Schena F, Salvagno GL, Sanchis-Gomar F, Guidi GC. 

Serum Copeptin and Midregion Proadrenomedullin (MRproADM) 

After an Ultramarathon.J Clin Lab Anal. 2015 Jan 

;29(1):15-20.IF: 1,038 

3. Sanchis-Gomar F, Pareja-Galeano H, Perez-Quilis C, Santos- 

Lozano A, Fiuza-Luces C, Garatachea N, Lippi G, Lucia A. 

Effects of allopurinol on exercise-induced muscle damage: 

new therapeutic approaches?Cell Stress Chaperones. 2015 

Jan ;20(1):3-13.IF: 3,163 

4. Alis R, Romagnoli M, Primo-Carrau C, Pareja-Galeano H, 

Blesa JR, Sanchis-Gomar F. Effect of exhaustive running 

exercise on red blood cell distribution width.Clin Chem Lab 

Med. 2015 Feb 1 ;53(2):e29-31.IF: 2,707 

5. Pareja-Galeano H, Alis R, Sanchis-Gomar F, Cabo H, 

Cortell-Ballester J, Gómez-Cabrera MC, Lucia A, Viña J. 

Methodological considerations to determine the effect of 

exercise on brain-derived neurotrophic factor levels.Clin 

Biochem. 2015 Feb ;48(3):162-6.IF: 2,275 

6. Forman HJ, Augusto O, Brigelius-Flohe R, Dennery PA, 

Kalyanaraman B, Ischiropoulos H, Mann GE, Radi R, Roberts 

LJ 2nd, Vina J, Davies KJ. Even free radicals should follow 

some rules: A Guide to free radical research terminology and 

methodology.Free Radic Biol Med. 2015 Jan ;78:233-5.IF: 5,736 

7. Sanchis-Gomar F, Lucia A, Yvert T, Ruiz-Casado A, Pareja- 

Galeano H, Santos-Lozano A, Fiuza-Luces C, Garatachea 

N, Lippi G, Bouchard C, Berger NA. Physical inactivity and 

low fitness deserve more attention to alter cancer risk and 

prognosis.Cancer Prev Res (Phila). 2015 Feb ;8(2):105-10.IF: 

4,444 

8. Gómez-Cabrera MC, Salvador-Pascual A, Cabo H, Ferrando 

B, Viña J. Redox modulation of mitochondriogenesis in 

exercise. Does antioxidant supplementation blunt the 

benefits of exercise training?Free Radic Biol Med. 2015 Sep 

;86:37-46.IF: 5,736 

9. Alis R, Ibañez-Sania S, Basterra J, Sanchis-Gomar F, 

Romagnoli M. Effects of an acute high-intensity interval 

training protocol on plasma viscosity.J Sports Med Phys 

Fitness. 2015 Jun ;55(6):647-53.IF: 0,972 

10. Alis R, Sanchis-Gomar F, Primo-Carrau C, Lozano-Calve 

S, Dipalo M, Aloe R, Blesa JR, Romagnoli M, Lippi G. 

Hemoconcentration induced by exercise: Revisiting the 

Dill and Costill equation.Scand J Med Sci Sports. 2015 Dec 

;25(6):e630-7.IF: 2,896 

11. Gambini J, Gimeno-Mallench L, Inglés M, Olaso G, Abdelaziz 

KM, Avellana JA, Belenguer Á, Cruz R, Mas-Bargues C, Borras 

C, Viña J. [Identification of single nucleotide polymorphisms 

in centenarians].Rev Esp Geriatr Gerontol. 2015 Nov 2 ;.IF: 0 

12. Di Domenico F, Pupo G, Giraldo E, Badìa MC, Monllor P, 

Lloret A, Eugenia Schininà M, Giorgi A, Cini C, Tramutola 

A, Butterfield DA, Viña J, Perluigi M. Oxidative signature 

of cerebrospinal fluid from mild cognitive impairment and 

Alzheimer disease patients.Free Radic Biol Med. 2015 Dec 

8 ;91:1-9.IF: 5,736 

13. Belenguer Varea Á, Mohamed Abdelaziz K, Avellana 

Zaragoza JA, Borrás Blasco C, Sanchis Aguilar P, Viña Ribes 

J. [Oxidative stress and longevity; a case-control study].Rev 

Esp Geriatr Gerontol. 2015 Jan-Feb ;50(1):16-21.IF: 0 

14. Llana-Belloch S, Priego Quesada JI, Pérez-Soriano P, Lucas- 

Cuevas ÁG, Salvador-Pascual A, Olaso-González G, Moliner- 

Martínez Y, Verdú-Andres J, Campins-Falco P, Gómez- 

Cabrera MC. Disinfection by-products effect on swimmers 

oxidative stress and respiratory damage.Eur J Sport Sci. 

2015 Sep 12 ;:1-9.IF: 1,55 

Letter 

15. Sanchis-Gomar F, Garatachea N, Catalán P, López M, Lucia 

A, Serrano-Ostáriz E. Strenuous endurance exercise and 

right ventricular systolic function: no evidence of long-term 

sequelae.Int J Cardiol. 2015 Jan 20 ;179:297-8.IF: 4,036 

16. Pareja-Galeano H, Sanchis-Gomar F, Lucia A. Physical 

activity and depression: type of exercise matters.JAMA 

Pediatr. 2015 Mar 1 ;169(3):288-9.IF: 7,148 

17. Viña J, Inglés M, Borrás C. Response to vidal and colleagues.J 

Am Geriatr Soc. 2015 Apr ;63(4):838-9.IF: 4,572 

18. Lippi G, Jansen-Duerr P, Viña J, Durrance-Bagale A, 

Abugessaisa I, Gómez-Cabrero D, Tegnér J, Grillari J, 

Erusalimsky J, Sinclair A, Rodriguez-Manãs L, FRAILOMIC 

consortium. Laboratory biomarkers and frailty: presentation 

of the FRAILOMIC initiative.Clin Chem Lab Med. 2015 Sep 1 

;53(10):e253-5.IF: 2,707 

Review 

19. Lloret A, Fuchsberger T, Giraldo E, Viña J. Molecular 

mechanisms linking amyloid ? toxicity and Tau 

hyperphosphorylation in Alzheimer?s disease.Free Radic 

Biol Med. 2015 Mar 5 ;83:186-191.IF: 5,736 

163

4 

Scientific 

activity 

164 

20. Gambini J, Inglés M, Olaso G, López-Grueso R, Bonet-Costa V, 

Gimeno-Mallench L, Mas-Bargues C, Abdelaziz KM, Gómez- 

Cabrera MC, Vina J, Borras C. Properties of Resveratrol: In 

Vitro and In Vivo Studies about Metabolism, Bioavailability, 

and Biological Effects in Animal Models and Humans.Oxid 

Med Cell Longev. 2015 ;2015:837042.IF: 3,516 

Editorial 

21. Venditti P, Gómez-Cabrera MC, Zhang Y, Radak Z. Oxidant 

antioxidants and adaptive responses to exercise.Oxid Med 

Cell Longev. 2015 ;2015:290190.IF: 3,516 


RESEARCH 


Title: Red Temática de Investigación Cooperativa en 

Envejecimiento y Fragilidad (RETICEF) 

Principal Investigator: José Viña Ribes 





Reference: FRAILOMIC 

Title: Utility of OMIC-Based biomarkers in characterizing 

older individuals at risk for frailty, its progression to disability 

and general consequences to health and well-being - THE 

FRAILOMIC INITIATIVE (FRAILOMIC) 







Title: Señalización por radicales libres de oxígeno en células 

madre: importancia en medicina regenerativa 


Funding Body: Consellería de Educación, Cultura y Deporte 





Title: Identificación de biomarcadores de fragilidad y de 

estrategias para su prevención y tratamiento. Centenarios 

como un modelo de envejecimiento saludable 

Principal Investigator: Jose Viña Ribes 





Reference: Convocatoria 2014 de ayudas para la 

internacionalización de grupos INCLIVA 

Title: Applied Nanotechnologies for AGEING related clinical 

decisions (ANAGEING) 

Principal Investigator: Jose Viña Ribes 









Title: Efecto de la administración de genisteína y/o bexaroteno 

para el tratamiento de la enfermedad de Alzheimer en el 

modelo de ratón transgénico APP/PS1 

Principal Investigator: Consuelo Borrás Blasco 





Duration: 2014 - 2015 




Title: Estudio de parámetros de longevidad en mujeres 

con tratamiento de estrógenos y progestágenos tras una 

menopausia inducida con GnRH 






Duration: 2013-2015


4 



Title: Ejercicio físico controlado como intervención en el 

tratamiento de la fragilidad en el anciano y en la prevención 

de la dependencia. Bases moleculares. 

Principal Investigator: Mari Carmen Gómez Cabrera 





Duration: 2014 - 2015 


165

4 

Scientific 

activity 

Research Group on Anesthesiology and Reanimation 


166 

“El Hospital Clínico presenta un protocolo de la organización asistencial en el manejo del paciente 

politraumatizado”. Rafael Badenes. 26/11/2015 | elperiodic.com 

http://www.anestesiaclinicovalencia.org 

Group members 


Francisco Javier Belda Nácher 


H Index: 14 


Marina Soro Domingo. Hospital. University 

Gerardo Aguilar Aguilar. Hospital 

José García de la Asunción. Hospital 

Francisco Martí Canoves. Hospital 

Beatriz Garrigues Olivé. Hospital 

Juan Vicente Llau Pitarch. Hospital. University 

Rafael Badenes Quiles. Hospital 

Armando Maruenda Paulino. Hospital. University 

María Luisa García Pérez. Hospital 

Carlos Tornero Tornero. Hospital 

Benigno Escamilla Cañete. Hospital 

María Luisa Laredo Alcázar. Hospital 

Arturo Carratalá Calvo. Hospital 

Jaime Pérez-Griera. Hospital 

José Miguel Alonso Iñigo. Hospital 

Blanca Arocas Chicote. Hospital 

José Antonio Carbonell López. Hospital 

Pedro Charco Mora. Hospital 

Mario De Fez Barberá. Hospital 

Mar Garzando Civera. Hospital 

Andrea Gutiérrez Valcárcel. Hospital 

Irene León Carsi. Hospital 

Mª Jesús Montero Hernández. Hospital 

Mª José Parra González. Hospital 

Ernesto Pastor Martínez. Hospital 

Jaume Puig Bernabéu. Hospital 

Ana Mugarra Llopis. Hospital 

Laura Reviriego Agudo. Hospital 


Carlos Ferrando Ortolá. Hospital


4 


• To demonstrate the usefulness of molecular methods for 

the diagnosis of peritoneal candidiasis 

• To identify the combination of RXR agonists with low-dose 

statins as a new and safe treatment for AAA control 

• To validate a predictive scale of postoperative pulmonary 

complications 

• To study the effect on blood flow of long radial arterial 

catheters 

• Identify risk factors in predicting active Cytomegalovirus 

infection in HIV-positive patients liver transplant recipients 

• To establish the role of insulin and analogues in critically 

ill patients 

• To assess the epidemiology of invasive candidiasis in the 

intensive care unit 

• To develop different maneuvers optimization oxygenation 

and pulmonary mechanics in patients undergoing mechanical 

ventilation 

• To assess the possible liver and kidney toxicity caused by 

prolonged administration of sevoflurane 


• Studying gases used in anesthesia: halogenated agents, 

xenon and oxygen; and the effects of anesthetics; oxidative 

stress and protection of organs in ischemia-reperfusion 

surgery 

• Study of oxidative stress biomarkers in exhaled lung water 

• Ventilatory and pharmacological strategies to decrease 

organ damage in the lungs associated with mechanical 

ventilation in healthy and injured lungs 

• To study safety and potential benefit in terms of protection 

of government bodies of halogenated agents during 

prolonged sedation 

• Development of hemodynamic monitoring and its application 

in the field of patients undergoing surgery or admitted 

to critical care units 

• Study and development of instruments and drugs to 

quantify or involved in different pathways of hemostasis 

in two ways: prevention of thrombotic complications and 

bleeding prevention in the perioperative period 

• Study and development of methods of detection of infections, 

especially fungal and virological, and how to prevent 

them 

• Development of neurological monitoring and study measures 

to protect brain damage 

• Development of new strategies and drugs for pain treatment 


Carlos Ferrando Ortolá 

Some of the ongoing research lines in 

our group that I am leading are: 

1. Role of anaesthetics in the inflammatory 

response in anaesthesia and critical 

care patients. 

2. Strategies to optimize and individualized intraoperative ventilatory 

management (precision medicine) 

3. Role of the perioperative ventilatory strategies in postoperative 

complications. Protocol published in Trials (Ferrando et 

al. Trials 2015). This multicenter randomized controlled trial was 

performed in 20 Spanish Hospitals and enrolled 1012 patients. 

We are currently drafting the manuscript for the NEJM. 

4. Role of perioperative supplemental oxygen in postoperative 

complications. We are going to start a multicentre randomized 

controlled trial with a sample size of 756 patients in 26 Spanish 

Hospitals to investigate whether an individualized perioperative 

approach with High versus Conventional FIO2 prevents postoperative 

SSI (Clinicaltrials.gov NCT02776046. PI: Carlos Ferrando). 



38 103,64 2,65 

National 



International 


Corresponding 

author 

14 14 12 

1. Torregrosa I, Montoliu C, Urios A, Andrés-Costa MJ, 

Giménez-Garzó C, Juan I, Puchades MJ, Blasco ML, Carratalá 

A, Sanjuán R, Miguel A. Urinary KIM-1, NGAL and L-FABP 

for the diagnosis of AKI in patients with acute coronary 

syndrome or heart failure undergoing coronary angiography. 

Heart Vessels. 2015 Nov ;30(6):703-11.IF: 2,065 

2. Ferrando C, Soro M, Belda FJ. Protection strategies during 

cardiopulmonary bypass: ventilation, anesthetics and oxygen. 

Curr Opin Anaesthesiol. 2015 Feb ;28(1):73-80.IF: 1,979 



167

4 

Scientific 

activity 

168 



;26(1):42-8.IF: 2,891 

4. Ferrando C, Suárez-Sipmann F, Gutierrez A, Tusman G, 

Carbonell J, García M, Piqueras L, Compañ D, Flores S, Soro 

M, Llombart A, Belda F. Adjusting tidal volume to stress 

index in an open lung condition optimizes ventilation and 

prevents overdistension in an experimental model of lung 

injury and reduced chest wall compliance.Crit Care. 2015 

Jan 13 ;19(1):9.IF: 5,035 

5. Corrales I, Giménez E, Aguilar G, Delgado C, Puig J, Izquierdo 

A, Belda J, Navarro D. Detection of fungal DNA in peritoneal 

fluids by a PCR DNA low-density microarray system and 

quantitation of serum (1-3)-?-D-glucan in the diagnosis of 

peritoneal candidiasis.Med Mycol. 2015 Feb 1 ;53(2):199- 

204.IF: 2,335 

6. Escudero P, Navarro A, Ferrando C, Furio E, González-Navarro 

H, Juez M, Sanz MJ, Piqueras L. Combined treatment with 

bexarotene and rosuvastatin reduces angiotensin-II-induced 

abdominal aortic aneurysm in apoE(-/-) mice and angiogenesis. 

Br J Pharmacol. 2015 Jun ;172(12):2946-60.IF: 4,842 

7. Ferrando C, Soro M, Canet J, Unzueta MC, Suárez F, Librero 

J, Peiró S, Llombart A, Delgado C, León I, Rovira L, Ramasco 

F, Granell M, Aldecoa C, Diaz O, Balust J, Garutti I, de la 

Matta M, Pensado A, González R, Durán ME, Gallego L, 

Del Valle SG, Redondo FJ, Diaz P, Pestaña D, Rodríguez A, 

Aguirre J, García JM, García J, Espinosa E, Charco P, Navarro 

J, Rodríguez C, Tusman G, Belda FJ, iPROVE investigators 

(Appendices 1 and 2).. Rationale and study design for an 

individualized perioperative open lung ventilatory strategy 

(iPROVE): study protocol for a randomized controlled trial. 

Trials. 2015 Apr 27 ;16(1):193.IF: 1,731 

8. García-de-la-Asunción J, García-del-Olmo E, Perez-Griera 

J, Martí F, Galán G, Morcillo A, Wins R, Guijarro R, Arnau A, 

Sarriá B, García-Raimundo M, Belda J. Oxidative lung injury 

correlates with one-lung ventilation time during pulmonary 

lobectomy: a study of exhaled breath condensate and blood. 

Eur J Cardiothorac Surg. 2015 Sep ;48(3):e37-44.IF: 3,304 

9. Canet J, Sabaté S, Mazo V, Gallart L, de Abreu MG, Belda 

J, Langeron O, Hoeft A, Pelosi P, PERISCOPE group. 

Development and validation of a score to predict 

postoperative respiratory failure in a multicentre 

European cohort: A prospective, observational study.Eur J 

Anaesthesiol. 2015 Jul ;32(7):458-70.IF: 2,942 

10. Villar J, Blanco J, del Campo R, Andaluz-Ojeda D, Díaz- 

Domínguez FJ, Muriel A, Córcoles V, Suárez-Sipmann 

F, Tarancón C, González-Higueras E, López J, Blanch L, 

Pérez-Méndez L, Fernández RL, Kacmarek RM, Spanish 

Initiative for Epidemiology, Stratification & Therapies 

for ARDS (SIESTA) Network. Assessment of PaO?/FiO? for 

stratification of patients with moderate and severe acute 

respiratory distress syndrome.BMJ Open. 2015 Mar 27 

;5(3):e006812.IF: 2,271 

11. Balcells E, Gimeno-Santos E, de Batlle J, Ramon MA, 

Rodríguez E, Benet M, Farrero E, Ferrer A, Guerra S, Ferrer 

J, Sauleda J, Barberà JA, Agustí À, Rodriguez-Roisin R, Gea 

J, Antó JM, García-Aymerich J, PAC-COPD Study Group. 

Characterisation and prognosis of undiagnosed chronic 

obstructive pulmonary disease patients at their first 

hospitalisation.BMC Pulm Med. 2015 Jan 17 ;15:4.IF: 2,404 

12. HIV-CAUSAL Collaboration, Cain LE, Phillips A, Olson A, Sabin 

C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van 

Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, 

Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, 

Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall 

S, Costagliola D, Hernán MA. Boosted lopinavir- versus 

boosted atazanavir-containing regimens and immunologic, 

virologic, and clinical outcomes: a prospective study of HIVinfected 

individuals in high-income countries.Clin Infect Dis. 

2015 Apr 15 ;60(8):1262-8.IF: 8,886 

13. Redondo Calvo FJ, Bejarano Ramirez N, Uña Orejon R, 

Villazala García R, Yuste Peña AS, Belda FJ. Elevated 

Extravascular Lung Water Index (ELWI) as a Predictor 

of Failure of Continuous Positive Airway Pressure Via 

Helmet (Helmet-CPAP) in Patients With Acute Respiratory 

Failure After Major Surgery.Arch Bronconeumol. 2015 Nov 

;51(11):558-563.IF: 1,823 

14. Rovira L, Aguilar G, Cuñat A, Belda FJ. Late evaluation of 

upper limb arterial flow in patients after long radial (PiCCO) 

catheter placement.Ann Intensive Care. 2015 ;5:1.IF: 3,311 

15. Badenes R, Lozano A, Belda FJ. Postoperative pulmonary 

dysfunction and mechanical ventilation in cardiac surgery. 

Crit Care Res Pract. 2015 ;2015:420513.IF: 0 

16. Esquinas AM, Jover JL, Úbeda A, Belda FJ, International Working 

Group on Critical and Noninvasive Mechanical Ventilation 

Anesthesiology. [Non-invasive mechanical ventilation in the 

pre- and intraoperative period and difficult airway].Rev Esp 

Anestesiol Reanim. 2015 Nov ;62(9):502-11.IF: 0


4 

17. Hidalgo F, Gómez-Luque A, Ferrandis R, Llau JV, de Andrés 

J, Gomar C, Sierra P, Castillo J, Torres LM. [Perioperative 

management of direct oral anticoagulant in emergency surgery 

and bleeding. Haemostasis monitoring and treatment].Rev 

Esp Anestesiol Reanim. 2015 Oct ;62(8):450-60.IF: 0 

18. Bourguet M, Amselem Albuixec L, Benavent Corai V, 

Tornero C. [Rectal mass in 31-year-old man with human 

immunodeficiency virus: diferential diagnosis].Enferm 

Infecc Microbiol Clin. 2015 Aug-Sep ;33(7):493-4.IF: 2,172 

19. Fernández-Ruiz M, Corrales I, Arias M, Campistol JM, 

Giménez E, Crespo J, López-Oliva MO, Beneyto I, Martín- 

Moreno PL, Llamas-Fuente F, Gutiérrez A, García-Álvarez 

T, Guerra-Rodríguez R, Calvo N, Fernández-Rodríguez A, 

Tabernero-Romo JM, Navarro MD, Ramos-Verde A, Aguado 

JM, Navarro D, OPERA Study Group. Association between 

individual and combined SNPs in genes related to innate 

immunity and incidence of CMV infection in seropositive 

kidney transplant recipients.Am J Transplant. 2015 May 

;15(5):1323-35.IF: 5,683 

20. Bilotta F, Badenes R, Lolli S, Belda FJ, Einav S, Rosa G. Insulin 

infusion therapy in critical care patients: regular insulin vs 

short-acting insulin. A prospective, crossover, randomized, 

multicenter blind study.J Crit Care. 2015 Apr ;30(2):437. 

e1-6.IF: 1,995 

21. Llorens J, Rovira L, Ballester M, Moreno J, Hernández- 

Laforet J, Santonja FJ, Cassinello N, Ortega J. Preoperative 

inspiratory muscular training to prevent postoperative 

hypoxemia in morbidly obese patients undergoing 

laparoscopic bariatric surgery. A randomized clinical trial. 

Obes Surg. 2015 Jun ;25(6):1003-9.IF: 3,747 

22. Gallego L, Soro M, Alvariño A, Noguera I, Belda FJ. Renal 

and hepatic integrity in long-term sevoflurane sedation 

using the anesthetic conserving device: a comparison with 

intravenous propofol sedation in an animal model.Rev Esp 

Anestesiol Reanim. 2015 Apr ;62(4):191-203.IF: 0 

23. Llau JV, Acosta FJ, Escolar G, Fernández-Mondéjar E, Guasch 

E, Marco P, Paniagua P, Páramo JA, Quintana M, Torrabadella 

P. Multidisciplinary consensus document on the management 

of massive haemorrhage (HEMOMAS document).Med 

Intensiva. 2015 Nov ;39(8):483-504.IF: 1,336 

24. Ferrando C, Belda FJ. The Effects of Flow Waveform on 

Oxygenation in Pediatric Patients.Anesth Analg. 2015 Oct 

;121(4):1111.IF: 3,472 

25. Perel A, Saugel B, Teboul JL, Malbrain ML, Belda FJ, 

Fernández-Mondéjar E, Kirov M, Wendon J, Lussmann 

R, Maggiorini M. The effects of advanced monitoring on 

hemodynamic management in critically ill patients: a pre 

and post questionnaire study.J Clin Monit Comput. 2015 

Dec 10 ;.IF: 1,985 

26. Broch O, Carbonell J, Ferrando C, Metzner M, Carstens A, 

Albrecht M, Gruenewald M, Höcker J, Soro M, Steinfath 

M, Renner J, Bein B. Accuracy of an autocalibrated pulse 

contour analysis in cardiac surgery patients: a bi-center 

clinical trial.BMC Anesthesiol. 2015 Nov 26 ;15:171.IF: 1,375 

27. Badenes R, Gruenbaum SE, Bilotta F. Cerebral protection 

during neurosurgery and stroke.Curr Opin Anaesthesiol. 

2015 Oct ;28(5):532-6.IF: 1,979 

28. Badenes R, Bilotta F. Neurocritical care for intracranial 

haemorrhage: a systematic review of recent studies.Br J 

Anaesth. 2015 Dec ;115 Suppl 2:ii68-ii74.IF: 4,853 

29. Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, 

van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi 

N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi 

G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis 

F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin 

C, Hernán MA, HIV-CAUSAL Collaboration. Comparative 

effectiveness of immediate antiretroviral therapy versus 

CD4-based initiation in HIV-positive individuals in highincome 

countries: observational cohort study.Lancet HIV. 

2015 Aug ;2(8):e335-43.IF: 0 

30. Aguilar G, Delgado C, Corrales I, Izquierdo A, Gracia E, 

Moreno T, Romero E, Ferrando C, Carbonell JA, Borrás R, 

Navarro D, Belda FJ. Epidemiology of invasive candidiasis in 

a surgical intensive care unit: an observational study.BMC 

Res Notes. 2015 Sep 29 ;8:491.IF: 0 

31. van Zaane B, van Klei WA, Buhre WF, Bauer P, Boerma EC, 

Hoeft A, Metnitz P, Moreno RP, Pearse R, Pelosi P, Sander M, 

Vallet B, Pettilä V, Vincent JL, Rhodes A, European Surgical 

Outcomes Study (EuSOS) group for the Trials groups of 

the European Society of Intensive Care Medicine and the 

European Society of Anaesthesiology. Nonelective surgery 

at night and in-hospital mortality: Prospective observational 

data from the European Surgical Outcomes Study.Eur J 

Anaesthesiol. 2015 Jul ;32(7):477-85.IF: 2,942 

32. Sakr Y, Alhussami I, Nanchal R, Wunderink RG, Pellis T, 

Wittebole X, Martín-Loeches I, François B, Leone M, 

Vincent JL, Intensive Care Over Nations Investigators. 

169

4 

Scientific 

activity 

170 

Being Overweight Is Associated With Greater Survival in 

ICU Patients: Results From the Intensive Care Over Nations 

Audit.Crit Care Med. 2015 Dec ;43(12):2623-32.IF: 6,312 

33. Salinas M, López-Garrigós M, Flores E, Uris J, Leiva-Salinas 

C, Pilot Group of the Appropriate Utilization of Laboratory 

Tests. Larger differences in utilization of rarely requested 

tests in primary care in Spain.Biochem Med (Zagreb). 2015 

;25(3):410-5.IF: 2,667 

Letters 

34. Mazo V, Sabaté S, Canet J, Gallart L, de Abreu MG, Belda J, 

Langeron O, Hoeft A, Pelosi P. In reply.Anesthesiology. 2015 

Mar ;122(3):716-7.IF: 5,879 

35. Llopis M, Cioaia S, Poquet I, Tornero C. [Is necessary monitoring 

CD4 lymphocytes in HIV patients virologically stables?]. 

Enferm Infecc Microbiol Clin. 2015 Aug-Sep ;33(7):504.IF: 

2,172 

Review 

36. Esquinas AM, Jover JL, Úbeda A, Belda FJ, International 

Working Group on Critical and Noninvasive Mechanical 

Ventilation Anesthesiology. [Non-invasive mechanical ventilation 

in postoperative patients. A clinical review].Rev Esp 

Anestesiol Reanim. 2015 Nov ;62(9):512-22.IF: 0 

Editorial 

37. Ferrando C, Belda FJ. Inverse ratio ventilation: back to the 

future?Crit Care Med. 2015 Mar ;43(3):724-5.IF: 6,312 

38. European Society of Anaesthesiology task force reports on 

place of aprotinin in clinical anaesthesia. Aprotinin: is it time 

to reconsider?Eur J Anaesthesiol. 2015 Sep ;32(9):591-5.IF: 

2,942 

• THESIS 

Thesis title: Continuous cardiac index trending (proaqt) via 

a radial arterial line versus standard care in general surgical 

patients 

Doctoral candidate: Jaume Puig Bernabeu 

Director(s): Francisco Javier Belda Nácher, Daniel Arnulf 

Reuter 



Thesis title: Efecto de las diferentes ondas de flujo y de la 

pausa teleinspiratoria sobre la oxigenación y ventilación en 

modelo animal 

Doctoral candidate: María Luisa García Perez 

Director(s): Rafael Badenes Quiles, Carlos Ferrando Ortolá, 

Marina Soro Domingo 




RESEARCH 

Reference: EC10-318 

Title: Tratamiento anticipado con ganciclovir de la infección 

activa por el citomegalovirus (CMV) en el paciente crítico en 

ventilación mecánica con sepsis grave o shock séptico 

Principal Investigator: Gerardo Aguilar Aguilar 







Title: Prospective observational study of the direct oral 

anticoagulants perioperative management 

Principal Investigator: Raquel Ferrandis Comes 







Title: Reducción de las asincronías y de la duración de 

la ventilación mecánica mediante la Ventilación Asistida 

Ajustada Neuralmente (NAVA) en pacientes con insuficiencia 

respiratoria aguda 

Principal Investigator: Jesús Villar Hernández (Francisco Javier 

Belda as collaborating researcher) 


Beneficiary institution: Fundación Canaria de Investigación y 

Salud (FUNCIS) 




4 


Title: Reducción de la complicaciones postoperatorias y de 

la estancia hospitalaria con una estrategia perioperatoria 

individualizada de ventilación de protección pulmonar. Estudio 

comparativo, prosprectivo. 

Principal Investigator: Carlos Ferrando Ortolá 






• AWARDS 

Carlos Ferrando Ortolá was awarded with the Young Investigator 

Start-Up Grant 2015 by the European Society of Anaesthesiology 

(ESA). 

171

4 

Scientific 

activity 

Research Group on Translational Genomics 


172 

“No descarto promover la creación de más empresas y aportar mi modesta contribución al panorama 

de la Biotecnología en España” 

Manuel Pérez Alonso. Genetic Insider. 5-5-2015 

http://blog.genetic-insider.com/entrevista-a-manuel-perez-alonso-imegen/ http://www.uv.es/gt/ 

Group members 


Rubén D. Artero Alepuz 

University 

H Index: 13 


Manuel Pérez Alonso. University 

Mª Beatriz Llamusí Troísi. University 

Ariadna Bargiela Schönbrunn. University 

Juan M. Fernandez Costa. University 

PhD students 

Estefanía Cerro Herreros. University 

Piotr Konieczny. University 

Mouli Chakraborty. University 

Anna Serafina Rapisarda. University 

Estela Selma Soriano. University 

María Sabater Arcis. University 

Eleni Foteinou. University


4 


• To describe that increased autophagy and apoptosis 

contribute to muscle atrophy in a Myotonic Dystrophy 

type 1 Drosophila model, which also suggest new therapeutic 

strategies for the disease 

• To show that pentamidine rescues heart contractility 

and rhythmicity in the same model of Myotonic Dystrophy 

in Drosophila making use of a quite unique equipment 

and know-how 


RESEARCH 


Title: Utilización de microRNAs como dianas terapéuticas y 

biomarcadores de progresión en Distrofia Miotónica 

Principal Investigator: Rubén Artero Allepuz 






• Using miRNAs as therapeutic targets in myotonic dystrophy 

(DM) 

• Drug discovery and development in DM 

• Study of the causes of cardiac alterations in DM 

• Study of the molecular causes of muscle and CNS degeneration 

in DM 

• Study of the molecular mechanisms associated with spinal 

muscular atrophy and search for potential therapies 

• Development of a model in Drosophila for the discovery 

of inhibitors of protein-protein interactions 

• Understanding human podocyte function through Drosophila 

nephrocytes 



2 9,94 4,97 

National 



International 


Corresponding 

author 

1 1 2 

1. Bargiela A, Cerro-Herreros E, Fernandez-Costa JM, Vilchez 

JJ, Llamusi B, Artero R. Increased autophagy and apoptosis 

contribute to muscle atrophy in a myotonic dystrophy type 

1 Drosophila model.Dis Model Mech. 2015 Jul 1 ;8(7):679- 

90.IF: 4,973 

2. Chakraborty M, Selma-Soriano E, Magny E, Couso JP, 

Pérez-Alonso M, Charlet-Berguerand N, Artero R, Llamusi 

B. Pentamidine rescues contractility and rhythmicity in a 

Drosophila model of myotonic dystrophy heart dysfunction. 

Dis Model Mech. 2015 Dec 1 ;8(12):1569-78.IF: 4,973 

Reference: FPA/2015/085 

Title: Utilización de microRNAs como dianas terapéuticas y 

biomarcadores de progresión en distrofia miotónica 


Funding body: Conselleria d´Educació, Cultura i Esport 





Title: Estudio de las causas de los defectos cardiacos en las 

Distrofias Miotónicas 

Principal Investigator: Mª Beatriz Llamusí Troisi 







Title: Instituto Superior de Investigación Cooperativa de 

Biotecnología y Biomedicina (ISIC BIOTECMED) 

Principal Investigator: Juan Ferre Manzanero (Rubén Darío 

Artero as collaborating researcher) 






Title: Development of pharmacological therapies for myotonic 

dystrophy 

Principal Investigator: Manuel Pérez Alonso 



173

4 

Scientific 

activity 




Reference: 73 

Title: Analysis of the structure-activity relationships of antimyotonic 

dystrophy hexapeptides 

Principal Investigator: Mª Beatriz Llamusí Troisi 

Funding Body: Telemaratón RTVE Todos somos raros, todos 

somos únicos 





Thesis title: Regulación transcripcional de muscleblind y 

nuevos mecanismos de patogénesis en un modelo de Distrofia 

Miotónica en Drosophila 

Doctoral candidate: Ariadna Bargiela Schönbrunn 

Director(s): Rubén Artero, Beatriz Llamusi 



Thesis title: Implicación de miRNAs en la toxicidad mediada 

por expansiones de repeticiones CTG en Distrofia Miotónica 

Doctoral candidate: Juan M. Fernández Costa 

Director(s): Rubén Artero Allepuz 



174 


Title: Aproximaciones genéticas para el estudio de patologías 

humanas y del desarrollo en Drosophila. Programa Prometeo. 

Fase II 

Principal Investigator: Nuria Paricio Ortiz (Rubén Artero as 

collaborating Research) 

Funding Body: Conselleria d´Educació, Cultura i Esport 




• AWARDS 

Manuel Pérez Alonso was awarded with the Premio a la Innovación 

Sanitaria given annually by the Instituto de Investigación 

y Desarrollo Social de Enfermedades Poco Frecuentes (INDEPF). 

Reference: 2014/063 

Title: Characterization of novel suppressors of 

neurodegeneration in myotonic dystrophy type1 

Principal Investigator: Manuel Pérez Alonso 

Funding body: Fundación La Marató de TV3 

Beneficiary institution: INCLIVA 



• THESIS 

Thesis title: Descubrimiento y caracterización de la 

estefenantrina como fármaco para la distrofia miotónica tipo 1. 

Doctoral candidate: Irma García Alcover 

Director(s): Arturo López Castel, Manuel Pérez Alonso, Rubén 

Artero Allepuz 



In the upper panels two images of muscles of Drosophila in 

which cell nuclei in blue and activation process of autophagy in 

red are detected when the charge of myotonic dystrophy (CTG 

expansions) mutation is expressed. In the two lower images 

show something similar but in human myoblasts, in which there 

is abnormal activation of autophagy (absence of red signal in the 

lower left panel), but if patient myoblasts (lower right panel).


4 

Research Group on General and Digestive Surgery 


175 

Group members 


Joaquín Ortega Serrano 

Hospital 

H Index: 12 


Bruno Camps Vilata. Hospital 

Luis Sabater Ortí. Hospital 

Elena Muñoz Forner. Hospital 

Francisco Morera Ocón. Hospital 

Vicente Martí Martí. Hospital 

José Martín Arévalo. Hospital 

David Moro Valdezate. Hospital 

Vicente Pla Martín. Hospital 

Norberto Cassinello Fernández. Hospital 

Consuelo Sebastián Pastor. Hospital 

Fernando López Mozos. Hospital 

Roberto Martí Obiol. Hospital 

Julio Calvete Chornet. Hospital 

Elena Martí Cuñat. Hospital 

Marina Garcés Albir. Hospital

4 

Scientific 

activity 

176 


• Incorporation of the retroperitoneoscopy as a new surgical 

technique for the department, as a treatment of adrenal 

tumours 

• Development of the clinical pathway for thyroidectomy 

• International edition of a book on esophageal cancer: 

“Esophageal cancer: symptoms, management and 

prognosis” 

• Completion of the national multicenter trial on the 

differences between the pancreato-gastrostomy and 

pancreato-jejunostomy in cephalic pancreaticoduodenectomy 

technique 


• About coloproctological surgery: study of the quality 

standards for coloproctology 3D endorectal ultrasound, 

sacral neuromodulation and perianal fistula surgery 

• About hepatobiliary and pancreatic surgery: acute pancreatitis, 

gene transfection, pancreaticoduodenectomy 

• About endocrine surgery: laparoscopic adrenal tumours, 

recurrences study in thyroid surgery, parathyroid adenomas 

intraoperative localization 

• About metabolic and bariatric surgery: pathophysiology 

of postoperative changes 

• About breast surgery: utility of fibrin sealants in postoperative 

seroma 

• About gastroesophageal surgery: mutations in GIST tumours, 

overexpression of HER2 and HER3 in gastric tumours, 

perioperative QT in advanced gastric cancer 



15 36,82 2,45 

National 



International 


Corresponding 

author 

6 1 8 

1. Casáns-Tormo I, Prado-Wohlwend S, Díaz-Expósito R, Cassinello-Fernández 

N, Ortega-Serrano J. [Initial experience in 

intraoperative radiolocalization of the parathyroid adeno- 

ma with freehand SPECT and comparative assessment with 

portable gamma-camera].Rev Esp Med Nucl Imagen Mol. 

2015 Mar-Apr ;34(2):116-9.IF: 1,054 

2. Ciga Lozano MÁ, Codina Cazador A, Ortiz Hurtado H, Cancer 

Project Recto of the Spanish Association of Surgeons. 

Oncological results according to type of resection for rectal 

cancer.Cir Esp. 2015 Apr ;93(4):229-35.IF: 0,743 

3. Espín E, Ciga MA, Pera M, Ortiz H, Spanish Rectal Cancer 

Project. Oncological outcome following anastomotic leak in 

rectal surgery.Br J Surg. 2015 Mar ;102(4):416-22.IF: 5,542 

4. Panach Navarrete J, Moro Valdezate D, Garcés Albir M, 

Boscá Watts MM, Barreda-Estuardo L, Ortega Serrano J. 

Acute gastric dilatation in the context of bulimia nervosa. 

Rev Esp Enferm Dig. 2015 Jul 14 ;.IF: 1,414 

5. Villar del Moral JM, Soria Aledo V, Colina Alonso A, Flores 

Pastor B, Gutiérrez Rodríguez MT, Ortega Serrano J, Parra 

Hidalgo P, Ros López S. Clinical Pathway for Thyroidectomy. 

Cir Esp. 2015 May ;93(5):283-99.IF: 0,743 

6. Gómez-Ramírez J, Sitges-Serra A, Moreno-Llorente P, 

Zambudio AR, Ortega-Serrano J, Rodríguez MT, del Moral 

JV. Mortality after thyroid surgery, insignificant or still an 

issue?Langenbecks Arch Surg. 2015 May ;400(4):517-22.IF: 

2,191 

7. Höftberger R, van Sonderen A, Leypoldt F, Houghton D, 

Geschwind M, Gelfand J, Paredes M, Sabater L, Saiz A, 

Titulaer MJ, Graus F, Dalmau J. Encephalitis and AMPA 

receptor antibodies: Novel findings in a case series of 22 

patients.Neurology. 2015 Jun 16 ;84(24):2403-12.IF: 8,286 

8. Pérez S, Pereda J, Sabater L, Sastre J. Pancreatic ascites 

hemoglobin contributes to the systemic response in acute 

pancreatitis.Free Radic Biol Med. 2015 Apr ;81:145-55.IF: 

5,736 

9. Llorens J, Rovira L, Ballester M, Moreno J, Hernández- 

Laforet J, Santonja FJ, Cassinello N, Ortega J. Preoperative 

inspiratory muscular training to prevent postoperative 

hypoxemia in morbidly obese patients undergoing 

laparoscopic bariatric surgery. A randomized clinical trial. 

Obes Surg. 2015 Jun ;25(6):1003-9.IF: 3,747 

10. Marinello FG, Baguena G, Lucas E, Frasson M, Hervás D, Flor- 

Lorente B, Esclapez P, Espí A, García-Granero E. Anastomotic 

leaks after colon cancer resections: Does the individual 

surgeon matter?Colorectal Dis. 2015 Nov 12 ;.IF: 2,351 

11. Fernandez Mdel C, Diaz M, López F, Martí-Obiol R, Ortega J.


4 

Cardiac complications after laparoscopic large hiatal hernia 

repair. Is it related with staple fixation of the mesh? -Report 

of three cases.Ann Med Surg (Lond). 2015 Dec ;4(4):395-8. 

IF: 0 

Letter 

12. Díaz-Tobarra M, Garcés-Albir M, Moro-Valdezate D, Ortega- 

Serrano J. Hemocholecyst: A rare cause of acute abdomen. 

Rev Esp Enferm Dig. 2015 Jun ;107(6):394-5.IF: 1,414 

13. Ferro O, Soria J, Garcés M, Guijarro J, Gámez JM, Sabater L. 

[Pseudoaneurysm of the superior mesenteric artery after 

pancreatoduodenectomy].Gastroenterol Hepatol. 2015 Jun 

18 ;.IF: 0,838 

14. Ledezma Peredo NV, Díaz-Tobarra M, Soria Estrems J, Alberto 

León Espinoza C, Calvete Chornet J. Early aortic clamping in 

the surgical treatment of splenic artery aneurysm rupture. 

Cir Esp. 2015 Apr ;93(4):263-4.IF: 0,743 

Review 

15. Pérez S, Pereda J, Sabater L, Sastre J. Redox signaling in acute 

pancreatitis.Redox Biol. 2015 Jan 28 ;5:1-14.IF: 0 

Thesis title: Impacto del tratamiento neoadyuvante en los resultados 

de la cirugía del cáncer de recto localmente avanzado 

Doctoral candidate: Rafael Estevan Estevan 

Director(s): Luis Sabater Ortí, Rafael Alos Company 



Thesis title: Identificación de los perfiles de expresión en el adenocarcinoma 

ductal de páncreas. Implicaciones clínicas. 

Doctoral candidate: María del Carmen Gómez Mateo 

Director(s): Felipe Javier Chaves Martínez, Antonio Ferrández 

Izquierdo, Luis Sabater Ortí 



• AWARDS 

The Investigator Luis Sabater had received in 2015 the National 

Surgery award. 

177 

• THESIS 

Thesis title: Efectos de un programa de fisioterapia respiratoria 

preoperatoria sobre la oxigenación y la función respiratoria 

perioperatoria en pacientes obesos mórbidos sometidos a 

cirugía bariátrica laparoscópica. 

Doctoral candidate: Lucas Rovira Soriano 

Director(s): Joaquín Ortega Serrano, Julio Llorens Herrerías 



4 

Scientific 

activity 

Research Group on Personal Autonomy, Dependence and Severe Mental Disorders 

(TMAP) 


178 

Group members 


Rafael Tabarés Seisdedos 

University 

H Index: 26 


Gabriel Selva Vera. University. Hospital 

Manuel Gómez Beneyto. University 

Patricia Correa Ghisays. University 

Inmaculada Fuentes Durá. University 

Cristina Amézcua García. CIBERSAM 

Ferrán Catalá López. University


4 


• To participated in the publication of the Global Burden 

of Disease study 2013 in The Lancet (2015 Nov 

28;386(10009):2145-91). Among the most relevant findings 

of this study is the epidemiologic transition, on 

a global level, from infectious diseases to chronic noncommunicable 

diseases during the period 1990-2013 

• To edit a Research Topic in Frontiers entitled “Direct 

and Inverse comorbidities between complex disorders” 

with the aim of helping to understand unexpected associations 

between apparently different diseases/illnesses. 

We have also published 7 original articles, with 

diverse perspectives ranging from epidemiology to 

bioinformatics, about diseases such as malaria, bipolar 

disorder, dementia (e.g. Alzheimer’s), Down’s syndrome, 

glioblastoma and lung cancer 

• To play an active role in defining a clinically useful position 

regarding Mild Cognitive Decline as members of 

the Cognitive Decline Group of the European Innovation 

Partnership for Active and Healthy Ageing (EIPAHA) 


• Study of neurocognitive endophenotypes in schizophrenia 

and bipolar disorder 

• Study of pharmacological strategies for improving cognitive 

function in bipolar disorder 

• Epidemiology and disability associated with TMG 

• Identification of biomarkers in TMG 

• Study of the direct and reverse comorbidity in TMG in 

relation to cancer and diabetes 

• Development and efficacy study of psychoeducation 

and neurocognitive therapy and functional rehabilitation 

for people with SMI 

• Establishment of a clinical staging system (ClinicalStaging) 

applied to bipolar disorder by the combination of 

biomarkers, neurocognitive and functional performance 



32 247,51 7,73 

National 


International 


Corresponding 

author 

19 13 4 


1. Catalá-López F, Hutton B, Núñez-Beltrán A, Mayhew AD, 

Page MJ, Ridao M, Tobías A, Catalá MA, Tabarés-Seisdedos 

R, Moher D. The pharmacological and non-pharmacological 

treatment of attention deficit hyperactivity disorder in 

children and adolescents: protocol for a systematic review 

and network meta-analysis of randomized controlled trials. 

Syst Rev. 2015 Feb 27 ;4(1):19.IF: 0 

2. Bonnín CM, Reinares M, Hidalgo-Mazzei D, Undurraga 

J, Mur M, Sáez C, Nieto E, Vázquez GH, Balanzá-Martínez 

V, Tabarés-Seisdedos R, Vieta E. Predictors of functional 

outcome after a manic episode.J Affect Disord. 2015 Aug 15 

;182:121-5.IF: 3,383 

3. Balanzá-Martínez V, Tabarés-Seisdedos R. The prevalence 

of bipolar disorders in the general population: a growing 

trending topic?Rev Bras Psiquiatr. 2015 Apr-Jun ;37(2):91-2. 

IF: 1,765 

4. Solé B, Bonnin CM, Mayoral M, Amann BL, Torres I, González- 

Pinto A, Jimenez E, Crespo JM, Colom F, Tabarés-Seisdedos 

R, Reinares M, Ayuso-Mateos JL, Soria S, García-Portilla MP, 

Ibañez Á, Vieta E, Martínez-Aran A, Torrent C, CIBERSAM 

Functional Remediation Group. Functional remediation for 

patients with bipolar II disorder: improvement of functioning 

and subsyndromal symptoms.Eur Neuropsychopharmacol. 

2015 Feb ;25(2):257-64.IF: 4,369 

5. Girón M, Nova-Fernández F, Mañá-Alvarenga S, Nolasco A, 

Molina-Habas A, Fernández-Yañez A, Tabarés-Seisdedos R, 

Gómez-Beneyto M. How does family intervention improve 

the outcome of people with schizophrenia?Soc Psychiatry 

Psychiatr Epidemiol. 2015 Mar ;50(3):379-87.IF: 2,537 

6. Ayesa-Arriola R, Alcaraz EG, Hernández BV, Pérez-Iglesias R, 

López Moríñigo JD, Duta R, David AS, Tabarés-Seisdedos R, 

Crespo-Facorro B. Suicidal behaviour in first-episode nonaffective 

psychosis: Specific risk periods and stage-related 

factors.Eur Neuropsychopharmacol. 2015 Dec ;25(12):2278- 

88.IF: 4,369 

7. Medel-Herrero A, Amate JM, Saz-Parkinson Z, Gómez- 

Beneyto M. Changing trends in hospitalization rates 

associated with psychosis: Spain, 1980-2009.Soc Psychiatry 

Psychiatr Epidemiol. 2015 Dec ;50(12):1843-55.IF: 2,537 

8. Soler MJ, Ruiz JC, Dasí C, Fuentes-Durá I. Implicit memory 

functioning in schizophrenia: explaining inconsistent 

findings of word stem completion tasks.Psychiatry Res. 

2015 Mar 30 ;226(1):347-51.IF: 2,467 

179

4 

Scientific 

activity 

180 

9. Feigin VL, Mensah GA, Norrving B, Murray CJ, Roth GA, 

GBD 2013 Stroke Panel Experts Group. Atlas of the Global 

Burden of Stroke (1990-2013): The GBD 2013 Study. 

Neuroepidemiology. 2015 ;45(3):230-6.IF: 2,784 

10. Krishnamurthi RV, Moran AE, Feigin VL, Barker-Collo S, 

Norrving B, Mensah GA, Taylor S, Naghavi M, Forouzanfar MH, 

Nguyen G, Johnson CO, Vos T, Murray CJ, Roth GA, GBD 2013 

Stroke Panel Experts Group. Stroke Prevalence, Mortality 

and Disability-Adjusted Life Years in Adults Aged 20-64 Years 

in 1990-2013: Data from the Global Burden of Disease 2013 

Study.Neuroepidemiology. 2015 ;45(3):190-202.IF: 2,784 

11. Krishnamurthi RV, deVeber G, Feigin VL, Barker-Collo S, 

Fullerton H, Mackay MT, O’Callahan F, Lindsay MP, Kolk A, Lo 

W, Shah P, Linds A, Jones K, Parmar P, Taylor S, Norrving B, 

Mensah GA, Moran AE, Naghavi M, Forouzanfar MH, Nguyen 

G, Johnson CO, Vos T, Murray CJ, Roth GA, GBD 2013 Stroke 

Panel Experts Group. Stroke Prevalence, Mortality and 

Disability-Adjusted Life Years in Children and Youth Aged 0-19 

Years: Data from the Global and Regional Burden of Stroke 

2013.Neuroepidemiology. 2015 ;45(3):177-89.IF: 2,784 

12. Feigin VL, Krishnamurthi RV, Parmar P, Norrving B, Mensah 

GA, Bennett DA, Barker-Collo S, Moran AE, Sacco RL, 

Truelsen T, Davis S, Pandian JD, Naghavi M, Forouzanfar 

MH, Nguyen G, Johnson CO, Vos T, Meretoja A, Murray CJ, 

Roth GA, GBD 2013 Writing Group, GBD 2013 Stroke Panel 

Experts Group. Update on the Global Burden of Ischemic 

and Hemorrhagic Stroke in 1990-2013: The GBD 2013 

Study.Neuroepidemiology. 2015 ;45(3):161-76.IF: 2,784 

13. GBD 2013 Risk Factors Collaborators, (et al). Global, regional, 

and national comparative risk assessment of 79 behavioural, 

environmental and occupational, and metabolic risks or 

clusters of risks in 188 countries, 1990-2013: a systematic 

analysis for the Global Burden of Disease Study 2013.Lancet. 

2015 Dec 5 ;386(10010):2287-323.IF: 44,002 

14. GBD 2013 DALYs and HALE Collaborators, (et al). Global, 

regional, and national disability-adjusted life years (DALYs) 

for 306 diseases and injuries and healthy life expectancy 

(HALE) for 188 countries, 1990-2013: quantifying 

the epidemiological transition.Lancet. 2015 Nov 28 

;386(10009):2145-91.IF: 44,002 

15. Hernández-Blanco B, Catala-López F. Are licensed canine 

parvovirus (CPV2 and CPV2b) vaccines able to elicit 

protection against CPV2c subtype in puppies?: A systematic 

review of controlled clinical trials.Vet Microbiol. 2015 Oct 

22 ;180(1-2):1-9.IF: 2,564 

16. Global Burden of Disease Cancer Collaboration, (et al). 

The Global Burden of Cancer 2013.JAMA Oncol. 2015 Jul 

;1(4):505-27.IF: 0 

17. Macías Saint-Gerons D, de la Fuente Honrubia C, González 

Bermejo D, Montero D, Gil MJ, Salvador Sanz A, de Andrés- 

Trelles F, Catalá-López F. [Clinical-Epidemiological Profile 

of Patients Initiating Intensive Statin Therapy for the 

Secondary Prevention of Vascular Disease in Spain].Rev Esp 

Salud Publica. 2015 Apr ;89(2):159-71.IF: 0,606 

18. Catalá-López F, Corrales I, de la Fuente-Honrubia C, González- 

Bermejo D, Martín-Serrano G, Montero D, Saint-Gerons DM. 

Risk of thromboembolism with thrombopoietin receptor 

agonists in adult patients with thrombocytopenia: Systematic 

review and meta-analysis of randomized controlled trials. 

Med Clin (Barc). 2015 Dec 21 ;145(12):511-9.IF: 1,267 

19. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, 

Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow 

C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman 

DG, Moher D. The PRISMA extension statement for reporting 

of systematic reviews incorporating network meta-analyses 

of health care interventions: checklist and explanations.Ann 

Intern Med. 2015 Jun 2 ;162(11):777-84.IF: 16,44 

20. Catalá-López F, González-Bermejo D, de la Fuente Honrubia 

C, Macías Saint-Gerons D. [Clinical equipoise and systematic 

reviews of randomized controlled trials].Med Clin (Barc). 

2015 Dec 7 ;145(11):496-8.IF: 1,267 

21. Fernández de Larrea-Baz N, Morant-Ginestar C, Catalá- 

López F, Gènova-Maleras R, Álvarez-Martín E. Disabilityadjusted 

Life Years Lost to Ischemic Heart Disease in Spain. 

Rev Esp Cardiol (Engl Ed). 2015 Nov ;68(11):968-75.IF: 0 

22. GBD 2013 Mortality and Causes of Death Collaborators. 

Global, regional, and national age-sex specific all-cause and 

cause-specific mortality for 240 causes of death, 1990-2013: 

a systematic analysis for the Global Burden of Disease Study 

2013.Lancet. 2015 Jan 10 ;385(9963):117-71.IF: 44,002 

23. Catalá-López F, Fernández de Larrea-Baz N, Morant-Ginestar 

C, Álvarez-Martín E, Díaz-Guzmán J, Gènova-Maleras R. The 

national burden of cerebrovascular diseases in Spain: a 

population-based study using disability-adjusted life years. 

Med Clin (Barc). 2015 Apr 20 ;144(8):353-9.IF: 1,267 

Letters 

24. Catalá-López F, Tabarés-Seisdedos R. Alzheimer’s disease 

and cancer: the need of putting research into context with


4 

previous published systematic reviews.J Cancer Res Clin Oncol. 

2015 Mar ;141(3):569-70.IF: 3,081 

25. Greciano V, Macías Saint-Gerons D, González-Bermejo 

D, Catalá-López F. Antihypertensive Medication: On the 

Right Path? Response.Rev Esp Cardiol (Engl Ed). 2015 Dec 

;68(12):1191-2.IF: 4,596 

26. Greciano V, Macías Saint-Gerons D, González-Bermejo D, 

Montero D, Catalá-López F, de la Fuente Honrubia C. Use of 

Antihypertensive Drugs in Spain: National Trends From 2000 

to 2012.Rev Esp Cardiol (Engl Ed). 2015 Oct ;68(10):899- 

903.IF: 0 

27. Saint-Gerons DM, Honrubia Cde L, Montero D, González- 

Bermejo D, de Andrés-Trelles F, Catalá-López F. Statins use 

and risk of cataracts: firm conclusions are still far off.J Cardiovasc 

Pharmacol Ther. 2015 May ;20(3):344-5.IF: 2,538 

28. Macías Saint-Gerons D, de la Fuente Honrubia C, de Andrés- 

Trelles F, Catalá-López F. [Primary prevention of cardiovascular 

diseases with statins in patients with diabetes].Med 

Clin (Barc). 2015 Mar 15 ;144(6):285-7.IF: 1,267 

29. Aleixandre-Benavent R, Alonso-Arroyo A, Vidal-Infer A, Catalá-López 

F. [Promotion of public access and share of raw 

data from scientific research].Med Clin (Barc). 2015 Mar 15 

;144(6):283-4.IF: 1,267 

Editorial 

30. Catalá-López F, González-Bermejo D. [Cost-effectiveness 

analysis in the management of arterial hypertension].Hipertens 

Riesgo Vasc. 2015 Apr-Jun ;32(2):45-7.IF: 0 

Review 

31. Barker-Collo S, Bennett DA, Krishnamurthi RV, Parmar P, 

Feigin VL, Naghavi M, Forouzanfar MH, Johnson CO, Nguyen 

G, Mensah GA, Vos T, Murray CJ, Roth GA, GBD 2013 

Writing Group, GBD 2013 Stroke Panel Experts Group. 

Sex Differences in Stroke Incidence, Prevalence, Mortality 

and Disability-Adjusted Life Years: Results from the Global 

Burden of Disease Study 2013.Neuroepidemiology. 2015 

;45(3):203-14.IF: 2,784 

32. Global Burden of Disease Study 2013 Collaborators. Global, 

regional, and national incidence, prevalence, and years 

lived with disability for 301 acute and chronic diseases and 

injuries in 188 countries, 1990-2013: a systematic analysis 

for the Global Burden of Disease Study 2013.Lancet. 2015 

Aug 22 ;386(9995):743-800.IF: 44,002 


RESEARCH 


Title: Identificación y validación de biomarcadores periféricos 

para el déficit neurocognitivo en el trastorno bipolar, 

depresión, esquizofrenia y diabetes. 

Principal Investigator: Rafael Tabarés Seisdedos 







Title: Understanding obesity (ob), metabolic syndrome (mets), 

type 2 diabetes (t2dm) and fatty liver disease (fl): a multidisciplinary 

approach. 

Principal Investigator: José María Mato De La Paz (as collaborating 

researcher Rafael Tabarés Seisdedos) 


Beneficiary Institution: CIBERSAM 



Reference: PROMETEOII /2015/021 

Title: INverse and direct CANCER comorbidity in people with 

Central Nervous System disorders: from drug repurposing to 

effective strategies for cancer prevention (INCANCER/CNSd) 


Funding Body: Conselleria de Educación Cultura y Deporte 

Beneficiary Institution: Universitat de València 



Reference: IntraCIBER2015 

Title: CANCER comorbidity in people with Central Nervous 

System disorders 


Funding Body: CIBER 

Beneficiary Institution: CIBERSAM 



181

4 

Scientific 

activity 

4.1.4 Reproductive medicine area 

Research Group on Women Health 181 

Research Group on Stem Cells Applied to Reproduction, Embryo Viability and Endometrial Receptivity 184 

Research Group on Male Infertility and Embrionary Stimulation 191 

Impact 

Factor (IF) 

Total: 375,87 

Average: 4,75 

80 

Publications 

31 

International 


182 

JCR: 

1 in D1 

60 in Q1 

7 in Q2 

Author: 




author


4 

Research Group on Women Health. 


183 

“Nuestro objetivo es crear mecanismos para que podamos avanzar en la reducción de la vulnerabilidad 

frente a la enfermedad o, incluso, a la muerte” 

Antonio Cano. Valencia Económica. 11/05/2015 

Group members 


Antonio Cano Sánchez 

University 

H Index: 26 


Juan José Tarín Folgado. University 


Raúl Gómez Gallego. INCLIVA 

Technician 

Rosa Aliaga Corachán. University

4 

Scientific 

activity 

184 


• Vitamin D in women’s health. We have continued with 

the inclusion of the cohort, which has already reached 

1200 participants. To extend the study of bone metabolism 

during pregnancy 

• Postmenopausal osteoporosis: role of the calcium sensor 

receptor in the osteo-formation and osteoblastogenesis. 

Intervention with calcium sensor receptor has 

been discarded in its actions on bone bone-forming cells 

• Initial aterogenesis and gonadal steroids. Experiences 

have been completed in ApoE mutated mice. To publish 

a systematic review on bone metabolism in pregnancy 

• Gonadal protection in pre-menopausal women treated 

with chemotherapy. Progress has been made in the cohort 

inclusion process, which is now close to 100 members. 

To include endocrine studies in a database 


• In the postmenopausal osteoporosis field, to analyze 

the role of calcium sensing receptor in bone formation 

and osteoclastogenesis and to study calcium and vitamin 

D supplementation and its impact on bone metabolism 

• With regard to endometriosis: 

·To analyze the role of microRNA and vascularization 

regulators and pain mechanisms. Role of the TNF cytokine 

family 

·To analyze the initial atherogenesis and selective estrogen 

receptor modulators 

·To study the role of vitamin D in women’s health 

·To determine the general and cognitive frailty on women 


Raúl Gómez Gallego 

Raúl Gómez´s lines of research are 

focused on dissecting how deregulation 

of the angiogenic component is 

related to the onset and maintenance 

of gynecological disorders such us endometriosis, 

ovarian hyperstimulation 

syndrome, recurrent miscarriage or preeclampsia. We routinely 

employ animal models to mimic human disorders in which the 

effects of drugs are non-invasively assessed by monitorization of 

signal emitted by fluorescently or bioluminiscently labeled xenografted 

pathological tissue. We are also interested in developing 

test for the early non-invasive diagnosis of endometriosis through 

combined analysis of multiple biomarkers simultaneously. 



13 33,397 2,56 

National 



International 


Corresponding 

author 

6 2 12 

1. Sanz-Salvador L, García-Pérez MÁ, Tarín JJ, Cano A. 

ENDOCRINOLOGY IN PREGNANCY: Bone metabolic changes 

during pregnancy: a period of vulnerability to osteoporosis and 

fracture.Eur J Endocrinol. 2015 Feb ;172(2):R53-R65.IF: 4,069 

2. Artero A, Artero A, Tarín JJ, Cano A. The impact of moderate 

wine consumption on health.Maturitas. 2015 Jan ;80(1):3- 

13.IF: 2,942 

3. Darocas M, Ruiz N, Bergoglio MT, Cano A. A decision 

dilemma: Cushing syndrome during pregnancy.J Obstet 

Gynaecol. 2015 Jan ;35(1):93-4.IF: 0,551 

4. Tarín JJ, García-Pérez MA, Hamatani T, Cano A. Infertility 

etiologies are genetically and clinically linked with other 

diseases in single meta-diseases.Reprod Biol Endocrinol. 

2015 Apr 15 ;13(1):31.IF: 2,226 

5. Panach L, Mifsut D, Tarín JJ, Cano A, García-Pérez MÁ. Serum 

Circulating MicroRNAs as Biomarkers of Osteoporotic 


6. Castro A, González M, Tarín JJ, Cano A. [Role of probiotics 

in Obstetrics and Gynecology].Nutr Hosp. 2015 Feb 7 ;31 

Suppl 1:26-30.IF: 1,04 

7. Fernández-Murga ML, Vinué Á, Caeiro JR, Guede D, Tarín JJ, 

Andrés V, Cano A. Impact of estrogens on atherosclerosis 

and bone in the apolipoprotein E-deficient mouse model. 

Menopause. 2015 Apr ;22(4):428-36.IF: 3,361 




Bone. 2015 Nov 7 ;83:94-103.IF: 3,973 

9. Cano A, Gómez R. Mir-661: A key Factor in Embryo- 

Maternal dialog With Potential Clinical Application to 

Predict Implantation Outcome?EBioMedicine. 2015 Oct 

;2(10):1312-3.IF: 0


4 

Letter 

10. Raga F, Llinares C, Cholvi S, Bonilla F, Pascual C, Cano A. 

HDlive imaging of cystic uterine leiomyma degeneration. 

Ultrasound Obstet Gynecol. 2015 Aug 19 ;.IF: 3,853 

Review 

11. Tarín JJ, García-Pérez MA, Cano A. Deficiencies in reporting 

results of lesbians and gays after donor intrauterine 

insemination and assisted reproductive technology 

treatments: a review of the first emerging studies.Reprod 

Biol Endocrinol. 2015 May 29 ;13(1):52.IF: 2,226 

Editorial 

12. Cano A, Simoncini T, Rees M. Personalized health care for 

midlife and beyond.Maturitas. 2015 Sep ;82(1):1-2.IF: 2,942 

13. Cano A. Cognitive frailty, a new target for healthy ageing. 

Maturitas. 2015 Oct ;82(2):139-40.IF: 2,942 


RESEARCH 


Title: Activación del receptor sensor del calcio por sales de 

calcio y vitamina D. Estudio básico y clínico 

Principal Investigator: Antonio Cano Sánchez 






Title: Efectos de la inactivación de CD276 y activación de 

CD137 sobre el tamaño de las lesiones y el dolor en la 

endometriosis 

Principal Investigator: Raúl Gómez Gallego 







Title: Global multivariant analysis of putative biomarkers 

identified through combined multi-technical approach for the 

non-invasive detection of endometriosis 









Title: Evaluación del papel terapéutico de la inhibición del 

PAI-1 sobre la endometriosis humana en un modelo murino 

heterólogo 






Duration: 2014 - 2015 


Reference: FOCUS 

Title: Frailty management Optimisation though EIP AHA 

Commitments and Utilisation of Stakeholders input. 

Principal Investigator: Antonio Cano Sánchez (Juan José Tarín 

and Miguel Ángel García Pérez as collaborating researchers) 

Funding body: Comisión Europea- DG SANCO. 


Duration: 2015-2018. 


• THESIS 

Thesis title: Papel de la vitamina D durante el embarazo: su 

influencia en la etapa fetal. 

Doctoral candidate: Lorena Sabonet Morente 

Director(s): Antonio Cano Sánchez, Juan José Tarín Folgado, 

María Reyes Balanza Chancosa 



Thesis title: Efectos del tratamiento con agonistas 

dopaminérgicos sobre las lesiones endometriósicas 

Doctoral candidate: Sílvia Tamarit Bordes 

Director(s): Antonio Pellicer Martínez, Raúl Gómez Gallego, 

José Bellver Pradas 



185

4 

Scientific 

activity 

Research Group on Stem Cells Applied to Reproduction, Embryo Viability and Endometrial 

Receptivity 


186 

“No se trata de disponer de bebés a la carta, este tema no es trivial, estamos hablando de poder 

corregir enfermedades que causan sufrimiento y muerte”. 

Carlos Simón. Encuentros de Excelencia de VLC/Campus. 1-7-2015. 

http://www.carlos-simon.com/es/ 

Group members 


Carlos Simón Vallés 

IVI. University 

H Index: 61 


Amparo Mercader Bayarri. IVI 

Ana Cristina Cerveró Sanz. IVI 

María José de los Santos Molina. IVI 

Tamara Garrido Gómez. IVI 

Alicia Quiñonero Villora. IVI 

Xavier Santamaría Costa. IVI 

Hortensia Ferrero Cháfer. INCLIVA 

Diana Valbuena Perilla. IVI 

Pilar Alamá Faubel. IVI 

Marta Gonzalo Moja. IVI 

Mª Amparo Faus Esteve. IVI 

José Bellver Pradas. IVI 

Ernesto Bosch Aparicio. IVI 

David Blesa Jarque. IVI 

Inmaculada Moreno Gimeno. IVI 

Patricia Díaz Gimeno. IVI 

Elena Labarta Demur. IVI 

Antonio Díez Juan. IVI


4 


Francisco Domínguez Hernández. INCLIVA 

Irene Cervelló Alcaraz. IVI 

Felip Vilella Mitjana. INCLIVA 

PhD students 

Nuria Balaguer Cuenca. University. 

José Manuel Mínguez Forján. University 

Anna Buigues Monfort. University 

Stefania Salsano. INCLIVA 

Alessia Grasso. INCLIVA 

Hannes Marcus Campo. IVI 

Silvia Pérez Deben. University 

Nuria López Pérez. University 

Technician 

María Herrero Baena. INCLIVA 


• Our research was focused on two main objectives: (1) 

The identification of specific SSCs markers described in 

the human endometrium in the last ten years (W5C5, 

ICAM, PDGF, CD146, CD133 and Side Population) by in 

vitro and in vivo experiments; and (2) to investigate cell 

therapies using stem cells derived from bone marrow as 

well as their secreted paracrine factors to regenerate the 

endometrium in endometrial pathologies 

• We have performed a comparative proteomic analysis 

using I-TRAQ technique to determine the protein expression 

profile of receptive endometria coming from fertile 

donors, with refractory endometrium coming from patients 

with and IUD and finally patients with Recurrent 

Implantation Failure (RIF). Thus proteomic comparative 

will allow us to design and develop and interactome of 

the endometrial receptivity, knowing the most important 

proteins for the acquisition of this vital ability of the endometrium 

to achieve a correct implantation 

• We currently start to analyze by arrays the first set of 

samples collected 8 control patients (8 samples obtained 

in the phase of the cycle LH+2 and 8 samples in 

LH+7) and 6 obese patients. The disparity in the number 

of samples within each study group is associated 

to the difficulty of collecting endometrial fluid from the 

patients suffering obesity. Regardless of this setback 

and with the aim to identify a miRNA profile intrinsically 

linked to the transfer of obesity from mothers to 

offspring, two approximations in the “in silico” analyses 

of the raw data obtained were done. We are recruiting 

more patients 


• Adult stem cells in the human endometrium 

• Study of endometrial proteomics and embryo viability 

• Study of endometrial receptivity 


Irene Cervelló Alcaraz 

Research is based on the identification, 

characterization and isolation of 

Somatic Stem Cells in the endometrium. 

Endometrial Stem Cells have 

been identified in human and murine 

models, the regenerative potential of these cells has been proven 

and there is an ongoing research on the existence of Lgr5 

marker in the endometrial tissue. 

Moreover, the work is also focused on essential processes 

based on the regenerative medicine related with the porcine 

and human uterus. 


Felip Vilella Mitjana 

The research line of Endometrial Receptivity 

is based on the study of endometrial 

secretions, specifically the 

endometrial fluid. 

We use secretomic and genomic 

approach so we can describe new molecules that can be correlated 

with the days of the menstrual cycle and may be involved 

in obtaining the window of implantation period, opening 

a new field of study for the analysis of the changes in the endometrium 

during the menstrual cycle and the cross-talk between 

the embryo and the endometrium. 

We have demonstrated that human endometrial epithelium 

secretes specific microRNAs (miRNAs) during the time frame 

when the embryo enters the uterine cavity and initiates its ad- 

187

4 

Scientific 

activity 

188 

hesion to the uterine wall. Maternal miRNAs are secreted to 

the endometrial fluid, transported through exosomes or bound 

to proteins, and are uptaken by the preimplantation embryo, 

before implantation occurs, suffering thus transcriptomic 

modifications that induce profound molecular and functional 

changes. 


Francisco Domínguez Hernández 

Francisco Dominguez, Ph.D is principal 

investigator in the Reproductive 

Medicine group at INCLIVA. He was 

doctorate in 2003 at Valencia University 

at Carlos Simón´s lab focusing its 

research career in the molecular biology of implantation and 

the search of biomarkers of endometrial receptivity. He is reviewer 

of several leading journals in reproductive medicine and 

has more than 35 peer reviewed papers and 15 book chapters 

specialized in the reproductive medicine. He has also been the 

Chief Scientific Officer of Embryomics, a technology-based company 

devoted to the development of non-invasive diagnostics 

of chromosome abnormalities in the pre-implantation embryo 

using metabolomic techniques and he is actually acting as associate 

editor of the Human Reproduction journal, the first original 

article journal specialized in reproductive medicine. 



40 215,23 5,38 

National 



International 


Corresponding 

author 

14 19 23 

1. Galliano D, Bellver J, Díaz-García C, Simón C, Pellicer A. 

ART and uterine pathology: how relevant is the maternal 

side for implantation?Hum Reprod Update. 2015 Jan-Feb 

;21(1):13-38.IF: 10,165 

2. Gómez E, Ruíz-Alonso M, Miravet J, Simón C. Human 

Endometrial Transcriptomics: Implications for Embryonic 

Implantation.Cold Spring Harb Perspect Med. 2015 Mar 27 

;5(7):a022996.IF: 9,469 

3. Gil-Sanchis C, Cervelló I, Khurana S, Faus A, Verfaillie C, Simón 

C. Contribution of different bone marrow-derived cell types 

in endometrial regeneration using an irradiated murine 

model.Fertil Steril. 2015 Jun ;103(6):1596-605.e1.IF: 4,59 

4. Mas A, Nair S, Laknaur A, Simón C, Diamond MP, Al-Hendy 

A. Stro-1/CD44 as putative human myometrial and fibroid 

stem cell markers.Fertil Steril. 2015 Jul ;104(1):225-34. 

e3.IF: 4,59 

5. Aleixandre-Benavent R, Simón C, Fauser BC. Trends in 

clinical reproductive medicine research: 10 years of growth. 

Fertil Steril. 2015 Jul ;104(1):131-7.e5.IF: 4,59 

6. Díez-Juan A, Simón C. Converting a Problem into an 

Opportunity: mtDNA Heteroplasmy Shift.Cell Stem Cell. 

2015 May 7 ;16(5):457-8.IF: 22,268 

7. Martínez-Arroyo AM, Míguez-Forján JM, Remohí J, Pellicer 

A, Medrano JV. Understanding Mammalian Germ Line 

Development with In Vitro Models.Stem Cells Dev. 2015 Sep 

15 ;24(18):2101-13.IF: 3,727 

8. Garrido N, Bosch E, Alamá P, Ruiz A. The time to prevent 

mendelian genetic diseases from donated or own gametes 

has come.Fertil Steril. 2015 Oct ;104(4):833-5.IF: 4,59 

9. Díez-Juan A, Rubio C, Marin C, Martínez S, Al-Asmar N, Riboldi 

M, Díaz-Gimeno P, Valbuena D, Simón C. Mitochondrial DNA 

content as a viability score in human euploid embryos: less 

is better.Fertil Steril. 2015 Sep ;104(3):534-41.e1.IF: 4,59 

10. Campos-Galindo I, García-Herrero S, Martínez-Conejero JA, 

Ferro J, Simón C, Rubio C. Molecular analysis of products of 

conception obtained by hysteroembryoscopy from infertile 

couples.J Assist Reprod Genet. 2015 May ;32(5):839-48.IF: 

1,718 

11. Dominguez F, Meseguer M, Aparicio-Ruiz B, Piqueras P, 

Quiñonero A, Simón C. New strategy for diagnosing embryo 

implantation potential by combining proteomics and timelapse 

technologies.Fertil Steril. 2015 Oct ;104(4):908-14.IF: 

4,59 

12. Serra V, Bellver J, Garrido N. Doubtful association between 

progesterone therapy and fetal nuchal translucency.Am J 

Obstet Gynecol. 2015 Sep ;213(3):437.IF: 4,704 

13. Kova B, Plas C, Woodward BJ, Verheyen G, Prados FJ, 

Hreinsson J, De Los Santos MJ, Magli MC, Lundin K, Plancha 

CE. The educational and professional status of clinical 

embryology and clinical embryologists in Europe†.Hum 

Reprod. 2015 Aug ;30(8):1755-62.IF: 4,569


4 

14. Bellver J, De Los Santos MJ, Alamá P, Castelló D, Privitera 

L, Galliano D, Labarta E, Vidal C, Pellicer A, Domínguez F. 

Day-3 embryo metabolomics in the spent culture media is 

altered in obese women undergoing in vitro fertilization. 

Fertil Steril. 2015 Jun ;103(6):1407-15.e1.IF: 4,59 

15. Moreno JM, Núñez MJ, Quiñonero A, Martínez S, de la 

Orden M, Simón C, Pellicer A, Díaz-García C, Domínguez F. 

Follicular fluid and mural granulosa cells microRNA profiles 

vary in in vitro fertilization patients depending on their 

age and oocyte maturation stage.Fertil Steril. 2015 Oct 

;104(4):1037-1046.e1.IF: 4,59 

16. Rekker K, Saare M, Roost AM, Kaart T, Sõritsa D, Karro H, 

Sõritsa A, Simón C, Salumets A, Peters M. Circulating 

miR-200-family micro-RNAs have altered plasma levels in 

patients with endometriosis and vary with blood collection 

time.Fertil Steril. 2015 Oct ;104(4):938-946.e2.IF: 4,59 

17. Vassena R, Eguizabal C, Heindryckx B, Sermon K, Simón C, 

van Pelt AM, Veiga A, Zambelli F, ESHRE special interest 

group Stem Cells. Stem cells in reproductive medicine: 

ready for the patient?Hum Reprod. 2015 Sep ;30(9):2014- 

21.IF: 4,569 

18. Vera-Rodriguez M, Chavez SL, Rubio C, Pera RA, Simón C. 

Prediction model for aneuploidy in early human embryo 

development revealed by single-cell analysis.Nat Commun. 

2015 Jul 7 ;6:7601.IF: 11,47 

19. Bosch E, Nyboe Andersen A, Barri P, García-Velasco JA, de Sutter 

P, Fernández-Sánchez M, Visnova H, Klein BM, Mannaerts B, 

Arce JC. Follicular and endocrine dose responses according to 

anti-Müllerian hormone levels in IVF patients treated with a 

novel human recombinant FSH (FE 999049).Clin Endocrinol 

(Oxf). 2015 Dec ;83(6):902-12.IF: 3,457 

20. Anderson RA, Anckaert E, Bosch E, Dewailly D, Dunlop CE, 

Fehr D, Nardo L, Smitz J, Tremellen K, Denk B, Geistanger A, 

Hund M. Prospective study into the value of the automated 

Elecsys antimüllerian hormone assay for the assessment 

of the ovarian growing follicle pool.Fertil Steril. 2015 Apr 

;103(4):1074-1080.e4.IF: 4,59 

21. Bosch E. High responders and patients with a good prognosis 

are not immune to the negative impact on live birth rate 

of elevated P on the day of triggering.Fertil Steril. 2015 Jun 

;103(6):1423.IF: 4,59 

22. Mendoza R, Perez S, de Los Santos MJ, Larreategui Z, Ayerdi 

F, Expósito A, Burgos J, Martínez Indart L, Pijoan JI, Matorras 

R. Congenital malformations, chromosomal abnormalities 

and perinatal results in IVF/ICSI newborns resulting from 

very poor quality embryos: a case-control study.Gynecol 

Obstet Invest. 2015 ;79(2):83-9.IF: 1,696 

23. Mas A, Cervelló I, Fernández-Álvarez A, Faus A, Díaz A, 

Burgués O, Casado M, Simón C. Overexpression of the 

truncated form of High Mobility Group A proteins (HMGA2) 

in human myometrial cells induces leiomyoma-like tissue 

formation.Mol Hum Reprod. 2015 Apr ;21(4):330-8.IF: 3,747 

24. Thouas GA, Dominguez F, Green MP, Vilella F, Simón C, 

Gardner DK. Soluble ligands and their receptors in human 

embryo development and implantation.Endocr Rev. 2015 

Feb ;36(1):92-130.IF: 21,059 

25. García-Pascual CM, Martínez J, Calvo P, Ferrero H, Villanueva 

A, Pozuelo-Rubio M, Soengas M, Tormo D, Simón C, Pellicer 

A, Gómez R. Evaluation of the potential therapeutic effects of 

a double-stranded RNA mimic complexed with polycations 

in an experimental mouse model of endometriosis.Fertil 

Steril. 2015 Nov ;104(5):1310-8.IF: 4,59 

26. Cervelló I, Santamaría X, Miyazaki K, Maruyama T, Simón C. 

Cell Therapy and Tissue Engineering from and toward the 

Uterus.Semin Reprod Med. 2015 Sep ;33(5):366-72.IF: 2,352 

27. Vilella F, Moreno-Moya JM, Balaguer N, Grasso A, Herrero 

M, Martínez S, Marcilla A, Simón C. Hsa-miR-30d, secreted 

by the human endometrium, is taken up by the preimplantation 

embryo and might modify its transcriptome. 

Development. 2015 Sep 15 ;142(18):3210-21.IF: 6,462 

28. García NA, Ontoria-Oviedo I, González-King H, Díez-Juan 

A, Sepúlveda P. Glucose Starvation in Cardiomyocytes 

Enhances Exosome Secretion and Promotes Angiogenesis in 

Endothelial Cells.PLoS One. 2015 ;10(9):e0138849.IF: 3,234 

29. García-Velasco JA, Fassbender A, Ruiz-Alonso M, Blesa 

D, D’Hooghe T, Simón C. Is endometrial receptivity 

transcriptomics affected in women with endometriosis? A 

pilot study.Reprod Biomed Online. 2015 Nov ;31(5):647-54. 

IF: 3,015 

30. Cervelló I, Gil-Sanchis C, Santamaría X, Cabanillas S, Díaz A, 

Faus A, Pellicer A, Simón C. Human CD133(+) bone marrowderived 

stem cells promote endometrial proliferation in a 

murine model of Asherman syndrome.Fertil Steril. 2015 Dec 

;104(6):1552-1560.e3.IF: 4,59 

31. Ferrero H, García-Pascual CM, Pellicer N, Simón C, Pellicer 

A, Gómez R. Dopamine agonist inhibits vascular endothelial 

189

4 

Scientific 

activity 

190 

growth factor protein production and secretion in granulosa 

cells.Reprod Biol Endocrinol. 2015 Sep 17 ;13:104.IF: 2,226 

32. Martín J, Asan, Yi Y, Alberola T, Rodríguez-Iglesias B, Jiménez- 

Almazán J, Li Q, Du H, Alama P, Ruiz A, Bosch E, Garrido N, 

Simón C. Comprehensive carrier genetic test using nextgeneration 

deoxyribonucleic acid sequencing in infertile 

couples wishing to conceive through assisted reproductive 

technology.Fertil Steril. 2015 Nov ;104(5):1286-93.IF: 4,59 

33. Kawamura K, Cheng Y, Sun YP, Zhai J, Díaz-García C, Simón C, 

Pellicer A, Hsueh AJ. Ovary transplantation: to activate or not 

to activate.Hum Reprod. 2015 Nov ;30(11):2457-60.IF: 4,569 

34. Zdravkovic T, Nazor KL, Larocque N, Gormley M, Donne M, 

Hunkapillar N, Giritharan G, Bernstein HS, Wei G, Hebrok 

M, Zeng X, Genbacev O, Mattis A, McMaster MT, Krtolica A, 

Valbuena D, Simón C, Laurent LC, Loring JF, Fisher SJ. Human 

stem cells from single blastomeres reveal pathways of 

embryonic or trophoblast fate specification.Development. 

2015 Dec 1 ;142(23):4010-25.IF: 6,462 

35. Martínez-Varea A, Pellicer B, Serra V, Hervás-Marín D, 

Martínez-Romero A, Bellver J, Perales-Marín A, Pellicer A. 

The Maternal Cytokine and Chemokine Profile of Naturally 

Conceived Gestations Is Mainly Preserved during In Vitro 

Fertilization and Egg Donation Pregnancies.J Immunol Res. 

2015 ;2015:128616.IF: 0 

36. de Los Santos MJ, Gámiz P, de Los Santos JM, Romero 

JL, Prados N, Alonso C, Remohí J, Dominguez F. The 

Metabolomic Profile of Spent Culture Media from Day-3 

Human Embryos Cultured under Low Oxygen Tension.PLoS 

One. 2015 ;10(11):e0142724.IF: 3,234 

37. García-Velasco JA, Bosch E. The necessity to define the suboptimal 

responders.Hum Reprod. 2015 Dec ;30(12):2958.IF: 

4,569 

Editorial 

38. Simón C, Sakkas D, Gardner DK, Critchley HO. Biomarkers 

in reproductive medicine: the quest for new answers.Hum 

Reprod Update. 2015 Nov ;21(6):695-7.IF: 10,165 

Review 

39. Miravet-Valenciano JA, Rincon-Bertolin A, Vilella F, Simón C. 

Understanding and improving endometrial receptivity.Curr 

Opin Obstet Gynecol. 2015 Jun ;27(3):187-92.IF: 2,067 

40. Moreno I, Míguez-Forjan JM, Simón C. Artificial gametes from 

stem cells.Clin Exp Reprod Med. 2015 Jun ;42(2):33-44.IF: 0 

• THESIS 

Thesis title: Patrón de decidualización en mujeres con preeclampsia 

mediante la aplicación de métodos de transcriptómica 

y proteómica 

Doctoral candidate: Pablo Padilla Iserte 

Director(s): Alfredo Perales Marín, Carlos Simón Vallés 




RESEARCH 

Reference: SARM 324509 

Title: Endometrial and Embryonic Genomics, Searching for 

Biomarkers in Assisted Reproduction 

Funding body: European Commission (Marie Curie Program) 

Principal Investigator: Carlos Simón Vallés 

Beneficiary institution: Igenomix 

Duration: 2013 - 2015 


Reference: E6478-NOTED 

Title: Non-invasive Tests for Endometrial Dysfunction – 

Novel Clinical Perspectives for Infertility and Endometriosis 

Diagnostics 

Funding body: European Comission (Eurostars-Eureka 

Programme) 


Beneficiary institution: Igenomix 

Duration: 2013 - 2015 


Reference: PROMETEO II/2013/018 

Title: Isolation and characterization of endometrial somatic 

stem cells in endometriosis. Pathogenic and therapeutic 

implications. Identification of Endometrial Stem Cell Markers. 

From Animal Models to Human Endometrial Stem Cell Therapy 







4 

Reference: SAF 2012/31017 

Title: Demostración de que Leucine-rich repeat-containing 

G-protein coupled receptor 5(Lgr5) es un marcador de células 

madre endometriales. Desde los modelos animales hasta su 

contribución en terapia celular e ingeniería tisular 








Title: Nuevas terapias en el abordaje del Síndrome de 

Asherman y atrofia endometrial basadas en transplante 

autólogo de células madre de médula ósea 


Funding body: Ministerio de Sanidad, Servicios Sociales e 

Igualdad 





Reference: Grant for Fertility Innovation 

Title: Analysis of miRNAs in endometrial fluid as a tool for 

noninvasive diagnosis of endometrial receptivity 


Funding Body: EMD Serono Research Institute, Inc. 

Beneficiary institution: Fundación IVI 




Title: Descripción del perfil proteómico endometrial del Fallo 

de Implantación recurrente. Creación del interactoma del fallo 

de implantación 

Principal Investigator: Francisco Domínguez Hernández 







Title: Diagnostic tool to predict obesity and T2D in offspring. 

Role of maternal miRNAs on the transmission of obesity and 

type 2 diabetes to the embryo 

Principal Investigator: Felipe Vilella Mitjana 







Title: Global multivariant analysis of putative biomarkers 

identified through combined multi-technical approach for the 

non-invasive detection of endometriosis 








Title: Desarrollo de una herramienta diagnóstica de fallo de 

implantación. Descripción del perfil proteómico y definición del 

interactoma del fallo de implantación 


Funding Body: ISCA - Instituto de Salud Carlos III 





Title: Expresión, localización y estudio funcional de la proteína 

PGRMC1 (Progesterone Receptor Membrane Component 1) en 

el endometrio 








Reference: GV/2013/136 

Title: Análisis de miRNAs en fluido endometrial como 

diagnóstico no invasivo de receptividad endometrial 


Funding Body: Generalitat Valenciana 


191

4 

Scientific 

activity 






Title: Reconstrucción del endometrio humano a través de 

xenotrasplante de células madre (LGR5+) en el modelo de 

ratón NOD-SCID 

Principal Investigator: Irene Cervelló Alcaraz 







The regeneration, proliferation, differentiation and regression processes 

in the human endometrium could be due to the presence of SSCs in 

the epithelial and stromal fractions (from Cervelló et al., 2011). 

192 



Title: Identificación de miRNAs secretados al liquido 

endometrial en pacientes con obesidad y diabetes tipo 2 








Venn diagram of the miRNAs differentially expressed associated to the 

LH variable. 

• AWARDS: 

In 2015 Felipe Vilella was awarded with the New Investigator 

Plenary Session Award by the Society for Reproductive Investigation 

(SRI) in the 62 nd Annual Meeting in San Francisco (USA). 

Moreover Aymara Más received the Best New Investigator Poster 

Award by Society for Reproductive Investigation (SRI) in the 

62nd Annual Meeting in San Francisco (USA). 

I-TRAQ comparative proteomic study design, comparing receptive endometria


4 

Research Group on Male Infertility and Embrionary Stimulation 


193 

“Congela tu tiempo, preserva tu futuro y conserva tus sueños”. 

José Remohí. Posted by Official Press Date: 16 junio, 2015 

Group members 


José Remohí Giménez 

IVI. University 

H Index: 57 


Amparo Ruiz Jorro. IVI 

Carmen Rubio Lluesa. IVI 

Jaime Ferro Camargo. IVI 

Jose Antonio Martínez Conejero. IVI 

Rocío Rivera Egea. INCLIVA 

Lorena Rodrigo Vivó. IVI 

Inmaculada Campos Galindo. IVI 

José María de los Santos Molina. IVI 

Tamara Viloria Samochín. IVI 

Mª del Carmen Vidal Martínez. IVI 

Juan Giles Jiménez. IVI 


Marcos Meseguer Escrivá. IVI 

Nicolás Garrido Puchalt. IVI

4 

Scientific 

activity 

194 


• Our results obtained by inducing the exogenous 

expression of a combination of selected key germ 

cell developmental factors over human somatic 

cells demonstrate the ability of human male somatic 

cells to directly convert into a meiotic germlike 

phenotype. Nevertheless, our study must be 

considered an initial attempt to create an in vitro 

model for the direct conversion of somatic cells 

from patients with gamete-alterations production 

into germ cells in vitro, opening the field to discover 

new cell therapies to treat them in the future. 

• Based on a pilot study that we carried out with 17 

infertile couples of oocyte donation program, we 

have settled down an initial model with potential 

diagnostic which combines embryo oxidative 

profile and time-lapse morphokinetic. Through a 

logistic regression analyses we have been able to 

identify two parameters: cell cycle duration (cc2) 

(morphokinetic parameter) and the presence/absence 

of interleukin 6 (IL-6). Regarding these two 

factors, it has been established four embryo categories 

to develop a hierarchical selection model 

of embryos. It was observed a positive correlation 

between embryo categories and implantation rate 


• Artificial gamete creation through germ line reprogramming 

from human somatic cells 

• Use of Oxidative stress as a biomarker for embryo viability 

in human IVF and its use as an additional marker 

to the existing morphokinetic algorithms provided by 

time-lapse 


Nicolás Garrido Puchalt 

In this research line about male 

fertility, factors related to sperm 

physiology are intended to be discovered, 

and sperm selection techniques 

in order to improve reproductive 

results are being evaluated. Using 

assisted reproduction techniques and 

several instrumental tools, the genetic, proteomic and metabolo- 

mic profiles, together with DNA integrity are being scrutinized 

in order to determine the relevance of these parameters and 

improve the diagnosis and the design of new optimal sperm 

selection techniques to achieve parenthood. 


Marcos Meseguer Escrivá 

Traditionally, embryo incubation and 

assessment daily has been under a 

light microscope, these observations 

are inevitably restricted to specific 

times and considering that the development 

of the embryo is a dynamic 

process, several critical stages in between observations may go 

unnoticed. For this reason, the new technologies, time lapse monitoring; 

have focused on the research for additional markers of 

viability to supplement current criteria for embryo selection and 

thus, achieve a reduction in the number of embryos transferred 

and so multiple pregnancies, making the selection procedure 

even easier for the embryologist. Our group is pioneer in the 

introduction and development of time-lapse technology, being 

a reference in the scientific community. Time-lapse allows embryo 

analysis without using an invasive technique. 

The processes in our laboratory have changed, since it is not 

needed to take out the embryos from the incubator to be observed, 

and we have more information of each embryo. Time-lapse 

incubators take continuous pictures of development that allows 

selecting those that have major implantation rate according to 

its morphokinetic patterns. In this way we also achieved a much 

more stable incubation. 

Capturing images is done in multiple focal planes and preprogrammed 

time intervals. The sum of each embryo frame 

generates a recording that displays the embryonic development 

continuously. It represents a major conceptual advance in the 

quality assessment by measuring embryonic developmental processes 

against embryo stages. Control randomized studies have 

demonstrated an increase up to 20% in the chance of success 

of assisted reproductive technology. Parallel projects with new 

hardware time-lapse technologies as Auxogyn-Eeva and Geri- 

Genea are being performed validating and improving the existing 

tool for the embryology lab. 

New software is being tested to improve current algorithms 

for embryo selection. New projects underway are combining 

time-lapse technology with non-invasive analysis of surrounding 

embryo culture media. Our research is focused in oxygen


4 

consumption, oxidative profile and embryo protein secretions. 

Special interest is done in the use of TCL analyzer, a biochemical 

measurement that examines the oxidative profile, also connected 

to signal transduction which is based on free radicals activity 

and the metabolism of the embryo with the culture media where 

it grows. 



25 127,25 5,09 

National 



International 


Corresponding 

author 

9 10 8 

1. Dupont C, Grati FR, Choy KW, Jaillard S, Toutain J, Maurin 

ML, Martínez-Conejero JA, Beneteau C, Coussement A, 

Molina-Gomes D, Horelli-Kuitunen N, Aboura A, Tabet AC, 

Besseau-Ayasse J, Bessieres-Grattagliano B, Simóni G, Ayala 

G, Benzacken B, Vialard F. Prenatal diagnosis of 24 cases of 

microduplication 22q11.2: an investigation of phenotypegenotype 

correlations.Prenat Diagn. 2015 Jan ;35(1):35-43. 

IF: 3,268 

2. Muñoz E, Fernandez I, Martínez M, Tocino A, Portela S, 

Pellicer A, García-Velasco JA, Garrido N. Oocyte donation 

outcome after oncological treatment in cancer survivors. 

Fertil Steril. 2015 Jan ;103(1):205-13.IF: 4,59 

3. Basile N, Vime P, Florensa M, Aparicio Ruiz B, García Velasco 

JA, Remohí J, Meseguer M. The use of morphokinetics as a 

predictor of implantation: a multicentric study to define and 

validate an algorithm for embryo selection.Hum Reprod. 

2015 Feb ;30(2):276-83.IF: 4,569 

4. Grau N, Escrich L, Galiana Y, Meseguer M, García-Herrero S, 

Remohí J, Escribá MJ. Morphokinetics as a predictor of selfcorrection 

to diploidy in tripronucleated intracytoplasmic 

sperm injection-derived human embryos.Fertil Steril. 2015 

Sep ;104(3):728-35.IF: 4,59 

5. Martínez-Arroyo AM, Míguez-Forján JM, Remohí J, Pellicer 

A, Medrano JV. Understanding Mammalian Germ Line 

Development with In Vitro Models.Stem Cells Dev. 2015 Sep 

15 ;24(18):2101-13.IF: 3,727 

6. Díez-Juan A, Rubio C, Marin C, Martínez S, Al-Asmar N, Riboldi 

M, Díaz-Gimeno P, Valbuena D, Simón C. Mitochondrial DNA 

content as a viability score in human euploid embryos: less 

is better.Fertil Steril. 2015 Sep ;104(3):534-41.e1.IF: 4,59 

7. Moreno-Moya JM, Franchi NA, Martínez-Escribano S, 

Martínez-Conejero JA, Bocca S, Oehninger S, Horcajadas JA. 

Transcriptome of early embryonic invasion at implantation 

sites in a murine model.Reprod Fertil Dev. 2015 May 5 ;.IF: 2,4 

8. Campos-Galindo I, García-Herrero S, Martínez-Conejero JA, 

Ferro J, Simón C, Rubio C. Molecular analysis of products of 

conception obtained by hysteroembryoscopy from infertile 

couples.J Assist Reprod Genet. 2015 May ;32(5):839-48.IF: 

1,718 

9. Dominguez F, Meseguer M, Aparicio-Ruiz B, Piqueras P, 

Quiñonero A, Simón C. New strategy for diagnosing embryo 

implantation potential by combining proteomics and timelapse 

technologies.Fertil Steril. 2015 Oct ;104(4):908-14.IF: 

4,59 

10. Basile N, Caiazzo M, Meseguer M. What does 

morphokinetics add to embryo selection and in-vitro 

fertilization outcomes?Curr Opin Obstet Gynecol. 2015 Jun 

;27(3):193-200.IF: 2,067 

11. Salas-Huetos A, Blanco J, Vidal F, Godo A, Grossmann M, 

Pons MC, F-Fernández S, Garrido N, Anton E. Spermatozoa 

from patients with seminal alterations exhibit a differential 

micro-ribonucleic acid profile.Fertil Steril. 2015 Sep 

;104(3):591-601.IF: 4,59 

12. Vera-Rodriguez M, Chavez SL, Rubio C, Pera RA, Simón C. 

Prediction model for aneuploidy in early human embryo 

development revealed by single-cell analysis.Nat Commun. 

2015 Jul 7 ;6:7601.IF: 11,47 

13. Bronet F, Nogales MC, Martínez E, Ariza M, Rubio C, García- 

Velasco JA, Meseguer M. Is there a relationship between 

time-lapse parameters and embryo sex?Fertil Steril. 2015 

Feb ;103(2):396-401.e2.IF: 4,59 

14. Martín J, Asan, Yi Y, Alberola T, Rodríguez-Iglesias B, Jiménez- 

Almazán J, Li Q, Du H, Alama P, Ruiz A, Bosch E, Garrido 

N, Simón C. Comprehensive carrier genetic test using nextgeneration 

deoxyribonucleic acid sequencing in infertile 

couples wishing to conceive through assisted reproductive 

technology.Fertil Steril. 2015 Nov ;104(5):1286-93.IF: 4,59 

15. Cobo A, Garrido N, Pellicer A, Remohí J. Six years’ 

experience in ovum donation using vitrified oocytes: report 

of cumulative outcomes, impact of storage time, and 

195

4 

Scientific 

activity 

196 

development of a predictive model for oocyte survival rate. 

Fertil Steril. 2015 Dec ;104(6):1426-1434.e8.IF: 4,59 

16. Marcos J, Pérez-Albalá S, Mifsud A, Molla M, Landeras J, 

Meseguer M. Collapse of blastocysts is strongly related 

to lower implantation success: a time-lapse study.Hum 

Reprod. 2015 Nov ;30(11):2501-8.IF: 4,569 

17. Galliano D, Garrido N, Serra-Serra V, Pellicer A. Difference in 

birth weight of consecutive sibling singletons is not found 

in oocyte donation when comparing fresh versus frozen 

embryo replacements.Fertil Steril. 2015 Dec ;104(6):1411- 

1418.e3.IF: 4,59 

18. de Los Santos MJ, Gámiz P, de Los Santos JM, Romero 

JL, Prados N, Alonso C, Remohí J, Dominguez F. The 

Metabolomic Profile of Spent Culture Media from Day-3 

Human Embryos Cultured under Low Oxygen Tension.PLoS 

One. 2015 ;10(11):e0142724.IF: 3,234 

Letter 

19. Freour T, Basile N, Barriere P, Meseguer M. Systematic 

review on clinical outcomes following selection of human 

preimplantation embryos with time-lapse monitoring.Hum 

Reprod Update. 2015 Jan ;21(1):153-4.IF: 10,165 

20. Basile N, Barrière P, Meseguer M, Fréour T. Time-lapse in 

the IVF lab: how should we assess potential benefit?Hum 

Reprod. 2015 May ;30(5):1276.IF: 4,569 

21. Serra V, Bellver J, Garrido N. Doubtful association between 

progesterone therapy and fetal nuchal translucency.Am J 

Obstet Gynecol. 2015 Sep ;213(3):437.IF: 4,704 

22. García-Velasco JA, Bosch E. The necessity to define the suboptimal 

responders.Hum Reprod. 2015 Dec ;30(12):2958. 

IF: 4,569 

Review 

23. Gardner DK, Meseguer M, Rubio C, Treff NR. Diagnosis 

of human preimplantation embryo viability.Hum Reprod 

Update. 2015 Nov-Dec ;21(6):727-47.IF: 10,165 

24. Sakkas D, Ramalingam M, Garrido N, Barratt CL. Sperm 

selection in natural conception: what can we learn 

from Mother Nature to improve assisted reproduction 

outcomes?Hum Reprod Update. 2015 Nov-Dec ;21(6):711- 

26.IF: 10,165 

Editorial 

25. Garrido N, Bosch E, Alamá P, Ruiz A. The time to prevent 

mendelian genetic diseases from donated or own gametes 

has come.Fertil Steril. 2015 Oct ;104(4):833-5.IF: 4,59 

• THESIS 

Thesis title: La adición de LH a la estimulación ovárica no 

produce más maduración endometrial prematura ni diferente 

patrón de expresión génica endometrial que la estimulación 

con solo fsh. Un estudio comparativo en donantes de ovocitos 

Doctoral candidate: Elkin Albeiro Muñoz Muñoz 

Director(s): José Remohí Giménez 



Thesis title: Cuantificación de la calidad embrionaria mediante 

el consumo de oxígeno durante el proceso rutinario de 

incubación y desarrollo in vitro 

Doctoral candidate: Alberto Tejera Pastor 

Director(s): Marcos Meseguer Escrivá, Mª José De Los Santos 

Molina, Nicolás Garrido Puchalt 




RESEARCH 


Title: Artificial gamete creation through germ line 

reprogramming from human somatic cells 

Principal Investigator: José Remohí Giménez 







Title: Estudio clínico del estrés oxidativo como biomarcador 

adicional de viabilidad embrionaria en fecundación in vitro 

combinado con la selección por morfocinética 

Principal Investigator: Nicolás Garrido Puchalt y Marcos 

Meseguer Escrivá 

Funding Body: Instituto de Salud Carlos III


4 






Title: Isolation and characterization of endometrial somatic 

stem cells in endometriosis. Pathogenic and therapeutic 

implications. Identification of endometrial stem cell markers. 

From animal models to human endometrial stem cell therapy 

Principal Investigator: Carlos Simón Vallés (José Remohí as 

investigator researcher) 





197 

Sequential culture media recruitment and 

storage.

4 

Scientific 

activity 

Hospital divisions areas 

198 

Department of Admission and Clinical Documentation 199 

Allergology Unit 199 

Department of Otolaryngology 200 

Department of Maxillofacial Surgery 200 

Department of Pharmacy 201 

Department of Thoracic Surgery 202 

Department of Radiologic Diagnosis 202 

Department of Biochemistry and Clinical Analysis 203 

Department of Nephrology 205 

Department of Dermatology 206 

Department of Gastroenterology and Hepatology 207 

Department of Traumatology and Orthopedic Surgery 208 

Department of Intensive Medicine 209 

Department of Microbiology 210 

Cardiac Stimulation Unit 211 

Department of Urology 212 

Department of Neurophysiology 213 

Department of Neurology 213 

Department of Ophthalmology 214 

Department of Pediatrics 214 

Department of Radiologic Protection 215 

Department of Radiotherapy 216 

Department of Rheumatology 216 

Department of Nuclear Medicine 216 

Department of Pneumology 217 

Impact 

Factor (IF) 

Total: 202,47 

Average: 2,56 

79 

Publications 

9 

International 


JCR: 

8 in D1 

20 in Q1 

12 in Q2 

Author: 




author


4 

4.2 Other scientific contributions from the Hospital Divisions 

and the Valencia Clínico-Malvarrosa Health Department 

Department of Admission and Clinical 

Documentation 


National Registry of Childhood Cancer 

• Epidemiology of childhood cancer: incidence and survival 

of childhood cancer in Spain, geographic, temporal, 

national and international variations, epidemiology of 

the biological characteristics that have a clinical relevance 

in childhood cancer 


RESEARCH 


Title: Red temática de investigación cooperativa de cáncer 

(RTICC). 

Principal Investigator: Rafael Peris-Bonet 








2 50,63 25,31 

National 



International 


Corresponding 

author 

- 1 - 

1. Steliarova-Foucher E, Stiller C, Colombet M, Kaatsch P, Zanetti 

R, Peris-Bonet R. Registration of childhood cancer: 

Moving towards pan-European coverage?Eur J Cancer. 2015 

Jun ;51(9):1064-79.IF: 5,417 

2. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang 

XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos- 

Gragera R, Stiller C, Azevedo e Silva G, Chen WQ, Ogunbiyi 

OJ, Rachet B, Soeberg MJ, You H, Matsuda T, Bielska-Lasota 

M, Storm H, Tucker TC, Coleman MP, CONCORD Working 

Group. Global surveillance of cancer survival 1995-2009: 

analysis of individual data for 25,676,887 patients from 279 

population-based registries in 67 countries (CONCORD-2). 

Lancet. 2015 Mar 14 ;385(9972):977-1010.IF: 45,217 

Allergology Unit 


• Application of the basophil activation test (Basotest) for 

the diagnosis of respiratory and medication allergies 

• Relationship between patient’s allergenic profiles and 

the efficiency of the immunotherapy with mites 

• Use of the anti-IgE (omalizumab) in the treatment for 

the cutaneous allergic pathology 



2 8,26 4,13 

National 



International 


Corresponding 

author 

1 - 1 

1. Burches E, Revert A, Martín J, Iturralde A. Occupational 

systemic allergic dermatitis caused by sevoflurane.Contact 

Dermatitis. 2015 Jan ;72(1):62-3.IF: 3,747 




199

4 

Scientific 

activity 




Bachiller-Corral J. [Epidemiologic and public-health issues 

of progressive fibrodysplasia ossificans in Spain].Med Clin 

(Barc). 2015 Feb 20 ;144(4):183.IF: 1,417 

Department of Otolaryngology 

Department of Maxillofacial Surgery 

200 

Un médico valenciano, elegido Presidente de la Sociedad 

Española de ORL y Cirugía de Cabeza y Cuello. 

El Levante. 19-12-2015. 

El Dr. Jaime Marco Algarra nombrado Presidente de la Sociedad 

Española de ORL y Cirugía de Cabeza y Cuello. 


Elperiodic.com 19/12/2015 


3 3,49 1,16 

National 



International 


Corresponding 

author 

3 - 1 

1. Martínez MT, González I, Tarazona N, Roselló S, Saiz R, Sanmartín 

A, Martínez-Agulló Á, Caballero A, Mas P, Franco J, 

Martínez-Jabaloyas J, García-Callejo J, Martín V, Navarro 

J, Teruel A, Lluch A, Chirivella I. Implementation and assessment 


between primary and specialized care in patients 

with suspected cancer: how to shorten time between initial 



2. Canals P, Pérez Del Valle B, López F, Marco A. The efficacy 

of individual treatment of subjective tinnitus with cognitive 

behavioural therapy.Acta Otorrinolaringol Esp. 2015 Nov 

26.IF: 0 

Letters 


• Traslational phase of the research project for the development 

of implants with high added value through 

additive manufacturing 


• Evaluation of surgical implantation technique of the 

sphenopalatine ganglion neurostimulator to treat chronic 

cluster headache and disabling chronic migraine 

• Radiological evaluation of predictive factors of access to 

pterygopalatine fossa. Research surgical approach for 

installation neuromodulator in the sphenopalatine ganglion 

treatment of certain chronic headaches 

• Research on materials involved in bone regeneration 

• Evaluation of platelet factors (PRP) and fibrin rich plasma 

in the treatment of osteonecrosis associated with 

drugs intake (bisphosphonates) 



1 3,589 3,589 

National 



International 


Corresponding 

author 

1 - - 

1. Jovani-Sancho MD, Sheth CC, Marqués-Mateo M, Puche-Torres 

M. Platelet-Rich Plasma: A Study of the Variables that 

May Influence Its Effect on Bone Regeneration.Clin Implant 

Dent Relat Res. 2015 Jul 1 ;.IF: 3,589 

3. Morales-Piga AA, García Callejo FJ, González Herranz P,


4 

Patents 

Title: Prótesis maxilo-mandibular y método de fabricación 

Inventors: M Puche, V Petrovic, JA Gómez, JR Blasco, L 

Portolés, J Ferrís, C Atienza 

Applicants: Fundación Investigación Hospital Clínico Valencia 

(INCLIVA), IBV y AIMME 

Application number: WO 2014/188036 A1 


Territory: Spain 



4 6,38 1,59 

National 



International 


Corresponding 

author 

3 - 3 

Department of Pharmacy 


• Implementation of a new therapeutical drug monitoring 

system in a clinical analytical laboratory for pharmacokinetic 

control of antibiotic (meropenem, piperacillin, 

ceftazidime) and antifungals (voriconazole) in the hospitalized 

patient, with the aim of optimal and rational use 

of antimicrobials 

• Study of pharmacokinetics of caspofungin in patients 

under hemodiafiltration 

1. Guglieri-López B, Pérez-Pitarch A, Porta-Oltra B, Ferriols- 

Lisart F, Climente-Martí M, Alós-Almiñana M. Effectiveness, 

toxicity, and economic evaluation of vinflunine for the 

treatment of patients with transitional cell carcinoma in 

the Spanish outpatient setting.Anticancer Drugs. 2015 Sep 

;26(8):860-5.IF: 1,784 

2. Ferriols-Lisart R, Ferriols-Lisart F. Dose modifications of 

anti-TNF drugs in rheumatoid arthritis patients under real 

world settings: a systematic review.Rheumatol Int. 2015 Jul 

;35(7):1193-210.IF: 1,516 

3. Pérez-Pitarch A, Ferriols-Lisart R, Alós-Almiñana M, Mínguez- 

Pérez M. A pharmacokinetic approach to model-guided 

design of infliximab schedules in ulcerative colitis patients. 

Rev Esp Enferm Dig. 2015 Mar ;107(3):137-42.IF: 1,414 

Review 

201 


• Pharmacokinetics/Pharmacodinamics of anidulafungin 

in plasma and intraperitoneal fluid in the critical patient 

with secondary peritonitis and suspected/evidenced 

candida spp. Infection. Efficacy Study 

• Observational Study of population pharmacokinetic model 

of voriconazole in allogeneic stem cell transplantation 

• Implementation of a new therapeutical drug monitoring 

system in a clinical analytical laboratory for pharmacokinetic 

control of antineoplastics in the oncological patient, 

with the aim of optimal and rational use of oncological 

medication 

• Cost effectiveness analysis of direct-acting antiviral therapy 

for treatment-of patients with chronic HCV infection 

4. Vivas-Consuelo D, Usó-Talamantes R, Trillo-Mata JL, Mendez-Valera 

P. Methods to control the pharmaceutical cost 

impact of chronic conditions in the elderly.Expert Rev Pharmacoecon 

Outcomes Res. 2015 Jun ;15(3):425-37.IF: 1,669 


RESEARCH 


Title: Tratamiento anticipado con ganciclovir de la infección 

activa por el citomegalovirus (CMV) en el paciente crítico en 

ventilación mecánica con sepsis grave o shock séptico 

Principal Investigator: Gerardo Aguilar Aguilar (Teresa 

Torrecilla as collaborating researcher) 






4 

Scientific 

activity 

Title: Validación de una técnica de cuantificación de 

antibióticos carbapenémicos en plasma humano mediante 

cromatografía líquida de alta resolución (Parte II) 

Principal Investigator: Rafael Ferriols Lisart 



Fellow: Carlos Ezquer Garín 



Duration: 2014 - 2015 

Department of Thoracic Surgery 


• Tracheal surgery in benign lesions, trauma and malignancies 

• Implementation of VATS surgery 

• Surgical rescue in advanced lung cancer 

202 

Title: Evolución del consumo de los antipsicóticos atípicos en 

el Departamento de Salud Clínico Malvarrosa, mediante el 

análisis de series temporales 

Principal Investigator: Carmen Carrión Carrión 



Fellow: Mercedes Jiménez Heredia 



Duration: 2014 - 2015 

Title: Evaluación económica de la triple terapia en pacientes 

monoinfectados por el virus de la hepatitis C. (Parte II) 

Principal Investigator: Manuel Alós Almiñana 



Fellow: Raquel Pardillo Almiñana 



Duration: 2014 - 2015 



2 3,30 3,30 

National 



International 


Corresponding 

author 

1 - 2 

1. García-de-la-Asunción J, García-del-Olmo E, Perez-Griera J, 

Martí F, Galán G, Morcillo A, Wins R, Guijarro R, Arnau A, 



lobectomy: a study of exhaled breath condensate and 

blood.Eur J Cardiothorac Surg. 2015 Sep ;48(3):e37-44.IF: 

3,304 

2. Franco J, Llopis E, Galán G. Hemothorax After Endobronchial 

Ultrasound-guided Transbronchial Needle Aspiration.J 

Bronchology Interv Pulmonol. 2015 Oct 22 ;.IF: 0 

Department of Radiologic Diagnosis 


• To participate in several clinical trials of Hematology 

and Oncology Service by performing CT and / or biopsies 

to check-inclusion of patients in new chemotherapy 

treatments 

• To evaluate cerebral reperfusion syndrome after 

treatment of carotid stenosis by stent


4 

• To study gastric pre oesophagectomy conditioning to 

reduce the incidence of dehiscence of sutured anastomoses 

Department of Biochemistry and Clinical 

Analysis 



3 4,37 1,45 

National 



International 


Corresponding 

author 

3 - 2 

1. Rovira L, Aguilar G, Cuñat A, Belda FJ. Late evaluation of upper 

limb arterial flow in patients after long radial (PiCCO) 

catheter placement.Ann Intensive Care. 2015 ;5:1.IF: 3,311 

2. Sanchís García JM, Sánchez Oro R, Molla Landete MÁ. 

Cardiac herniation with torsion: complication after pleuropneumonectomy.Rev 

Esp Cardiol (Engl Ed). 2015 Apr 

;68(4):339.IF: 0 

3. Sánchez Oro R, Julve Parreño AM, Gil Viana R. Abdominal 

mass in the right flank.Rev Clin Esp. 2015 Apr ;215(3):e20-1. 

IF: 1,063 


RESEARCH 

Reference: EPI-CT 

Title: Estudio de cohorte de niños con exposición diagnóstica 

sustancial a radiaciones ionizantes 

Principal Investigator: Elisabeth Cardis (Julio Palmero as 


Funding body: European Comission 

Beneficiary institution: CREAL (Centre de Recerca en 

Epidemiología Ambiental) 



• To adequate the analytical demand through electronic 

request laboratory information system GestLab 

• Implementation of immunoassays against monoclonal 

light-chain isotypes in the diagnosis and monitoring of 

diseases chain gammopathy 


• To collaborate with others investigation groups: Cardiology 

Clinic (ischemic heart disease and heart failure), 

cardiometabolic risk and Diabetes (lipid metabolism and 

insulin resistance) and Women’s Health (bone metabolism 

in postmenopausal osteoporosis, genetic diagnosis 

prenatal noninvasive and biochemical evaluation of the 

role of ovarian function in Assisted reproduction) 



8 15,78 1,97 

National 



International 


Corresponding 

author 

6 1 2 

1. Torregrosa I, Montoliu C, Urios A, Andrés-Costa MJ, Giménez-Garzó 

C, Juan I, Puchades MJ, Blasco ML, Carratalá A, 

Sanjuán R, Miguel A. Urinary KIM-1, NGAL and L-FABP for 

the diagnosis of AKI in patients with acute coronary syndrome 

or heart failure undergoing coronary angiography.Heart 

Vessels. 2015 Nov ;30(6):703-11.IF: 2,065 





;26(1):42-8.IF: 2,891 

3. García-de-la-Asunción J, García-del-Olmo E, Perez-Griera J, 

Martí F, Galán G, Morcillo A, Wins R, Guijarro R, Arnau A, 

203

4 

Scientific 

activity 

204 



lobectomy: a study of exhaled breath condensate and 

blood.Eur J Cardiothorac Surg. 2015 Sep ;48(3):e37-44.IF: 

3,304 





Coronary Syndromes.Can J Cardiol. 2015 Dec ;31(12):1462- 

8.IF: 3,711 


E, Consuegra-Sánchez L, Roqué M, Bertomeu-González 

V, Chorro FJ, Núñez E, Núñez J. Usefulness of delta troponin 


elevation acute chest pain.Eur Heart J Acute Cardiovasc 

Care. 2015 Jul 1 ;.IF: 0 

6. Panach-Navarrete J, Carratalá-Calvo A, Valls-González L, 

Sales-Maicas MA, Martínez-Jabaloyas JM. Prostate Specific 

Antigen (PSA) use in a national health department.Arch Esp 

Urol. 2015 Oct ;68(8):647-654.IF: 0,309 


C, Pilot Group of the Appropriate Utilization of Laboratory 

Tests (REDCONLAB) working group. Request of laboratory 

liver tests in primary care in Spain: potential savings if 

appropriateness indicator targets were achieved.Eur J 

Gastroenterol Hepatol. 2015 Oct ;27(10):1130-6.IF: 2,253 


C, Pilot Group of Appropriate Utilization of Laboratory Tests 

(REDCONLAB) working group. Potential over request in 

anemia laboratory tests in primary care in Spain.Hematology. 

2015 Jul ;20(6):368-73.IF: 1,253 


RESEARCH 


Title: Papel de la vía de señalización NOTCH1/FBXW7/PI3K/ 

PTEN/AKT en la progresión de la Leucemia Linfocítica Crónica 

B (LLC-B) a formas avanzadas. 

Principal Investigator: Mª José Terol Casterá (Ana Cuesta 

Peredo as collaborating researcher) 







Title: Comparación aleatoria entre un estrategia de 

intervención sobre fragilidad frente a la estrategia habitual en 

pacientes frágiles después de un infarto agudo de miocardio. 

Principal Investigator: Juan Sanchis Forés (Enrique Rodríguez 

Borja as collaborating researcher) 







Title: Activación del receptor sensor del calcio por sales de 

calcio y vitamina D. Estudio básico y clínico 

Principal Investigator: Antonio Cano Sánchez (Paz Laporta 

Martín as collaborating researcher) 






Title: Loop diuretics dosage in patients with acute heart failure 

and renal failure: conventional strategy versus strategy guided 

by CA125 plasma levels 

Principal Investigator: Julio Núñez Villota (Juana María Vaquer 




Clínico Universitario de Valencia


4 



Title: Implantación y gestión del registro de los resultados 

de las gasometrías que se realizan en distintos Servicios del 

Hospital Clínico en el Sistema Informático del Laboratorio (SIL) 

Principal Investigator: Arturo Carratalá Calvo 

Funding Body: Radiometer 

Beneficiary Institution: Hospital Clínico Universitario de 

Valencia 



Title: Apoyo de laboratorio a proyectos de investigación del 

Hospital Clínico Universitario de Valencia 

Principal Investigator: Arturo Carratalá Calvo (Celia Villalba 

Martínez) 

Funding Body: Radiometer 

Beneficiary Institution: Hospital Clínico Universitario de 

Valencia 



• AWARDS 

The participation of Arturo Carratalá in the quality project of 

SSCC was recognized by the Ministry of Health and the Instituto 

Aragonés de Ciencias de la Salud. 

The Agencia de Evaluación de Tecnologías Sanitarias de Andalucía 

recognized the contribution of Ana Cuesta on the scientific 

guideline Guía para la toma de decisiones sobre incorporación de 

nuevas pruebas genéticas en el Sistema Nacional de Salud. 

Department of Nephrology 


• To start two new investigation lines of research: Kidney 

damage in hematopoietic stem cell transplantation and 

myeloma kidney treatment by chemotherapy and dialysis 

filters PMMA 


• Study of oxidative stress, nutrition and inflammation in 

patients with chronic kidney disease in stages 3a, 3b, 4 

and 5 

• Implications of hepcidin on iron metabolism in dialysis 

patients 

• Treatment of cardio-renal syndrome by peritoneal dialysis 

• Biomarkers of acute renal failure 

• Kidney damage in hematopoietic stem cell transplantation 

• Myeloma kidney treatment by chemotherapy and dialysis 

filters PMMA 



2 3,28 1,64 

National 



International 


Corresponding 

author 

2 - 1 






Vessels. 2015 Nov ;30(6):703-11.IF: 2,065 






Mar-Apr ;35(2):172-178.IF: 1,223 

THESIS 






Tormo, Carmina Montoliu Félix 



205

4 

Scientific 

activity 

Department of Dermatology 


• To continue making a biobank of melanoma patients 


• About melanoma: to study cytokines involved in the regression 

of melanocytic lesions 

• Psoriasis: to study the application of new molecules for 

the treatment of patients with severe psoriasis 

Carnicero A, Puertolas T, Godoy E, Cerezuela P, Ochoa de 

Olza M, Campos B, Perez-Ruiz E, Soria A, Gil-Arnaiz I, González-Cao 

M, Galvez E, Arance A, Belon J, de la Cruz-Merino 

L, Martín-Algarra S, Spanish Multidisciplinary Group of 

Melanoma (GEM). Frequency and characteristics of familial 

melanoma in Spain: the FAM-GEM-1 Study.PLoS One. 2015 

;10(4):e0124239.IF: 3,234 

Letters 

6. Escandell I, Cabezas M, Martín JM, Terradez L, Pinazo MI. 

Effective treatment with Dabrafenib and Trametinib for a 

BRAF-mutated metastatic dedifferentiated malignant spindle 

cell neoplasm.J Eur Acad Dermatol Venereol. 2015 Apr 

27 ;.IF: 2,826 

206 



6 12 2 

National 



International 


Corresponding 

author 

1 - 5 

• THESIS 

Thesis title: Determinación de parámetros clínico-patológicos 

y moleculares implicados en la regresión espontánea de 

neoplasias melanocíticas cutáneas. 

Doctoral candidate: José María Martín Hernández 

Director(s): Carlos Monteagudo Castro, Esperanza Jordá 

Cuevas 



1. González Rodríguez AJ, Jordá Cuevas E. Idiopathic facial 

aseptic granuloma.Clin Exp Dermatol. 2015 Apr ;40(3):298- 

300.IF: 1,092 

2. Gavrilova M, Cabezas Macian M, Martín-Gorgojo A, Beteta 

LG, Posadas V, Jorda-Cuevas E. A rapidly enlarging mass on 

the right leg.Pediatr Dermatol. 2015 Jan-Feb ;32(1):143-4. 

IF: 1,015 

3. Saravia M, Pellicer Z, Martín JM, Monteagudo C. Clinically 

atypical spitzoid lesions: semi-quantitative histologic 

index correlation with dermoscopic scores (ABCD rule, 

7-point checklist and pattern analysis).J Eur Acad Dermatol 

Venereol. 2015 Apr ;29(4):668-72.IF: 2,826 

4. Martín JM, Beteta G, Allende A, Jordá E. Parvovirus B19-Associated 

Microvesicular Eruption.Pediatr Dermatol. 2015 

Nov ;32(6):e303-4.IF: 1,015 

5. Márquez-Rodas I, Martín González M, Nagore E, Gómez- 

Fernández C, Avilés-Izquierdo JA, Maldonado-Seral C, Soriano 

V, Majem-Tarruella M, Palomar V, Maseda R, Martín- 

Thesis title: Carcinoma epidermoide cutáneo: relación con los 

trastornos respiratorios del sueño y definición de la variante 

alto riesgo 

Doctoral candidate: Tania Díaz Corpas 

Director(s): Esperanza Jordá Cuevas, María Manuela Morales 

Suárez-Varela, Estrella Fernández Fabrellas 




RESEARCH 



cutaneous malignant melanoma, and their value as prognostic 

and therapeutic biomarkers 

Principal Investigator: José Carlos Monteagudo Castro 

(Esperanza Jordá as collaborating researcher) 

Funding Body: Instituto de Salud Carlos III


4 





Department of Gastroenterology and 

Hepatology 


• On the section of gastroenterology, to continue the 

studies on digestive hemorrhage, acute pancreatitis, inflammatory 

bowel disease, motion sickness and digestive 

benign anorectal pathology 

• On the hepatology division continue the analysis of hepatic 

encephalopathy, the nonalcoholic, epidemiological, 

therapeutic and immunoprophylaxis on Hepatitis 

Virus steatohepatitis. Also hepatocellular damage and 

nitric oxide and liver tumours 

• About endoscopy division: study on the therapeutic 

dilatation, the ecoendoscopia diagnostics and therapeutics, 

ampulectomia, diverticulotomy of Zencker and 

digestive prostheses 



8 38,98 4,87 

National 



International 


Corresponding 

author 

7 - 2 

1. Crespo J, Diago M, Cabezas J, Berenguer M, Broquetas T, 

Serra MÁ, Morillas R, García-Samaniego J, Calleja JL, Sánchez 

JJ, Lens S, Soto-Fernández S, Sacristán B, Fernández I, 

López-Núñez C, Buti M, Romero-Gómez M, Sáez-Royuela F, 

Fernández C, Jorquera F, Sánchez-Antolín G, Pascasio JM, 

Cuadrado A, Hernández-Guerra M. High efficacy and safety 

of triple therapy in HCV genotype 1 and moderate fibrosis: a 

multicenter study of clinical practice in Spain.Ann Hepatol. 

2015 Jul-Aug ;14(4):477-86.IF: 2,065 

2. Uribe N, Balciscueta Z, Mínguez M, Martín MC, López M, 

Mora F, Primo V. “Core out” or “curettage” in rectal advancement 

flap for cryptoglandular anal fistula.Int J Colorectal 

Dis. 2015 May ;30(5):613-9.IF: 2,449 

3. Catalán-Serra I, Huguet-Malavés JM, Mínguez M, Torrella E, 

Paredes JM, Vázquez N, Ramírez JJ, Calvo F, Nos P, Gutiérrez 

A, Palau A, Cortés J, Ramón-Monllor P, Hinojosa J. Information 

resources used by patients with inflammatory bowel 

disease: Satisfaction, expectations and information gaps. 

Gastroenterol Hepatol. 2015 Jun-Jul ;38(6):355-63.IF: 0,838 

4. Ampuero J, Simón M, Montoliú C, Jover R, Serra MÁ, Córdoba 

J, Romero-Gómez M. Minimal Hepatic Encephalopathy 

and Critical Flicker Frequency Are Associated With Survival 

of Patients With Cirrhosis.Gastroenterology. 2015 Nov 

;149(6):1483-9.IF: 16,716 

5. Salmerón J, Vinaixa C, Berenguer R, Pascasio JM, Sánchez 

Ruano JJ, Serra MÁ, Gila A, Diago M, Romero-Gómez M, 

Navarro JM, Testillano M, Fernández C, Espinosa D, Carmona 

I, Pons JA, Jorquera F, Rodriguez FJ, Pérez R, Montero JL, 

Granados R, Fernández M, Martín AB, Muñoz de Rueda P, 

Quiles R, Alhambra Spanish Study Group. Effectiveness and 

safety of first-generation protease inhibitors in clinical practice: 

Hepatitis C virus patients with advanced fibrosis.World 

J Gastroenterol. 2015 Aug 14 ;21(30):9163-74.IF: 2,369 

6. Boscá Watts MM, Marco Marqués A, Savall-Núñez E, 

Artero-Fullana A, Lanza Reynolds B, Andrade Gamarra V, 

Puglia Santos V, Burgués Gasión O, Mora Miguel F. IBD or 

strongyloidiasis?Rev Esp Enferm Dig. 2015 Dec 4 ;.IF: 1,414 

Letter 

7. Marco-Marqués A, Sanahuja-Martinez A, Bosca-Watts MM, 

Tosca-Cuquerella J, Mas-Mercader P, Andrade-Gamarra V, 

Mora-Miguel F. Could HLA-DQ suggest why some patients 

have olmesartan-related diarrhea and others don’t?Am J 

Gastroenterol. 2015 Oct ;110(10):1507-8.IF: 10,755 

Review 

8. Lluch P, Segarra G, Medina P. Asymmetric dimethylarginine 

as a mediator of vascular dysfunction in cirrhosis.World J 

Gastroenterol. 2015 Aug 28 ;21(32):9466-75.IF: 2,369 

207

4 

Scientific 

activity 

208 

• THESIS 

Thesis title: Enfermedad hepática grasa no alcohólica en la 

obesidad mórbida: Implicaciones patogénicas y diagnósticas 

Doctoral candidate: María Luisa García Torres, José Manuel 

Rodrigo Gómez. 

Director(s): Desamparados Escudero García 




RESEARCH 


Title: Caracterización de las alteraciones neurológicas con encefalopatía 

hepática mínima y de las alteraciones cerebrales 

responsables. Contribución del estrés oxidativo y la inflamación 

Principal Investigator: Carmina Montoliu Félix (Miguel Ángel 

Serra Desfilis as collaborating researcher) 


Beneficiary institution: Fundación Investigación Hospital Clínico 





• Cellular oxidative stress and its relation with idiopathic 

femoral osteonecrosis 

• Cellular regulatory mechanisms of the inflammatory 

response in chronic inflammatory diseases 

• Protection strategies against osteoarticular degradative 

processes 

• Robotics as a precision procedure in reconstructive orthopedic 

surgery 

• Role of microRNA as risk factors responsible for the 

pathogenesis of osteoarthritis and as a potential target 

for new biological therapies for osteoarthritis 

• Rehabilitation as an improvement process in results 

after total knee arthroplasty. Randomized prospective 

study 

• Local mechanical stimulation of mesenchymal cells 

towards their chondrogenic and osteogenic differentiation 

in regenerative medicine 



2 7,24 3,62 

National 


International 


Corresponding 

author 

2 - 2 


Department of Traumatology and 

Orthopedic Surgery 

1. Panach L, Mifsut D, Tarín JJ, Cano A, García-Pérez MÁ. Serum 

Circulating MicroRNAs as Biomarkers of Osteoporotic 





Bone. 2015 Nov 7 ;83:94-103.IF: 3,973 


• To study the determination of oxidative stress, getting 

results on the degree of oxidation and its correlation 

with the diagnosis / prognosis of the disease 

• To describe the specific oxidation mechanism of the 

pathology 

• THESIS 

Thesis title: Papel del nf-K946 Y MIrna-34A en la patogénesis 

de la osteoartritis y como posible diana de las nuevas terapias 

biológicas 

Doctoral candidate: Francisco Argüelles Linares 

Director(s): Antonio Silvestre Muñoz, José Miguel Cerdá 

Nicolás


4 




RESEARCH 

Reference: SAF2013-48724R 

Title: Mecanismos celulares reguladores de la respuesta 

inflamatoria en patologías inflamatorias crónicas 

Principal Investigator: Mª José Alcaraz Tormo (Francisco 

Gomar as collaborating researcher) 




Reference: MAT2013-46467-C4-4-R. 

Title: Estimulación mecánica local de células mesenquimales 

de cara a su diferenciación osteogénica y condrogénica en 

medicina regenerativa 

Principal Investigator: María Fe Mínguez Rey (Carmen Carda 

Batalla and María Sancho Tello as collaborating researcher) 





Department of Intensive Medicine 


• Bleeding acute spontaneous intraparenchymal (HIP) 

• Study of Biomarkers of brain injury (BNP, D-dimer, 

neuron-specific enolase (NSE) and S-100B) and 

inflammatory markers as prognostic and related 

mortality and quality of life in the short and medium 

term in patients with HIP factors 

• Study of the ratio of the volume of the hematoma and 

other prognostic factors in relation to mortality and 

quality of life in the short and medium term in patients 

with HIP 

• Sepsis: biomarkers study, metabolic pathways and 

oxidative stress critic septic patient 

• Modes of Mechanical Ventilation and therapeutic 

strategies for ARDS 

• Hyperglycemia and variability in critically ill patients 

• Test of Platelet Aggregation 



11 26,28 2,38 

National 



International 


Corresponding 

author 

11 - 3 






Vessels. 2015 Nov ;30(6):703-11.IF: 2,065 

2. Grau-Carmona T, Bonet-Saris A, García-de-Lorenzo A, Sánchez-Alvarez 

C, Rodríguez-Pozo A, Acosta-Escribano J, 

Miñambres E, Herrero-Meseguer JI, Mesejo A. Influence of 

n-3 Polyunsaturated Fatty Acids Enriched Lipid Emulsions 

on Nosocomial Infections and Clinical Outcomes in Critically 

Ill Patients: ICU Lipids Study*.Crit Care Med. 2015 Jan 

;43(1):31-9.IF: 6,312 





;26(1):42-8.IF: 2,891 

4. Lorente L, Martín MM, Almeida T, Hernández M, Ferreres 

J, Solé-Violán J, Labarta L, Díaz C, Jiménez A. Association 

between serum substance P levels and mortality in patients 

with severe sepsis.J Crit Care. 2015 Oct ;30(5):924-8.IF: 

1,995 

5. Lorente L, Martín MM, Borreguero-León JM, Barrios Y, 

Solé-Violán J, Ferreres J, Labarta L, Díaz C, Jiménez A. The 

4G/4G Genotype of PAI-1 Polymorphism Is Associated with 

Higher Plasma PAI-1 Concentrations and Mortality in Patients 

with Severe Sepsis.PLoS One. 2015 ;10(6):e0129565. 

IF: 3,234 

6. Lorente L, Martín MM, Abreu-González P, de la Cruz T, 

209

4 

Scientific 

activity 

210 

Ferreres J, Solé-Violán J, Labarta L, Díaz C, Jiménez A, 

Borreguero-León JM. Serum melatonin levels are associated 

with mortality in severe septic patients.J Crit Care. 2015 

Aug ;30(4):860.e1-6.IF: 1,995 

7. Lorente L, Martín MM, Almeida T, Abreu-González P, 

Ferreres J, Solé-Violán J, Labarta L, Díaz C, Jiménez A. 

Association between serum total antioxidant capacity and 

mortality in severe septic patients.J Crit Care. 2015 Feb 

;30(1):217.e7-12.IF: 1,995 

8. Canadell L, Martín-Loeches I, Díaz E, Trefler S, Grau S, Yebenes 

JC, Almirall J, Olona M, Sureda F, Blanquer J, Rodriguez A, 

GETGAG. Degree of adherence to recommended antiviral 

treatment during the pandemic and post-pandemic periods 

of influenza A(H1N1)pdm09 in 148 intensive care units in 

Spain.Med Intensiva. 2015 May ;39(4):222-33.IF: 1,336 






Mar-Apr ;35(2):172-178.IF: 1,223 



Olivas J, Monleón D. Prognosis Biomarkers of Severe Sepsis 

and Septic Shock by 1H NMR Urine Metabolomics in the 

Intensive Care Unit.PLoS One. 2015 ;10(11):e0140993.IF: 

3,234 

11. Mesejo A, Montejo-González JC, Vaquerizo-Alonso C, Lobo- 

Tamer G, Zabarte-Martínez M, Herrero-Meseguer JI, Acosta- 

Escribano J, Blesa-Malpica A, Martínez-Lozano F. Diabetesspecific 

enteral nutrition formula in hyperglycemic, 

mechanically ventilated, critically ill patients: a prospective, 

open-label, blind-randomized, multicenter study.Crit Care. 

2015 Nov 9 ;19:390.IF: 0 



Department of Microbiology 


• Production of virus-like particles (VLPs) and P particles 

representative of diverse genotypes norovirus 

• Characterization of a new conformational epitope in the 

GII.4 norovirus capsid protein identified by a neutralizing 

monoclonal antibody 

• Epidemiological surveillance of circulating strains of rotavirus 

and norovirus in Valencia and different geographical 

areas of Spain (Valladolid, Zaragoza, Barcelona, 

Murcia) 


• Molecular epidemiology of rotavirus (EuroRotaNet Project) 

• Characterization of norovirus genotypes causing outbreaks 

and sporadic cases of acute gastroenteritis 

• Study of the interaction between norovirus VLPs and P 

particles and receptors in saliva and intestinal cells (MI- 

NECO SAF2012-38368 Project) 

• Phylogenetic analysis of rotavirus G12 strains isolated in 

different Spanish regions 

• Analysis of the relationship between histo-blood group 

antigens (HBGAs) and rotaviruses 

• Analysis by site-directed mutagenesis of a conformational 

epitope in the norovirus capsid protein recognized 

by a monoclonal antibody (MINECO SAF2012-38368 

Project) 

• THESIS 

Thesis title: Diagnóstico precoz de la neumonía asociada al 

ventilador. Evaluación seriada de biomarcadores en minilavado 

broncoalveolar y monitorización microbiológica, complementada 

con condensado de aire exhalado y sangre. 


Director(s): José Blanquer Olivas, Francisco Javier Chorro Gascó, 

Manuel Mata Roig 



7 35,52 5,07 

National 


International 


Corresponding 

author 

5 2 2


4 





community architecture but drives stable metabolome 

responses.ISME J. 2015 Oct ;9(10):2206-20.IF: 9,302 

2. Carmona-Vicente N, Fernández-Jiménez M, Ribes JM, Téllez- 

Castillo CJ, Khodayar-Pardo P, Rodríguez-Diaz J, Buesa J. 

Norovirus infections and seroprevalence of genotype GII.4- 

specific antibodies in a Spanish population.J Med Virol. 

2015 Apr ;87(4):675-82.IF: 2,347 

3. Díez-Domingo J, Weinke T, García de Lomas J, Meyer CU, 

Bertrand I, Eymin C, Thomas S, Sadorge C. Comparison of 

intramuscular and subcutaneous administration of a herpes 

zoster live-attenuated vaccine in adults aged ?50 years: a 

randomised non-inferiority clinical trial.Vaccine. 2015 Feb 4 

;33(6):789-95.IF: 3,624 




emerging North-American outbreak in 2014.J Clin Virol. 

2015 Oct ;71:1-9.IF: 3,016 

5. Alcalá L, Reigadas E, Marín M, Martín A, Catalán P, Bouza E, 

Spanish Clostridium difficile Study Group. Impact of clinical 

awareness and diagnostic tests on the underdiagnosis of 

Clostridium difficile infection.Eur J Clin Microbiol Infect Dis. 

2015 Aug ;34(8):1515-25.IF: 2,668 

Letters 

6. Falcón R, Madrid S, Tormo N, Casañ C, Albert E, Gimeno 

C, Navarro D. Intra- and Interinstitutional Evaluation of an 

Etest for Vancomycin Minimum Inhibitory Concentration 

Measurement in Staphylococcus aureus Blood Isolates.Clin 

Infect Dis. 2015 Nov 1 ;61(9):1490-2.IF: 8,886 

7. Fernández-Ruiz M, Corrales I, Amat P, González E, Andrés 

A, Navarro D, Aguado JM. Influence of Age and HLA Alleles 

on the CMV-Specific Cell-Mediated Immunity Among CMV- 

Seropositive Kidney Transplant Candidates.Am J Transplant. 

2015 Sep ;15(9):2525-6.IF: 5,683 

• THESIS 

Thesis title: Patrón infeccioso de la población extranjera. 

Período 2006-2010 

Doctoral candidate: Elena Navarro Calderón 

Director(s): Rafael Borras Salvador and Juan José Camarena 

Miñana 




RESEARCH 


Title: Especificidad de receptores y antigenicidad de variantes 

epidémicas de norovirus genotipo gii.4 causantes de 

gastroenteritis aguda 

Principal Investigator: Francisco Javier Buesa Gómez 





Title: Rotavirus surveillance in Europe: Determining the 

diversity of cocirculating rotavirus strains in consecutive 

rotavirus seasons. 

Investigador Principal: Miren Iturriza Gómara (Jesús Rodríguez 

Díaz as collaborating Research) 

Funding Body: Sanofi Pasteur y Glaxo Smith Kline Biologicals, 

coordinado por University of Liverpool, auspiciado por la 

Organización Mundial de la Salud. 

Beneficiary Institution: Universitat de València 

Duration: 2006 - 2016. 

Cardiac Stimulation Unit 


• Acreditation courses on Cryoballoon ablation have started 

successfully, with participants from Europe (Great 

Britain, Italy, Portugal) and from other countries (Russia, 

Lebanon, Iran...) 

• The series on endoepicardial approach in VT ablation 

has been published in Circulation Arrhythmias and Electrophysiology 

• Fire&Ice trial was finished 

211

4 

Scientific 

activity 

212 

• A new randomized multicentre study on cryoballoon 

ablation leaded by our unit has been initiated 


• Cryoballoon ablation: dose of cryoenergy based on time 

to effect 

• VT ablation 

• Silent brain damage (biomarkers) in ablation procedures 

• CTI ablation with zero x-ray exposition and guided by 

electrogram amplitude 

• Ventricular activation modelling (colaborative project 

with UPV, CICYT grant) 

• Heart innervation and multipoint left ventricular pacing 

• Characterization of atrial signal in the beginning of paroxysmal 

atrial fibrillation episodes 

• Physiologic signals monitoring during driving (collaborative 

with UPV, CICYT grant) 

• ARTESIA study: NOAC in silent episodes of atrial tachyarrhythmias 

detected by implanted devices 



2 5,75 2,78 

National 



International 


Corresponding 

author 

2 - - 

1. Lacunza-Ruiz FJ, Moya-Mitjans A, Martínez-Alday J, Barón- 

Esquivias G, Ruiz-Granell R, Rivas-Gándara N, González- 

Enríquez S, Leal-Del-Ojo J, García-Heil N, García-Alberola 

A. Differences in the yield of the implantable loop recorder 

between secondary and tertiary centers.Cardiol J. 2015 

;22(3):241-6.IF: 1,062 







Department of Urology 


• To complete the projects: 

• TMPRSS2-ERG gene fusión AND DNA metilation in prostate 

cancer 

• Immunohistochemical analysis of tissue microarrays in 

non musculoinvasive bladder cancer 

• Genetic analysis of renal cancer using Multiplex ligation 

dependent probe amplification 

• To Start the Project: Metabolomic profile in prostate 

cancer 

• To advance in the Project: Clinical utility of serum and 

urine MicroRNAs expression as bladder cancer biomarker 


• Nuclear Magnetic Resonance spestroscopy-based metabolomic 

profiling of prostate cancer 

• MicroRNAs expression in bladder cancer 

• Prognosis value of Immunohistochemical markers in 

bladder cancer 

• Multiplex ligation dependent probe amplification 

(MLPA) in renal cancer 

• TMPRSS2-ERG gene fusion AND DNA metilation in prostate 

cancer 



6 7,61 1,26 

National 



International 


Corresponding 

author 

1 1 5 


Sanmartín A, Martínez-Agulló Á, Caballero A, Mas P, 

Franco J, Martínez-Jabaloyas J, García-Callejo J, Martín V, 

Navarro J, Teruel A, Lluch A, Chirivella I. Implementation


4 

and assessment of a fast-track programme to improve 

communication between primary and specialized care 

in patients with suspected cancer: how to shorten time 

between initial symptoms of cancer, diagnosis and initiation 

of treatment.Clin Transl Oncol. 2015 Feb ;17(2):167-72.IF: 

2,077 

2. Brock G, Montorsi F, Costa P, Shah N, Martínez-Jabaloyas 

JM, Hammerer P, Ludovico GM, Lee JC, Henneges C, Hamidi 

K, Rossi A, Mulhall J, Büttner H. Effect of Tadalafil Once Daily 

on Penile Length Loss and Morning Erections in Patients 

After Bilateral Nerve-sparing Radical Prostatectomy: Results 

From a Randomized Controlled Trial.Urology. 2015 May 

;85(5):1090-6.IF: 2,188 

3. Panach-Navarrete J, García-Morata F, Hernández-Medina JA, 

Martínez-Jabaloyas JM. When to biopsy seminal vesicles. 

Actas Urol Esp. 2015 May ;39(4):203-9.IF: 1,022 

4. Panach-Navarrete J, Martínez-Jabaloyas JM. Is a retention 

time after the instillation of anesthetic lubricant necessary 

when performing male flexible cystoscopy?J Endourol. 2015 

Feb ;29(2):223-5.IF: 1,708 

5. Panach-Navarrete J, Carratalá-Calvo A, Valls-González L, 

Sales-Maicas MA, Martínez-Jabaloyas JM. Prostate Specific 

Antigen (PSA) use in a national health department.Arch Esp 

Urol. 2015 Oct ;68(8):647-654.IF: 0,309 

6. Panach-Navarrete J, Ferrandis-Cortés C, Sales-Maicas 

MA, Martínez-Jabaloyas JM. Mitomycin extravasation 

after postoperative instillation.Arch Esp Urol. 2015 Sep 

;68(7):633-636.IF: 0,309 

THESIS 

Thesis title: Utilidad clínica de la expresión de marcadores 

inmunohistoquímicos en el tumor vesical urotelial no músculoinvasivo 

grado 2. 

Doctoral candidate: José Antonio March Villalba 

Director(s): José M. Martínez Jabaloyas, David Ramos Soler, 

Cristina Domenech Pérez 



Department of Neurophysiology 


Letter 


1 0,83 0,83 

National 


International 


Corresponding 

author 

1 - 1 

1. de Entrambasaguas M, Ponz A, Sánchez-Monzó P, Peñaranda 

N. [Fasciculations, cramps, and statins].Rev Neurol. 2015 

Apr 16 ;60(8):380-1.IF: 0,83 

Department of Neurology 



7 25,69 3,21 

National 



International 


Corresponding 

author 

3 4 3 

1. Lovestone S, Boada M, Dubois B, Hüll M, Rinne JO, Huppertz 

HJ, Calero M, Andrés MV, Gómez-Carrillo B, León T, del 

Ser T, ARGO investigators. A phase II trial of tideglusib in 

Alzheimer’s disease.J Alzheimers Dis. 2015 ;45(1):75-88.IF: 

4,151 

2. Láinez MJ, Jensen R. Noninvasive neuromodulation in 

cluster headache.Curr Opin Neurol. 2015 Jun ;28(3):271-6. 

IF: 5,307 

3. Láinez-Andrés JM, Gascón-Giménez F, Coret-Ferrer F, 

Casanova-Estruch B, Santonja JM. [Therapeutic plasma 

exchange: applications in neurology].Rev Neurol. 2015 Feb 

1 ;60(3):120-31.IF: 0,83 

4. Sergott RC, Bennett JL, Rieckmann P, Montalban X, Mikol 

213

4 

Scientific 

activity 

214 

D, Freudensprung U, Plitz T, van Beek J, ATON Trial Group. 

ATON: results from a Phase II randomized trial of the B-celltargeting 

agent atacicept in patients with optic neuritis.J 

Neurol Sci. 2015 Apr 15 ;351(1-2):174-8.IF: 2,474 

5. Villar LM, Costa-Frossard L, Masterman T, Fernandez O, 

Montalban X, Casanova B, Izquierdo G, Coret F, Tumani H, 

Saiz A, Arroyo R, Fink K, Leyva L, Espejo C, Simó-Castelló M, 

García-Sánchez MI, Lauda F, Llufriú S, Álvarez-Lafuente R, 

Olascoaga J, Prada A, Oterino A, de Andrés C, Tintoré M, 

Ramió-Torrentà L, Rodríguez-Martín E, Picón C, Comabella 

M, Quintana E, Agüera E, Díaz S, Fernandez-Bolaños R, 

García-Merino JA, Landete L, Menéndez-González M, 

Navarro L, Pérez D, Sánchez-López F, Serrano-Castro 

PJ, Tuñón A, Espiño M, Muriel A, Bar-Or A, Álvarez- 

Cermeño JC. Lipid-specific immunoglobulin M bands in 

cerebrospinal fluid are associated with a reduced risk of 

developing progressive multifocal leukoencephalopathy 

during treatment with natalizumab.Ann Neurol. 2015 Mar 

;77(3):447-57.IF: 9,977 

6. Langguth B, Hund V, Busch V, Jürgens TP, Laínez JM, 

Landgrebe M, Schecklmann M. Tinnitus and Headache. 

Biomed Res Int. 2015 ;2015:797416.IF: 1,579 

7. Gascón-Giménez F, Coret-Ferrer F. Reversible subacute 

chorea caused by vitamin B12 deficiency.Neurologia. 2015 

Dec 15 ;.IF: 1,381 

Department of Ophthalmology 



3 0 0 

National 



International 


Corresponding 

author 

3 - 3 

1. Ruiz Del Río N, Abelairas Gómez JM, Alonso García de la 

Rosa FJ, Peralta Calvo JM, de Las Heras Martín A. Genetic 

analysis in retinoblastoma and peripheral blood correlation. 

Arch Soc Esp Oftalmol. 2015 Dec ;90(12):562-565.IF: 0 

2. Ruiz del Río N, Abelairas Gómez JM, Alonso García de la 

Rosa FJ, Peralta Calvo JM, de las Heras Martín A. [Genetic 

analysis results of patients with a retinoblastoma refractory 

to systemic chemotherapy].Arch Soc Esp Oftalmol. 2015 

Sep ;90(9):414-20.IF: 0 

3. Vila-Arteaga J, Díaz-Céspedes RA, Suriano MM. Plateau iris 

secondary to iridociliary cysts.Arch Soc Esp Oftalmol. 2015 

Nov ;90(11):542-545.IF: 0 

Department of Pediatrics 



11 26,23 2,38 

National 



International 


Corresponding 

author 

11 - 1 

1. Cantón R, Máiz L, Escribano A, Olveira C, Oliver A, Asensio 

O, Gartner S, Roma E, Quintana-Gallego E, Salcedo A, Girón 

R, Barrio MI, Pastor MD, Prados C, Martínez-Martínez MT, 

Barberán J, Castón JJ, Martínez-Martínez L, Poveda JL, 

Vázquez C, de Gracia J, Solé A, en representación del Grupo 

Español de Consenso del Tratamiento Antimicrobiano en el 

Paciente con Fibrosis Quística. Spanish consensus on the 

prevention and treatment of Pseudomonas aeruginosa 

bronchial infections in cystic fibrosis patients.Arch 

Bronconeumol. 2015 Mar ;51(3):140-50.IF: 1,823 

2. Pérez-Yarza EG, Moreno-Galdó A, Ramilo O, Rubí T, Escribano 

A, Torres A, Sardón O, Oliva C, Pérez G, Cortell I, Rovira-Amigo 

S, Pastor-Vivero MD, Pérez-Frías J, Velasco V, Torres-Borrego 

J, Figuerola J, Barrio MI, García-Hernández G, Mejías A, 

SAREPREM 3235 investigators. Risk factors for bronchiolitis, 

recurrent wheezing, and related hospitalization in preterm 

infants during the first year of life.Pediatr Allergy Immunol. 

2015 Dec ;26(8):797-804.IF: 3,397 

3. Snijders D, Fernandez Dominguez B, Calgaro S, Bertozzi I, 

Escribano Montaner A, Perilongo G, Barbato A. Mucociliary 

clearance techniques for treating non-cystic fibrosis


4 

bronchiectasis: Is there evidence?Int J Immunopathol 

Pharmacol. 2015 Jun ;28(2):150-9.IF: 1,617 

4. Moreno-Pérez D, Andrés Martín A, Tagarro García A, 

Escribano Montaner A, Figuerola Mulet J, García García 

JJ, Moreno-Galdó A, Rodrigo Gonzalo de Lliria C, Saavedra 

Lozano J. [Community acquired pneumonia in children: 

Treatment of complicated cases and risk patients. Consensus 

statement by the Spanish Society of Paediatric Infectious 

Diseases (SEIP) and the Spanish Society of Paediatric Chest 

Diseases (SENP)].An Pediatr (Barc). 2015 Sep ;83(3):217.e1- 

11.IF: 0,833 

5. de la Oliva P, Menéndez-Suso JJ, Iglesias-Bouzas M, Álvarez- 

Rojas E, González-Gómez JM, Roselló P, Sánchez-Díaz 

JI, Jaraba S, Spanish Group for Preload Responsiveness 

Assessment in Children. Cardiac preload responsiveness 

in children with cardiovascular dysfunction or dilated 

cardiomyopathy: a multicenter observational study.Pediatr 

Crit Care Med. 2015 Jan ;16(1):45-53.IF: 2,338 

6. Moreno-Pérez D, Andrés Martín A, Tagarro García A, 

Escribano Montaner A, Figuerola Mulet J, García García 

JJ, Moreno-Galdó A, Rodrigo Gonzalo de Lliria C, Ruiz 

Contreras J, Saavedra Lozano J, en representación de 

la Sociedad Española de Infectología Pediátrica (SEIP), 

Sociedad Española de Neumología Pediátrica (SENP) y el 

Comité Asesor de Vacunas de la Asociación Española de 

Pediatría (CAV-AEP). [Community acquired pneumonia in 

children: Outpatient treatment and prevention].An Pediatr 

(Barc). 2015 Dec ;83(6):439.e1-7.IF: 0,833 

7. Díez N, Giner E, Latorre I, Lacoma A, Roig FJ, Mialdea I, 

Díaz J, Serra-Vidal M, Escribano A, Domínguez J. Use of 

interferon-gamma release assays to calculate the annual 

risk of tuberculosis infection.Pediatr Infect Dis J. 2015 Feb 

;34(2):219-21.IF: 2,723 

8. de la Oliva P, Menéndez-Suso JJ, Iglesias-Bouzas M, Álvarez- 

Rojas E, González-Gómez JM, Roselló P, Sánchez-Díaz JI, 

Jaraba S. The authors reply.Pediatr Crit Care Med. 2015 May 

;16(4):395.IF: 2,338 

9. Serrano-Pariente J, Rodrigo G, Fiz JA, Crespo A, Plaza V, 

High Risk Asthma Research Group. Identification and 

characterization of near-fatal asthma phenotypes by cluster 

analysis.Allergy. 2015 Sep ;70(9):1139-47.IF: 6,028 

10. Pérez-Yarza EG, Castro-Rodriguez JA, Villa Asensi JR, Garde 

Garde J, Hidalgo Bermejo FJ, Grupo VESCASI. [Validation 

of a Spanish version of the Childhood Asthma Control 

Test (Sc-ACT) for use in Spain].An Pediatr (Barc). 2015 Aug 

;83(2):94-103.IF: 0,833 

11. de Dios Caballero J, Del Campo R, Royuela A, Solé A, Máiz 

L, Olveira C, Quintana-Gallego E, de Gracia J, Cobo M, de la 

Pedrosa EG, Oliver A, Cantón R, GEIFQ (Grupo Español para 

el Estudio de la Colonización/Infección Broncopulmonar en 

Fibrosis Quística), GEIFQ Grupo Español para el Estudio 

de la Colonización/Infección Broncopulmonar en Fibrosis 

Quística. Bronchopulmonary infection-colonization patterns 

in Spanish cystic fibrosis patients: Results from a national 

multicenter study.J Cyst Fibros. 2015 Sep 28 ;.IF: 3,475 

Department of Radiologic Protection 



2 2,403 1,20 

National 



International 


Corresponding 

author 

2 - - 

1. López-Tarjuelo J, Luquero-Llopis N, García-Mollá R, Quirós- 

Higueras JD, Bouché-Babiloni A, Juan-Senabre XJ, de Marco- 

Blancas N, Ferrer-Albiach C, Santos-Serra A. Statistical 

process control for electron beam monitoring.Phys Med. 

2015 Jul ;31(5):493-500.IF: 2,403 

2. Juste B, Miro R, Verdu G, Díez S, Campayo JM. Neutron 

distribution and induced activity inside a Linac treatment 

room.Conf Proc IEEE Eng Med Biol Soc. 2015 Aug 

;2015:6896-9.IF: 0 

215

4 

Scientific 

activity 

Department of Radiotherapy 



1 4,363 4,363 

National 



International 


Corresponding 

author 

1 - - 

1. Arana E, Kovacs FM, Royuela A, Asenjo B, Pérez-Ramírez U, 

Zamora J, Spanish Back Pain Research Network Task Force 

for the improvement of inter-disciplinary management 

of spinal metastasis. Agreement in the assessment of 

metastatic spine disease using scoring systems. Radiother 

Oncol. 2015 Apr ;115(1):135-40.IF: 4,363 

S, Acosta Pereira A, Ruiz Martín JM, Lamua Riazuelo 

JR, Expósito Moliner R, Ruiz Vilchez D, Veiga Cabello R, 

Fernández JC, Noguera Pons JR, Garrido Puñal NP, Giralt 

Celiméndiz P, Cortés Verdú R, Aragón Díez A, Tomás Roura 

C, Moll Turudi C, Taverner Torrent D, Rivas Santirso FJ, Lerma 

Garrido JJ, García Portales R, Ordoñez Palau S, Paredes 

González-Albo S, Gracia Pérez A, Conesa Mateos A, Calvo 

Alén J, Graña Gil J, Navarro Alonso MP, Martínez Blasco 

MJ, (RENACER StudyGroup). RENACER study: Assessment 

of 12-month efficacy and safety of 168 certolizumab PEGol 

rheumatoid arthritis-treated patients from a Spanish 

multicenter national database. Mod Rheumatol. 2015 Nov 

7 ;:1-6.IF: 2,397 

Department of Nuclear Medicine 

216 


Department of Rheumatology 



2 2,397 1,19 

National 



International 


Corresponding 

author 

2 - - 

1. Tornero Molina J, Ballina García FJ, Calvo Alén J, Caracuel 

Ruiz MÁ, Carbonell Abelló J, López Meseguer A, Moreno 

Muelas JV, Pérez Sandoval T, Quijada Carrera J, Trenor 

Larraz P, Zea Mendoza A. Recommendations for the use of 

methotrexate in rheumatoid arthritis: Up and down scaling 

of the dose and administration routes. Reumatol Clin. 2015 

January - February ;11(1):3-8.IF: 0 


2 5,159 2,57 

National 



International 


Corresponding 

author 

1 1 2 

1. Díaz-Expósito R, Vidal-Sicart S, Rioja-Martín ME. [Selective 

biopsy of sentinel node in melanoma. Survey results of 

nuclear medicine services in Spain].Rev Esp Med Nucl 

Imagen Mol. 2015 Mar-Apr ;34(2):120-2.IF: 1,054 

2. Bouyoucef SE, Uusitalo V, Kamperidis V, Casans Tormo I, 

Díaz-Expósito R (et al). Poster Session 2: Monday 4 May 

2015, 08:00-18:00Room: Poster Area.Eur Heart J Cardiovasc 

Imaging. 2015 May ;16 Suppl 1:i38-i55.IF: 4,105 

2. Torrente-Segarra V, Urruticoechea Arana A, Sánchez- 

Andrade Fernández A, Tovar Beltrán JV, Muñoz Jiménez A, 

Martínez-Cristóbal A, González Ferrández JA, Fernández 

Prada M, Vázquez Fuentes N, Corominas H, García-Díaz


4 

Department of Pneumology 



3 5,49 1,82 

National 



International 


Corresponding 

author 

1 - 3 

1. Llopis Pastor E, Pérez Guzmán E, Ávila Martínez R, Villena 

Garrido MV, Sobradillo Ecenarro P. Provision of care 

by medical residents and the impact on quality.Arch 

Bronconeumol. 2015 Oct ;51(10):515-9.IF: 1,823 

2. Lizarzábal Suárez PC, Núñez Savall E, Carrión Valero F. Lipoid 

pneumonia due to accidental aspiration of paraffin in a 

“fire-eater”.Arch Bronconeumol. 2015 Oct ;51(10):530-1. 

IF: 1,823 

3. Rosario Martín C, Navarro Cubells B, Carrión Valero F. 

Immune-mediated leukopenia due to Chlamydophila 

pneumoniae pneumonia.Arch Bronconeumol. 2015 Dec 

;51(12):663-664.IF: 1,823 

;28(4):e134-9.IF: 1,573 

2. Schüz J, Espina C, Villain P, Herrero R, Leon ME, Minozzi S, 

Romieu I, Segnan N, Wardle J, Wiseman M, Belardelli F, 

Bettcher D, Cavalli F, Galea G, Lenoir G, Martín-Moreno JM, 

Nicula FA, Olsen JH, Patnick J, Primic-Zakelj M, Puska P, van 

Leeuwen FE, Wiestler O, Zatonski W, Working Groups of 

Scientific Experts. European Code against Cancer 4th Edition: 

12 ways to reduce your cancer risk.Cancer Epidemiol. 2015 

Dec ;39 Suppl 1:S1-S10.IF: 2,711 

3. Vila-Candel R, Soriano-Vidal FJ, Navarro-Illana P, Murillo- 

Llorente MT, Martín-Moreno JM. [Relationship between 

maternal body mass index, gestational weight gain and 

birth weight; prospective study in a health department]. 

Nutr Hosp. 2015 Apr 1 ;31(4):1551-7.IF: 1,04 

4. Pérez-Cebrián M, Suárez-Varela MM, Font-Noguera I, 

Monte-Boquet E, Poveda-Andrés JL, Martín-Moreno JM, 

Rubio-López N, Ruiz-Rojo E, Llopis-González A. Study on 

the Linezolid Prescription According to the Approval of 

Indication in a University Hospital.Iran J Pharm Res. 2015 

Summer ;14(3):857-64.IF: 1,065 

217 

Quality Central Unit 



4 6,38 1,59 

National 


International 


Corresponding 

author 

3 1 - 


1. Vila Candel R, Soriano-Vidal FJ, Hevilla Cucarella E, Castro- 

Sánchez E, Martín-Moreno JM. Tobacco use in the third 

trimester of pregnancy and its relationship to birth weight. 

A prospective study in Spain.Women Birth. 2015 Dec

4 

Scientific 

activity 

4.3 Other scientific contributions from scientific platforms 

4.3.1 Biobank resources 

218 

biobanco@incliva.es 

Biobank members 

Principal Investigator 

Dr. Antonio Ferrández Izquierdo 



Dr. Lorena Peiró Chova. INCLIVA 

Technicians 

Olga Bahamonde Ponce. INCLIVA 

Marta Belda Moscardó. INCLIVA


4 

ACTIVITIES DEVELOPED 

Incorporation of samples in pre-existing collections: 

Oncological Node: 

• Collection of solid tumours (Tumor Bank): around 53 new cases 

(98 aliquots). 

• Collection of peripheral blood and derivative products in patients 

suffering from breast cancer (CM-S [Blood-Breast Cancer]): 

around 267 new cases (3912 aliquots). 

• Collections of peripheral blood and derivative products in patients 

suffering from lung cancer (CP-S [Blood-Lung Cancer): 



suffering from melanoma (MM-S [Blood-Melanoma]): 



suffering from gastrointestinal (GAS-S [Blood-Gastrointestinal]): 


Immunological Diseases Node: 


suffering from Systemic Lupus Erythematosus (LES-S 

[Blood-Systemic Lupus Erythematosus]) or other autoimmune 

diseases: around 18 new cases (313 aliquots). 

Cardiovascular Node: 

• Collections from the cardiovascular node: around 17 new cases 


Other collections: 

• Collection sepsis gravis and septic shock (SGSS): around 54 

new sample donations (629 aliquots). 


suffering from Multiple Esclerosis: around 37 new cases 


2015 new collections: 

• Collection of peripheral blood and derivative products in standard 

population: around 21 cases (263 aliquots). 

In summary, 701 new cases have been received, 2172 samples 

have been processed and 9399 aliquots have been stored in 

2015 at INCLIVA Biobank facilities. 

219 

Transfer of samples 

Project 

Ref./Agency 

Principal Researcher/Institution 

Samples 

Posible implicación de la bacteria Helicobacter Pilori 

en enfermedad tiroidea autoinmune. 

UGP-14-459 

FISABIO 

Dr. Alejandro Mira 

Obrador 

FISABIO 

Solid tumours: FFPE 

Exosomas urinarios en el Lupus Eritematoso 

Sistémico: potenciales biomarcadores y mediadores 

de señalización intrarrenal. 

X 

Dr. Raquel Cortés 

Vergaz 

INCLIVA 

Blood-Systemic Lupus 

Erythematosus: DNA and 

plasma 

Identificación de mecanismos de resistencia a 

nuevos anticuerpos anti-HER2 en cáncer de mama. 

PI12-01421, 

ISCIII, Ministerio 

de Economía y 

Competitividad 

Dr. Ana Lluch 

Hernández 

HCUV/INCLIVA 

Breast cancer: DNA, RNA, 

FFPE 

Nuevas estrategias dirigidas a pacientes de cáncer 

de mama con tumores triples negativos. Targeting 

TNBC. 

VLC-Bioclínic. 

INCLIVA9, 

INCLIVA 

Dr. Ana Lluch 

Hernández 

HCUV/INCLIVA 

Breast cancer: DNA, tissue

4 

Scientific 

activity 

Estudio de la implicación de determinados miRNAs 

en la progresión tumoral del melanoma cutáneo 

y su utilidad como biomarcadores pronósticos y 

terapéuticos. 

PI13/02786, 




Dr. Carlos 

Monteagudo Castro 

HCUV/UV/INCLIVA 

Melanoma: RNA 

Análisis trascriptómico y proteómico de los cambios 

condicionados por miRNAs en el melanoma 

cutáneo: identificación de nuevos biomarcadores 

proteicos con significación pronóstica. 

PROMETE- 

OII/2015/009, Generalitat 

Valenciana. 

Conselleria d’Educació, 

Cultura i Esport 

Dr. Carlos 

Monteagudo Castro 

HCUV/UV/INCLIVA 

Melanoma: plasma 

Fenotipo clínico y fisiopatogenia de los procesos 

desmielinizantes del sistema nervioso central 

debidos a hipermutaciones somáticas en los genes 

que codifican para anticuerpos monoclonales del 

tipo IgM de producción intratecal. 

PI13/00663, 




Dr. Bonaventura 

Casanova 

HUPF/ Instituto 

La Fe 

Multiple Esclerosis: trizol 

cells and cell pellets 

HIST-BIRTH: innovative and rapid point-of-care 

histone test strips for early diagnosis of sepsis in 

pregnancy and childbirth. 

Grand Challenges 

Canadat 

Dr. Federico V. 

Pallardó Calatayud 

UV/CIBERER/ 

INCLIVA 

Standard population: 

plasma and cell pellets 

In summary, 533 aliquots have been provided in 2015 to respond to these 8 sample requests. 

220 

Projects supported by sepsis gravis and septic shock (SGSS) collection. 

Project Ref./Agency PR/Institution 

Estudio de la especificidad y sensibilidad de un método basado 

en la detección de histonas circulantes como biomarcadores 

de sepsis grave y shock séptico. 

Emergente GV2014, 

Generalitat Valenciana 

Dr. García-Giménez 

(CIBERER/UV/INCLIVA) 

Identificación de histonas circulantes mediante procedimientos 

de espectrometría de masas en plasmas de pacientes 

con sepsis grave y shock séptico. 

Emergente INCLIVA 

Dr. García-Giménez 

(CIBERER/UV/INCLIVA) 


RESEARCH 


Title: Biobank network 

Principal Investigator: Dr. Josep Redón i Mas 







Primary Site, From The Spanish Nhs Perspective. 

Value Health. 2015 Nov;18(7):A356-7. doi: 10.1016/j. 

jval.2015.09.672. Epub 2015 Oct 20. PubMed PMID: 

26532012. IF: 3,279. 

2. Gómez M. et al. Risk factors for non-melanoma skin cancer in 

patients with essential thrombocythemia and polycythemia 

vera. Eur J Haematol. 2015 May 21. doi: 10.1111/ejh.12588. 

IF: 2,066 

3. Guillem V. et al. BCL2 gene polymorphisms and splicing 

variants in chronic myeloid leukemia. Leuk Res. 2015 

Aug 28. pii: S0145-2126(15)30367-2. doi: 10.1016/j. 

leukres.2015.08.014. IF: 2.351 


1. Gracia A. et al. Economic Analysis Of Epicup, An Epigenetic 

Test To Predict The Tissue Of Origin In Cancer Of Unknown


4 

4.3.2 Oncology Phase I Clinical Trials Unit 

INCLIVA is the only hospital of Valencia performing Phase I cancer 

clinical trials, and one of the few in Spain. Phase I trials are 

those in which a substance or product is tested in humans for 

the first time. 

INCLIVA is conducting, through the Oncology and Hematology 

Department, 189 clinical trials, 99 of them related to treatment 

in the early stages of testing (34 phase I or “first in human” and 

66 phase II). INCLIVA’s new facilities provide a full floor and a half 

specifically dedicated to host the unit. 

The unit aims to develop and select new drugs through clinical 

trials and performing studies related to the pathogenesis, prognosis 

and new experimental therapies in solid tumours 

FUNCTIONS: 

The unit implements early clinical trials with experimental 

agents in the field of Oncology. 

EQUIPMENTS: 

• -80º C Freezer 

• -20º C Freezer 

• Refrigerated desktop centrifuge 

• Scientific refrigerator 

• Conventional fridge 

• Defibrillator 

• Electrocardiographic equipment 

• 7 monitors (blood pressure, heart rate and 0 2 saturation) 

• 7 double medication infusion pumps 

• 7 heads gases (oxygen and vacuum) 

LOCATION: 

The following facilities are located on the second floor: 

• Reception and waiting room 

• 2 Consulting rooms 

• Staff room 

• Meeting room 

• Therapy room 

The third floor hosts the following facilities 

• Clinical trials office 

• Monitoring room 

• Clinical Trials archives 

PERSON IN CHARGE: 

Head of Unit: Prof. Andres Cervantes Ruipérez 

E-mail: Andres.Cervantes@uv.es 

Contact phone: +34 961973528 

HUMAN RESOURCES 

Medical doctors 

Dr. Alejandro Pérez Fidalgo 

Dr. Susana Roselló Keränen 

Dr. Cristina Herrando Meliá 

Dr. Marisol Huerta Lázaro 

Dr. Gema Bruixola Campos 

Nurses 

Inmaculada Blasco Blasco 

Celia Martínez Ridaura 

221

Clinical trials 

and other 

studies 

5

5 

Clinical 

trials and other studies 

5.1. Ethical Committee in Clinical Research 

(ECCR) Activity 

INCLIVA Health Research Institute –through its Ethical Committee 

in Clinical Research (ECCR) – manages the clinical studies 

(trials, observational studies, and research projects) carried out 

by the Hospital Clínico Universitario and the Valencia Clínico- 

Malvarrosa Health Department. 

The ECCR of the Hospital Clínico was awarded in 2013 with the 

ISO 9001 certification, a well-known international quality standard. 

This recognition guarantees the quality of the assessment 

performed by the ECCR, whose main goal is to ensure respect for 

the rights and safety of participants in clinical studies and other 

research initiatives. 

As a result of its activity along 2015, the ECCR has processed a 

total of 120 studies (clinical trials and observational studies): 115 

assessed, all positively valued. 

The distribution of these trials by phase is: Phase I: 11, Phase II: 

21, Phase III: 37, Phase IV: 7, Observational studies: 37, others: 6. 

The following table shows the number of clinical trials and other 

studies according to their typology. 

Distribution of trials 

224 

Once again, the Department of Medical Oncology and Haematology 

leads the number of trials presented to the ECCR. It is 

followed by the departments of Neurology, Cardiology, Internal 

Medicine and Endocrinology. These five departments make over 

75 % of the total processed trials. The following table shows the 

number of trials presented per departments and its percentage. 

Service Number % 

Medical Oncology and Haematology 52 43,3 

Neurology 14 11,7 

Cardiology 12 10,0 

Internal Medicine 7 5,8 

Endocrinology 6 5,0 

Anesthesia and Reanimation 4 3,3 

Digestive Medicine 4 3,3 

Ginecology 3 2,5 

Neumology 3 2,5 

Unit of Infectious Diseases 3 2,5 

Others 12 10,0 

Total 120 100

Clinical trials and other studies 

5 

In turn, the Principal Investigator (PI) distribution shown below indicates that 9 PI involved in clinical trial development belong to 

the Department of Medical Oncology and Haematology. They are followed by the Departments of Cardiology and Endocrinology with 

6 and 5 PI respectively. 

Service 

Number 

of PI’s 

% 

Medical Oncology and Haematology 9 17.6 

Cardiology 6 11.8 

Endocrinology 5 9.8 

Anesthesia and Reanimation 4 7.8 

Internal Medicine 4 7.8 

Neurology 4 7.8 

Digestive Medicine 2 3.9 

Ginecology 2 3.9 

Nephrology 2 3.9 

Neumology 2 3.9 

Psychiatry 2 3.9 

Radiology 2 3.9 

Others 7 13.7 

Total 51 100 

225 

Trials presented to ECCR

5 

Clinical 


Regarding the distribution of studies per promoter, 24 trials are considered Independent Clinical Research (trials from associations, 

groups, foundations, and private individuals), and the rest of them have been promoted by the pharmaceutical industry. 

226 

PROMOTOR Nº 

AbbVie Deutschland GmbH and Co. 1 

Ablynx 1 

Amgen Inc 1 

Ariad Pharmaceuticals, Inc 1 

Astellas Pharma S.A 2 

AstraZeneca AB 5 

AVEO Pharmaceuticals, Inc. 1 

Bayer Healthcare AG 9 

Biogen Idec Ibeica 1 

Biotronik SE&CO.KG 1 

Boehringer Ingelheim España S.A. 2 

Bristol-Myers Squibb International Corp. 1 

Campofrío Food Group 1 

Celldex Therapeutics, Inc. 1 

Codman Neuro 1 

Coretherapix SLU 1 

Daiichi Sankyo Development Limited 1 

ElectroCore, LLC 1 

Eli Lilly and Company Limited UK 1 

F. Hoffmann-La Roche Ltd. 4 

Ferrer Internacional S.A. 1 

Fresenius Medical Care España S.A. 2 

GE Healthcare Ltd. And its affiliates 1 

Genentech, Inc. 5 

Genzyme Corporation 1 

Gilead Sciencies, Inc 2 

PROMOTOR Nº 

GlaxoSmithkline S.A. 2 

Hamilton Health Sciences Corporation 1 

Hanmi Pharmaceutical Co., Ltd. 1 

Hospira UK Ltd. 1 

Independent Clinical Research 24 

Janssen-Cilag 4 

Janssen Sciences Ireland UC 1 

Lilly S.A. 4 

MacroGenics, Inc 1 

Merck Sharp & Dohme Corp 4 

Merrimack Pharmaceuticals Inc. 1 

Mirati Therapeutics, Inc. 1 

Novartis Farmacéutica S.A. 7 

Orion Pharma SL 1 

Pfizer INC 1 

Pharma Mar S.A. 1 

Portóla Pharmaceuticals, Inc 1 

ProNAi Therapeutics, Inc. 1 

Receptos, Inc. 1 

Roche Farma S.A. 3 

Sanofi-aventis S.A 4 

Shire Human Genetic Therapies, Inc. 1 

Synageva BioPharma Corp. 1 

Sysmex Inostics GmbH 1 

Thermo Fisher Scientific/BRAHMS GmbH 1 

UCB Biopharma SPRL. 2

Clinical trials and other studies 

5 

5.2. Assessment activity during last 5 years 

The table below confirms the importance of the Committee’s activity during the last five years. The number of studies processed 

yearly remains close to a hundred. 

Number of processed studies 

One of INCLIVA’s main goals is to develop clinical research at its early stages, thus contributing to translational research that moves 

scientific knowledge from bench to bedside. With this regard, during the period 2011-2015, Phase I and Phase II trials are prioritized 

and its number remains stable as shown in the graph below 

227 

Evolution of clinical trial distribution by phase

5 

Clinical 


5.3. Ongoing studies in the Valencia Clínico-Malvarrosa Health Department 

During 2015, 396 studies have been active. The distribution of clinical trials per department analysed below uses a semilogarithmic 

scale due to the great difference between the Department of Medical Oncology and Haematology and the rest of the Departments. 

228 

The distribution of ongoing trials and other studies according to their typology is the following:

Initiatives 

for research 

promotion 

6

6 

Initiatives 

for research promotion 

232 

6.1. VLC-BIOCLINIC grants 

Being aware that the processes of innovation and knowledge 

transfer require multidisciplinary collaboration among professionals 

from various fields, the University of Valencia, is interested 

in establishing concrete partnerships with hospital foundations 

which are related to the area of specialization in health and IN- 

CLIVA, whose general objective is to promote, encourage, favour 

and implement the scientific and technical research, launched in 

2015 VLC-Bioclinic Program. 

The main aim of VLC-Bioclinic program is to promote the cooperation 

in research, technological development and innovation 

in health, in order to generate synergies and partnerships between 

researchers and professionals in the field of health and 

strengthen translational research with innovative results that 

benefit patients. 

In 2015 the following projects were funded. 

VLC- BIOCLINIC Subprogram A 

Title: Soportes tridimensionales biodegradables basados en 

macropartículas para la regeneración del cartílago articular 








Title: Nuevas estrategias dirigidas a pacientes con cáncer de 

mama con tumores triples negativos 

Principal Investigator: Ana Lluch 




Clínico Universitario de Valencia, – Fundación CETIR 



Title: Marcadores metabolómicos del crecimiento ocular axial 

humano 

Principal Investigator: Daniel Monleón Salvado 






Title: Terapia génica del infarto agudo de miocardio mediante 

inyección hidrodinámica del gen humano IL-10 en el seno 

coronario del cerdo 

Principal Investigator: Luis Mainar Latorre 






VLC- BIOCLINIC Subprogram B 

Title: Desarrollo de una herramienta para el diagnóstico 

temprano, monitorización y seguimiento, por imagen cerebral, 

del deterioro cognitivo leve (encefalopatía hepática mínima) 

en pacientes cirróticos 

Principal Investigator: Carmina Montoliu 







Title: Búsqueda de dianas terapéuticas en los puntos de 

contacto de la célula tumoral en el neuroblastoma infantil con 

su matriz extracelular. Estudio piloto 


Funding Body: Universidad de Valencia 




Title: Desarrollo de fármacos bloqueadores de la toxicidad de 

expansiones CUG responsables de la distrofia miotónica 








Initiatives for research promotion 

6 

Title: Estudio de las consecuencias de la activación de 

receptores TLR en cultivos celulares de glioblastoma 

Principal Investigator: José Miguel Cerdá Nicolás 





Title: Biosensor molecular para la detección espacio-temporal 

de miRNAs 






Title: Ensayo plasmódico de espermia en orina como 

biomarcador de cáncer correctal 






Title: Sistema basado en datos como ayuda a la decisión 

clínica 

Principal Investigator: Fernando Martínez García y María 

Téllez 







Title: Herramienta de ayuda al diagnóstico de angina 

Principal Investigator: Juan Sanchís Forés 







Title: Análisis de los perfiles de expresión de microRNAs 

utilizando mapas auto organizados para el diagnóstico y 

pronóstico de individuos con déficit de alfa-1 antitripsina 






Title: Desarrollo de sistemas de análisis y visualización de 

datos complejos en estudios de expresión génica con series 

temporales: estudio de ARN de linfomonocitos tras sobrecarga 

oral con grasa insaturada en pacientes con resistencia a la 

insulina y su implicación en aterosclerosis 

Principal Investigator: Ana Bárbara García García 







6.2 Grants for intramural projects by emerging 

researchers 

Like previous years, INCLIVA launched an intramural call for 

research projects with the aim of improving the quality of their 

projects and promoting publishing in high impact journals, available 

exclusively to their emerging researchers. During 2015 the 

14 projects granted in 2014 were extended. 



Title: Reconstrucción del endometrio humano a través de 

xenotrasplante de células madre (LGR5+) en el modelo de 

ratón NOD-SCID 

Principal Investigator: Irene Cervelló Alcaraz 





Duration: 2014 - 2015 




Title: Expresión, localización y estudio funcional de la proteína 

PGRMC1 (Progesterone Receptor Membrane Component 1) en 

el endometrio 

233

6 

Initiatives 


234 

Principal Investigator: Francisco Domínguez 





Duration: 2014 - 2015 




Title: Identificación de miRNAs secretados al líquido 

endometrial en pacientes con obesidad y diabetes tipo 2. 






Duration: 2014 - 2015 




Title: Arquitectura genómica del cáncer de mama triple 

negativo. Análisis mediante genética de sistemas del riesgo a 

la progresión tumoral y respuesta terapéutica 

Principal Investigator: Joan Bataller Climent 





Duration: 2014 - 2015 




Title: Papel del complejo RUNX1/CBF-beta/p300/HIPK2 en la 

progresión leucémica de las neoplasias 

Principal Investigator: Juan Carlos Hernández Boluda 





Duration: 2014 - 2015 




Title: Study of new molecular and inflammatory mechanisms 

involved in abdominal aortic aneurysm 






Duration: 2014 - 2015 




Title: Análisis de parámetros de estrés oxidativo, función 

mitocondrial, longitud de telómeros y perfil de miRNAs 

circulantes en pacientes con déficit de alfa-1-antitripsina 






Duration: 2014 - 2015 




Title: Papel de la calcineurina y de su regulador RCAN en la 

respuesta cerebral al estrés oxidativo y la apoptosis: estudio 

en ratones RCAM-/- 

Principal Investigator: Ana Lloret 





Duration: 2014 - 2015 




Title: Efecto de la administración de genisteína y/o bexaroteno 

para el tratamiento de la enfermedad de Alzheimer en el 

modelo de ratón transgénico APP/PS1 






Duration: 2014 - 2015


6 




Title: Identificación de Histonas circulantes en plasmas de 

pacientes con sepsis y sepsis grave 

Principal Investigator: José Luis García Giménez 





Duration: 2014 - 2015 




Title: Mecanismos de resistencia al tratamiento en cáncer de 

mama triple negativo 

Principal Investigator: Pilar Eroles 





Duration: 2014 - 2015 




Title: Evaluación del papel terapéutico de la inhibición del 

PAI-1 sobre la endometriosis humana en un modelo murino 

heterólogo 

Principal Investigator: Raúl Gómez 





Duration: 2014 - 2015 




Title: ADN circulante y daño orgánico en individuos con 

Diabetes Mellitus tipo 2 

Principal Investigator: Ana Bárbara García 





Duration: 2014 - 2015 




Title: Ejercicio físico controlado como intervención en el 

tratamiento de la fragilidad en el anciano y en la prevención 

de la dependencia. Bases moleculares 

Principal Investigator: Mª Carmen Gómez 





Duration: 2014 - 2015 


6.3 Grants for secondments in centers of excellence 

As every year, the Institute has announced its Grants for research 

secondments in centers of excellence, to allow the staff 

to acquire new knowledge for clinical and research techniques. 

Since the establishment of this scholarship program, over 100 

professionals have visited national and foreign centers. In 2015 

the average number of awards was a total of 17 scholarships, 12 

of them to international centers and 5 to national ones. 

The awarded researchers and the assigned training centers in 

2015 are shown in the following table: 

Laura Álvarez Bravos 

Institut balear de Salut mental de la infància i l’adolescència 

(IBSMIA), Hospital Universitario Son Espases, Palma de 

Mallorca 

Julio Calvete Chornet 

Divisione di Senologia dell’Instituto Europeo di Oncologia, 

Milano 

Irene del Canto Serrano 

Laboratorio de órganos y matrices bioartificiales, Instituto De 

Investigación Sanitaria Gregorio Marañón, Madrid 

235

6 

Initiatives 


236 

Carlos Delgado Navarro 

Management Department, Roswell Park Cancer Institute, 

Buffalo 

Inés Escandell González 

Dermatopathology Service, University of San Francisco, 

California. 

Inmaculada Galán Chilet 

Comparative Medicine, Dr. Carlos Fernandez-Hernando Lab, 

Yale University, New Heaven 

Juan Carlos Herrera Navarro 

Hospital de la Sant Creu i Sant Pau, Barcelona 

José Santiago Ibáñez Cabellos 

Computational & Systems Biology, Faculty of Life Sciences, 

University of Manchester 

Ana Izquierdo Palomares 

Pain Management Department, Roswell Park Cancer Institute, 

Buffalo 

Anna Martín Bechet 

Movement Disorders Department, Mount Sinai Hospital, New 

York 

Sara Pastor Puente 

Laboratorio Dra. Janciauskiene, Dpto. Medicina Respiratoria, 

Hannover Medical School 

Daniel Perez Gil 

Computational Biology Lab, Universidad de Cambridge 

Begoña Pineda Merlo 

Laboratorio Epigenética del Cáncer, IDIBELL 

Alba Sanchís Juan 

Proteomic Services, European Bioinformatics Institute, 

Wellcome Genome Campus, Cambridge 

Tania Socorro Artiles 

Department of Surgery, University of Pittsburgh Medical 

Center, Pennsylvania. 

Cristina Tormo Martín 

Complexo Hospitalario Juan Canalejo, La Coruña 

Esteban Herminio Vega Torres 

Laboratório de Microcirurgia do Hospital Beneficência 

Portuguesa, São Paulo 

6.4 Training and Teaching Activities 

INCLIVA and its researchers play an important role in the training 

of researchers and health sciences degree and master students, 

which come from Valencian universities and other national 

and international regions. 

Thus, the number of internal secondments in 2015 was 5, an 

aggregate of 10 months of training during the period. Moreover 

INCLIVA has hosted over 55 students throughout the year, from 

the University of Valencia, Polytechnic University and the University 

of Lleida, an aggregate of 2.178 months of training during 

the period. 

The Institute has kept on developing, along the year, the Training 

Program with seminars and courses. The courses, seminars 

and educational conferences that have been developed during 

the year 2015 have been the following: 

Courses 

• Curso de formación en investigación biomédica: Como 

estructurar y presentar un proyecto de investigación clínica. 

• Curso de formación en investigación biomédica: Bioestadística 

I. Análisis exploratorio de datos. 


II. Comparación de grupos. 


III. Análisis estadístico de ensayos clínicos. 

• Curso de formación en interpretación de HER2 en cáncer 

de mama. 

• Curso de formación en investigación biomédica: Búsquedas 

bibliográficas. 

• VIII Curso de ventilación mecánica pediátrica (asistencia 

inicial y transporte). 

• Fundamental Critical Care Support Course. Dirigido a titulados 

en enfermería.


6 

• Fundamental Critical Care Support Course. Dirigido a 

médicos. 

• Fundamental Critical Care Support Course. Dirigido a titulados 

en enfermería. 

• Fundamental Critical Care Support Course. Dirigido a 

médicos. 

• Enfermedades Infecciosas VIH. Curso para Residentes. 

• Curso de actualización sobre el uso de antiagregantes 

orales en la cardiopatía isquémica. 

• I Workshop Internacional de Ecografía y Resonancia 

Anorrectal. 

• Curso de Anatomía Quirúrgica Aplicada Hepatobiliopancreática. 

INCLIVA Seminars 

• Eliseo Guallar, MD: “Estudios epidemiológicos basados 

en exámenes rutinarios de salud – Experiencia en el 

Kangbuk Samsung Health Study”. 

• Damiá Tormo: “Nuevos inhibidores orales del receptor 

de linfocitos para el tratamiento de enfermedades autoinmunes”. 

• Prof. Dr. Patrice D. Cani: “Obesity and diabetes: when 

adipose tissue talks to the gut microbes…”. 

• Dr. Rubén Artero: “Drosophila como herramienta para el 

descubrimiento de fármacos”. 

• Dr. Fco. Javier Puertas: “Consecuencias metabólicas y 

cardiovasculares de los trastornos del sueño”. 

• Dr. Esteban Ballestar: “Perspectivas de la Epigenómica 

en enfermedades del sistema inmune: Aplicaciones clínicas 

en procesos neoplásicos”. 

• Dr. Jaume Marrugat: “Evolución de la incidencia de cardiopatía 

isquémica en Europa 1980-2010 y proyecciones 

hasta 2049”. 

• Fernando Macián: “Mecanismos moleculares que regulan 

la tolerancia en los linfocitos T. Relevancia para el 

desarrollo de inmunoterapia”. 

• Dr. Joaquín Dopazo. Seminario INCLIVA noviembre. 

Workshops 

• Jornada de meta-análisis en anestesiología. 

• Jornada de investigación en neurociencia. 

• Jornada de situación de la investigación en tratamiento 

del dolor. 

• Jornada “Síndrome de Discinesia Ciliar Primaria: Pers- 

pectiva biomédicas y aspectos sociales”. 

• Jornadas sobre comunicación con el paciente y la sociedad. 

• I Jornada de enfermería pediátrica. 

• 7ª Jornada Valenciana “Tabaquismo y Respiración”: Tabaquismo 

y Pulmón. 

• Jornada Actualización de Patología Prostática. 

Conferences 

• Dra. Vannina González: “Perfil genómico y metabolómico 

asociado a la Microalbuminuria”. 

• Dra. Tania Romacho: “Inter-organ crosstalk: tejido adiposo 

en el centro de la diana”. 

• Dr. Carlos Romá: “Enfermedad de Lafora, ayer y hoy”. 

• Daniel Pérez Cremades: “Alteraciones de las células endoteliales 

en respuesta a histonas extracelulares”. 

• Dra. Irene del Canto: “Metodología experimental para el 

abordaje electrofisiológico de los parámetros ligados al 

desencadenamiento de las arritmias cardiacas”. 

• Lucía Rodríguez: “Papel de las calpaínas en la pérdida de 

los anclajes celulares en la glándula mamaria: estudio 

en modelos fisiológicos y patológicos”. 

• Sara Martorell: “Estudio del receptor nuclear VDR como 

posible diana terapéutica para el tratamiento del aneurisma 

aortico abdominal”. 

• Taller de Meta-análisis en anestesiología. 

• Avances en carcinoma de ovario y en carcinoma de 

mama hormonosensible. 

• Conferencia Jose Luis Ribelles: “Soportes sintéticos para 

el cultivo y trasplante en células en Ingeniería Tisular”. 

• INCLIVA Biomedical Research Institute & Turkish Society 

of Hypertension and Renal Diseases: “Hypertension 

Treatment: From Past to Future”. 

• Proyecto ESCARVAL de formación y mejora en práctica 

clínica sobre anticoagulación y antiagregación en atención 

primaria. 

• Formación de médicos residentes y adjuntos sobre calidad 

asistencial en unidades de salud mental. 

• Preceptorship en cáncer de mama avanzado. 

• UniBS Agreement seminar 

• Seminario “Investigación y divulgación: una carretera de 

doble sentido” 

• Actualización en el tratamiento de la insuficiencia cardíaca 

• Curso de terapia de resincronización cardíaca. 

237

6 

Initiatives 


• Formación de médicos residentes y adjuntos sobre la 

calidad asistencial en las unidades de salud mental del 

área clínico. 

• Lunch Seminar: “La investigación básica y la medicina 

actual”. 

• Lunch Seminar: “ELISA, quimioluminiscencia y otras”. 

• Lunch Seminar: “Citometría de flujo”. 

• Lunch Seminar: “Geles de proteínas y de ácidos nucleicos 

- Interacción genómica –clínica. Aspectos prácticos”. 

• Lunch Seminar: “Bases genéticas de las enfermedades. 

Técnicas genéticas de interés en clínica”: - Básicas: PCR 

y secuenciación. - Avanzadas: microarrays y secuenciación 

de nueva generación. 

• Lunch Seminar: “Bases genéticas de las enfermedades. 

Técnicas genéticas de interés en clínica”. 

• Lunch Seminar: “Expresión en E. Coli”. 

• Lunch Seminar: “Expresión de proteínas en células eucariotas.” 

• Lunch Seminar: “Cultivos primarios y cocultivos”. 

• Lunch Seminar: “C. Elegans”. 

• Lunch Seminar: “Animales transgénicos”. 

Other activities in which INCLIVA participates 

• “Máster oficial en bioinformática”, October 2014-June 

2015. Organized by Universitat de València, INCLIVA and 

CIPF. 

238


6 

Doctoral Thesis 

AUTHOR TITLE DATE DIRECTOR GROUP 

Pablo Padilla Iserte 

Patrón de decidualización en mujeres con 

preeclampsia mediante la aplicación de 

métodos de transcriptómica y proteómica 

13/01/2015 Alfredo Perales 

Marín, Carlos 

Simón 

Carlos Simón 

Silvia Tamarit Bordes 

Efectos del tratamiento con agonistas dopaminérgicos 

sobre las lesiones endometriósicas 

14/01/2015 Raúl Gómez 

Gallego 

Carlos Simón 

Iván Ferrer Vicens 

NF-KB E ID2 como nodos de regulación de 

redes transcripcionales en diferentes modelos 

biológicos 

16/01/2015 Juan Viña Ribes Juan Viña 

Irene Tadeo Cervera 

Estudio del armazón arquitectónico y del 

sistema vascular de los tumores neuroblásticos 

16/01/2015 Samuel Navarro 

Fos 

Samuel Navarro 

Manuel Koninckx 

Cañada 

Estudio de la posible participación de la 

corriente IKATP en las modificaciones que 

sobre estabilidad y heterogeneidad miocárdica 

produce el ejercicio físico crónico, en 

corazón aislado, normalmente oxigenado y 

tras isquemia regional aguda 

30/01/2015 Luis Such Belenguer 

Francisco Javier 

Chorro 

José María Martín 

Hernández 

Determinación de parámetros clínico-patológicos 

y moleculares implicados en la 

regresión espontánea de neoplasias melanocíticas 

cutáneas 

13/02/2015 Esperanza Jordá 

Cuevas 

José Carlos 

Monteagudo 

Alberto Tejera Pastor 

Cuantificación de la calidad embrionaria 

mediante el consumo de oxígeno durante el 

proceso rutinario de incubación y desarrollo 

in vitro 

18/02/2015 Marcos 

Meseguer 

Escrivá 

José Alejandro 

Remohí 

239 

Esther Carramolino 

Cuéllar 

Estudio clínico de la correlación de los niveles 

de glucosa en sangre y saliva; y la importancia 

de las citoquinas proinflamatorias en 

la enfermedad periodontal de los pacientes 

diabéticos. 

20/02/2015 Antonio 

Hernández 

Mijares 

Antonio 

Hernández 

Mijares 

Irma García Alcover 

Descubrimiento y caracterización de la estefenantrina 

como fármaco para la Distrofia 

Miotónica tipo 1 

13/03/2015 Rubén Darío 


Rubén Darío 

Artero 

Lucas Rovira Soriano 

Efectos de un programa de fisioterapia respiratoria 

preoperatoria sobre la oxigenación 

y la función respiratoria perioperatoria 

en pacientes obesos mórbidos sometidos a 

cirugía bariátrica laparoscópica 

13/03/2015 Joaquín Ortega 

Serrano 

Joaquín Ortega

6 

Initiatives 


José Francisco Folgado 

Montesinos 

Análisis de la relación del genotipado y 

marcadores de estrés oxidativo con la presencia 

y grado de vasculopatía periférica en 

pacientes con diabetes tipo 2 

14/04/2015 Juan Francisco 

Ascaso Gimilio 

Rafael Carmena 

Mercedes Molina 

Méndez 

Estudio del estrés oxidativo en la polineuropatía 

diabética 




Mónica Giménez Alcalá 

Beneficios de la terapia de resincronización 

cardíaca en pacientes con severa disfunción 

y dilatación ventricular izquierda en la insuficiencia 

cardíaca leve respecto a la avanzada 

23/04/2015 Francisco Javier 

Chorro Gascó 


Chorro 

Santiago Borrás Pallé 

Diagnóstico precoz de la neumonía asociada 

al ventilador. evaluación seriada de biomarcadores 

en minilavado broncoalveolar 

y monitorización microbiológica, complementada 

con condensado de aire exhalado 

y sangre 


Chorro Gascó 


Chorro 

Jordi Ferri Císcar 

Efecto del género y parámetros antropométricos 

en marcadores de estrés oxidativo e 

inflamación en situación postprandial. 




Ariadna Bargiela 

Schönbrunn 

Regulación transcripcional de muscleblind 

y nuevos mecanismos de patogénesis en 

un modelo de Distrofia Miotónica en Drosophila 



Rubén Darío 

Artero 

Vanessa Martínez 

Barquero 

Identificación de variantes exómicas en diabetes 

tipo 2 




240 

Tania Díaz Corpas 

Carcinoma epidermoide cutáneo: relación 

con los trastornos respiratorios del sueño y 

definición de la variante alto riesgo 

11/06/2015 Esperanza Jordá 

Cuevas 

José Carlos Monteagudo 

Marta Maia Boscá 

Watts 

HLA-DQ de enfermedad celíaca en pacientes 

con enfermedad inflamatoria intestinal 

crónica 

14/06/2015 Miguel Mínguez 

Pérez 

Gastroenterology 

Service 

Jaume Puig Bernabeu 

Continuous cardiac index trending (PROA- 

QT) via a radial arterial line versus standard 

care in general surgical patients 


Belda Nácher 


Belda 

María Luisa García 

Pérez 

Efecto de las diferentes ondas de flujo y de 

la pausa teleinspiratoria sobre la oxigenación 

y ventilación en modelo animal 

29/06/2015 Marina Soro 

Domingo 


Belda 

María Díaz Ruiz 

Alteraciones metabólicas de la Hiperlipemia 

Familiar Combinada y su asociación 

con la obesidad abdominal y la inflamación 

de bajo grado. 

02/07/2015 Antonio Hernández 

Mijares 

Antonio 

Hernández 

Mijares


6 

Marta Juan Aguilar 

Modelización farmacocinética de vancomicina 

en pacientes neonatos prematuros 

03/07/2015 Rafael Ferriols 

Lisart 

Pharmacy service 

María del Carmen 

Gómez Mateo 

Identificación de los perfiles de expresión 

en el adenocarcinoma ductal de páncreas. 

Implicaciones clínicas. 

08/07/2015 Felipe Javier 

Chaves Martínez 

Felipe Javier 

Chaves 

Ana Berbegall Beltrán 

Integración de la genómica en la modelización 

de los tumores neuroblásticos 


Fos 


Lorena Sabonet 

Morente 

Papel de la vitamina D durante el embarazo: 

su influencia en la etapa fetal 

13/07/2015 Antonio Cano 

Sánchez 

Antonio Cano 

Elkin Albeiro Muñoz 

Muñoz 

La adición de LH a la estimulación ovárica 

no produce más maduración endometrial 

prematura ni diferente patrón de expresión 

génica endometrial que la estimulación con 

solo FSH. Un estudio comparativo en donantes 

de ovocitos 

17/07/2015 José Alejandro 

Remohí Jiménez 

José Alejandro 

Remohí 

Isidro Antonio 

Torregrosa Maicas 

Biomarcadores precoces de fracaso renal 

agudo tras angiografía coronaria o cirugía 

cardiaca en pacientes con síndrome coronario 

o fallo cardiaco agudo 

23/07/2015 Carmina Montoliu 

Félix 

Carmina 

Montoliu 

Gloria Gema Báguena 

Requena 

Cirugía del cáncer de colon. análisis de los 

resultados en una unidad especializada 

21/09/2015 Eduardo García 

Granero Ximenez 

Andrés Cervantes 

María Luisa García 

Torres 

Enfermedad hepática grasa no alcohólica 

en la obesidad mórbida: implicaciones patogénicas 

y diagnósticas 

21/09/2015 Amparo Escudero 

García 

Carmina 

Montoliu 

Ángela Leticia Riffo 

Campos 

Chromatin regulatory mechanisms of gene 

expression at mononucleosomal level: nucleosome 

occupancy and epigenetic modifications 

28/09/2015 Luis Franco Vera Luis Franco 

241 

Gonzalo Martín Martín 

Resonancia magnética pélvica dinámica 

versus videodefecografía en el estudio del 

síndrome de defecación obstrutiva 

13/10/2015 Alejandro Espí 

Macías 

Andrés Cervantes 

Leonardo Margardel 

Pérez Llorente 

Aproximación diagnóstica al teratoma quístico 

benigno de ovario con ultrasonidos hd 

live 

14/10/2015 Francisco Raga 

Baixauli 

Service Gynaecology 

- Obstetrics 

María Inmaculada 

Navarro Hidalgo 

Sobrecarga oral con grasa insaturada y estrés 

oxidativo en sujetos con obesidad abdominal 

16/10/2015 Sergio Martínez 

Hervás 


María Cernada Badía 

Perfiles de expresión genómica: nuevo enfoque 

diagnóstico para la sepsis en recién 

nacidos menores de 1500 gramos 

19/10/2015 Eva Serna 

García 

Juan Viña

6 

Initiatives 


Susana Rovira LLopis 

Estudio de los mecanismos moleculares de 

estrés oxidativo, disfunción mitocondrial, 

estrés de retículo endoplasmático y autofagia 

en leucocitos de pacientes con diabetes 

tipo 2 

19/10/2015 Antonio Hernández 

Mijares 

Antonio Hernández 

Mijares 

Pablo García Molina 

Adaptación cultural y validación de la escala 

de valoración de riesgo de desarrollar úlceras 

por presión en neonatos hospitalizados 

(Neonatal Skin Risk Assessment Scale). 

23/10/2015 Cecilia Martínez 

Costa 

Cecilia Martínez 

Costa 

Santiago Peydró Tomas 

Regeneración tisular: estudio de la diferenciación 

in vitro de las células madre de la 

pulpa dental 

09/11/2015 Carmen Carda 

Batalla 

Carmen Carda 

Laura Martínez 

Rodríguez 

Análisis de los factores epidemiológicos y 

clínicos implicados en el desarrollo de la enterocolitis 

necrosante 

17/11/2015 Cecilia Martínez 

Costa 

Cecilia Martínez 

Costa 

Nuria Santonja López 

Estudio clínico, histopatológico, inmunohistoquímico 

y citogenético de los tumores 

mesenquimales uterinos de músculo liso. 

Búsqueda de dianas terapéuticas. 


Fos 


Francisco Argüelles 

Linares 

Papel del nf-K946 Y MIrna-34A en la patogénesis 

de la osteoartritis y como posible 

diana de las nuevas terapias biológicas 

10/12/2015 José Miguel 

Cerdá Nicolas 

José Miguel 

Cerdá 

Rafael Estevan Estevan 

Impacto del tratamiento neoadyuvante en 

los resultados de la cirugía del cáncer de 

recto localmente avanzado. 

17/12/2015 Luis Sabater 

Ortí, Rafael Alós 

Company 

Joaquín Ortega 

Juan Manuel 

Fernández Costa 

Implicación de miRNAs en la toxicidad mediada 

por expansiones de repeticiones CTG 

en Distrofia Miotónica 



Rubén Darío 

Artero 

242 

María del Carmen Peña 

Chilet 

Expresión diferencial de microRNAs en tumores 

de mujeres jóvenes con cáncer de mama: 

Cribado de dianas moleculares. 

18/12/2015 Ana Lluch Hernández 

Ana Lluch 

Eva Rumiz González 

Estudio de la afectación del ventrículo derecho 

en el infarto anterior reperfundido. 

21/12/2015 Vicente Bodí 

Peris 

Vicente Bodí

Highlights 

7

7 Higlights 

A research advances in reducing lung injury caused by mechanical ventilation. 

INCLIVA is visited by Eliseo Guallar, an epidemiologist at Johns Hopkins University. 

JANUARY 

INCLIVA and the University of Valencia created the first Regional Center for Rare Diseases. 

FEBRUARY 

The Minister of Health recognizes the research of Dr. Pallardó, Dr. Cervantes 

and Dr. Sanfélix. 

Chromosome 21 involved in Down Syndrome protective agent against cancer. 

INCLIVA presents its research to the Southwestern University of Dallas. 

MARCH 

The cardiologist Vicente Bodí, Prize of the Valencian Royal Academy of Medicine. 

Molecules generating resistance in breast cancer tumors have been identified. 

INCLIVA adscribes the Patent Bank’s of Generalitat Valenciana. 

A mechanism responsible of oxidation of fats in adipose tissue it is presented in INCLIVA. 

APRIL 

INCLIVA researcher, Maider Ibarrola receives the Garcia-Blanco medal, in its 35th edition . 

A study in which Hospital Clinico of Valencia participates, confirms that the combined use 

of two antibodies slows colon cancer. 

The Race Dona at Gandia donated over 24.000€ to investigate breast cancer. 

A research on rare diseases by INCLIVA is doubly awarded by the Valencian Society of 

Pneumology. 

MAY 

246 

A joint investigation by INCLIVA and UV is awarded by the Spanish Society of Geriatrics 

and Gerontology. 

Eighth edition of the Paediatric Mechanical Ventilation Course. 

Success in ALIMARA show for the benefit of cancer research. 

Researchers from INCLIVA and IVI awarded at the XXIV edition of the Merck Serono 

Research Grants. 

RUBIÓ LABORATORIES and INCLIVA sign an agreement to promote research. 

Success in INCLIVA colloquium with the Nobel Prize Erwin Neher, Ferid Murad and 

Richard J. Roberts. 

JUNE

Higlights 

7 

JULY 

INCLIVA and Lanzadera sign a cooperation agreement. 

AGOST 

INCLIVA joins to the first Spanish company in epigenetics . 

SEPTEMBER 

INCLIVA’s Biobank receives the ISO 9001 quality certificate. 

Investigators show that genetic variants in a gene are related to the severity of the 

myeloid leukaemia. 

Maite Girau, Councillor for Health and Sports Valencia visits INCLIVA. 

OCTOBER 

The European Respiratory Society awards Dr. Francisco Dasí. 

INCLIVA researchers discover a protein that protects against diabetes. 

The VLC Health Ecosystem initiative is presented in the Botanic. 

Andrés Cervantes, awarded by the European Society for Therapeutic Radiology and 

Oncology (ESTRO). 

NOVEMBER 

MoTriColor: pan-European project for the development of new therapies in patients 

with advanced colorectal cancer. 

A new application to facilitate monitoring and improving adherence to treatment of 

patients with psychosis has been designed. 

Blood marker which indicate the mild neurological impairment in patients with minimal 

hepatic encephalopathy has been identified. 

The European Society for Medical Oncology recognizes INCLIVA and the Clinical Hospital 

of Valencia for the excellence of their training. 

The Obra Social “la Caixa” collaborates with the Paula Project led by INCLIVA with 6,000 

euros for research on diabetes. 

The association between extracellular vesicles and the degree of renal involvement in 

lupus is demonstrated. 

A new antibody could be effective against solid tumours. 

247 

DECEMBER 

Resolution of the announcement of the Strategic Action in Health with a result of 

support to fund 12 research projects with 1.762.145€ and 9 research contracts funded 

with 745.560€. 

Highlighting the Integrated Project Excellence of Dr. Vicente Bodí. 

INCLIVA and REDIT signed a collaboration agreement to boost biomedical innovation. 

Dr. Cervantes gets into the Royal Academy of Medicine of Valencia. 

INCLIVA and REDIT signed a collaboration agreement to boost biomedical innovation.

INCLIVA 

Solidary 

8

8 

INCLIVA 

Solidary 

PROYECTO MAMA 

INCLIVA’s mission is “to contribute to improving the health and 

quality of life of citizens”, therefore, in addition to our own research 

projects, it is also involved and committed to initiatives 

promoted by individuals who live near some illness. 

INCLIVA is currently working on four joint initiatives: Proyecto 

Mama, Proyecto Paula, Fundacion Le Cadó and Nico contra el 

Cancer. One of the fundamental premises of the institute is the 

maximum transparency in the management of the contributions 

received. 

Proyecto Mama started in September 2012 promoted by Pedro 

Alarcon after the death of his mother as a result of breast cancer. 

The purpose of this initiative is to get public and private funds to 

investigate this disease. 

Breast cancer is the most common tumor in women, begins to 

appear around age 30, gradually increasing its impact, affecting 

up to 9% of the female population at 70 years of age. 

These donations provide tax benefits under the Article 66 of 

the Law 30/1994 of 24 November on Foundations and Tax to 

private participation in activities of general interest incentives. 

8.1 Solidary Projects 

PROYECTO PAULA 

This project was born in 2011 from the hand of Cristina Ponce, 

when her 8 years old daughter, Paula, was diagnosed with type 

1 diabetes mellitus, a disease that completely destroyed their 

insulin-producing cells. 

Proyecto Paula focuses its work in raising the necessary funds 

and resources, both public and private, to investigate the 

Diabetes and in the future to find a cure for Paula and other 

people with this illness. 

INCLIVA has several groups dedicated to research in diabetes 

and belongs to the Biomedical Research Centre in Diabetes and 

Associated Metabolic Diseases (CIBERDEM), a public consortium 

led by Spain’s research effort of excellence in diabetes and 

related metabolic diseases, as well as the translation of research 

results into clinical practice. 

Since its inception, Proyecto Paula has contributed with more 

than 93.000€. 

FUNDACION LE CADO 

Fundación Le Cado was created in 2010 under the leadership of 

its president Elvira Monferrer Daudi. This initiative seeks to unite 

efforts and resources in supporting this kind of tumor research, 

which is currently the fourth leading cause of death of women. 

Fundación Le Cado collaborates with the INCLIVA funding the 

research project “Study of breast cancer in young women under 

35 years,” conducted by Dr. Gloria Ribas. It also involves other 

researchers such as Dr. Isabel Chirivella (a genetic diagnosis specialist 

physician), Dr. Jaime Ferrer Lozano (a pathologist) and Ms. 

Carmen Peña Chilet, all this team led by the oncologist Dr. Ana 

Lluch. 

Almost 30.000€ have been donated for the Project so far. 

250

INCLIVA Solidary 

8 

NICO CONTRA EL CANCER 

The movement “Nico contra el cancer” was formed in November 

2015 in Ourense, after Nicolas Rodriguez Leal came back 

from his surgery intervention at the Hospital La Paz in Madrid. 

The movement is led by his mother and aunts as a dependent 

activity of the Asociación NEN, whose main objective is to finance 

research projects against childhood cancer, and more specifically 

solid tumours. 

neighboring countries, to encourage donations from businesses 

and individuals that may deduct contributions in full and not a 

small percentage “. 

In turn, Jorge Navarro stated that “INCLIVA Research Groups 

are the representation of health excellence in the Valencian 

health, and at the Hospital Clínico in particular.” He also thanked 

the contribution of “la Caixa” as an example of public-private 

partnership that should be encouraged in our society. 

Meanwhile researcher Herminia González presented the research 

being done on genetic polymorphisms of diabetes, particularly 

those that predispose or protect people who have them, 

and new markers of inflammation associated with diabetes and 

thus new therapeutic pathways that act on these pathways. “In 

this way we hope to be able to improve the treatment and outcome 

of complications of diabetes.” She stated that “without the 

support of Paula Project we had not be able to prove that a protein, 

CdK5a / 2b is a protective agent insulin resistance and fatty 

liver, as we published this past October.” 

A show from INCLIVA’s benefit to investigate in cancer. 

8.2 Solidary news 

The Obra Social “la Caixa” collaborates with Paula Project 

INCLIVA with 6,000 euros for research on diabetes. 

Coinciding with the World Diabetes Day, which was held last 

Saturday, this morning, INCLIVA, received from the hands of representatives 

of the Obra Social “la Caixa” a contribution of six 

thousand euros to support the Paula Project and diabetes research. 

The Director General of INCLIVA, Rafael Carmena, CFO Juan 

Luis Huguet, Medical Director of the Clinical Hospital, Jorge Navarro, 

Cristina Ponce and Paula Botella from the Paula Project 

and researcher Herminia González from Research Group Inflammation 

participated in the event. 

According to Professor Carmena “Patronage is a pending subject 

in our society, we cannot expect it to be the state that will 

meet the Spanish investigation as a whole; civil society must also 

contribute. But to do this, we must have a similar law to other 

The Palau de la Música in Valencia hosts this Saturday June 20 

at 19:30 pm a charity event for research against breast cancer. 

The dance group ALIMARA represent his show “El Somni”, 

a journey through the different shows that Alimara has done 

throughout its 40 years of existence. 

The event is organized by the Fundación Le Cado and all 

proceeds will go to the study of breast cancer in young women 

which is carried out in INCLIVA. 

Tickets can be purchased at the ticket office in Palau de la 

Música. 

La Carrera de la Dona de Gandia donated over 24,000€ to 

investigate breast cáncer. 

The Management of Club Atletisme la Safor and the Director 

General of Delizia, its sponsor, have been received today by the 

Research Institute INCLIVA, the Managing Director of the Clinical 

Hospital, Luis Martí, the oncologist Ana Lluch, and his research 

group in breast cancer biology, after the solidarity race celebra- 

251

8 

INCLIVA 

Solidary 

nia Torre, Cesar Navarro and Cristobal Jimenez very sincerely for 

252 

ted in April in Gandia. 

During the interventions, the Director General of the Institute, 

Rafael Carmena, thanked the work of the club and the sponsor, 

not only by the collected amount (24.747€) but for their solidarity 

and work. “The 100% of the proceeds will go to research.” 

“Acts like the one held in Gandia show us that we are not alone 

and that citizens value the work of professionals and researchers 

in public health,” said Dr. Martí. 

Dr. Lluch presented the research project that the funds raised 

will be dedicated to: “Analyzing the biological differences of 

breast cancer in women under 35 years old. We want to know 

why in young women the tumours are more aggressive, larger 

and less responsive to treatment” she says. In this sense the researcher 

sincerely thanked the support of the Club Atletisme La 

Safor. 

The Club Atletisme La Safor explained that the race has become 

a big event in Gandia in which the whole city is involved. Vicent 

Mengual, from the Board, expressed its intention to continue 

working with INCLIVA and research in breast cancer in future 

editions of the Carrera de la Dona. 

Success in “III Tirada contra el Cáncer” in favor of INCLIVA 

For second consecutive year, the courts of the range of the Lidonero 

in Cheste, hosted on Saturday a competition skeet in favor 

of cancer research at the Institute of Health Research INCLI- 

VA, the “III Tirada contra el Cáncer”, Estelles Vicente Memorial 

and Tribute to Juan Ruiz Pedrosa. 

The facilities that runs the Valencian world champion, Christopher 

Jimenez, welcomed more than 120 shooters from different 

categories, from veterans to hunter’s sharpshooters in a festive 

gathering. Some of the national champions of their own categories 

where among there participants. 

The Dr. Joan Climent, from the research Group on Breast Cancer 

Biology, came on behalf of INCLIVA. 

At the end of the day, during the awards ceremony, 3.516€ 

were donated to INCLIVA which will go to breast cancer research. 

From INCLIVA we want to recognize the commitment and solidarity 

of the entire organization with the initiative and participants 

in the event. 

In particular, INCLIVA wants to thank Enrique Alhambra, Anto- 

their work and their solidarity with biomedical research in the 

Valencian Community. 

April 19th Cursa de la Dona in Gandia in favor of INCLIVA 

Next Sunday, April 19 th is going to celebrate the eighth edition 

of the “Cursa de la Dona de Gandia” for INCLIVA, the Institute of 

Health Research of the Clinical Hospital of Valencia. 

The organization is in charge of Club Atletisme Safor. Around 

seven thousand inscriptions are overcome and the organization 

encourages register to exceed the number of brokerages previous 

editions. 

Following the example of previous years, the Club Atlestisme 

Safor allocate each one euro entry to the research project 

“Breast cancer in women under 35 years,” Research Group Biology 

of breast cancer led by Dr. Ana Lluch in INCLIVA. 

The route of the race will pass through the old town of Gandia 

and the expected distance is 5.700 meters. 

Inscriptions on the race can be made through the network on 

the page, www.cursadeladonagandia.com or in person at various 

establishments of Gandia, Alcoy, Javea, Denia, Cocentaina, Xàtiva, 

Onteniente, Sueca, Tavernes and Oliva. 

In addition, the organization has also initiated a parallel action 

selling a solidary bracelets, which can be purchased in the same 

establishments where enrolment to benefit fully from INCLIVA 

research project is carried out. 

8.3 Solidary private donations and acknowledgment 

On behalf of INCLIVA we want to thank the support and solidarity 

to all the people who help with their donations. For us, your 

collaboration means much more than an economic contribution, 

is the encouragement we need to keep investigating and working 

for research. 

Private donations 

Paula Besó Roig, Esteban Borreda Bolinches, Francisco Botella 

Aparicio, Rafael Pascual Caballer Molina, Guillermo Caballero De 

Luján, Joaquín Casado Catalina, Ana María Castán Subias, Lino

INCLIVA Solidary 

8 

Clemente, María Luisa Ebri Méndez, Natalia Font Ferrando, Nuria 

Gelonch Soler, José Luis Gómez Lluch, María Jesús Luis Calleja, 

Alicia Martínez Espinosa, Óscar Martínez Vila, Cristina Ponce 

Costa, Antonio Pulido Carrillo, Leonor Rodríguez Marín, Fernando 

Rodríguez Miguelez, Rosalía Sánchez Rilla, Ana Sanz Moliner, 

Rosa María Torregrosa Segura. 

Corporative donations 

Abbott Laboratories S.A., Abbvie Spain S.L.U., Amgen S.A. 

Asociació Familiars I Amics Pacients Amb Neuroblastoma, 

Asociación de afectados de cáncer, Asociación Garmitxa, 

Astellas Pharma S.A., Bilbao Bizkaia Kutxa, Cem Biotronik S.A., 

Cepal Asesores S.L., Cordoplas S.A., Covidien Spain S.L., Ferrer 

Internacional S.A., Ferring S.A., Fundación Bancaria Caixa 

d’estalvis i pensions de Barcelona, Fundación Española De 

Hematología Y Hemoterapia, Fundación IVI, Fundación Lecadó, 

Fundación Patrimonio Benéfico Marqués De Dos Aguas, Ge 

Healthcare Biosciences S.A., Grupo Gasmedi S.L.U., Helados 

Y Postres S.A., Humana Spain S.L., Jbz Diseño Técnico S.L.U., 

Kern Pharma S.L., Laboratorios Dr. Esteve S.A., Laboratorios 

Farmacéuticos Rovi S.A., Medtronic Ibérica S.A., Merck S.L., 

Nutricia S.R.L., Pfizer S.L.U., Quialmedic S.L., Radiometer Ibérica 

S.L., Roche Farma S.A., Sanofi-Aventis S.A., Seguros El Corte 

Inglés Vida, Pensiones Y Reaseguros S.A., Sobi S.L., Sofpromed 

Investigación Clínica S.L.U., Springer Helalthcare Ltd, St. Jude 

Medical España S.A., Sumedex S.A., Variocana Asoc. Interna de 

reiki y terapias alternativas, W.L. Gore Y Asociados S.L., Zambon 

S.A.U. 

253

Avda. Menéndez Pelayo, 4 accesorio · 46010 Valencia (España) 

Tel. 34 96 197 35 17 Fax 34 96 197 35 40 

www.incliva.es incliva@incliva.es

memoria2015

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?